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Development and Applications  
of Palladium(0)-catalyzed-C(sp3)-H Activation 
Abstract 
Over the last decade, the transition metal-catalyzed intramolecular activation of unactivated C-
H bonds has emerged as a powerful method to transform otherwise inert entities allowing access 
to molecular complexity in an atom- and step-economical fashion. 
Research in our group is centered on the activation and functionalization of C(sp3)-H bonds that 
lead to the development of new methodologies and applications including asymmetric catalysis, 
mechanistic studies and total synthesis of complex molecules. 
Recently, our group developed a straightforward access to hexahydroindoles scaffolds by 
intramolecular C(sp3)-H alkenylation. As a follow-up, we first investigated the application of 
this new methodology in combination with a directed C(sp3)-H arylation to achieve a collective 
synthesis of aeruginosins. 
In a second part, we extended this methodology to the development of a modular C(sp3)-H 
alkenylation for the synthesis of a wide variety of g -lactams, which are prevalent scaffolds 
found in numerous bioactive natural molecules. 
Finally, we developed a highly efficient synthesis of b-lactams, which are valuable compounds 
widely used in pharmaceutical chemistry, by palladium(0)-catalyzed-C(sp3)-H carbamoylation. 
Keywords : C-H functionalization, C-H activation, organometallic catalysis, palladium, total 
synthesis, aeruginosins, g-lactams, b-lactams 
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 Chapter 1  
  Bibliographic part 
1.  Generality 
Organic chemistry started in the nineteenth century with the synthesis of urea by Friedrich 
Wöhler in 1828 and of the mauveine by Henry Perkin in 1856, which led to the rise of both the 
chemical industry and academic research1. Since the emergence of organic chemistry, classical 
approaches used by chemists to build and/or functionalize organic compounds consisted in 
transforming pre-existing functional groups into the desired chemical functions. This strategy 
can solve many regio- and/or chemoselectivity issues by using the impressive catalogue of 
organic reactions and a well-designed synthetic route. However, the need of prefunctionnalized 
starting materials which are often obtained after several transformations has prompted chemists 
to investigate more atom and step economical alternatives (Scheme 1 a.).  
 
Scheme 1 : Overview of different approaches to functionalize organic compounds 
Over the past decades, transition metal catalysis has witnessed a rapid and comprehensive 
development. Notably, palladium-catalyzed cross-coupling emerged as a powerful tool for 
carbon-carbon bond formation. Indeed, this synthetic approach allowed new disconnections for 
synthetic chemists from academia and industry to access molecular complexity in a rapid, 
convenient and selective fashion (Scheme 1 b.). This is emphasized by the continuously 
growing literature in this field (Figure 1) and the attribution of the Nobel Chemistry Prize to 
Heck, Negishi and Suzuki in 20102. 
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Figure 1 : Growth in the number of publications and patents on named metal-catalyzed cross-coupling reactions 
Such palladium-catalyzed cross-coupling reactions are initiated by the oxidative addition of a 
Pd(0) complex into a carbon-halide/pseudohalide bond generating an electrophilic Pd(II) 
organometallic species, which then undergoes transmetallation with a nucleophilic 
organometallic compound. The resulting Pd(II) complex affords the desired cross-coupled 
compound after reductive elimination (Scheme 2). Various advantages were offered by this 
catalytic system in terms of retrosynthetic analysis3, step-economy and industrial applications4. 
Nevertheless, some limitations such as the pre-functionalization of starting materials and the 
production of stoichiometric toxic metal wastes stimulated chemists to turn their attention to 
direct C-H functionalization.  
 
Scheme 2 : Simplified general catalytic cycle for palladium-catalyzed cross-coupling reaction 
Indeed, due to the ubiquity of C-H bonds in organic compounds, their direct and selective 
functionalization provides new strategic and economic benefits for organic chemists, in 
agreement with the atom economy idea (Scheme 1 c.)5. However, C-H functionalization 
remains challenging due to the intrinsic reactivity of C-H bonds and selectivity issues. 
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2. C(sp3)-H bond functionalization in organic synthesis 
2.1.  Reactivity of aliphatic C-H bonds 
For a long time, the functionalization of C-H bonds has been ignored in retrosynthetic analysis 
due to the relative inertness of these bonds. Aliphatic compounds also known as “parrafins” 
from the Latin parum affinis (without affinity) can be called “noble gases of organic chemistry”. 
Indeed, alkanes such as methane have a high bond dissociation energy (BDE) of 104 Kcal/mol 
and they are entirely saturated, which means they do not contain p- nor n-electrons allowing 
classical reactivities6. Nevertheless, alkanes can react promptly with extremely active species 
such as radicals, carbenes and highly acidic compounds7. Such reactivities were exploited by 
scientists in total synthesis of natural products leading to pioneering applications of C-H bonds 
functionalization. Generally, these strategies relied on the generation of radicals, carbenes or 
nitrenes in structural proximity to the alkyl groups, thus allowing C-H abstraction or insertion. 
2.2. Early contributions in total synthesis 
Early results were obtained by Löffler taking advantage of the photochemical homolysis of N-
halomamine 1.1 to generate a highly energetic N-centered radical 1.2 which affords 1.3 via a 
1,5-hydrogen transfer (6-membered transition state) and radical recombination. Finally, the 
halogen atom is displaced by the secondary amine leading to the synthesis of nicotine (Scheme 
3)8. Much later, exploiting the same Hofmann-Löffler-Freytag methodology, Corey and 
Arigoni were independently able to functionalize the unactivated C-18 methyl group of steroid 
derivatives to provide natural aminosteroids in few steps9.  
 
Scheme 3 : Early total syntheses based on the Hofmann-Löffler-Freytag reaction  
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In 1960, Barton and coworkers developed a new photochemical reaction relying on nitrite ester 
photolysis10. Starting from readily available corticosterone acetate 1.7, they initiated, under 
photochemical conditions, homolysis of the nitrite ester leading to highly reactive O-radical 
1.8, which undergoes a selective 1,5-hydrogen transfer to afford 1.9. This latter recombines 
with the nitroxyl radical and give 1.11 after tautomerization. Final hydrolysis of the oxime 1.11 
leads to aldosterone acetate 1.12 in moderate yield (Scheme 4)11. 
 
Scheme 4 : Total synthesis of Aldosterone acetate based on Barton oxydation 
Analogous to radicals, nitrenes and carbenes are highly reactive species able to perform C-H 
functionalization. In 1964, Masamune and coworkers studied the unstability of acyl azide 1.13 
under photoirradiation generating acyl nitrene 1.14. This latter reacts with the spatially close 
methyl C-H bonds via a remarkable nitrene insertion to afford C-H amination product 1.15. 
After further transformations, garryine 1.17 was obtained in low overall yield (Scheme 5)12. 
 
Scheme 5 : Total synthesis of garryine based on nitrene insertion  
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Exploring the total synthesis of the tetracyclic sesquiterpene ishwarane 1.21, Cory’s group 
demonstrated the synthetic utility of carbene C-H insertion. Starting from advanced 
intermediate 1.18, they prepared diastereoselectively gem-dibromocyclopropane 1.19, which 
upon treatment with methyllithium, provided cyclopropylcarbene 1.20. Carbene C-H insertion 
takes place with the most accessible methyl C-H bond to give in low yield a concise 6-step total 
synthesis of ishwarane 1.21 (Scheme 6)13. 
 
Scheme 6 :  Total synthesis of ishwarane based on carbene insertion  
Despite moderate to low yields, these selected pioneering examples highlight the synthetic 
potential of direct C-H functionalization in total synthesis. However, these advances suffered 
from a lack of reactivity and generality until the eighties. Nevertheless, these remarkable 
contributions served chemists as an inspiration for the development of more practical and 
general C-H bonds functionalization methodologies and their applications in total synthesis14. 
Chemists turned their attention to the study of transition-metal catalysis, based on early 
organometallic observations15. 
3. Transition metal catalyzed C(sp3)-H functionalization 
3.1. General mechanistic aspect 
Transition metal catalyzed C(sp3)-H functionalization processes were subdivided into two 
different classes based on the C-H bond breaking mechanism involved16. Robert Crabtree 
distinguishes coordination chemistry from the organometallic approach. This was then taken 
up and labelled by Melanie Sandford as “outer-sphere” and “inner-sphere” mechanisms17. 
In “outer-sphere”, the alkane interacts first with a highly-activated ligand of a metal complex 
(X= carbene18, nitrene18c, 19, oxene7b) before the C-H bond functionalization event. Two distinct 
mechanisms can be considered (C-H insertion or H atom abstraction/radical rebound). No 
formation of a metal-alkyl intermediate is involved. Both pathways show preferential 
selectivity for weaker C-H bonds (tertiary>secondary>primary) due to the radical and/or 
cationic character at the carbon center (Scheme 7 a.). 
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Scheme 7 : Different approaches for the transition-metal catalyzed C-H functionalization 
Based on transition-metal catalysis, which offers more control over the reaction course due to 
the modulation of the reactivity of the metal complex by the ligand properties, numerous 
applications in total synthesis were achieved14, 20. One of the most impressive ones is the total 
synthesis of the structurally complex (-)-tetrodotoxin 1.27 by the group of Du Bois (Scheme 8). 
Thanks to two key rhodium-catalyzed C-H functionalizations (C-H insertion followed by C-H 
amination), they have built this functionalized bridged natural product in twice less steps than 
the previous synthesis, thus highlighting the synthetic power of transition-metal catalyzed C-H 
functionalization21.  
 
Scheme 8 : Total synthesis of (-)-tetrodotoxin  
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In “inner-sphere”, C-H bond breaking generates an organometallic intermediate, which reacts 
to obtain the functionalized product (Scheme 7 b.). In this mechanism, the C-H bond cleavage 
event can be called “true C-H activation” as defined by Shilov and Shul’pin and includes 
reactions involving an agostic interaction between the metal center and the C-H bond prior to 
C-H activation (via oxidative addition or CMD) leading to an organometallic species7b, 16, 22. 
This approach tends to give a selectivity trend opposite compared to the one observed in “outer-
sphere” (C(sp2)-H>primary>secondary>tertiary). This can be partially explained by looking at 
the basicity of the C-H bond to activate23. In fact, transition metal-catalyzed C(sp2)-H bonds 
activations are generally favored over C(sp3)-H bonds which is in agreement with the higher 
acidity of aromatic and vinyl protons over aliphatic protons. On the other hand, alkanes do not 
contain p-electrons allowing p-metal pre-coordination lowering the energy barrier for C−H 
activation. These combined effects tend to make transition metal-catalyzed C(sp3)-H activation 
a more challenging process24. 
3.2. Metalation step 
Despite these obstacles, C(sp3)-H functionalization can be facilitated by pre-complexation 
strategies. This means that the substrate coordinates to the metal complex prior to the C-H bond 
breaking event. Indeed, the substrate becomes ligand of the metal, which will modulate their 
reactivity. Furthermore, it brings the transition metal in close proximity to the targeted C-H 
bond, thus enhancing selectivity and lowering the activation barrier triggerring the 
intramolecular C-H activation. First, such coordinations is possible using Lewis basic directing 
groups such as heteroatoms or unsaturated bonds (mainly L-type ligand) (Scheme 9 a.). On the 
other hand, oxidative addition of a carbon-leaving group such as halides (I, Br or Cl) or pseudo-
halides (OTf) (X-type ligand) to a low valent metal can be used (Scheme 9 b.)24a. 
 
Scheme 9 :Complexation strategies to trigger aliphatic C-H activation 
Baudoin’s group research focuses mainly on Oxidative-Addition-Initiated C(sp3)-H activation. 
The next chapters will be devoted to this research area.  
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4. Oxidative-Addition-Initiated C(sp3)-H Activation 
4.1.  Early examples and inspiration 
In 1992, Dyker reported a new domino coupling reaction based on the palladium-catalyzed C-
H activation of methoxy groups, which was then extended to the activation of tert-butyl groups. 
In both cases, these intramolecular processes led to a simple synthesis of substituted 
dibenzopyrans25 and benzocyclobutenes26 (BCB) based on self-condensation of two or three 
aryl iodides (Scheme 10).  
  
Scheme 10 : Synthesis of annelated rings by intramolecular C(sp3)-H activation 
Mechanistically, the catalytic cycle starts with an oxidative addition to 1.35 followed by the 
intramolecular C(sp3)-H activation of the proximal methoxy group to afford the five-membered 
palladacycle 1.36 (Scheme 11). This complex reacts with another equivalent of aryl iodide 
leading to 1.37. Based on previous observations27, this procedure was first reported by Dyker 
as a PdII-PdIV-PdII process. Theoretical studies by Echavarren & Cardenas tend to indicate that 
this arylation step go through a bimetallic PdII mechanism28. Finally, intermediate 1.37 is 
subjected to an intramolecular C(sp2)-H arylation giving, after reductive elimination, 
dibenzopyran 1.39.  
As an extension, Dyker thought to use palladacycle intermediates 1.29, 1.32 or 1.36 wisely. 
Indeed, he intercepted these palladacycle species with bromoalkenes to develop a new approach 
for the synthesis of substituted indenes26 (Scheme 12 a.) and benzofurans29 (Scheme 12 b.), 
thus highlighting the synthetic opportunity for organic chemists to consider palladacycles also 
as reactive intermediates30. 
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Scheme 11 : Proposed mechanism for the formation of dibenzopyrans  
 
 
Scheme 12 : Interception of palladacycle intermediates 
Even though a lack of control on the reaction course was observed in this ligandless palladium 
catalysis, these results represent a formidable proof-of-concept for palladium-catalyzed C(sp3)-
H activation leading to advanced structures in a limited number of steps. These landmark results 
are a defining moment for the future development of palladium-catalyzed C(sp3)-H activation.  
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4.2. Generalization of Palladium-catalyzed C(sp3)-H activation 
4.2.1. Initial results  
Based on the previous examples described by Dyker, Baudoin and coworkers reported the first 
example of Pd(0)/ligand-catalyzed intramolecular C(sp3)-H arylation31. Thanks to the use of 
suitable ligands, they avoided condensation and cross-coupling by-products starting from the 
same aryl halides than Dyker. Furthermore, depending on the benzylic gem-Dialkyl 
substitutions of starting material 1.42, two different classes of products were obtained. Indeed, 
using the same catalytic system based on Pd(OAc)2, potassium carbonate and the sterically 
demanding tri-o-tolylphosphine (TOTP) ligand, both olefins 1.43 and BCB 1.44 were obtained 
in good yield (Scheme 14 a.). After further studies, they found out that two distinct phosphines 
could favor each reaction pathway. First, they designed an electron-deficient triarylphosphine 
ligand (tri(5-fluoro-2-methylphenyl)phosphine : F-TOTP) which provides higher efficiency 
(reaction operates at 100°C instead of 150°C), selectivity, notably for the disubstituted olefins 
(i.e. TOTP 81:19; F-TOTP 93:7 1.43a:1.43b) and reactivity for hindered substrates (i.e. access 
to cyclic olefins 1.43c) and nitriles derivatives (Scheme 13 b.)32. On the other hand, they 
discovered that PtBu3 ligand allows a higher efficiency and a broader scope for the synthesis of 
BCB as well as the use of aryl chlorides as starting materials33. 
 
Scheme 13 : Initials results for Pd(0)/Ligand−Catalyzed Intramolecular C(sp3)−H Activation   
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4.2.2. Mechanistic insights 
Since the development of transition-metal-catalyzed C(sp2)-H activation for the synthesis of 
biaryls, numerous mechanisms have been proposed such as carbopalladation (Heck-type), 
electrophilic aromatic substitution or s-bond metathesis34. Thanks to experimental and 
computational studies by Davies & MacGregor35 and Echavarren & Maseras36 on the C(sp2)-H 
activation, such mechanisms have been excluded. Instead, they described the concerted 
metalation deprotonation (CMD) mechanism37. Then, the groups of Fagnou38 and Baudoin33a, 
39 have corroborated that this CMD mechanism is also involved in the activation of C(sp3)-H 
bonds. The accepted catalytic cycle for this transformation starts with the oxidative addition of 
a monoligated Pd(0) complex into the carbon-halide or pseudohalide bond of 1.45. Ligand 
exchange with a base such as carboxylate or carbonate then generates electrophilic Pd(II) 
species 1.46. Depending on the substitution pattern of the precursors of C-H activation, different 
scaffolds can be built. After the C-H activation step, 5- 1.47, 6-1.48 or rarely 7-membered 
palladacycles were obtained which after decoordination of the base and reductive elimination, 
generally generate cyclized products such as 1.49-1.50. On the other hand, olefins can be 
obtained via proton transfer of 1.47 leading to intermediate 1.51, which then undergoes base-
mediated b-hydride elimination to afford olefins 1.52 (Scheme 14). 
 
Scheme 14 : General mechanism of C(sp3)-H activation for the synthesis of carbocycles and olefins 
Mechanistically, different pathways for the C(sp3)-H activation step were studied via DFT 
calculations39-40. In 2008, Baudoin & Clot described a complete investigation of the whole 
mechanism with different ligands and bases for the formation of BCB.  
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Thanks to preliminary experimental observations, notably a significant kinetic isotope effect 
(KIE), they were able to fine-tune their study. Notably, they excluded the results computed for 
PMe3 instead of P(t-Bu)3 or for AcO- and HCO3- instead of CO32- which show energy profiles 
in disagreement with experimental observations (rate-limiting step associated to C-Br oxidative 
addition). Using the experimental ligand and base system for the BCB formation (i.e. bulky P(t-
Bu)3 and carbonate base) in the calculations, they were able to locate three plausible transition 
states. Whereas the transition state (TS) for an intermolecular proton abstraction was eliminated 
due to high activation barrier, which can be imputed to the high entropic cost, two TSs 
corresponding to an intramolecular proton abstraction seemed to be promising. Cis-activation 
mode proposed by Fagnou & Gorelsky was calculated and occurs via a more stable precomplex 
1.54 due to favorable k2-carbonate coordination. This strong coordination has a significant 
impact on the energy required to reach the transition state 1.55 (37.9 kcal/mol). On the other 
hand, trans-activation mode proposed by Baudoin & Clot led to the less stable k1-precomplex 
1.57. Interestingly, compared to 1.54, agostic interaction was observed in the precomplex 1.57 
which enhances the protic character of the geminal proton. Thanks to this interaction and k1-
precomplex coordination, a lower activation barrier is required to reach transition state 1.58. 
Interestingly, the C-H bond cleaved in this mode is the geminal proton and not the agostic one. 
Whereas for the BCB 1.60 synthesis, trans-coordination mode seems to be the most adequate, 
both pathways should be considered in mechanistic studies regarding other substrates (Scheme 
15). 
 
Scheme 15 : Plausible mechanism for the formation of BCB (B3PW91(DMF))  
29 
 
Thanks to these computational studies and experimental data, a selectivity guideline for the 
Pd(0)-catalyzed intramolecular C(sp3)-H activation can be proposed. This selectivity trend is 
dominated by several factors. Nevertheless, the size of the palladacycle formed after C-H 
activation (5-membered>6-membered>>7-membered) as well as the acidity of the cleaved C-
H bond (benzylic>aromatic>cyclopropyl>methyl>methylene>methine) are predominant. Other 
considerations such as steric environment, stability and ring-strain of the product as well as 
reaction conditions can influence the reaction course. A compromise between all these factors 
has to be considered when designing new substrates to prevent side-reactions. 
4.2.3. Intramolecular activation of unactivated C(sp3)-H bonds 
Inspired by initial works (Scheme 13) and interested by the synthetic potential of such C-H 
bonds functionalization, some research groups turned their attention to the generalization of the 
intramolecular activation of unactivated C(sp3)-H bonds leading to molecular complexity in a 
step- and atom-economic fashion. Broad varieties of ring systems were accessed and literature 
in this field is chronologically summarized below (Scheme 16). They are mainly based on 5-
membered ring systems (1.61 to 1.70) except 1.7141, which also allows direct access to N-H 
lactams thanks to the use of non protected precursors (Scheme 16).  
 
Scheme 16 : Scope of the Pd(0)-Catalyzed C(sp3)-H arylation of unactivated C-H bonds 
Fused carbacycles such as indanes 1.6132, 33b, indanones 1.6433b, indanols 1.6942, indanamines 
1.7042 and fused heterocycles such as dihydrobenzofurans 1.6233b, indolines 1.6333b, 43, 
benzolactams 1.6544 and benzosultams 1.6644 were accessed in high yield and selectivity for   
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methyl C-H bonds. Interestingly, scarce methylene activation was observed in the synthesis of 
indolines 1.6343. Attractive tricyclic compounds 1.6745 were also built via double C(sp3)-H 
activation or starting from bicyclic precursors 1.6846. Selective C(sp3)-H activation in a to 
heteroatoms was also observed in the synthesis of benzolactams 1.6544 and benzosultams 
1.6644. 
4.2.4. Intramolecular activation of more activated C(sp3)-H bonds 
Pd(0)-catalyzed intramolecular activation of more activated C(sp3)-H bonds was also exploited. 
Several examples were described and can be subdivided based on the type of oxidative addition 
involved. Firstly, classical O.A into aryl-halides leads to C(sp3)-H arylated compounds 
(Scheme 17 a.). Knochel and coworkers initially took advantage of benzylic positions to yield 
indoles 1.72 and isoquinolines 1.73 derivatives in high yield47. Later, Cramer and Charette 
developed syntheses of spiroindolines 1.7448 and spirooxindoles 1.7549 via C(sp3)-H activation 
of methine bonds. By contrast, O.A can take place into non-aromatic C(sp2)-halides bonds as 
already described in cross-coupling reactions. In 2012, Takemoto and coworkers achieved  the 
synthesis of various oxindoles using the C(sp3)-H carbamoylation of benzylic bonds 1.7650 and 
have further extended this methodology to methine bonds, thus furnishing a new route to spiro-
oxindoles 1.7751. Following this work, the same group reported an efficient synthesis of 
indoloquinazolinones 1.78 via the activation of chloroquinazolinones52. Using the same idea of 
non-classical oxidative addition, Cramer and coworkers described the synthesis of valuable 
perfluoroalkylated indoles based on the C(sp3)-H imidoylation of benzylic C-H bonds 1.7953. 
Finally, Charette recently reported a method to access cyclopropyl-fused azacycles through 
C(sp3)-H alkenylation 1.8054 (Scheme 17).  
 
Scheme 17 : Scope of the Pd(0)-Catalyzed intramolecular C(sp3)-H arylation of activated C-H bonds  
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4.2.5. Enantioselective intramolecular C(sp3)-H bonds activation 
In most biological compounds, homochirality is observed inducing high levels of chemical 
chirality in living systems. This structural complexity often leads to different behaviours among 
various enantiomers, notably in drug effectiveness (e.g. Thalidomide drama). Therefore, 
development of asymmetric synthesis is of great interest for the pharmaceutical as well as the 
agrochemical and fragrance industries. In intramolecular C(sp3)-H bond activation, two main 
strategies were used to discriminate enantiotopic alkyl groups. Thanks to experimental and 
computational studies, it is well accepted that the CMD process involving an ancillary ligand 
and a base is the enantiodetermining step. Taking advantage of a chiral ligand and/or a chiral 
base, enantioenriched compounds can be obtained (Scheme 18). 
 
Scheme 18 : Two main strategies for enantioselective C(sp3)-H activation 
These two strategies were successfully applied to the synthesis of highly enantioenriched 
(fused)indolines 1.63 which are important scaffolds among natural products and active 
pharmaceutical ingredients (API) (Scheme 19)55. In 2011, Kündig and coworkers reported the 
first enantioselective Pd(0)-catalyzed C(sp3)-H activation using C2-symmetric N-heterocyclic 
carbenes (NHCs)56. Moving to chiral phosphine ligands, Kagan57 and Cramer58 could reach 
similar enantiomeric ratio. In these latter reports, they interestingly showed that it could be 
possible to discriminate enantiotopic alkyls groups using chiral bases, however with moderate 
e.r. and reactivity. In 2016, Baudoin and coworkers described the first highly enantioselective 
Pd(0)-catalyzed C(sp3)-H activation involving a binol-derived chiral base and an achiral 
ligand59 (Scheme 19). 
 
Scheme 19 : Synthesis of chiral indolines  
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Simultaneously to the work based on chiral ligands for the synthesis of enantioenriched 
indolines, Baudoin reported a highly diastereoselective and moderately enantioselective 
synthesis of fused cyclopentanes60 1.61 (Scheme 16) using binepine-type ligands. Thanks to 
further improvements on the ligand structure and reaction conditions, high d.r. and e.r. were 
achieved, leading to fused cyclopentanes with two or three contiguous stereocenters61. 
On the other hand, applications of the intramolecular activation of more activated C(sp3)-H 
bonds in an enantioselective fashion was also explored by Cramer. Using TADDOL-type 
ligands such as phosporamidites or phosphonites to discriminate benzylic or cyclopropane C-
H bonds62, they provided efficient enantioselective syntheses of chiral tetrahydroquinolines63, 
chiral dihydroquinolones and dihydroisoquinolones64, chiral b-lactams65 and cyclopropane-
fused g-lactams66. 
4.2.6. Extension to intramolecular C(sp3)-H alkenylation 
Until 2012 and still today, methodologies using C(sp3)-H activation were mostly restricted to 
the use of aryl halides or triflates that led, after C-H activation, to fused benzocycles. With this 
in mind, Baudoin and coworkers hypothesized that it could be possible to move from C-H 
arylation to C-H alkenylation (Scheme 20 a.). Starting from bromoalkenes, this could lead to 
interesting sp3-rich compounds. With the optimal bromoalkene substrate 1.81 in hand, they 
developed a unique route to hexahydroindole compounds 1.82 by C(sp3)-H alkenylation 
(Scheme 20 b.)67. More details on this strategy are provided in paragraph 1 of Chapter 2 and 
paragraph 1.1 of Chapter 3. 
 
Scheme 20 : First general Pd(0)-catalyzed intramolecular C(sp3)-H alkenylation 
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4.2.7. Applications of C(sp3)-H activation to the total synthesis of natural products 
In organic synthesis, the decisive testimony of value is synthetic utility. Despite significant 
developments, applications of oxidative-addition-initiated activation of unactivated C(sp3)-H 
bonds for the total synthesis of natural products or API remain scarce. Nevertheless, the group 
of Baudoin reported pioneering examples. 
In 2007, they achieved the total synthesis of Verapamil, a calcium-channel blocker. Taking 
advantage of the newly designed F-TOTP phosphine allowing dehydrogenation under milder 
conditions, they obtained the product 1.84 in high yield and selectivity (ethyl vs. i-Pr) starting 
from the readily available compound 1.83. After optimization of a three-step sequence 
including notably a ruthenium-catalyzed hydroamidation leading to 1.85, they successfully 
obtained Verapamil in good overall yield (Scheme 21)32. 
 
Scheme 21 : Total synthesis of verapamil 
In 2009, the same research group described a new synthesis of 3,4-dihydroisoquinolines 
(DHIQ) based on two pivotal C-H activations and pericyclic reactions68. Thanks to the 
previously reported BCB synthesis (Scheme 13), they obtained in high yield the BCB 1.87, 
which after hydrolysis followed by a Curtius rearrangement yielded the amine 1.88. Then, after 
condensation with the appropriate aldehyde, they triggered, under thermal activation, an 
electrocyclic ring-opening/6p-electrocyclization furnishing the DHIQ 1.89. Finally, a three-
step sequence allowed the total synthesis of the tetrahydroprotoberberine alkaloid (±)-
coralydine in good overall yield (Scheme 22).  In addition, thanks to a collaboration with Servier, 
they showed that the synthesis of BCB via C-H activation could be applied to the synthesis of 
the cardiotonic drug Ivabradine. 
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Scheme 22 : Total synthesis of (±)-coralydine  
On the other hand, applications of intramolecular activation of more activated C(sp3)-H bonds 
was also developed by Takemoto69 and Cramer64.  
4.2.8. Research aim and work described in this thesis 
In the last decade, the transition metal-catalyzed intramolecular activation of unactivated C-H 
bonds has emerged as a powerful method to transform otherwise inert entities. Within this field, 
we recently developed a straightforward access to hexahydroindoles by intramolecular C(sp3)-
H alkenylation starting from bromoalkenes (Scheme 20). 
In this thesis, we will first report the use of this intramolecular C(sp3)-H alkenylation in 
combination with a directed C(sp3)-H arylation to achieve a divergent synthesis of aeruginosins.   
In a second part, based on this intramolecular C(sp3)-H alkenylation, we will report the 
development of a modular C(sp3)-H alkenylation leading to g-lactams, which are prevalent 
scaffolds found in numerous bioactive natural molecules. 
Finally, a highly efficient synthesis of b-lactams by palladium(0)-catalyzed-C(sp3)-H 
carbamoylation, will be described. These latter are valuable compounds widely used in 
pharmaceutical chemistry   
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1. Initials work 
As mentioned in paragraph 4.2.6 of Chapter 1, Baudoin and coworkers have established a new 
route to hexahydroindoles based on intramolecular C(sp3)–H alkenylation67. During this study, 
an interesting diastereodivergent behaviour was observed. Indeed, 2.1 gave an undesired 
mixture of olefin by-products 2.2 arising from C-H activation followed by b-hydride 
elimination, whereas 2.3 furnished the desired cis-configured cyclized product 2.4 with a 
remarkable site-selectivity even in the presence of benzylic and C(sp2)-H bonds. Such 
regiodivergent behaviour was already observed by Kündig in enantioselective C(sp3)-H 
arylation70 and results mainly from steric/conformational aspects and ligand effect. 
Interestingly, product 2.4 arising from syn-precursor 2.3 provided the desired cis-configuration 
observed in aeruginosins (red arrow). Furthermore, hydrogenation of these indoles 1.82-2.4 
allows to obtain cis-octahydroindoles 2.5 which are typical moieties that can be found in the 
aeruginosin marine natural products. We thus envisioned to apply this methodology to the 
synthesis of this family of natural products (Scheme 23). 
 
Scheme 23 : Diastereodivergent synthesis of hexahydroindoles – Road to aeruginosins 
2. Aeruginosins marine natural products 
2.1. Introduction 
In 1994, Murakami and coworkers reported the isolation of aeruginosin 298A from the toxic 
blue algae Microcystis aeruginosa. This was the first compound of a new family of linear 
peptides71. This family currently contains more than sixty different congeners isolated from 
sponges or cyanobacterial sources72. These congeners are structurally close to the structure of 
aeruginosin 298A depicted in Figure 2, but present some variations such as alteration of the 2-  
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carboxy-6-hydroxyoctahydroindole (Choi) moiety (dysinosin A), a halogenated 
hydroxyphenyllactic acid (HPLA) residue (aeruginosin 98A; Scheme 24), an additional 
carbohydrate moiety (aeruginosin 828A)… Moreover, among those of them which were 
biologically tested, inhibition against serine proteases, which are involved in the blood 
coagulation cascade, was observed73. 
 
Figure 2 : Structural variety of aeruginosin congeners 
Since the first isolation by Murakami and full-characterization using X-ray crystallography by 
Tulinsky74, numerous groups investigated the total synthesis of these marine natural products. 
Two main disconnections were established to allow the synthesis of the L-Choi core. First, 
Bonjoch75 and Wipf76 described an intramolecular Michael-type addition strategy employing 
L-tyrosine in a reductive or oxidative process to build the C7a-N bond. Notably, completion of 
the total synthesis of aeruginosins 298A by Bonjoch has permitted a structural revision with re-
assignment of the Leu- amide subunit (from L- to D-Leu). For their part, Shibasaki77 and 
coworkers have used a catalytic asymmetric phase-transfer alkylation of a glycine derivative. 
In all these cases, mixture of diastereoisomers were obtained requiring additional 
thermodynamic equilibration to obtain reasonable yield of the desired configuration of the Choi 
unit. In contrast, methodologies used by Trost78 or Carreira79 allow a direct access to the 
required configuration of the octahydroindole. On the other hand, Hanessian and coworkers80 
have developed an aza-Prins bromocarbocyclization which leads to the bicyclic system through 
the formation of the C7-C7a bond (Figure 3). 
 
Figure 3 : Previous disconnections for the synthesis of the L-Choi core 
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3. Total synthesis of Aeruginosins 298A, 98A, 98B and 98C. 
3.1. Goal of this project and retrosynthetic analysis 
The goal of this study was to develop a general approach for the synthesis of various 
aeruginosins as well as suggesting new disconnections based on methodologies relying on 
metal-catalyzed C-H activation. The following retrosynthetic plan was considered for the 
synthesis of these aeruginosins. The use of three classical peptide couplings would give us 
access to compounds 2.6 to 2.9. Then, we envisioned to obtain the L-Choi core 2.6 in a 
straightforward and scalable manner through our recently developed intramolecular C(sp3)-H 
alkenylation67 shown previously in (Scheme 23). In addition, an intermolecular C-H arylation 
starting from 2.13 and 2.14 would lead to the HPLA fragment 2.9 in an efficient manner81. 
Finally, the C-H activation precursors 2.10-2.13 would be easily prepared from the readily 
available starting materials 2.11-2.12-2.15 (Scheme 24). 
 
Scheme 24 : Retrosynthetic analysis 
3.2. Synthesis of the Choi core 
3.2.1. Initial mechanistic study 
After having considered different ways to obtain the enantiomerically pure precursor of C-H 
activation 2.10 with the desired trans-relationship, we hypothesized that we could take 
advantage of the intrinsic reactivity of easily accessible gem-dihalocyclopropanes to provide a 
short and efficient access to 2.1082. Indeed, gem-dihalocyclopropanes are readily available via   
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the mild addition of a dihalocarbene83 to the corresponding alkenes and are useful building-
blocks for the preparation of valuable substituted hydrocarbon systems. Offering new 
retrosynthetic possibilities, these precursors were widely used in the total synthesis of 
alkaloids84. Notably, such gem-dihalocyclopropane intermediates are prone to electrocyclic 
ring-opening under thermal or silver-promoted conditions generating the corresponding p-
allylic cation, which can be trapped inter- or intramolecularly by various nucleophiles. Starting 
from the protected cyclopent-3-enol 2.16, we envisioned a three-step sequence involving 
dibromocyclopropanation followed by electrocyclic ring-opening and nucleophilic substitution 
to reach in an efficient manner the desired trans-product 2.18 despite possible 
diastereoselectivity issues. Indeed, Banwell and coworkers, during their total synthesis of the 
crimine alkaloid hamayne, have reported the cis-diastereoselective synthesis of the product 
2.19a using a similar sequence with nucleophilic substitution with sodium azide85. Starting 
from a 6:1 diastereoisomeric ratio of 2.17a, they have obtained product 2.19a with a 
diastereoselectivity of 9:1, thereby indicating a SN1-type mechanism. Interestingly, this cis-
configuration was not expected considering the steric hindrance of the TBS-group, thereby that 
the stereoselectivity of this reaction is controlled by stereoelectronic effects. Nevertheless, we 
surmised that stereoselectivity could be mainly controlled by steric effects when using a bulkier 
alaninol-derived nucleophile and hydroxy-protecting group (Scheme 25). 
 
Scheme 25 : Synthetic plan of precursor 
In order to test our hypothesis, we studied both the influence of the nucleophile and of the 
protecting group on the diastereoselectivity. Thanks to a four-step sequence, we have efficiently 
prepared two racemic silyl-protected dibromocyclohexenols 2.17a-2.17b with a 
diastereoisomeric ratio of 6:1. To conduct this study, we submitted dibromocyclohexenols 
2.17a-2.17b to nucleophilic substitution with azide and primary amines. First, in contrast to the 
cis-selectivity observed with azide as nucleophile (entry 1), primary amines (entries 2-4) led to 
an inversion of diastereoselectivity in favour of the trans product 2.18. Interestingly, even the 
use of the non-sterically demanding N-propyl amine resulted in significant inversion (entry 2), 
thereby supporting a stereoselective control by stereoelectronic and steric effects.  
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Indeed, more-hindered a-substituted amines increased significantly the diastereoselectivity 
(entries 2-4 and 6-8). Moreover, high influence of the silyl protecting group was observed for 
each considered nucleophile. Particularly, the bulkier TBDPS group of 2.17b has considerable 
impact (two-fold higher) compared to the TBS group of 2.17a on the diastereomeric ratio for 
both cis and trans isomers 2.18-2.19 (entries 5-8 vs. 1-4). This preliminary study allowed us to 
access both cis and trans diastereoisomers of 5-aminocyclohex-3-en-1-ols in high d.r. 
depending on the nucleophiles and protecting groups used. Nevertheless, it could be interesting 
to try various other nucleophiles to get a better understanding of the factors controlling these 
opposite selectivities (Table 1).  
 
 
 
 
 
 
 
 
 
Figure 4 : X-ray structures of major diastereoisomers  
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Table 1 : Study of the allylic nucleophilic substitution 
 
Entry R Nucleophile (Nu) d.r.b 
1 
TBS 
N3– 1 : 8 
2 n-PrNH2c 3 : 1 
3 i-BuNH2c 3 : 1 
4 i-PrNH2c 6 : 1 
5 
TBDPS 
N3– 1 : 15 
6 n-PrNH2c 7 : 1 
7 i-BuNH2c 8 : 1 
8 i-PrNH2c 11 : 1 
 
aTBDPS = tert-butyldiphenylsilyl; TEBAC = Et3BnNCl. b Ratio of 2.18:2.19 
determined by 1H NMR of the crude reaction mixture. Relative 
configurations of the major diastereoisomers obtained with sodium azide and 
isopropylamine were determined by X-ray analysis of ferrocene derivatives 
2.21-2.21’ (Figure 4). For other primary amines, the trans configuration was 
ascribed to major diastereoisomers by analogy of their chemical shifts in 1H 
NMR. c In combination with 1.1 equiv. K2CO3. 
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3.2.2. Scale-up synthesis of the precursors of C(sp3)-H activation 
Starting from 1,6-heptane-dien-3-ol 2.11, we have conducted the protection of the hydroxy 
function with the bulky TBDPS silyl group followed by olefin metathesis to afford 2.16 in 
quantitative yield. Of note, the use of Grubbs I catalyst at room temperature proved to be crucial 
to avoid polymerized by-products. Under modified Makosza’s conditions83, gem-
dibromocyclopropane 2.22 was obtained quantitatively in an undetermined mixture of trans/cis 
products due to complicated NMR interpretation. Taking advantage of work reported by 
Fleming and Thomas86, where they described that the reaction proceeded via a stereospecific 
rearrangement of the gem-dichlorocyclopropane to the allyl chloride, we assume that the 
trans:cis ratio of 2.22 should be close to 6:1 (in favor of the trans isomer) due to the ratio for 
compound 2.17b. This latter was obtained by the thermal electrocylic ring-opening of 2.22, as 
an inconsequential 6:1 mixture of diastereoisomers in high yield. Subsequent nucleophilic 
substitution of TBS-protected L-alanilol 2.23 with dibromocyclohexenol 2.17b furnished a 1:1 
mixture of two diastereoisomers 2.24a-2.24b both possessing the required trans relationship at 
the cyclohexene ring. This outcome can be explained by the formation of the expected 
symmetrical allyl cation arising from the SN1-type mechanism, which can be attacked by the 
nucleophile 2.23 unselectively on both electrophilic positions, opposite to the sterically-
demanding OTBDPS group. Gratifyingly, desired diastereoisomer 2.24a was easily isolated by 
flash column chromatography and protected as a trifluoroacetamide. At this stage, 
intermolecular asymmetric allylic alkylation was also tried using classical conditions and chiral 
ligands, introduced by Trost and coworkers87, to obtain 2.24a in enantiomerically pure form 
starting from 2.17b and derivatives, without success (Scheme 26).  
 
Scheme 26 : Multi-gram scale synthesis of precursor of C(sp3)-H activation  
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Despite the loss of 50% of the material through the production of the undesired diastereoisomer 
2.24b, this synthetic strategy has proved to be highly efficient allowing the production of 8g of 
bromocyclohexene 2.10 in 33% overall yield over 6 steps (83% average yield per step). 
3.2.3. Palladium-catalyzed intramolecular C(sp3)-H activation 
Then, we investigated the key intramolecular C(sp3)-H alkenylation step. Using previously 
reported conditions as starting point, we were pleased to find that the desired product 2.25 was 
obtained in 45% yield with concomitant debrominated and mixture of olefin by-products (entry 
1). Thanks to palladium sources and ligands screening, we established that a combination of 
the well-defined palladium complex (Pd(PCy3)2) with potassium pivalate as active base in 
toluene at 120°C furnished the bicyclic system 2.25 with good yield (Table 2).  
Table 2 : Selected conditions of the optimization 
 
a NMR yield, determined by 1H NMR using trichloroethylene as an internal 
standard. b Using 5 mol% of Pd(PCy3)2. 
Then, we gradually scaled up the reaction allowing the preparation of almost 5g of the 
hexahydroindole moiety in a reproducible manner. Furthermore, the absolute configuration of 
the bicyclic product was confirmed by NMR and X-ray analysis (Scheme 27).  
 
Scheme 27 : Scale-up of the C(sp3)-H alkenylation  
Entry [Pd] Ligand Base T °C Yield %a 
1 Pd(OAc)2 PCy3•HBF4 Rb2CO3 120 45 
3 Pd2dba3 PCy3•HBF4 Rb2CO3 120 45 
2 Pd(PPh3)4 – Rb2CO3 120 32 
4 Pd(PCy3)2 – Rb2CO3 120 75 
5 Pd(PCy3)2 – Rb2CO3 110 70 
6 Pd(PCy3)2 – Rb2CO3 100 18 
7 Pd(PCy3)2 – Cs2CO3 120 40 
8 Pd(PCy3)2 – K2CO3 120 85 
9b Pd(PCy3)2 – K2CO3 120 50 
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3.2.4. Hydrogenation of the hexahydroindole system 
With the hexahydroindole compound 2.25 in our hand, we studied the reduction of the 
trisubstituted alkene to access the octahydroindole moiety 2.26 using either homogeneous or 
heterogeneous catalysis. First, both the homogeneous Wilkinson’s catalyst and the more 
reactive cationic Crabtree’s catalyst were totally inefficient (entries 1-2). We next turned our 
attention to heterogenous catalysts such as Adam’s or Pearlman’s catalyst which already proved 
to be efficient on simplified hexahydroindole scaffolds (entries 3-4)67. Unfortunately, no 
conversion was observed on the more advanced intermediate 2.25. Finally, we were pleased to 
find complete reactivity with rhodium on activated charcoal. Interestingly, diastereoselectivity 
of the reduction of this trisubstituted alkene was affected by the hydrogen pressure. 
Gratifyingly, this latter was maximal with one atmosphere of hydrogen (entry 7), whereas a 
decreased d.r. was observed when a higher pressure was applied (entry 8-10). Importantly, the 
complete diastereocontrol of the reduction was observed on the convex face (induced by the 
angular carbon) of the hexahydroindole 2.25. The desired cis-configuration was confirmed by 
2D-NOESY NMR and by X-ray analysis (Table 3). 
Table 3 : Optimization of the hydrogenation of 2.25 
 
a NMR yield, determined by 1H NMR using trichloroethylene as an internal standard. 
 
3.2.5. Completion of the synthesis of the Choi core 
During the scale-up of the hydrogenation reaction furnishing the octahydroindole 2.26 
concomitant removal of the TBS group was observed. This could be imputed to residual acidity 
of the rhodium catalyst. We thus thought to carry out a one-pot sequential 
hydrogenation/selective deprotection of the primary silyl group under acidic conditions. After 
optimization, we found out that 0.5% HCl in MeOH allowed to obtain 2.27 in almost 
quantitative yield over two steps. Finally, after optimization of a three-step sequence involving 
Jones oxidation (using freshly prepared Jones reagent), esterification using a diazomethane   
Entry catalyst solvent PH2 (bar) 
Conv. 
(%) a d.r.
a 
1 RhCl(PPh3)3 EtOAc 1 – – 
2 [Ir(COD)(C5H5N)(PCy3)]PF6 EtOAc 1 – – 
3 Pd(OH)2/C THF 1 – – 
4 PtO2 MeOH 1 < 10 – 
5 Ru/Al2O3 EtOAc 1 < 10 – 
6 Ru/C EtOAc 1 < 10 – 
7 Rh/C EtOAc 1 100 >20:1 
8 Rh/C EtOAc 3 100 10:1 
9 Rh/C EtOAc 10 100 8:1 
10 Rh/C EtOAc 20 100 6:1 
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equivalent and reductive cleavage of the N-trifluoroacetyl group allowed us to obtain more than 
1 g of the amino-ester 2.6 in good overall yield. Moreover, thanks to a two-steps sequence 
involving mixed carbonic anhydride approach to activate the carboxylic acid, which then reacts 
with ammonia before a reductive cleavage, we obtained the Choi core 2.29 relevant to the total 
synthesis of the aeruginosin 298B (Scheme 28). 
  
Scheme 28 : Synthesis of Choi cores 2.6 and 2.29 
3.3. Synthesis of the C-termini 
We first turned our attention to 2.7a, which is relevant to the synthesis of aeruginosin 298A. 
Starting from the commercially available tert-butoxycarbonyl (Boc)-protected L-ornithine 2.30, 
we have prepared protected L-arginine 2.32 using diprotected triflylguanidine reagent88 2.31 
under basic conditions. The residual carboxylic acid was reduced under mild conditions89 using 
the mixed carbonic anhydride approach avoiding undesired deprotection of Boc or Cbz groups 
(Scheme 29).  
Scheme 29 : Synthesis of C-termini 
Then, a two-steps sequence involving TBS protection of the primary alcohol 2.33 under 
classical conditions and Boc deprotection in the presence of TMSOTf allowed to obtain the  
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L-argol fragment 2.7a in good overall yield (56% over 4 steps). In parallel, protected L-agmatine 
fragment 2.7b was yielded using the two-step sequence previously described by Trost and 
coworkers78. 
3.4. Synthesis of the HPLA fragment and south part 
In parallel to the synthesis of the Choi core and C-termini fragments, we envisioned the 
synthesis of the HPLA fragment via direct C-H activation. In 2005, Daugulis and coworkers 
established a new approach to yield b- and g-arylation of unactivated C(sp3)-H bonds, thanks 
to bidentate coordinating groups such as 8-aminoquinoline and picolinamide which allow to 
obtain a high level of regioselectivity and high reactivity due to precoordination to the metal 
center.81a, 81c. Based on PdII/PdIV catalysis90, this pioneering work served as an inspiration for 
numerous developments of bidentate directing groups91, methodologies92 and applications in 
total synthesis of natural products and API93. 
In this regard, we first considered Daugulis’ only example of Beta-arylation of lactic acid 
derivative 2.37 using 2-methylthioaniline as a directing group81b. However, under these 
conditions, an undesired loss of optical purity was observed (2.38). Consequently, we further 
optimize this transformation in order to reduce the erosion of this sensitive stereogenic center 
(Scheme 30). 
 
Scheme 30 : Initial result on lactic acid derivative 
At the outset of our study, only directing groups based on 8-aminoquinoline81c, 2-
methylthioaniline81b and 2-pyridinylisopropyl (PIP)94, introduced by Bing-Feng Shi, proved 
suitable to obtain b-arylation of unactivated C(sp3)-H bonds. To design our protecting group 
strategy, we have first considered previous total syntheses of aeruginosins as well as the 
directed arylation of the lactate moiety. In agreement with these considerations, benzyl group 
was chosen for the lactate moiety whereas triisopropylsilyl ether (TIPS) was selected for the 
phenol derivatives. Of note, selective monoarylation is known to be sometimes complicated to 
control via directed C-H arylation notably due to the formation of hardly separable polyarylated 
by-products. These different directing groups were tested under some selected conditions, and 
PIP group was selected because this latter allowed the transformation without racemization and   
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with the highest monoarylation yield. We then turned our attention to the optimization of both 
the synthesis of the precursor 2.13 and its following intermolecular C(sp3)-H arylation. Starting 
from readily available methyl D-lactate 2.15, a three-step sequence allowed the multigram 
synthesis of 2.13 in high overall yield (Scheme 31). 
 
Scheme 31 : Synthesis of C-H arylation precursor 2.13 
After screening of various parameters such as base, equivalents of aryl iodide 2.14a, solvent, 
temperature, concentration as well as catalyst loading, we identified potassium carbonate and 
acetronitrile as optimal base and solvent to maintain a good ratio between 2.40a and 2.13. 
Importantly, four equivalents of aryl iodide 2.14a were required to achieve acceptable yield of 
b-arylated product 2.40a (Table 4). 
Table 4 : Selected conditions for optimization of the intermolecular arylation 
 
a NMR yield, determined by 1H NMR using trichloroethylene as an internal standard. 
 
With the optimal conditions in our hands, we gradually scaled up the reaction allowing the 
preparation of 1.4 g of 2.40a in a reproducible manner. Furthermore, no erosion of the 
enantiomeric excess was observed (Scheme 32). 
  
Entry [Pd] (mol %) ArI ( equiv) Base Solvent Temp. Yield % 2.40a/2.13a 
1 Pd(OAc)2 (10) 2 K2CO3 t-amylOH 110°C 50/10 
2 Pd(OAc)2 (10) 2 K2CO3 DMF 110°C 0/67 
3 Pd(OAc)2 (10) 2 K2CO3 Toluene 110°C 12/66 
4 Pd(OAc)2 (10) 2 K2CO3 Dioxane 110°C 20/60 
5 Pd(OAc)2 (10) 2 K2CO3 MeCN 110°C 42/45 
6 Pd(OAc)2 (10) 4 K2CO3 MeCN 110°C 65/7 
7 Pd(OAc)2 (20) 4 K2CO3 MeCN 110°C 60/15 
8 Pd(OAc)2 (10) 4 K2CO3 MeCN 90°C 50/30 
9 Pd(OAc)2 (10) 4 K2CO3 MeCN 130°C 32/30 
10 Pd(OAc)2 (10) 4 Na2CO3 MeCN 110°C 3/75 
11 Pd(OAc)2 (10) 4 Rb2CO3 MeCN 110°C 35/41 
12 Pd(OAc)2 (10) 4 Cs2CO3 MeCN 110°C 0/90 
13 Pd(OAc)2 (10) 4 K3PO4 MeCN 110°C 58/20 
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Scheme 32 : Scale-up of the C(sp3)-H arylation 
While directing groups allow highly regioselective transformations due to metal 
precoordination, they also have some drawbacks. For instance, the directing group has to be 
pre-installated and this latter remains into the products. Consequently, we turned our attention 
to the removal of the PIP directing group from compound 2.40a. Cleavage of this latter was not 
so trivial. Several known conditions such as acidic cleavage, various amide activation followed 
by Evans’ hydrolysis95, as well as the three-step sequence used by Shi and coworkers94, 
involving initial nitrosation with NaNO2/AcOH/Ac2O failed to give the desired carboxylic acid. 
Only starting material was recovered in this case. Nevertheless, we tried to improve this initial 
nitrosation using more reactive NO+ sources such as t-BuONO and NOBF4. Unlike all others 
reactants, NOBF4 provided consumption of the starting material 2.40a. We considered literature 
elements using NOBF4 and were pleased to find that N-nitroamide intermediates were unstable 
and prompt to rearrangement96. A lot of efforts were devoted to optimize this process. Notably, 
the temperature, the amount of pyridine as well as the concentration were found to be critical 
to obtain a high yield. Gratifyingly, using 10 equiv. of NOBF4 in pyridine at -30°C, the PIP 
directing group could be cleaved under new and mild conditions for this deprotection relying 
on the rearrangement of the N-nitrosamide A into the diazoester B to provide the desired 
carboxylic acid 2.9a and propenyl pyridine 2.41 (Scheme 33). 
 
Scheme 33 : Development of new cleavage conditions for the PIP directing group 
With the required carboxylic acid 2.9a, we carried on the synthesis of the south-part of 
aeruginosins 298A using a classical peptidic coupling with D-leucine methyl ester 2.8a to obtain  
49 
 
 2.42. Unfortunately, the following hydrolysis led to concomitant and undesired cleavage of the 
TIPS protecting group (Scheme 34). 
 
Scheme 34 : Attempt to synthesize the southern part of aeruginosin 298A 
As a consequence, we focused our attention on protecting groups insensitive to saponification 
conditions and have chosen benzyl group which can be deprotected during the final 
hydrogenolysis. Gratifyingly, the two-step sequence involving the directed C-H arylation and 
the PIP deprotection was more efficient with this benzyl group and more than 1 gram of b-
arylated product 2.9b could be prepared without any loss in the optical purity. This higher 
overall yield can be explained by a partial degradation of the TIPS group under the reaction 
conditions employed. Moreover, halogenated HPLA fragments relevant to the total synthesis 
of aeruginosins 98A, 98C and 101 were synthetized in good overall yield using this versatile 
strategy (Scheme 35). 
 
Scheme 35 : New route to HPLA fragment synthesis 
At last, with the required HPLA fragments in our hands, each southern part was accessed using 
classical peptide coupling with the appropriate amino ester (Scheme 36). 
 
Scheme 36 : Synthesis of southern parts of aeruginosins  
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3.5. Fragment coupling and completion of the total synthesis 
3.5.1.  First strategies employed 
Our first strategy to complete these total syntheses consisted in coupling the Choi core with the 
C-termini fragments. In both cases, peptide couplings allowed to obtain in acceptable yield 2.44 
and 2.45 relevant to the total synthesis of aeruginosins 298A and 98B. We then tried to cleave 
the N-trifluoroacetyl group of 2.44. While solvolysis conditions (K2CO3/MeOH and 
NH3/MeOH) led to no conversion, reductive cleavage using sodium borohydride in methanol 
provided degradation of the guanidine moiety. In parallel, the deprotection of the TBDPS was 
also investigated. Unfortunately, various conditions using fluorides or acid conditions furnished 
a mixture of degradation by-products and starting material. On the other hand, removal of the 
TBDPS group of 2.6 before coupling the C-termini part or southern part proved to be 
problematic. Due to degradation, only moderate yield of 2.46 was observed by 1H NMR 
analysis. Thanks to these experiments, we have been able to deduce the most appropriate 
synthetic sequence for the completion of these total syntheses. Both the N-trifluoroacetyl and 
the TBDPS groups should be cleaved before the installation of the C-termini parts due to the 
sensitive guanidine fragment. This means that the southern part should be coupled first (Scheme 
37).  
 
Scheme 37 : First attempts for deprotection and coupling strategy 
3.5.1. Completion of total synthesis 
In accordance with the new roadmap, we first focused our attention to the total synthesis of 
aeruginosin 298A. Hydrolysis of 2.43b followed by peptidic coupling with the Choi core 2.6 
afforded 1.5 g of 2.47 as a mixture of two rotamers (trans:cis 85:15). This was confirmed by 
2D NMR experiments and was in agreement with previously reported analytical data.   
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Then, deprotection of the TBDPS protecting group followed by peptidic coupling with the L-
argol fragment provided almost 2 g of intermediate 2.48 in almost quantitative yield. 
Interestingly, in contrast to the previously mentioned deprotection issue, the corresponding 
free-alcohol was obtained in quantitative yield using Olah’s reagent (HF·pyridine). Finally, a 
two-steps sequence involving the acid-mediated cleavage of the residual TBS group followed 
by classical hydrogenolysis and treatment with trifluoroacetic acid furnished aeruginosin 298 
as a salt. Importantly, a 1:1 solvent mixture of MeOH and EtOAc was required during the 
hydrogenolysis to provide full conversion. This could be explained by solubility issues of the 
starting material and of partially deprotected intermediates. Of note, 0.7g of aeruginosin 298A 
was obtained in 8.2% overall yield (86% yield per step) over 17 steps (longest linear sequence), 
which are both unprecedented in terms of overall yield and scale97 (Scheme 38). 
  
Scheme 38 : Total synthesis of aeruginosin 298A 
Taking advantage of this accomplishment, we applied the same strategy to reach the 
intermediates 2.51a-c in high overall yield. The resulting free alcohol group was sulphated 
using conditions previously described by Trost and coworkers78 (SO3·pyridine complex) 
furnishing intermediates 2.52a-c in good yield. Thanks to hydrogenolysis used as above for 
2.49, total synthesis of aeruginosin 98B was completed in acceptable overall yield. 
Unfortunately, in the case of aeruginosin 98A and C, total concomitant dehalogenation was 
observed starting from 2.52b-c under the same conditions, thus leading to aeruginosin 98B. 
Such by-reactions are recurrent in total synthesis of naturals products or API due to sensitivity 
of carbon-halogen bonds.  
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 This issue can be overcome in some specific cases through an internal poisoning of the catalyst 
by the substrate98 or by using halides salts to suppress this overreduction99. Unfortunately, 
generalization of these processes is often inefficient and substrate-dependent. Albeit, more than 
four thousand halogenated natural products were isolated and they often present halogen-
dependant bioactivity100 such as the antibiotic activity of the well-known vancomycin which 
depends on its chlorine substituents which control the atropisomeric distribution101. Gademann 
and coworkers also observed a halogen-dependant bioactivity for aeruginosin 
chlorosulfopeptides102. Recently, Wu and coworkers have developed a new chemoselective 
ZnX2-modulated palladium- or platinum/C catalyst for the hydrogenolysis and hydrogenation 
of halogen-substituted nitroarenes, alkenes, benzyl ethers as well as aromatic ketones103. This 
methodology does not seem to suffer from any substrates-dependence. Moreover, it is a simple 
process readily applicable for industrial and academic chemists. Gratifyingly, after optimization 
of Wu’s conditions with model substrates, the use of a 1:1 mixture of palladium on charcoal 
and zinc bromide in acetonitrile, prevented dehydrohalogenation  and allowed the first total 
synthesis of aeruginosins 98A and 98C104. No dehalogenation occurred in the case of the 
aeruginosin 98A whereas a 1:1 ratio of aeruginosin 98C and aeruginosin 98B was observed, in 
the case of the brominated precursor 2.52c (Scheme 39). 
 
 
Scheme 39 : Total syntheses of aeruginosins 98A, 98B, and 98C 
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4. Conclusion 
Taking advantages of two recently reported C(sp3)-H bonds activation reactions, we have 
elaborated a new synthetic route to access aeruginosin marine natural products which exhibit 
biological activities.  
First, we turned our attention to the synthesis of the Choi core. After optimization of the 
synthesis of the precursor of C-H activation, we were able to apply our recently developed 
intramolecular C(sp3)-H alkenylation conditions for the large-scale synthesis of the Choi core 
which is common to numerous aeruginosins. 
On the other hand, a new synthetic approach, using an intermolecular C(sp3)-H activation, was 
used to obtain the HPLA fragment of different aeruginosins, highlighting the synthetic 
versatility of this methodology. It could be interesting to further extend the scope of this 
methodology to obtain unconventional HPLA fragments or other functionalities, which after 
completion of the synthesis, would lead to a library of aeruginosins analogues. 
Finally, with all the fragments in our hands and thanks to the optimization of the end-game 
including fine-tuning of the hydrogenolysis step, we have achieved the total synthesis of four 
aeruginosins including the first total synthesis of halogenated aeruginosins 98A and 98C. Of 
note, we were able to scale-up the synthesis of aeruginosin 298A to obtain this latter with an 
unprecedent yield and scale (Scheme 40). 
 
Scheme 40 : Overview of the total syntheses of aeruginosins 298A, 98A, 98B and 98C 
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 by Palladium(0)-Catalyzed C(sp3) Alkenylation 
  and  
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1. Introduction 
1.1. Historical development of intramolecular C(sp3)-H alkenylation 
As mentioned in paragraph 4.2.6 of Chapter 1, methodologies using C(sp3)-H activation were 
mostly restricted to the use of aryl halides or triflates that led, after C-H activation, to fused 
benzocycles. Until 2012, as for intramolecular C(sp3)-H arylation, no straightforward 
methodology using intramolecular C(sp3)-H alkenylation was developed. This disinterest may 
be explained by the fact that the corresponding substrates are less readily accessible than the 
aromatic ones and often require multistep syntheses. Moreover, compared to intramolecular 
C(sp3)-H arylation, by-reactions are more prone to occur due to  the presence of adjacent 
aliphatic protons, to insaturation and additional conformational aspects. Nevertheless, our 
group envisioned to explore such a,b or b,g vinyl halides as precursors of C-H activation paving 
the way for the synthesis of new sp3-rich scaffolds, reactivity studies as well as new 
disconnections in target-oriented total synthesis (Scheme 41). 
 
Scheme 41 : Formation of sp3-rich scaffolds by intramolecular C(sp3)-H alkenylation 
Initial work on this topic in our group was reported by Dr. Alice Renaudat in her Ph.D. thesis. 
By analogy to benzocyclobutenes33a, our group hypothesized that cyclobutenes and 
cyclobutanes could be obtained through C(sp3)-H alkenylation. Often obtained by [2+2] 
cycloaddition, electrocyclization, metal-catalyzed enyne cycloisomerization as well as enyne 
metathesis, such scaffolds are interesting due to their widespread representation in natural 
products (Figure 5)105 and the synthetic utility of such building blocks106. 
 
Figure 5 : Examples of natural products containing a cyclobutene/cyclobutane moiety 
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Thanks to lots of efforts devoted to the synthesis of precursors of C(sp3)-H alkenylation 3.1-
3.4, initial results for this new strategy were obtained. Unfortunately, both substrates 3.1 and 
3.4 mostly led to diene by-products 3.3 and 3.6. First, exocyclic diene product 3.3 arises from 
electrocyclic ring-opening of the desired cyclobutene 3.2. Afterwards, desired product 3.5 was 
observed by GC/MS analysis together with the endocyclic diene 3.6 arising from a C-H 
activation/palladium migration/b-hydride elimination sequence (Scheme 42). These results can 
be imputed to the high ring strain of the desired compounds. 
 
Scheme 42 : Initial attempts toward C(sp3)-H alkenylation  
Taking advantage of these information and considering Ohno’s synthesis of indolines43, our 
group developed a straightforward access to hexahydroindoles 1.81 by intramolecular C(sp3)-
H alkenylation67 (Chapter 1; paragraph 4.2.6) that we already applied to the total synthesis of 
aeruginosins97, 104 (Chapter 2) (Scheme 43). 
 
Scheme 43 : Initial results using C(sp3)-H alkenylation 
As an extension, we wondered if this concept could be as efficient in the case of acyclic 
bromoalkenes. Indeed, previously published work was limited to the formation of 
hexahydroindoles 1.82 containing a stereogenetic center in the precursor of C-H activation, 
thereby preventing the development of an enantioselective catalysis (Scheme 44). Such 
simplifications of the starting material represent an interesting entry to monocyclic products, 
which are prevalent scaffolds found in numerous bioactive natural molecules, through C-H 
activation. Indeed, all previous reported methodologies were limited to formation of bicyclic 
products (Chapter 1). 
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Scheme 44 : Move to acyclic precursors of C-H activation 
At the outset of this study, our group turned his attention to cyclobutanes 3.8 and pyrrolidines 
3.10 products as initial targets for our C-H activation strategy starting from the corresponding  
acyclic bromoalkenes 3.7107 and 3.9108. However, classical reaction conditions only led to the 
obtention of allene by-products in both cases (Scheme 45 a.), via a plausible intramolecular 
base assisted deprotonation mechanism109 (Scheme 45 b.). Interestingly, such by-reaction were 
not observed in the case of cyclic bromoalkene 1.81. This can be imputed to the disfavored 
formation of highly strained endocyclic allenes. 
 
Scheme 45 :Initial attempts for the formation of monocyclic compounds via C(sp3)-H alkenylation 
Thanks to all these considerations, we have designed bromoalkene 3.13 which prevents 
elimination side-reactions and would provide a rapid access to g-lactams derivatives (Scheme 
46). 
 
Scheme 46 : Design of new acyclic precursors of C-H activation  
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2. Development of a modular C(sp3)-H alkenylation 
2.1. Interest of a-alkylidene-g-lactams 
g-lactams are important motifs found in numerous natural products such as (±)-clausenamide 
and salinosporamide A, which often present a high potential in medicinal chemistry. 
Accordingly, numerous synthetic approaches such as cyclization and cycloaddition/annulation 
reactions have been developed to obtain this structure in an efficient manner110. Of note, g-
lactams provide an entry to the synthesis of pyrrolidine alkaloids like broussonetines and 
plakoridines111. Interestingly, a few a-alkylidene-g-lactams natural products were isolated, 
exhibiting cytotoxic antitumor and anti-inflammatory activities112(Figure 6). 
 
Figure 6 : Examples of g-lactams rings in natural products and derivatives thereof 
Unlike g-lactams synthesis, access to a broad scope of a-alkylidene-g-lactams remained 
relatively unexplored until last decade113. Nevertheless, some biological studies112a, 112b, 114 have 
revived interest in accessing this moiety. Many synthetic approaches have been reported, but 
most of them suffer from severe scope limitation115 or selectivity issues116, thereby preventing 
the construction of a library of analogues for biological studies. Among all these synthetic 
strategies, the imine allylation strategy seems promising due to its broader scope and the relative 
simplicity of the process. While substitutions on the lactam core can be obtained with high 
selectivity, these processes are still limited to unsubstituted exo-methylene parts, thereby 
highlighting the interest to develop new approaches, in addition to the study of a new C-(sp3)-
H bonds transformation. 
 
Scheme 47 : Imine allylation/cyclization strategy for the synthesis of a-alkylidene-g-lactams  
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In addition to the growing interest for the synthesis of a-alkylidene-g-lactams, this architecture 
was used as a platform for the elaboration of interesting heterocycles taking advantage of the 
intrinsic properties of the double bond and the a-b-unsaturated carbonyl moiety115d, 116a, 117. 
Moreover, thanks to the accessible carbonyl chemistry, subsequent ring-opening as well as 
partial or full reduction of the amide can be envisaged (Figure 7).  
 
Figure 7 : Overview of the synthetic utility of a-alkylidene-g-lactams 
2.2. Modular synthesis of C(sp3)-H alkenylation precursor 
In order to prevent undesired side-reactions such as elimination reactions (Scheme 45), we have 
designed bromoalkene 3.13. Interestingly, this precursor of C-H activation is readily accessible 
from commercially available starting materials such as amines, brominated carboxylic acids 
and electrophiles, thus allowing facile construction of various g-lactam derivatives 3.14 after 
C-H activation. Thanks to the modular synthesis of a-alkylidene-g-lactams 3.14, fully-
decorated products 3.15 can be envisioned after further functionalization (Scheme 48). 
 
Scheme 48 : Straightforward synthesis of g-lactams thanks to modular synthesis 
2.1. Proof-of-concept 
To evaluate the feasibility of this intramolecular C(sp3)-H alkenylation, the reaction was first 
investigated on a simplified model substrate under classical conditions by the master student 
Janah Shaya118 under the supervision of Dr. P. Holstein. Starting from the commercially 
available carboxylic acid 3.16, dibromination followed by base-mediated elimination afforded 
the bromoalkene building block 3.17 in high yield. Amide bond formation between the 
corresponding acyl chloride of 3.17 and diisopropylamine yielded the precursors of C-H 
activation 3.13a in low yield. After having tested various classical conditions for C-H 
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activation, the desired cyclized product 3.14a was obtained in acceptable yield, thus providing 
a proof-of-concept for the cyclization of an acyclic substrate through palladium-catalyzed 
C(sp3)-H alkenylation. 
Scheme 49 : Proof-of-concept for the cyclization of acyclic bromoalkene 
2.2. Optimization and generalization 
At the outset of our study, we were seeking to develop a useful protocol to access functionalized 
g-lactams. We were interested in designing substrates allowing access to the free N-H lactams. 
Indeed, previous methodologies relying on C(sp3)-H activation were restricted to N-alkylated 
lactams 44 49 50-51, thereby limiting the synthetic utility of these latter. In order to overcome this 
limitation, we turned our attention to the design of N-protected amides which can potentially 
lead to the desired NH-lactams after deprotection. To circumvent potential side-reactions or 
degradation of the starting material, the protecting group should be stable under the reaction 
conditions applied and inert towards Pd-catalysis (no poisoning of the Pd-catalyst and no 
activated C-H bond). Moreover, it should be easily introduced and removed (Scheme 50). 
 
Scheme 50 :Envisioned synthesis of N-H free g-lactams 
In agreement with these considerations, we investigated both hemiaminal protecting groups 
which were already described to be competent in C-H activation119, and Boc-group. Following 
the same procedure as before (Scheme 49), regioisomers 3.19 and 3.19’ were obtained as an 
inseparable mixture (Scheme 51). The latter was obtained from the formation of the ketene 
intermediate 3.20 (base-mediated) which was then trapped by the isopropylamine. This side-
reaction can explain the low yield obtained for the synthesis of the amide 3.13a (Scheme 49).  
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Scheme 51 : Plausible pathway for the generation of by-product 3.19’ 
To overcome these limitations, we turned our attention to the optimization of the synthesis of 
amide 3.19. We first changed the acyl chloride formation conditions using near-stoichiometric 
amount of oxalyl chloride with catalytic DMF. Then, we envisioned to use the biphasic 
Schotten-Baumann protocol to avoid the formation of by-product 3.19’. Using this 
operationally simple and cheap procedure, formation of 3.19’ could be avoided and product 
3.19 was obtained in high yield (89%). The major limitation of this protocol is that the amine 
has to be used in excess.  This can be problematic in the case of expensive homemade amines 
or chiral amines. Of note, this procedure allows the multi-gram preparation of the desired 
amides, sometimes without purification. Finally, with the desired amide 3.19 in our hands, we 
carried out the synthesis of various N-protected amides 3.13b-e using the two different routes 
shown below. 
 
Scheme 52 : Synthesis of the N-protected precursors of C-H activation 
With the required N-protected precursors of C-H activation 3.13b-e in hand, we evaluated the 
compatibility of these protecting groups under the C-H activation conditions (Table 5). Whereas 
amide 3.19 was completely recovered when a Boc-group was used (entry1), low yield of 
cyclized products 3.14c-d were observed by GC/MS analysis with MOM and EOM protecting  
groups respectively (entry 2-3). Nevertheless, after slight modifications of the reaction 
conditions, acceptable yield  was obtained for EOM-substrate 3.13d (entry 4). Interestingly, 
under the same conditions, the SEM-protected amide 3.13e proved to be more efficient for the 
formation of the corresponding g-lactam (entry 5). 
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Table 5 : Evaluation of the protecting group 
 
a Yield estimated by GC/MS analysis using dodadecane as internal standard, 
isolated yield in bracket. b Only deprotection was observed 
 
Further optimization was performed using SEM-protected amide 3.13e as a model substrate for 
the synthesis of potential N-H free g-lactams. The following work was carried out by the master 
student Julien Vantourout under the supervision of Dr. Phillip Holstein120. Thanks to 1H proton 
NMR and GC/MS analysis, hydrodebrominated compound 3.21 was identified as the major by-
product, rendering the purification difficult due to its polarity which is close to the one of the desired 
product 3.14e. Therefore, the process was optimized in order to obtain the highest possible yield 
with a good ratio between 3.14e and 3.21. Using previously described conditions as a starting 
point (entry 5; Table 5), carbonate bases such as potassium and rubidium carbonate were tried 
(entries 2-3), degrading both the efficiency and the 3.14e/3.21 ratio. Lowering the temperature 
strongly impacted the reaction course. Indeed, high amount of hydrodebrominated side-propuct 
3.21 was observed at 150°C and 140°C (entries 4-5), thereby highlighting the crucial role of 
the energy required for the cyclization. Different phosphine ligands were tested. Similar 
diphenylphosphine ligands with methyl (entry 6) and cyclohexyl (entry 7) substituents instead 
of ethyl point out that steric bulk reduces the reaction efficiency. This is also verified in the 
trialkylphosphines’ series. Whereas, trialkylphosphines were clearly less efficient than 
diphenylalkylphosphine ligands (entries 8-9), the bulkier PCy3 phosphine provided a lower 
yield of 3.14e than PEt3 phosphine. Interestingly, the simplest triphenylphosphine proved to be 
the most efficient among all tested phosphines (entry 10), whereas modification of electronic 
properties of the phenyl ring resulted in sluggish reactions (entries 11-12). Afterwards, classical 
palladium sources were investigated (entries 13-15) providing lower or similar reactivities. Finally, 
the catalyst loading could be reduced to 2.5 mol% without alteration of the yield and 
chemoselectivity (entries 16-17) (Table 6).  
 
 
Entry PG [Pd] (mol %) L Yield %a 
1 Boc Pd(OAc)2 (10) PCy3•HBF4 0b 
2 MOM Pd(OAc)2 (10) PCy3•HBF4 15 
3 EOM Pd(OAc)2 (10) PCy3•HBF4 36 
4 EOM [Pd(η3-allyl)Cl]2  (5) PPh2Et 57 
5 SEM [Pd(η3-allyl)Cl]2 (5) PPh2Et 86 (73) 
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2.3. Deprotection of the SEM-substrate 
In order to develop a methodology with high synthetic utility, we turned our attention to the 
obtention of the free NH-lactam 3.22 through cleavage of the SEM-protecting group, which is 
widely used for the protection of alcohols and amines. Various deprotection conditions 
involving fluorine sources and Brønsted or Lewis acids were developed121, since its 
introduction by Lipshutz and coworkers122. Whereas the SEM deprotection of alcohol is 
efficient and reliable, the cleavage of the N-SEM bond can be tricky for some substrates123. 
Indeed, we were unable, under various conditions, to detect the slightest trace of the desired 
deprotected compound 3.22 (Table 7). We first tried the classical TBAF122, 124 reagent for such 
cleavage. Surprisingly, no conversion was observed (entry 1). Then, we turned our attention to 
Brønsted acids such as HCl, H2SO4 or TFA under various reactions conditions (entries 2-4). 
Whereas full conversion was observed in all cases, we were able to observe compounds 3.23, 
3.24 and 3.25 respectively in high quantities by GC/MS analysis. The formation of these 
unexpected compounds can be explained thanks to the mechanism proposed in Scheme 53. 
They certainly arise from the pivotal electrophilic intermediate 3.26, which is obtained via acid-
mediated elimination. Interestingly, dimer 3.25 should come from the reaction between 3.22 
and intermediate 3.26, thus providing a promising evidence for the formation of desired free   
Table 6 : Optimization of the reaction conditions 
 
Entry [Pd] (mol%) Ligand (mol%) Base T (°C) Ratio 3.14d/3.21 Yield %a 
1 [Pd(η3-allyl)Cl]2 (5) PPh2Et (20) Cs2CO3 160 91:9 86 (73) 
2 [Pd(η3-allyl)Cl]2 (5) PPh2Et (20) K2CO3 160 83:17 64 
3 [Pd(η3-allyl)Cl]2 (5) PPh2Et (20) Rb2CO3 160 86:14 76 
4 [Pd(η3-allyl)Cl]2 (5) PPh2Et (20) Cs2CO3 150 79:21 73 
5 [Pd(η3-allyl)Cl]2 (5) PPh2Et (20) Cs2CO3 140 46:54 20 
6 [Pd(η3-allyl)Cl]2 (5) PPh2Me·HBF4 (20) Cs2CO3 160 84:16 78 
7 [Pd(η3-allyl)Cl]2 (5) PPh2Cy (20) Cs2CO3 160 32:68 22 
8 [Pd(η3-allyl)Cl]2 (5) PEt3 (20) Cs2CO3 160 41:59 35 
9 [Pd(η3-allyl)Cl]2 (5) PCy3 (20) Cs2CO3 160 47:53 22 
10 [Pd(η3-allyl)Cl]2 (5) PPh3 (20) Cs2CO3 160 92:8 91 (81) 
11 [Pd(η3-allyl)Cl]2 (5) P(p-NMe2-C6H4)3 (20) Cs2CO3 160 86:14 49 
12 [Pd(η3-allyl)Cl]2 (5) P(p-CF3-C6H4)3 (20) Cs2CO3 160 - 0 b 
13 PdCl2 (10) PPh3 (30) Cs2CO3 160 76:24 65 
14 Pd(OAc)2 (10) PPh3 (30) Cs2CO3 160 76:24 67 
15 Pd2(dba)3 (5) PPh3 (20) Cs2CO3 160 91:9 81 
16 [Pd(η3-allyl)Cl]2  (2.5) PPh3 (10) Cs2CO3 160 92:8 91 (83) 
17 [Pd(η3-allyl)Cl]2 (1.25) PPh3 (5) Cs2CO3 160 84:16 79 
 
a Yield estimated by GC/MS analysis, using tetradecane as internal standard, isolated yield in bracket. b Only 20% conversion was 
observed 
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NH-lactam 3.22. Unfortunately, different Lewis acids (entries 5-7) which already proved to be 
efficient in laborious cases123a, 125, were completely inefficient on our substrate 3.14e leading to 
the formation of the N-hydroxymethyl compound 3.23. Nevertheless, this latter is stable enough 
to be isolated126, thus providing an alternative pathway toward product 3.22. Indeed, N-
hydroxymethyl compounds can be deprotected via formaldehyde elimination under high 
vacuum and temperature126, heating under basic conditions 124, 127 or with a trapping agent 128. 
At this stage, further investigations should lead us to the desired product 3.22.  
 
 
Scheme 53 : Plausible mechanism for the formation of compounds 3.23-25 
In parallel, we sought to find a new protecting group efficient in catalysis and easily cleavable. 
In this regard, we selected the TMB group already employed by Cramer and coworkers in 
palladium(0)-catalyzed C-H activation. Gratifyingly, we were able to obtain the cyclized 
product 3.14f in good overall yield as well as the desired free NH-lactam 3.22 using classical 
conditions for the deprotection of the TMB protecting group64, thus highlighting the synthetic 
utility of this new protocol. 
  
Table 7 : Attempted deprotection of SEM-pyrrolidinone 3.14e 
 
Entry Reagent  equiv. t (h) T(°C) Solvent conv. Ratioa  3.22/3.23/3.24/3.25 
1 TBAF 5 24 reflux THF 0 -/-/-/- 
2 HCl 1 24 RT Et2O >99 0/80/0/10 
3 H2SO4 0.03 3 RT THF/MeOH >99 0/0/100/0 
4 TFA 630 3 RT DCM >99 0/0/0/100 
5 SnCl4 14 4 0 to RT DCM >99 0/89/1/9 
6 AlMe3 5 2 -78°C to RT DCM >99 0/100/0/0 
7 AlMe2Cl/DIPEA 5 2 -78°C to RT DCM >99 0/100/0/0 
 
a Ratio estimated by GC/MS analysis 
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Scheme 54 : Access to the free NH-g-lactams 3.22 
2.4. Synthesis of acyclic precursors of C-H alkenylation 
At the outset of this study, we were confident, due to numerous reports, about the possibility to 
deprotect the SEM-group on the g-lactam derivative. Thus, we focused on the evaluation of the 
reaction scope. In this regard, we carried out the synthesis of diversely substituted SEM-amides 
3.13 using the Schotten-Baumann procedure previously used (Scheme 52). Taking advantages 
of this simple protocol, we were able to obtain precursors of C-H activation 3.13g-n in excellent 
yield (Scheme 55). 
 
Scheme 55 : Synthesis of SEM-protected amides 3.13g-n 
In addition, dialkylated substrates 3.13o-w were prepared in good yield, thus providing access 
to a broader scope. Precursors 3.13o-p were both synthetized from an E/Z-mixture of the 
corresponding carboxylic acids, thus explaining the lower yield obtained for these substrates 
(Scheme 56). 
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Scheme 56 : Synthesis of dialkylated amides 3.13o-w 
2.5. Scope and limitations of the intramolecular C(sp3)-H alkenylation 
With the precursors of C-H activation in our hands, we explored the scope and limits of this 
new intramolecular C(sp3)-H alkenylation. First, the nitrogen substituent was varied. As 
mentioned before, the reaction tolerated aminals 3.14c-e, alkyl groups 3.14a-3.14r in addition 
to the TMB group 3.14f and the respective g-lactams were obtained in good yield. Somewhat 
surprisingly, the N-isopropyl group of substrate 3.13r (R1 = Et, R2 = Me) underwent C–H 
activation selectively with regard to the less hindered N-ethyl group (3.14r). This points out an 
atypical behavior of the current acyclic bromoalkenes compared to previously studied 
substrates (Scheme 16 & Scheme 17). Then, we examined the nature of the alkyl groups 
undergoing C-H activation. First, ethyl-substrate 3.14g provided low amounts of the desired 
product together with a lot of protodebrominated product 3.21g (GC/MS area ratio 3.14g:3.21g 
14:86), thereby confirming the lack of reactivity of linear alkyl groups in the current system 
(see also 3.14r). Compound 3.13h containing the bulkier tert-butyl group was almost totally 
converted to the desired cyclized product 3.14h (92%). The reactivity trend 3.14g<3.14e<3.14h 
corresponds to one observed for previously reported C(sp3)-H activation systems. This impact 
on the reaction efficiency can be imputed to the Thorpe-Ingold effect as well as a statistic effect. 
Starting from commercially available enantiopure amines, chiral lactams 3.14i-j could be 
synthetized without any racemization. Interestingly, selective activation/cyclization of 3.13k 
gave rise to 3.14k, even in presence of competitive C-H bonds. Finally, activation of 
unactivated secondary C-H bonds was found to be unsuccessful. However, functionalization of 
more activated methylene and even methine C-H bonds of cyclopropyls provided the 
corresponding spirocyclic g-lactam 3.14l and fused g-lactam 3.14m in good yield. Then, the 
reactivity of bromoalkenes with a trisubstituted double bond was also examined.   
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Surprisingly, whereas Z-configured bromoalkenes 3.13o&3.13q underwent cyclization to 
furnish the corresponding E-products 3.14o&3.14q in high yield, E-isomers of 3.13o (3.13p) 
was found to undergo rapid base-promoted elimination to give the corresponding alkyne. 
Thanks to control experiments, we found out that this side-reaction occurred even in the absence 
of a palladium catalyst and selectively for the E-configured bromoalkene 3.14p, which is 
unexpected due to the relative syn-position of the hydrogen and bromine. It would be interesting 
to conduct further investigations to get a better understanding of the factors controlling this 
side-reaction. 
 
Scheme 57 : Scope, limitations and selectivity pattern of the intramolecular C-H activation 
2.6. Evaluation of feasibility for an enantioselective version 
At this stage, we evaluated the possibility to obtain enantioenriched compounds. At the outset 
of this study, the enantioselective discrimination of two enantiotopic methyl-groups were 
mostly achieved using a chiral ancillary ligand (paragraph 4.2.5 of Chapter1). Thus, we turned 
our attention to P-arylbinepine ligands which can be considered as chiral analogues of PPh3. 
Indeed, these are often considered as chiral surrogates for trialkylphosphines. Precise electronic 
and steric properties of a seriees of binepine ligands were measured and calculated by our 
group60-61, thereby demonstrating the analogy between P-arylbinepine and PPh3. After 
screening of different P-arylbinepine ligands, we found out that the ligand L* was competent 
to obtain moderate yield and acceptable enantioinduction (Scheme 58). The enantioselective 
version of this C(sp3)-H activation was not the purpose of this study but this preliminary result   
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constitutes a proof-of-concept for the preparation of enantioenriched compounds via C(sp3)-H 
alkenylation. 
 
Scheme 58 : Proof-of-concept for the enantioselective C(sp3)-H alkenylation 
2.7. Attempts toward a total synthesis of plakoridine A 
2.7.1. Introduction 
We were interested in applying our methodology to natural products synthesis. For this purpose, 
we selected plakoridine A as an initial target. Plakoridine A belongs to a family of three 
racemate members isolated from a marine sponge of the genus Plakortis in Okinawa, Japan, all 
characterized by an hexadecyl chain. Plakoridine A and B are structurally related pyrrolidines, 
while plakoridine C is a piperidine alkaloid129(Figure 8). 
 
Figure 8 : Structure of plakoridine A, B and C 
Up to now, a single asymmetric total synthesis of (2S,3S,4R)-plakoridine A was reported by 
Ma and coworkers130. Based on the chiral auxiliary approach developed by Davies and 
coworkers131, they achieved the synthesis of enantiopure plakoridine A in fourteen steps with 
an overall yield of 3%. Thanks to this total synthesis, they confirmed that natural plakoridine A 
is a racemate, which is consistent with Whitehead’s assumption based on a biomimetic 
synthesis132. Using a four-steps sequence, they obtained the chiral secondary amine 3.26 from 
commercially available ester 3.25, in good overall yield. A diastereoselective Michael reaction 
and sequential diastereoselective aldolisation furnished the enantiopure compound 3.28 after 
isolation of this latter from other diastereoisomers. Under hydrogenolysis conditions, in situ 
generation of the secondary amine prompted the desired cyclization to afford the g-lactam 3.29 
with concomitant cleavage of the benzyl protecting group. A four-steps sequence led to the 
formation of the thiolactam 3.30 in good overall yield.   
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Thanks to a base-mediated epimerization, the thermodynamically more stable thiolactam 3.31 
was obtained. Finally, Eschenmoser sulfide contraction and deprotection furnished plakoridine 
A (Scheme 59). 
 
Scheme 59 : Enantioselective total synthesis of plakoridine A. 
2.7.2. Retrosynthetic analysis 
The C16 aliphatic tail will be introduced through the Eschenmoser sulphide contraction 
reported by Ma (Scheme 59), thus leading to crucial g-lactam 3.37. This latter should be 
accessible thanks to the C(sp3)-H alkenylation methodology developed in this study. Finally, 
the amide 3.38 with appropriate substituents will be prepared using classical organic reactions 
(Scheme 60).  
 
Scheme 60 : Our retrosynthetic plan for the synthesis of plakoridine A 
2.7.3. Unsuccessful synthesis of plakoridine A 
First, we focused our attention to the synthesis of the precursor of C-H activation 3.13r. Starting 
from commercially available compound 3.39, a peptide coupling with 2-aminopentane 
followed by protection of the phenol residue allowed the formation of the amide 3.41 in good 
yield. Then, a two-steps sequence involving an amide reduction and the improved Schotten-
Baumann protocol (Scheme 52) furnished the desired compound 3.13w in acceptable yield.  
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Gratifyingly, under our optimized conditions for C-H activation, we were able to achieve multi-
gram synthesis of 3.14w with a remarkable site-selectivity for the desired primary C-H bond 
even in presence of more activated benzylic and (Csp2)-H bonds (multi-gram preparation of 
compound 3.14w was performed by Dr. Anthony Millet) (Scheme 61).  
 
Scheme 61 : Synthesis of the pyrrolidine core of plakoridine A 
Finally, a-ketolactam could be yielded using classical ozonolysis, thus furnishing more than 1 
gram of 3.43 (Scheme 61). This latter was found to be unstable on silica gel or alumina, thus 
precluding flash chromatography. Such a behaviour for a-ketolactams was already reported 
independently by Rapoport and Carlson133. In particular, they were able to identify self-
condensation which provides a dimeric side-product as a major issue. Nevertheless, we turned 
our attention to the installation of the required ester moiety. First, we envisaged to insert this 
latter through C-alkylation under basic conditions using an ester equivalent. This would furnish 
compound 3.44 in equilibrium with its enol-form 3.45. Considering literature elements 134 
(Scheme 62 b), we assumed that reduction would lead to compound 3.46 with good diastereo- 
and chemoselectivity (Scheme 62 a). 
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Scheme 62 : Envisioned route to advanced intermediate 3.46 
Unfortunately, we were unable to obtain the desired C-alkylated product 3.44. Indeed, reactions 
between the corresponding enolate and soft equivalents of methyl-ester such as Mander’s 
reagent135, 1H-Imidazole-1-carboxylate136 or methyl pentafluorophenyl carbonate137, provided 
only degraded compounds. Further investigations on the enolate formation (hard/soft base138, 
solvent, temperature, additive) were unsuccessful. Moving to hard electrophiles, such as methyl 
chloroformate, led to the exclusive formation of the expected but undesired O-alkylated 
product. We thus envisioned an alternative route to access the advanced intermediate 3.46 in an 
efficient manner. We turned our attention to the synthesis of compound 3.52 which can be 
considered as a Michael acceptor. We thus assumed that 1,4-addition of vinyl cuprate followed 
by ozonolysis in methanolic sodium hyodroxide139 would give access to the compound 3.54. 
Whereas compound 3.52 can be obtained in acceptable yield, Michael addition of the in situ 
generated vinyl cuprate was found to be inefficient, thus leading us to give up the total synthesis 
of plakoridine A (Scheme 63). 
 
Scheme 63 : Envisioned conjugate addition route 
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2.8. Selectivity of the activation of primary C-H bonds 
During the extension of the reaction scope, we studied the selectivity in the activation of non- 
equivalent primary C-H bonds starting from reactants 3.13s-v. In all cases, these reactants 
should give access to g-lactams 3.14s-v or highly strained b-lactams 3.14’s-v. First, a complete 
selectivity for the formation of the g-lactam 3.14s over the b-lactam 3.14s’ was observed. This 
is somewhat surprising since the activation occurs preferentially via the smaller palladacycle 
intermediate for aromatic substrates. Nevertheless, this result is in line with the selectivity 
obtained for the compound 3.14r. Indeed, this latter also afforded selectively g-lactam 3.14r 
over b-lactams 3.14r’ (methylene activation). Interestingly, when substrate 3.13t is submitted 
to the reaction conditions, a separable mixture of g- and b-lactams was observed. Moreover, in 
the case of substrate 3.13u, decreasing the population of Hb resulted in the selective formation 
of the corresponding b-lactam 3.14u’ in acceptable yield with concomitant protodebrominated 
side-product 3.21u. Finally, as expected from the lack of reactivity of methylene bonds and 
previous observations concerning compounds 3.14r and 3.14n, a complete selectivity for the 
formation of b-lactam 3.14v’ was observed (Table 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 8 : Selectivity of the activation of primary C-H bonds 
 
Entry      Reactant             Product(s)a 3.14/3.14’b 
1 
 
 
 
 
>98:2 
2 
71:29c 
3 7:93c 
4 <2:98c 
 
a Yield of isolated product in parentheses  b Determined by GCMS analysis of the crude mixture 
c The corresponding protodebrominated products 3.21s-v were also formed in the following GC ratios : 
3.14t/3.14t’/3.21t 53:22:25; 3.14u/3.14u’/3.21u 5:63:32; 3.14v’/3.21v 48:52. 
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2.9. Construction of bicyclic g-lactams  
2.9.1. Introduction and synthesis of precursors of C-H activation 
Next, the reactivity of monocyclic precursors, relevant to the synthesis of bicyclic alkaloids was 
studied. The flexible Schotten-Baumann protocol allowed the synthesis of 5-,6- and 7-
membered ring precursors 3.13w-z in an efficient manner (Scheme 64). 
 
Scheme 64 : Synthesis of C-H activation precursors 3.13x-aa 
2.9.2. Scope and limitations 
In general, desired bicycles 3.14x-aa were obtained in good yield except in the case of the 5,5-
bicyclic ring 3.14z most likely due to ring strain. Moreover, no side-product arising from the 
activation of methylene C-H bonds adjacent to the nitrogen was observed. Gratifyingly, the 
scale-up synthesis of product 3.14y was achieved in a reproducible manner, thus leading us to 
envision the total syntheses of indolozidine alkaloids (Scheme 65).  
 
Scheme 65 : Construction of bicyclic g-lactams through C-H activation 
2.9.3. Application to alkaloid synthesis 
Interestingly, these lactams can be viewed as an entry-platform to the synthesis of 
pyrrolidine111b, pyrrolizidine 140, indolizidine 141, and Stemona alkaloids142 (Scheme 65). For 
instance, we focused our attention to the total synthesis of (±)-d-coniceine. Thanks to a 
reductive ozonolysis, an inconsequential mixture of diastereoisomers of 3.55 was obtained in 
good yield. Of note, these latter should provide an access to poly-hydroxylated indolozidines143. 
Instead, we obtained after an Appel reaction and a radical reductive debromination the lactam   
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3.56. Finally, reduction of the amide resulted in the obtention of the completely saturated 
system, which was then protonated to furnish the total synthesis of (±)-d-coniceine 
hydrochloride salt in good overall yield (Scheme 66). 
 
Scheme 66 : Total synthesis of (±)-d-coniceine 
3. Conclusion  
In summary, we have developed a new straightforward access to a-alkylidene-g-lactams via 
C(sp3)-H alkenylation. Starting from easily available C-H activation precursors, this new 
methodology allows to obtain a broad range of g-lactams by modification of R1-R4 groups. 
Interestingly, compared to previous syntheses of amide derivatives by C(sp3)-H activation, the 
free-NH lactams can be obtained after removal of the TMB group. Moreover, these lactams can 
be used as valuable building blocks as demonstrated by the synthesis of the indolizidine alkaloid 
(±)-d-coniceine and of a plakoridine A precursor. In addition, a highly enantioselective version 
can be envisaged thanks to the preliminary result obtained. An extensive screening of ligands 
as well as reaction conditions could lead to highly enantioenriched a-alkylidene-g-lactams. 
 
Scheme 67 : Overview of the a-alkylidene-g-lactams synthesis via C(sp3)-H alkenylation 
During the course of this study, the extension of this methodology to d-lactams was initiated in 
our group by the master student Maria Vogler. Unfortunately, after many efforts devoted to the 
optimization of the reaction conditions, the scope of the reaction was found to be limited to few 
examples, thereby illustrating the difficulty to obtain 6-membered ring through C-H activation. 
(Scheme 68). 
 
Scheme 68 : Extension to d-lactams 
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Few months later, Charette and coworkers described an extension of this C(sp3)-H alkenylation 
based on the activation of relatively close substrates studied in our group. Thanks to well-
designed precursors of C-H activation, they developed a new route to 5-6-3 and 6-6-3 
cyclopropyl-fused azacycles through activation of cyclopropanes C-H bonds, thereby 
demonstrating the synthetic utility of this strategy (Scheme 69). 
 
Scheme 69 : Extension of the C(sp3)-H alkenylation scope 
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 Chapter 4  
  Synthesis of b-Lactams  
 by Palladium(0)-Catalyzed C(sp3) Carbamoylation 
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1. Introduction 
1.1. Interest of b-lactams 
Naturally-occuring b-lactam compounds may be classified into four subfamilies, namely as the 
penicillin/cephalosporins, the clavams, the carbapenems and the monocyclic b-lactams, 
depending on their structural properties and the mechanism of their biosynthesis. The first 
isolated b-lactams (i.e. the penicillin and the cephalosporin C) were both accidentally 
discovered from the fermentation of filamentous fungi. Moreover, they rapidly shown 
interesting activity as antibacterial drugs, thus engendering numerous biological studies and the 
synthesis of various b-lactam compounds and analogues. Nowadays, b-lactam antibiotics 
account for 65% of the total world market of antibiotics (20 billion dollars per year)144 (Figure 
9). 
 
Figure 9 : Subfamilies of b-lactam compounds 
In addition to their biological interest, b-lactams are valuable synthons in organic synthesis. 
Indeed, thanks to the ring strain of the 2-azetidinone core, selective ring opening can be 
achieved leading to a- and b-amino acids, peptidomimetic compounds or complex natural 
products. Of note, this strategy is employed in the highly efficient last synthetic step to well-
known Taxol® anticancer agent145 (Scheme 70).  
 
Scheme 70: b-lactam as acylating reagent of Baccatin III 
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1.2. Classical organic syntheses of b-lactams 
Due to these unique biological properties and synthetic utility, many efforts were devoted to 
deliver the 2-azetidinone core in an efficient manner. Among these synthetic approaches, the 
Staudinger reaction146, the Gilman-Speeter reaction147, the Alper reaction148, the Kinugasa 
reaction149, the Torii reaction150 as well as intramolecular cyclization151 are the most widely 
used because of their efficiency. These synthetic methodologies are highlighted below with 
recent examples from the literature152 (Scheme 71). 
 
Scheme 71 : Selected strategies to access b-lactam scaffolds 
2. Synthesis of b-lactams by C(sp3)-H functionalization 
Inspired by the pioneering results of Corey and coworkers153, using C-H insertion via photo-
decomposition of a diazo intermediate in their synthesis of penicillin, numerous transition-
metal catalyzed152, 154 or transition-metal-free152, 155 C-H insertion methodologies were 
developed to access b-lactams and derivatives. Whereas this strategy is well-employed, 
methodologies to access b-lactams via C(sp3)-H bonds activation are still limited and suffer 
from some limitations. The first approach was inspired by the synthesis of azetidines developed 
by the groups of Daugulis and Chen156, based on PdII/PdIV C-H activation using picolinamide 
as bidentate directing groups. Using respectively the PIP or the 8-aminoquinoline directing 
group, the groups of Shi157 and Wu158 were able to access b-lactams through the formation of 
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the N–Cb bond, thanks to a fine-tuning of the required stoichiometric oxidant. Whereas this 
approach is operationally simple, extra-steps are required for the installation and removal of the 
directing group, thereby potentially limiting its synthetic utility. Moreover, these methodologies 
were at that time restricted to the activation of methylene C-H bonds and the development of 
an enantioselective version should be limited by the bidentate nature of the directing group. 
Taking advantages of previously reported conditions as a starting point and reconsidering the 
mechanism of carbonylative C-H activation159, Gaunt and coworkers described a new protocol 
to access b-lactams via the direct carbonylation of simple aliphatic amines using PdII-Pd0-PdII 
catalysis160. Under an excess of CO (balloon) and with an oxidative system (CuII as co-catalyst 
and benzoquinone (BQ) as terminal oxidant) to regenerate in situ the PdII catalyst, they found 
that a sterically hindered carboxylic acid in combination with a nitrogen ligand are required to 
obtain an efficient process. Limited to the activation of primary C-H bonds, the reaction shows 
a broad scope with particularly good yield for unhindered aliphatic amines. Using an external 
nitrogen ligand, an enantioselective version, by desymmetrization of enantiotopic methyl-
groups could be envisioned. On the other hand, Cramer and coworkers disclosed the 
asymmetric synthesis of b-lactams from a-chloroamides161 by intramolecular C(sp3)–H 
alkylation in the presence of a chiral ligand65. In this remarkable work, they were for the first 
time able to both build a monocyclic ring system and to construct a C(sp3)–C(sp3) bond under 
Pd0-catalyzed C(sp3)–H activation. Whereas impressive levels of enantioselectivity were 
obtained, this methodology is limited to the functionalization of activated secondary C-H bonds 
adjacent to a (hetero)aryl or ester group (Scheme 72). 
 
Scheme 72 : Synthesis of b-lactams by PdII and Pd0 –catalyzed C(sp3)–H activation 
Recently, we were able to obtain b-lactams in moderate yields (Table 8), thus inspiring us to 
develop a more practical route to this moiety. Thanks to literature elements, we envisioned to 
use carbamoyl chlorides for the synthesis of b-lactams by Pd(0)-Catalyzed C(sp3) activation.  
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3. Carbamoyl chlorides in transition metal-catalysis 
3.1. Intermolecular processes 
The first efficient application of carbamoyl chlorides in catalysis was achieved in the field of 
cross-coupling. Indeed, using organotin reagents, Jousseaume and coworkers described an easy 
entry to amide synthesis via palladium-catalyzed cross-coupling reactions162. Few years later, 
this approach was extended to Suzuki cross-couplings thanks to a one-pot amidation of olefins 
through the palladium-catalyzed coupling of alkylboranes and carbamoyl chlorides163 (Scheme 
73). 
 
Scheme 73 : Carbamoyl chlorides in cross-coupling reactions 
Recently, Jiao and coworkers reported a new synthesis of phenanthridinones taking advantage 
of the Pd/norbornene (NBE) chemistry developed by Catelani and coworkers164. Thanks to dual 
C-H bond activation, they have described an efficient synthesis of phenanthridinones, starting 
from readily available aryl iodides and carbamic chlorides165 (Scheme 74). 
 
Scheme 74 : Synthesis of phenanthridinones via intermolecular dehydrogenative annulation 
3.2. Intramolecular processes 
Whereas reported classical intramolecular Heck processes (terminated via b-hydride 
elimination) were suffering from a lack of generality and efficiency115a, 166, Grigg and 
coworkers described the synthesis of oxindoles via palladium-catalyzed Heck cyclization 
followed by a cross-coupling reaction using organotin or organoborane reagents. Based on the 
same initial palladium-catalyzed Heck cyclization and by trapping the in situ generated p-
allylpalladium complex, Takemoto and coworkers reported a flexible synthesis of oxindoles167 
(Scheme 75).  
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Scheme 75 : Access to oxindole derivatives via sequential carbopalladation/functionalization  
On the other hand, carbamoyl chlorides can be used for the carbohalogenation of unsaturated 
C-C bonds. Based on the initial reports of Tong and coworkers168, Lautens and Schoenebeck 
turned their attention to develop an efficient and stereoselective synthesis of methylene 
oxindoles which are valuable intermediates to access biologically active compounds (Scheme 
76).  
 
Scheme 76 : Stereoselective synthesis of methylene oxindoles 
3.3. Palladium(0)-Catalyzed Carbamoylation of activated C(sp3) bonds 
During the course of their researches, Takemoto and coworkers exploited the use of readily 
accessible and relatively stable carbamoyl chlorides in palladium-catalyzed reactions. They 
envisioned to take advantage of carbamoyl chlorides to develop a new concise route to 
oxindoles via C-H activation. Starting from readily available secondary amines 4.1&4.3, they 
obtained the corresponding carbamoyl chlorides 4.2&4.5 in high yield after purification. After 
optimization of the reaction conditions, they completed a broad scope for the synthesis of 
oxindoles 4.3 and spiro-oxindoles 4.6, thanks to the functionalization of activated benzylic and 
cyclopropane C-H bonds (Scheme 77). 
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Scheme 77 : Scope of the Palladium(0)-Catalyzed C(sp3)-H Carbamoylation 
Of note, during the study of the reaction scope, they observed preferential activation of 
cyclopropane C-H bonds leading to compounds 4.6a&4.6b over benzylic or aromatic C-H 
bonds leading to 4.3a and 4.7 respectively. This highlights the special character of such strained 
hydrocarbons169. Indeed, they are easier to activate due to their special bonding properties and 
hybridization despite their higher pKa-value (46) compared to benzylic (41) or aromatic (43) C-
H bonds. Moreover, challenging methylene C-H activation does not occur in this methodology. 
Finally, when the alkene derivative 4.5b is engaged under the optimized conditions, exclusive 
carbopalladation was observed leading to g-lactams 4.10 (Scheme 78). 
 
Scheme 78 : Regioselectivity and reactivity issues 
  
87 
 
4. Synthesis of b-Lactams by Palladium(0)-Catalyzed C(sp3)-
Carbamoylation 
4.1. Optimization of the reaction 
Inspired by these seminal reports, we envisioned to access b-lactams efficiently, thanks to the 
construction of the C(O)-Ca bond through Pd(0)-catalyzed C(sp3)-H carbamoylation (Scheme 
79). 
 
Scheme 79 : Transformation envisioned 
Before beginning the optimization, we considered the mechanism of the reaction. The accepted 
catalytic cycle for this transformation starts with the oxidative addition of a monoligated Pd(0) 
complex into the acyl chloride bond of 4.11. At this stage, instead of the classical ligand 
exchange (with pivalate base for example), followed by the CMD mechanism leading to 
intermediate B and the desired product after reductive elimination, a competitive 
decarbonylation leading to the undesired intermediate C could occur. This latter can lead either 
to the free amine D or to the competent acyl palladium complex A after reinsertion of the carbon 
monoxide. At the outset of this study, we could not exclude the reversibility of this step (A↔C). 
Nevertheless, we were aware that this competitive decarbonylation could impact the reaction 
course (Scheme 80). 
 
Scheme 80 : Simplified mechanism 
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In line with our previously described methodology, we designed the substrate 4.11a for the 
optimization in order to obtain valuable compounds after C-H activation. Indeed, removal of 
the TMB group should deliver the corresponding free-NH-lactam which would be useful to 
access interesting compounds such as aztreonam or tigemonam through sulfatation (Figure 10). 
 
Figure 10 : Available targets thanks to access to free-NH-lactams 
Initially, we conducted the optimization with Pd(PPh3)4 as catalyst and cesium pivalate as the 
active base in various solvents (entries 1-6). We were pleased to find that the desired b-lactam 
4.12a was obtained in moderate yield (entries1-2;5-6), thereby confirming the feasibility of this 
transformation. After variation of different parameters without any improvement, we decided 
to use a CO atmosphere to limit the formation of undesired amine 4.13a and/or urea 4.14a side-
products. Surprisingly, using the same catalytic system under an atmosphere of CO, the reaction 
was negatively impacted providing only low yield for the desired product 4.13a (entries 7-8). 
Visually, formation of Pd black was clearly observed immediately after the addition of CO. 
Gratifyingly, we found out that the electron-rich and sterically demanding PAd2(n-Bu) 
phosphine (CataCXium A) was crucial to suppress this catalyst deactivation (entry 9) which is 
in agreement with observations of Beller and coworkers during their work on the formylation 
of aryl bromides170 as well as the catalytic system of Takemoto 50-51, 69. After variation of 
different parameters such as the palladium source (entries 9-15), equivalents of base (entry 16), 
solvent (entry 17) and temperature (entries 18-19), we have identified the optimal catalytic 
system for this transformation allowing the isolation of 4.12a in 85% yield (entry 17). Different 
ligands (entries 20-24) and the structurally close di(1-adamantyl)benzylphosphine ligand (entry 
25) were found to be less efficient. Employing the third generation of Buchwald’s precatalyst 
and the Pd(0)-L2 complex with the cataCXium A ligand allows to obtain the desired product 
4.12a with similar efficiency (entries 26-27). In addition, we were able to isolate the oxidative 
addition complex A (R = i-Pr, L = PPh3) following Gaunt’s procedure160. Submitting this latter 
to our optimized conditions allowed the formation of the corresponding b-lactam with 
comparable efficiency than the classical   
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reaction with the carbamoyl chloride (Scheme 81). These experiments confirm that the complex 
A is a competent intermediate and support the Pd0-PdII-Pd0 mechanism depicted in Scheme 80. 
 
Scheme 81 : Control experiments validating the Pd0-PdII-Pd0 mechanism 
Starting from amine 4.13a instead of carbamoyl chloride 4.11a, no trace of the b-lactam 4.12a 
was observed(entry 28), thereby confirming that our system differs from the PdII-Pd0-PdII 
developed by Gaunt and coworkers160. Interestingly, in absence of CO, the current catalytic 
system is still competent for the formation of b-lactam 4.12a, however with a slightly decreased 
yield (-22%) (entry 29). At this stage, we were looking to develop a more convenient protocol. 
Even if CO is an abundant chemical feedstock and is widely used in various industrial 
processes, a special safety equipment has to be used due to its toxicity. In order to develop a 
more user-friendly methodology, we turned our attention to the use of non-gaseous source of 
stoichiometric CO. Unfortunately, different sources of CO already competent in carbonylative 
methodologies such as the triruthenium dodecacarbonyl 171, paraformaldehyde172, 
trimethylacetic formic anhydride173 were found to be inneficient. Then, we envisioned to use 
the two-chamber (COware) system developed by Skrydstrup and coworkers174. Gratifyingly, 
the use of this two-chamber system allows the restoration of the reactivity (entries 30-31). Of 
note, when 3 equivalents of COgen were used, the reaction proceeds with higher efficiency 
(92%, entry 31) compared to the use of an excess of CO (85%, entry 17). Moreover, the reaction 
can be scaled up tenfold without loss of the efficiency (95%, entry 32). Finally, we were pleased 
to find that the reaction can proceed nicely when the experiment was set up with technical-
grade solvent without any precaution (75%, entry 33), thereby providing a robust and user-
friendly methodology (Table 9). 
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At this stage, we used the isotopically labelled 13COgen to study the reversibility of the CO 1,1-
deinsertion/1,1-reinsertion step (A↔C) depicted in Scheme 80. When the reaction was 
performed with this labelled 13COgen, very slight 13C incorporation was observed (2.5%). 
Thanks to this control experiment, we can suggest that the role of the CO  
  
Table 9 : Selected conditions of the optimization 
 
Entry [Pd] Ligand n Solvent 
CO source 
Temp [°C] Yield 4.12a [%]c balloon COgenb 
( equiv) 
1 Pd(PPh3)4 – 1.5 THF - - 120 45% 
2 Pd(PPh3)4 – 1.5 DME - - 120 37% 
3 Pd(PPh3)4 – 1.5 DMF - - 120 0% 
4 Pd(PPh3)4 – 1.5 DMSO - - 120 0% 
5 Pd(PPh3)4 – 1.5 Toluene - - 120 45% 
6 Pd(PPh3)4 – 1.5 Xylene - - 120 47% 
7 Pd(PPh3)4 – 1.5 Xylene ü  120 27% 
8 Pd(OAc)2 PPh3 1.5 Xylene ü  120 10% 
9 Pd(OAc)2 PAd2(n-Bu)•HI 1.5 Xylene ü  120 45% 
10 Pd(OPiv)2 PAd2(n-Bu)•HI 1.5 Xylene ü  120 62% 
11 Pd2(dba)3 PAd2(n-Bu)•HI 1.5 Xylene ü  120 42% 
12 Pd(MeCN)4HBF4 PAd2(n-Bu)•HI 1.5 Xylene ü  120 35% 
13 Pd(MeCN)2Cl2 PAd2(n-Bu)•HI 1.5 Xylene ü  120 64% 
14 PdMe2(TMEDA) PAd2(n-Bu)•HI 1.5 Xylene ü  120 66% 
15 PdCl2 PAd2(n-Bu)•HI 1.5 Xylene ü  120 76% 
16 PdCl2 PAd2(n-Bu)•HI 3 Xylene ü  120 82% 
17 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene ü  120 92% (85%) 
18 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene ü  110 57% 
19 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene ü  130 58% 
20 PdCl2 P(o-tol)3 3 Mesitylene ü  120 15% 
21 PdCl2 PPh3 3 Mesitylene ü  120 24% 
22 PdCl2 PCy2Ph 3 Mesitylene ü  120 41% 
23 PdCl2 PtBu3HBF4 3 Mesitylene ü  120 21% 
24 PdCl2 PCy3HBF4 3 Mesitylene ü  120 28% 
25 PdCl2 PAd2Bn 3 Mesitylene ü  120 18% 
26 PAd2(n-Bu)-Pd-G3 – 3 Mesitylene ü  120 80% 
27 Pd[PAd2(n-Bu)]2 – 3 Mesitylene ü  120 88% (85%) 
28d PdCl2 PAd2(n-Bu)•HI 3 Mesitylene ü  120 0% 
29 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene – – 120 70% 
30 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene  ü (1.5) 120 75% 
31 PdCl2 PAd2(n-Bu)•HI 3 Mesitylene  ü (3) 120 94% (92%) 
32e PdCl2 PAd2(n-Bu)•HI 3 Mesitylene  ü (3) 120 (95%)  
33e PdCl2 PAd2(n-Bu)•HI 3 Mesitylene  ü (3) 120 (75%)f 
 
aPerformed using 0.133 mmol of 1a unless otherwise stated. b9-Methylfluorene-9-carbonyl chloride (COgen), Pd(OAc)2/P(t-Bu)3•HBF4 
cat., Cy2NMe, mesitylene, two-chamber system (COware), both reaction chambers were placed at the same temperature. cDetermined by 
NMR analysis using trichloroethylene as internal standard. Yield of isolated product 4.12a is given within parentheses. dUsing amine 4.13a 
instead of 4.11a. ePerformed using 1.33 mmol (400 mg) of 4.11a . fPerformed using technical-grade mesitylene under non-inert conditions.  
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consists in saturating the reaction medium to limit the decarbonylation of intermediate A, 
thereby providing the mechanism shown below (Scheme 82). 
 
Scheme 82 : Revised mechanism 
4.2. Scope and limitations of the b-lactams synthesis 
With the optimal conditions in our hands, we turned our attention to the scope and limitations 
of this methodology. To this purpose, more than 45 secondary amines 4.13 and 50 carbamoyl 
chlorides 4.11 were synthetized. For the amine synthesis, we mainly used three different 
methods of reductive amination as well as Michael type reactions. All the related data can be 
found in the experimental part. In the case of carbamoyl chloride synthesis, employing classical 
conditions, we were pleased to obtain a series of carbamoyl chlorides in high yield without any 
purification, thus giving us a rapid access to the precursors of C-H activation (Scheme 83). 
 
Scheme 83 : Conditions for the synthesis of carbamoyl chlorides 4.11 
For comparison, for each substrate, we set up a reaction under both conditions. Importantly, in 
agreement with the optimization, the COgen conditions deliver in almost all cases the b-lactams 
with equal or higher efficiency compared to CO-balloon conditions. In addition, we were 
pleased to find that for several examples, such as 4.12e, 4.12o-p, 4.12r-u and 4.12ab-ad, the 
COgen could increase the yields from more than 20% yield, thereby highlighting the efficiency 
of this COgen-mediated reaction. We first examined the activation of primary C-H bonds with 
TMB-protected substrates 4.11a-i, which can potentially deliver the free-NH-b-lactam after 
deprotection of the TMB group. Of note, the reaction proceeds decently with reactant 4.11b 
bearing a disubstituted b-position, which is somewhat surprising.   
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Indeed, this latter does not benefit from Thorpe-Ingold and stastistic effects. This may point out 
the high reactivity of such intermediates in C-H activation. In line with this result, the reactions 
with reactants 4.11e-i bearing a trisubstituted b-position give excellent yields, including the 
formation of chiral b-lactams 4.12e-12h (obtained from the enantiopure secondary amines). Of 
note, when the substrate 4.11i is submitted to the optimized conditions, a mixture of b-lactam 
4.12i and oxindole 4.12j arising from the competition between C(sp3)-H and C(sp2)-H 
activation was observed. Interestingly, the b-lactam 4.12i was preferentially formed, thereby 
reflecting the higher reactivity of the kinetically favorable 5-membered palladacycle 
intermediate in C-H activation. Surprisingly, potentially due to excessive repulsion between the 
TMB group and the b-tetrasubstitution of compounds 4.11c-d, the reaction only proceeds 
through the decarbonylative pathway providing the undesired amine 4.13c-d and/or urea 4.14c-
d side-products. We next investigated the nature of the N-substituent. Whereas, the reaction 
occurred in acceptable yields with different substitution patterns 4.12k, 4.12l, 4.12o-p including 
functional groups such as ester 4.12q and a protected amine 4.12r, the reaction failed to deliver 
products 4.12m-n. We assume that this is due to competitive C(sp2)-H activation which leads 
to the formation of an unreactive palladacycle intermediate. Indeed, when the aryl moieties of 
precursors of C-H activation are substituted in ortho position, as it is the case for compounds 
4.11a and 4.11l, no C(sp2)-H activation can occur and the desired b-lactams 4.12a and 4.12l 
were obtained in good yield. Then, we turned our attention to reactants bearing a tetrasubstituted 
b-position. Whereas substrates 4.11c-d were inefficient due to an excessive steric repulsion, 
less-hindered N-substituted compounds 4.12k-l allow the formation of the corresponding 
b-lactams in good yield. Interestingly, b-lactams 4.12u-w derived from the acyclic and cyclic 
monoterpenes were prepared in good yield allowing introduction of alkenes in this 
methodology. Noteworthy, no competitive C(sp2)-H or carbopalladation was observed contrary 
 to the previous report of Takemoto (Scheme 78). Finally, the fused b-lactam 4.12x was 
obtained in good yield, thus furnishing potential entry to bicyclic antibiotic derivatives. In 
addition to the activation of primary C-H bonds, nonconventional spirocyclic 4.12y-z and fused 
b-lactams 4.12aa-ab were synthetized thanks to the activation of activated secondary and 
tertiary C-H bonds. Gratifyingly, we were pleased to find that the activation of less-activated 
methylene C-H bonds can occur, thus furnishing compounds 4.12ac-af with variable efficiency. 
Interestingly, the b-lactam 4.12ac was obtained quantitatively, thereby demonstrating the 
efficiency of this methodology and should pave the way for further developments (Scheme 84).  
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Scheme 84 :  Scope and limitations of the reaction 
4.3. Development of an enantioselective version 
4.3.1. Initial results 
As mentioned in paragraph 4.2.5 of Chapter 1, enantiodiscrimination in Pd(0)-catalyzed C(sp3)-
H activation can be achieved thanks to a chiral ancillary ligand or a chiral base. Taking 
advantage of previous reports, we first tried to identify a family of chiral ligands allowing 
reactivity as well as enantioinduction. After having tested various chiral NHCs, chiral 
binepines, chiral BINOL-derived phosphoramidites and phosphonites, we were pleased to find 
that chiral TADDOL-derived ligands seemed to be promising sources of chirality62. Indeed, 
whereas other chiral ligands only afforded low enantiomeric excess and low conversion, chiral 
TADDOL-derived ligands allowed to obtain partial conversion with low to moderate 
enantioinduction. Especially, identical reactivity and induction were observed between the 
phosphonite ligand 4.17a and the phosphoramidite ligand 4.17a’, modification of the aryl 
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substituents of the phosphonite ligand affects significantly the enantioselectivity (4.17 versus 
4.17a) (Scheme 85). However, phosphoramidites 4.17a’ and 4.17b’ provided the same 
selectivity. In order to improve the enantioselectivity, we thus turned our attention to modulate 
the electronic and steric properties of these chiral TADDOL-derived phosphonites thanks to the 
modification of the aryl substituents, the ketal moiety and the aryl part at the phosphorus atom. 
 
Scheme 85 : Inital results – Phosphonites versus Phosphoramidites 
4.3.2. Synthesis of TADDOL-derived phosphonites and optimization of the reaction 
In order to identify the best TADDOL-derived phosphonite, we decided to synthetize a series 
of ligands with modification of the aryl substituents next to the tertiary hydroxyl group. Since 
the initial report of Seebach and coworkers on the synthesis of TADDOL-derived 
phosphorus(III) ligands175, the seminal synthetic approach was subjected to only slight 
improvements. Starting from the readily available (+)-Diethyl L-tartrate, a two-step sequence 
involving the protection of the diol and nucleophilic addition of organometallic species allows 
the obtention of TADDOLs 4.16a-g. Thanks to this synthetic route, the reaction of TADDOLs 
4.16a-g with the commercially available P,P-Dichlorophenylphosphine allows the synthesis of 
a first batch of seven TADDOL-derived phosphonites 4.17a-g (Scheme 86). 
 
Scheme 86 : Synthesis of TADDOL-derived phosphonites 4.17a-g 
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We then tested these different ligands under the optimized racemic conditions. Whereas ligands 
4.17c-e were less efficient in term of enantiomeric excess compared to the initial result with 
ligand 4.17b, we were pleased to find that ligands with a 3,5-disubstituted aryl pattern 4.17f-g 
furnished higher enantioselectivity values compared to the others. Especially, ligand 4.17g was 
the most promising in terms of reactivity and enantioselectivity. We thus decided to continue 
the optimization with this 3,5-bis(trifluoromethyl)phenyl pattern (Scheme 87). 
 
Scheme 87 : Influence of the aryl moiety on the enantioselectivity and reactivity 
We next turned our attention to the modification of the backbone of ligand 4.17g. For this 
purpose, we synthetized three new TADDOL-derived phosphonites 4.17h-j using classical 
conditions (Scheme 88). 
 
Scheme 88 : Synthesis of backbone-modified ligands 4.17h-j 
Whereas ligand 4.17h bearing a cyclopentanonide resulted in slightly decreased reactivity and 
enantioselectivity, we were pleased to find that TADDOL 4.17i and 4.17j with acyclic 
backbones positively affected the enantioselectivity. Unfortunately, both TADDOL 4.17i and 
4.17j afforded lower yields than ligand 4.17g (Scheme 89). 
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Scheme 89 : Influence of the backbone moiety on enantioselectivity and reactivity 
At this stage, a slight optimization was performed using TADDOL ligand 4.17j. After having 
tested various other bases and acids (entries 4-7) as well as an additive (entry 3) without any 
improvement, higher reactivity was recovered using 1.5 instead of 3 equivalents of cesium 
carbonate (entry 1). 
 
 
 
 
 
 
 
 
After having modulated the steric bulk of our TADDOL ligands with variations of the backbone 
and aryl substituents, we turned our attention to tune both electronic and steric properties by 
introducing substituents on the aryl moiety at the phosphorus atom. To this purpose, we 
synthetized seven P,P-Dichloroarylphosphines 4.20a-g through the reaction of an 
organolithium or organomagnesium with the Bis(diethylamino)chlorophosphine 4.18 followed 
by an acidic treatment. Of note, this protocol allows to obtain the monosubstituted 
chlorophosphines 4.20a-g in an efficient manner by avoiding over-addition by-products often 
observed when organolithiums or organomagnesiums are reacted with phosphorus trichloride 
(Scheme 90). 
  
Table 10 : Optimization of the reaction conditions 
 
Entry Base (x equiv) Acid  Additive Yield %a e.r. 
1 Cs2CO3 (1.5 equiv) PivOH - 63 83:17 
2 Cs2CO3 (1.1 equiv) PivOH - 46 83:17 
3 Cs2CO3 (3 equiv) PivOH 4Å MS 23 84:16 
4 K2CO3 (3 equiv) PivOH - 23 83:17 
5 Rb2CO3 (3 equiv) PivOH - 49 83:17 
6 K3PO4 (3 equiv) PivOH - 29 84:16 
7 Cs2CO3 (3 equiv) PivNHOH - 53 82:18 
 
a Yield of isolated product 4.12a 
97 
 
 
Scheme 90 : Synthesis of dichloroarylphosphines 4.20a-g 
Thanks to the synthesis of these P,P-Dichloroarylphosphines 4.20a-g, we were able to obtain 
eight new TADDOL-derived phosphonites 4.17k-r in good yield with different aryls at the 
phosphorus atom (Scheme 91). 
 
Scheme 91 : Synthesis of TADDOL-derived phosphonites 4.17h-o  
We tested the new ligands 4.17k-r under the new optimized conditions. Ligand 4.17k was 
found to inhibit the catalytic system. We assume that the important steric bulk induced by the 
TRIP moiety hinders coordination of the phosphonite to the metal center. Consequently, only 
the background reaction occurs, thereby explaining the racemic product and the low yield 
obtained (Scheme 92). In the case of ligands 4.17l-n, no improvement was observed. 
Interestingly, electron-withdrawing groups on the ligand 4.17l clearly reduce the efficiency of 
the reaction, whereas electron-donating groups present in 4.17o and 4.17q-r positively affect 
the reaction. Of note, a 3,5-disubstitution pattern with a bulky group such as tert-butyl moiety 
(4.17q) increases the enantioinduction. Finally, we were pleased to find that a 3,5-disubstitution 
pattern with a methoxy group at the para position significantly improves both yield and 
enantioselectivity. At this stage, we decided to stop the ligand synthesis for this enantioselective 
version due to a lack of time. In order to rationalize the effect of the modification of the aryls 
substituents, the ketal moiety and the aryl part at the phosphorus atom, it would be interesting 
to characterize the steric and electronic properties of ligands 4.17a-r. 
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Scheme 92 : Influence of the aryl at the phosphorus atom on enantioselectivity and reactivity 
In parallel to the synthesis of these new ligands (4.17k-r), we optimized other parameters such 
as the palladium source and the solvent of the reaction. We first examined palladium sources 
(Table 11). In all cases, the reaction proceeded with similar efficiency using either Pd(0) or 
Pd(II) precatalysts. However, a slight fluctuation of the enantioselectivity was observed (entries 
1-7), thus leading us to continue with PdCl2 or Pd(MeCN)Cl2. 
 
 
 
 
 
 
 
 
We next investigated the influence of the solvent on both reaction efficiency and 
enantioselectivity (Table 12). Whereas non-aromatic polar aprotic solvents such as DMAc 
completely shut down the reaction (entry 1), aromatic solvents allow the formation of the 
desired product. Unfortunately, among all tested solvents (entries 2-14), mesitylene was found 
to be the most efficient. Despite all these optimizations, only an acceptable e.e. of 84% for the   
Table 11 : Selected source of palladium 
 
Entry [Pd] Yield %a e.r. 
1 Pd(dba2) 68 83:17 
2 Pd(MeCN)2Cl2 68 88:12 
3 Pd(OPiv)2 74 85:15 
4 Pd(TFA)2 57 83:17 
5 Pd(Me)2TMEDA 68 86:14 
6 Pd(COD)(Me)2 60 86:14 
7 PdCl2 63 88:12 
 
a Yield of isolated product 4.12a 
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desired product 4.12a was obtained. Nevertheless, this result represents an unprecedented 
example of desymmetrization of unactivated methyl groups65. 
 
 
 
 
 
 
 
 
 
 
4.3.3. Scope of the enantioselective version 
We next applied these optimized conditions to the same COware system as in the racemic 
version. As expected from previous results, a higher reactivity was observed using this system, 
furnishing compound 4.12a in 86% yield. However, somewhat surprisingly, the 
enantioselectivity of the reaction was significantly decreased, thus leading us to use a CO 
balloon for the scope of the enantioselective version. Interestingly, after a slight optimization, 
the TMB group can be removed by oxidative cleavage employing potassium persulfate176, thus 
providing the free lactam (R)-4.21. The absolute configuration was assigned considering the 
optical rotation of the enantiopure lactam, which was synthetized thanks to the separation of 
diastereoisomeric precursors177. 
 
Scheme 93 : Enantioselective synthesis of b-lactams through the desymmetrization of methyl groups  
Table 12 : Screening of the solvent 
 
Entry solvent Yield %a e.r. 
1 DMAc 0 - 
2 1,2,4-trimethylbenzene 60 81:19 
3 Xylene (o,m,p) 71 86:14 
4 p-xylene 69 86:14 
5 o-xylene 71 87:13 
6 m-xylene 46 85:15 
7 Anisole 66 86:14 
8 1,3-dimethoxybenzene 54 86:14 
9 Chlorobenzene 51 88:12 
10 Nitrobenzene 40 85:15 
11 p-Cymene 63 86:14 
12 Cumene 57 87:13 
13 Benzonitrile 26 78:22 
14 Mesitylene 75 92:8 
 
a Yield of isolated product 4.12a 
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We next investigated the scope of this enantioselective version (Scheme 94). Whereas, the 
enantiomeric excess slightly decreases in the case of N-isopropyl compounds 4.12l-p-q-r, 
almost no enantioinduction was observed for compound 4.12s bearing a tetrasubstituted carbon. 
Analogous to the compound 4.12p, steric hindrance brought by the tetrasubstituted carbon 
probably affects the enantiodetermining step. Finally, we investigated the possibility to activate 
methylene and methine C-H bonds of compounds 4.12ab and 4.12z under the optimized 
conditions for the activation of N-isopropyl C-H bonds. Unfortunately, as observed for 
compound 4.12s, no enantioinduction was obtained. Moreover, the yield was moderate. 
 
Scheme 94 : Scope of the enantioselective version 
4.4. Application of the methodology 
Finally, we sought to apply our methodology for the construction of valuable compounds. For 
this purpose, we turned our attention to the synthesis of the enantiopure b-aminoacid 4.24, 
initially obtained by enzymatic resolution178 and used for the construction of foldamers179. We 
envisioned taking advantage of our methodology (Scheme 84) to provide an efficient synthesis 
of (+)-4.24. Starting from the commercially available enantiopure tetrahydronaphthylamine 
4.22, the precursor of C-H activation (-)-4.11ac was prepared in 86% yield without purification. 
Then, we applied our optimized conditions to obtain the enantiopure tricyclic b-lactam (-)-
4.12ac in good yield. Finally, removal of the TMB group under oxidative conditions and ring 
opening of the residual b-lactam (-)-4.23 afforded the desired product in very good overall yield 
compared to the previous enzymatic synthesis, thereby highlighting the synthetic potential of 
C-H activation to reach valuable compounds in an efficient manner (Scheme 95). 
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Scheme 95 : Synthesis of enantiopure b-aminoacid (+)-4.24 
5. Conclusion 
In summary, we have developed a new synthesis of b-lactams through Palladium(0)-catalyzed 
C(sp3)-carbamoylation. Importantly, we described a user-friendly process using stoichiometric 
carbon monoxide in a two-chamber system allowing a good practicability and safe conditions. 
Starting from readily accessible carbamoyl chlorides, we were pleased to find that primary, 
secondary and activated tertiary C-H bonds were competent in this methodology, thereby 
furnishing a broad scope with different functional groups. Furthermore, interesting 
unconventional spirocyclic and fused b-lactams were obtained. Interestingly, an 
enantioselective version of this reaction was developed using a new TADDOL-derived 
phosphonite. Finally, application of this methodology allows to obtain valuable enantiopure 
free b-lactams and b-aminoacids in an efficient manner. 
 
Scheme 96 : Overview of our b-lactams synthesis 
During the writing of this manuscript, Gaunt and coworkers reported an impressive 
palladium(II)-catalyzed carbonylation of methylene C-H bonds from aliphatic amines allowing 
the synthesis of highly trans-disubstituted b-lactams180. 
 
Scheme 97 : Activation of methylene C-H bonds by Gaunt and coworkers
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 General conclusion 
Over the past decade, the transition metal-catalyzed intramolecular activation of unactivated C-
H bonds has emerged as a powerful method for organic chemists. Indeed, due to the ubiquity 
of C-H bonds, their direct and selective functionalization provides a rapid access to molecular 
complexity in an atom- and step-economical fashion. Within this field, my Ph.D thesis was 
centered on the total synthesis of marine natural products and bioactive compounds as well as 
the development of new methodologies based on palladium(0)-catalyzed C(sp3)-H bond 
activation. 
Recently, our group developed a straightforward access to hexahydroindoles by intramolecular 
C(sp3)-H alkenylation. We first investigated the application of this new methodology in 
combination with a directed C(sp3)-H arylation to achieve a collective synthesis of 
aeruginosins. Notably, we were able to scale-up the synthesis of aeruginosin 298A to obtain 
this latter in unprecedented yield and quantity. Moreover, we could achieve the first total 
synthesis of aeruginosins 98A and 98C thanks to a fine-tuning of the final hydrogenation step, 
which allowed limiting concomitant dehalogenation (Figure 11). 
 
Figure 11 : Collective synthesis of aeruginosins 
In the second part, we turned our attention to the development a new palladium(0)-catalyzed 
C(sp3)-H alkenylation starting from easily available acyclic bromoalkenes. This new 
methodology allows to obtain a broad range of g-lactams by modification of R1-R4 groups. 
Moreover, these lactams can be used as valuable building blocks as demonstrated by the 
synthesis of the indolizidine alkaloid (±)-d-coniceine and of a plakoridine A precursor 
(Scheme 98).  
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Scheme 98 : Overview of the a-alkylidene-g-lactams synthesis via C(sp3)-H alkenylation 
Finally, we developed a general and user-friendly synthesis of b-lactams using readily available 
starting materials. A broad scope including activation of primary, secondary, and activated 
tertiary C-H bonds was described, in contrast to previous methods based on C(sp3)-H bond 
activation. In addition, an enantioselective version was enabled thanks to a TADDOL-derived 
phosphonite ligand. Moreover, these lactams can be used as valuable building blocks as 
demonstrated by the synthesis of enantiopure free b-lactams and b-aminoacids (Scheme 99) 
 
Scheme 99 : Overview of the synthesis of β-lactams via C(sp3)−H Carbamoylation 
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1. General information 
Techniques: All reactions involving air-sensitive material were carried out in pre-dried 
glassware under an argon atmosphere by using Schlenk techniques employing double-line 
argon-vacuum lines and working in an argon-filled glove box. Analytical thin layer 
chromatography (TLC) was performed using pre-coated Merck silica gel 60 F254 plates (0.25 
mm). Visualization of the developed chromatogram was performed by UV absorbance (254 
nm) or TLC stains (KMnO4 and Phosphomolybdic acid). Flash chromatography was performed 
using Silicycle SiliaFlash P60 (230-400 mesh) with the indicated solvent system, using 
gradients of increasing polarity in most cases. 
Chemicals: 
Anhydrous solvents were obtained by distillation over calcium hydride (xylenes) or by 
distillation over sodium (mesitylene, toluene). Anhydrous THF, DME, DMF, DMSO, were 
purchased from Acros Organics. The solvents were degassed by three cycles of freeze-pump-
thaw and storing in single-necked flasks equipped with a J-Young PTFE valve when necessary. 
PdCl2, Pd(OAc)2, Pd(PPh3)4 were purchased from Strem. All other chemical reagents were 
purchased from Sigma-Aldrich, Acros Organics, Fisher, Solvias and Fluorochem and used as 
received without further purification unless otherwise stated. CO gas was purchased from 
PanGas in 3.8 quality. 
Instrumentation: 
HPLC analyses were performed using a Shimadzu Prominence system with SIL-20A auto 
sample, CTO-20AC column oven, LC-20AD pump system, DGU-20A3 degasser and SPD 
M20A Diode Array or UV/VIS detector. The following chiral columns from Daicel Chemical 
Industries were used: OD-H (chiralcel), OJ-H (chiralcel) or IA (chiralpak) in 4.6 x 250 mm 
size. Infrared spectra were taken on a Bruker ALPHA FT-IR spectrometer and are reported in 
reciprocal centimeters (cm–1). Nuclear magnetic resonance spectra were recorded on a Bruker 
Advance 250 (250 MHz), Bruker Advance 400 (400 MHz), Bruker Advance 500 (500 MHz) 
in deuterated chloroform (residual peaks 1H δ = 7.26 ppm, 13C δ = 77.16 ppm) unless otherwise 
noted. 31P NMR spectra were on a Bruker Advance 400 (400 MHz). 19F spectra were referenced 
to external CFCl3. 31P spectra were referenced to external 95% solution of H3PO4. Data are 
reported in parts per million (ppm) as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintuplet, sept = septuplet, m = multiplet and br s = 
broad signal), coupling constant in Hz and integration. High resolution mass spectra were   
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recorded by Dr. H. Nadig (Department of Chemistry, University of Basel) on a Bruker maXis 
4G QTOF ESI mass spectrometer. Optical rotations were measured on a Perkin Elmer 341 
Polarimeter in a 1 mL micro cuvette (cell length 100mm) with NaD-Line (λ = 589 nm) at 20 
°C. 
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2. Chapter II : Divergent synthesis of aeruginosinsn based on a C(sp3)–
H activation strategy 
2.1. Nucleophilic substitution study 
 
To a solution of 1,6-heptadien-4-ol (2.11) (2 g, 17.8 mmol) and imidazole (1.58 g, 23.2 mmol) 
in DCM (12 mL) under argon, tert-butylchlorodimethylsilane (3.5 g, 23.2 mmol) was added at 
0 °C. The resulting mixture was stirred at room temperature during 16 hours. The reaction was 
quenched with an aqueous solution of NaHCO3 saturated and then extracted three times with 
ethyl acetate. The combined organic layers were washed with water, brine, dried over MgSO4, 
filtered and concentrated under vacuum at 40°C. The crude mixture mixture was purified by 
column chromatography (SiO2, pentane / Et2O, 1/0 to 99/1) to give the compound 2.20a (3.8 g, 
95%) as colorless oil. 1H NMR (300 MHz, CDCl3) d = 5.92 – 5.71 (m, 2H), 5.09 – 5.04 (m, 
2H), 5.02 (t, J = 2.5 Hz, 2H), 3.75 (p, J = 5.8 Hz, 1H), 2.31 – 2.13 (m, 4H), 0.92 – 0.88 (m, 9H), 
0.08 – 0.04 (m, 6H).13C NMR (75MHz, CDCl3) d = 135.4, 117.0, 71.9, 41.7, 26.0, 18.3, -4.3. 
HRMS (ESI): calculated for C13H27OSi 227.1831 found 227.1836. 
 
To a solution of 2.20a (3.3 g, 14.6 mmol) in DCM (51 mL) under argon, Grubbs I (301 mg, 
0.37 mmol) was added in one portion. The resulting mixture was stirred at room temperature 
during 20 min and then concentrated under vacuum at 40 °C until the half volume was 
evaporated. After, NaOH (3.51 g, 87.7 mmol) and benzyltriethylammonium chloride (167 mg, 
0.73 mmol) was added to the resulting mixture followed by CHBr3 (2.6 mL, 29.2 mmol). The 
resulting mixture was placed in ultrasonic bath during 6 hours. After, the brown solid was 
removed by filtration through a pad of sand and rinced with DCM. The filtrate was concentrated 
under vacuum at 40 °C. The crude mixture mixture was purified by column chromatography 
(SiO2, pentane / Et2O, 1/0 to 99/1) to give the compound 2.20a’ (5 g, 92%) as yellow oil. 1H 
NMR (300 MHz, CDCl3) d = 4.47 – 4.23 (m, 1H), 2.31 (d, J = 5.2 Hz, 2H), 2.13 (dd, J = 14.8, 
6.8 Hz, 2H), 1.93 (ddd, J = 10.2, 8.1, 4.2 Hz, 2H), 0.86 (s, 9H), 0.01 (s, 6H).  
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13C NMR (75MHz, CDCl3) d = 76.3, 42.0, 40.2, 37.9, 26.0, 18.2, -4.7. HRMS (ESI): 
calculated for C12H23Br2OSi 368.9885 found 368.9885. 
 
2.20a’ (3.7 g, 10.1 mmol) was then heated neat at 45 °C during 6 hours and then at 130 °C 
during 1 hour. The crude mixture mixture was purified by column chromatography (SiO2, 
pentane / DCM, 1/0 to 97/3) to give the compound 2.17a (3.2 g, 87%) as a mixture of 
diastereoisomers in 6 to 1 ratio and as a yellow oil. 1H NMR (300 MHz, CDCl3) d = 6.06 (dd, 
J = 5.6, 2.7 Hz, 1H), 4.79 (s, 1H), 4.47 – 4.27 (m, 1H), 2.57 – 2.44 (m, 1H), 2.42 – 2.33 (m, 
1H), 2.27 – 2.12 (m, 2H), 0.89 (s, 9H), 0.10 (s, 6H).13C NMR (75MHz, CDCl3) d = 132.2, 
121.9, 63.3, 53.4, 42.6, 37.5, 25.9, 18.2, -4.6, -4.6. HRMS (ESI): calculated for C12H23Br2OSi 
368.9885 found 368.9885. 
 
 
To a solution of 1,6-heptadien-4-ol (2.11) (2 g, 17.8 mmol) and imidazole (1.58 g, 23.2 mmol) 
in DCM (12 mL) under argon, tert-butylchlorodiphenylsilane (6.37 g, 23.2 mmol) was added 
at 0 °C. The resulting mixture was stirred at room temperature during 16 hours. The reaction 
was quenched with an aqueous solution of NaHCO3 saturated and then extracted three times 
with ethyl acetate. The combined organic layers were washed with water, brine, dried over 
MgSO4, filtered and concentrated under vacuum at 40°C. The crude mixture mixture was 
purified by column chromatography (SiO2, pentane / Et2O, 1/0 to 99/1) to give the compound 
2.20b (6.3 g, 100%) as colorless oil. 1H NMR (300 MHz, CDCl3) d = 7.77 – 7.69 (m, 4H), 
7.49 – 7.38 (m, 6H), 5.79 (ddt, J = 17.3, 10.3, 7.1 Hz, 2H), 5.07 – 4.92 (m, 4H), 3.93 – 3.82 (m, 
1H), 2.38 – 2.14 (m, 4H), 1.12 (s, 9H).13C NMR (75MHz, CDCl3) δ =136.1, 134.9, 134.5, 
129.7, 127.6, 117.2, 72.6, 40.7, 27.2, 19.5. HRMS (ESI): calculated for C23H31OSi 351.2144 
found 351.2148. 
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To a solution of 2.20b (6.3 g, 17.9 mmol) in DCM (63 mL) under argon, Grubbs I (367 mg, 
0.45 mmol) was added in one portion. The resulting mixture was stirred at room temperature 
during 20 min and then concentrated under vacuum at 40 °C until the half volume was 
evaporated. After, NaOH (4.3 g, 107 mmol) and benzyltriethylammonium chloride (203 mg, 
0.89 mmol) was added to the resulting mixture followed by CHBr3 (3.1 mL, 35.7 mmol). The 
resulting mixture was placed in ultrasonic bath during 6 hours. After, the brown solid was 
removed by filtration through a pad of sand and rinced with DCM. The filtrate was concentrated 
under vacuum at 40 °C. The crude mixture was purified by column chromatography (SiO2, 
pentane / Et2O, 1/0 to 99/1) to give the compound 2.20b’ (8.7 g, 99%) as yellow oil. 1H NMR 
(300 MHz, CDCl3) complex mixture of isomers. 13C NMR (75MHz, CDCl3) complex mixture 
of isomers. HRMS (ESI): calculated for C22H27Br2OSi 493.0198 found 493.0194. 
 
2.20b’ (5.9 g, 11.92 mmol) was then heated neat at 45 °C during 6 hours and then at 130 °C 
during 1 hour. The crude mixture mixture was purified by column chromatography (SiO2, 
pentane / DCM, 1/0 to 97/3) to give the compound 2.17b (5.1 g, 88%) as a mixture of 
diastereoisomers in 6 to 1 ratio and as a yellow oil. 1H NMR (300 MHz, CDCl3) d = 7.71 – 
7.62 (m, 4H), 7.47 – 7.35 (m, 6H), 6.06 – 5.91 (m, 1H), 4.73 – 4.58 (m, 1H), 4.49 – 4.31 (m, 
1H), 2.54 – 2.08 (m, 4H), 1.06 (s, 9H).). 13C NMR (75MHz, CDCl3, mixture of isomers) 
d = 135.8, 135.7, 135.6, 133.9, 133.7, 131.9, 131.2, 129.9, 129.9, 129.5, 127.8, 127.8, 127.6, 
121.8, 66.2, 64.1, 52.7, 49.8, 43.4, 42.1, 37.1, 36.5, 27.0, 26.9, 19.2. HRMS (ESI): calculated 
for C22H27Br2OSi 493.0198 found 493.0195. 
 
General procedure: To a solution of 2.17 in DMF (1 M), the nucleophile (6 equiv.) and K2CO3 
(1.1 equiv.) when the amine was used as nucleophile, were added and the resulting mixture 
stirred during 16 hours at room temperature.   
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The reaction was then quenched with water and extracted three times with ethyl acetate. The 
combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated 
under vacuum at 40 °C. The diastereoselectivity was observed by 1H NMR analysis in the crude 
mixture mixture. Then, the crude mixture was purified in silica gel to confirm the formation of 
the compound. 
 
Following the general procedure, 2.17a (250 mg, 0.68 mmol) and sodium azide were used 
leading to a 1:8 ratio of diastereoisomers. The purification of the crude mixture (pentane / 
AcOEt 1/0 to 97/3) afforded 183 mg (82%) of 2.19aa with a diastereoisomeric ratio of 1:6. 1H 
NMR (300 MHz, CDCl3) d = 6.24 – 6.09 (m, 1H), 4.03 – 3.95 (m, 1H), 2.36 – 2.22 (m, 2H), 
2.21 – 2.12 (m, 1H), 2.12 – 1.97 (m, 1H), 1.97 – 1.83 (m, 1H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 
(s, 3H).13C NMR (75MHz, CDCl3) d = 131.4, 120.7, 64.8, 61.6, 39.0, 36.9, 25.9, 18.3, -4.6, -
4.8. 
 
Following the general procedure, 2.17a (100 mg, 0.27 mmol) and propylamine were used 
leading to a 3:1 ratio of diastereoisomers. The purification of the crude mixture (pentane / 
AcOEt 1/0 to 9/1) afforded 22 mg (23%) of 2.18ab with a diastereoisomeric ratio of 1:0. 1H 
NMR (300 MHz, CDCl3) d = 6.04 – 5.96 (m, 1H), 4.19 – 4.05 (m, 1H), 3.49 – 3.35 (m, 1H), 
2.68 – 2.46 (m, 2H), 2.31 (dt, J = 17.3, 5.0 Hz, 1H), 2.09 – 1.90 (m, 2H), 1.87 – 1.74 (m, 1H), 
1.62 – 1.45 (m, 3H), 0.95 (t, J = 7.4 Hz, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.06 (s, 3H).13C NMR 
(75MHz, CDCl3) d = 129.3, 125.7, 64.0, 59.2, 49.1, 37.8,  37.4, 26.0, 23.6, 18.3, 12.0, -4.6. 
 
Following the general procedure, 2.17a (100 mg, 0.27 mmol) and isobutylamine were used 
leading to a 3:1 ratio of diastereoisomers. The purification of the crude mixture (pentane / 
AcOEt 1/0 to 9/1) afforded 58 mg (59%) of 2.18ac with a diastereoisomeric ratio of 1:0.  
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1H NMR (300 MHz, CDCl3) d = 6.04 – 5.93 (m, 1H), 4.14 – 4.05 (m, 1H), 3.38 (s, 1H), 2.41 
(d, J = 6.6 Hz, 2H), 2.36 – 2.27 (m, 1H), 2.08 – 1.93 (m, 2H), 1.80 – 1.69 (m, 2H), 1.52 (s, 1H), 
0.96 – 0.91 (m, 6H), 0.88 (s, 9H), 0.06 (s, 3H), 0.06 (s, 3H).13C NMR (75MHz, CDCl3) 
d = 129.4, 125.7, 64.0, 59.7, 55.6, 38.0, 37.5, 28.9, 26.1, 21.0, 20.9, 18.3, -4.5. 
 
 
Following the general procedure, 2.17a (150 mg, 0.42 mmol) and isopropylamine were used 
leading to a 6:1 ratio of diastereoisomers. The purification of the crude mixture (pentane / 
AcOEt 1/0 to 9/1) afforded 58 mg (59%) of 2.18ad with a diastereoisomeric ratio of 1:0. 1H 
NMR (300 MHz, CDCl3) d = 5.94 (dd, J = 5.2, 2.9 Hz, 1H), 4.15 – 4.04 (m, 1H), 3.41 (s, 1H), 
2.98 – 2.81 (m, 1H), 2.31 (dt, J = 17.3, 5.2 Hz, 1H), 2.07 – 1.87 (m, 2H), 1.82 – 1.66 (m, 2H), 
1.10 – 1.04 (m, 6H), 0.89 (s, 10H), 0.07 (s, 3H), 0.06 (s, 3H). 13C NMR (75MHz, CDCl3) 
d = 129.2, 125.4, 63.7, 57.8, 47.4, 39.5, 37.5, 26.0, 24.5, 22.6, 18.3, -4.6. 
 
Following the general procedure, 2.17b (250 mg, 0.51 mmol) and sodium azide were used 
leading to a 1:15 ratio of diastereoisomers. The purification of the crude mixture (pentane / 
AcOEt 1/0 to 97/3) afforded 199 mg (86%) of 2.19ba with a diastereoisomeric ratio of 1:15. 
1H NMR (300 MHz, CDCl3) d = 7.74 – 7.66 (m, 4H), 7.48 – 7.40 (m, 6H), 6.16 – 5.97 (m, 
1H), 4.02 – 3.92 (m, 1H), 3.93 – 3.84 (m, 1H), 2.33 – 2.23 (m, 1H), 2.26 – 2.17 (m, 2H), 2.08 
– 1.93 (m, 1H), 1.12 (s, 9H). 13C NMR (75MHz, CDCl3) d = 135.8, 133.8, 133.7, 131.2, 130.0, 
130.0, 127.9, 127.8, 121.0, 65.9, 61.8, 38.9, 36.6, 27.0, 19.2. 
 
Following the general procedure, 2.17b (250 mg, 0.51 mmol) and propylamine were used 
leading to a 7:1 ratio of diastereoisomers. The purification of the crude mixture (pentane / 
AcOEt 1/0 to 9/1) afforded 98 mg (41%) of 2.18bb with a diastereoisomeric ratio of 14:1.  
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1H NMR (300 MHz, CDCl3) d = 7.76 – 7.62 (m, 4H), 7.50 – 7.33 (m, 6H), 5.96 (t, J = 3.9 Hz, 
1H), 4.25 – 3.86 (m, 1H), 3.41 (t, J = 4.5 Hz, 1H), 2.53 – 2.18 (m, 3H), 2.17 – 2.05 (m, 1H), 
1.96 – 1.79 (m, 2H), 1.46 – 1.30 (m, 3H), 1.08 (s, 9H), 0.88 (t, J = 7.4 Hz, 3H).13C NMR 
(75MHz, CDCl3) d = 135.9, 135.8, 134.3, 134.2, 129.8, 129.8, 129.0, 127.7, 127.7, 125.9, 65.0, 
58.9, 48.5, 37.3, 37.0, 27.0, 23.4, 19.3, 11.9. 
 
Following the general procedure, 2.17b (250 mg, 0.51 mmol) and isobutylamine were used 
leading to a 8:1 ratio of diastereoisomers. The purification of the crude mixture (pentane / 
AcOEt 1/0 to 9/1) afforded 122 mg (50%) of 2.18bc with a diastereoisomeric ratio of 14:1. 1H 
NMR (300 MHz, CDCl3) d = 7.76 – 7.66 (m, 4H), 7.49 – 7.37 (m, 6H), 5.97 (t, J = 3.9 Hz, 
1H), 4.30 – 3.92 (m, 1H), 3.42 (t, J = 4.3 Hz, 1H), 2.36 – 2.06 (m, 4H), 2.01 – 1.81 (m, 2H), 
1.69 – 1.52 (m, 1H), 1.45 (br. s, 1H), 1.10 (s, 9H), 0.89 (d, J = 6.5 Hz, 6H). 13C NMR (75MHz, 
CDCl3) d = 135.8, 135.8, 134.3, 134.2, 129.8, 129.8, 128.9, 127.7, 127.7, 125.9, 65.0, 59.0, 
54.7, 37.5, 37.0, 28.6, 27.1, 20.8, 20.7, 19.3. 
 
Following the general procedure, 2.17b (310 mg, 0.65 mmol) and isopropylamine were used 
leading to a 11:1 ratio of diastereoisomers. The purification of the crude mixture (pentane / 
AcOEt 1/0 to 9/1) afforded 217 mg (73%) of 2.18bd with a diastereoisomeric ratio of 11:1. 1H 
NMR (400 MHz, CDCl3) d = 7.60 – 7.53 (m, 4H), 7.31 – 7.21 (m, 6H), 5.75 (s, 1H), 4.17 – 
3.87 (m, 1H), 3.28 (s, 1H), 2.85 – 2.46 (m, 1H), 2.24 – 2.06 (m, 1H), 2.07 – 1.89 (m, 2H), 1.87 
– 1.64 (m, 2H), 1.00 – 0.95 (m, 9H), 0.86 (d, J = 6.0 Hz, 3H), 0.80 (d, J = 6.2 Hz, 4H).13C NMR 
(75MHz, CDCl3) d =135.9, 135.8, 134.4, 134.3, 129.8, 129.8, 128.7, 127.8, 127.7, 125.6, 64.6, 
57.1, 46.7, 38.9, 37.2, 27.1, 24.3, 22.4, 19.3. 
 
To a solution of 2.19aa (170 mg, 0.37 mmol) in THF (0.5 mL), a solution of TBAF in THF 
(450 µL, 0.450 mmol, 1M) was added dropwise at 0 °C. The resulting mixture was stirred at 
room temperature during 16h and quenched with water. The mixture was then extracted with   
115 
 
ethyl acetate three times. The combined organic layers was washed with brine, dried over 
MgSO4, filtered and concentrated under vacuum at 40 °C. . The crude mixture was filtrated on 
a short pad of which gave the compound 2.19aa’ pure enough to be engaged in esterification. 
To a mixture of ferrocencarboxylic acid (44.8 mg, 0.2 mmol), EDCI (44.8 mg, 0.23 mmol) and 
DMAP (4.8 mg, 0.04 mmol), a solution of 2.19aa’ (51 mg, 0.23 mmol) in DCM (0.7 mL) was 
added at 0 °C. The resulting mixture was stirred at room temperature during 16 h and quenched 
with brine. The reaction was then extracted with DCM three times and the combined organic 
layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuum at 
40 °C. The crude mixture was purified by preparative TLC (SiO2, pentane / AcOEt 1/0 to 9/1) 
which gave the compound 2.21 (48 mg, 35 % over two steps) as brown crystal. 1H NMR (300 
MHz, CDCl3) d = 6.28 (t, J = 3.8 Hz, 1H), 5.34 – 5.18 (m, 1H), 4.91 – 4.78 (m, 2H), 4.41 (t, J 
= 1.9 Hz, 2H), 4.25 – 4.15 (m, 6H), 2.53 (dt, J = 17.7, 4.5 Hz, 1H), 2.45 – 2.39 (m, 1H), 2.39 – 
2.33 (m, 1H), 2.21 (ddd, J = 13.8, 7.7, 6.2 Hz, 1H). 13C NMR (75MHz, CDCl3) d = 171.4, 
130.5, 120.5, 71.7, 70.8, 70.6, 70.3, 69.9, 64.9, 60.7, 34.7, 33.0. HRMS (ESI): calculated for 
C17H17BrFeN3O2 429.9854 found 429.9850. 
 
To a solution of 2.18ad (279 mg, 0.59 mmol) in THF (0.7 mL), a solution of TBAF in THF 
(709 µL, 0.71 mmol, 1M) was added dropwise at 0 °C. The resulting mixture was stirred at 
room temperature during 16h and quenched with water. The mixture was then extracted with 
ethyl acetate three times. The combined organic layers was washed with brine, dried over 
MgSO4, filtered and concentrated under vacuum at 40 °C. The crude mixture was filtrated on a 
short pad of which gave the compound 2.18ad’ pure enough to be engaged in esterification. To 
a mixture of ferrocencarboxylic acid (45.9 mg, 0.2 mmol), EDCI (45.8 mg, 0.24 mmol) and 
DMAP (4.9 mg, 0.04 mmol), a solution of 2.18ad’ (56 mg, 0.24 mmol) in DCM (0.7 mL) was 
added at 0 °C. The resulting mixture was stirred at room temperature during 16 h and quenched 
with brine. The reaction was then extracted with DCM three times and the combined organic 
layers were washed with brine, dried over MgSO4, filtered and concentrated under vacuum at 
40 °C. The crude mixture was purified by preparative TLC (SiO2, pentane / AcOEt 1/0 to 9/1) 
which gave the compound 2.21’ (26 mg, 11 % over two steps) as brown crystal. 
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1H NMR (300 MHz, CDCl3) d = 6.04 (t, J = 3.8 Hz, 1H), 5.46 – 5.10 (m, 1H), 4.92 – 4.65 (m, 
2H), 4.50 – 4.30 (m, 2H), 4.19 (s, 5H), 3.66 – 3.37 (m, 1H), 2.98 (sept, J = 6.2 Hz, 1H), 2.59 
(dt, J = 9.5, 4.5 Hz, 1H), 2.31 – 2.16 (m, 1H), 2.16 – 1.95 (m, 2H), 1.41 (br s, 1H), 1.12 (d, J = 
6.2 Hz, 3H), 1.09 (d, J = 6.2 Hz, 3H). 13C NMR (75MHz, CDCl3) d = (C=O) is missing, 127.9, 
125.9, 71.5, 70.3, 69.9, 66.1, 56.8, 47.4, 35.9, 33.5, 24.3, 22.8. HRMS (ESI): calculated for 
C20H25BrFeNO2 446.0418 found 446.0420. 
2.2. Synthesis of the Choi Core 
 
To a solution of 1,6-heptadien-4-ol (2.11) (5 g, 43.2 mmol) and imidazole (3.83 g, 56.3 mmol) 
in DCM (30 mL) under argon, tert-butylchlorodiphenylsilane (14.6 mL, 56.2 mmol) was added 
at 0 °C. The resulting mixture was stirred at room temperature during 16 hours. The reaction 
was quenched with an aqueous solution of NaHCO3 saturated and then extracted three times 
with ethyl acetate. The combined organic layers were washed with water, brine, dried over 
MgSO4, filtered and concentrated under vacuum at 40°C. The resulting residue was absorbed 
on a pad of silica gel (diameter 7 cm, length 10 cm) and filtered off using a mixture of pentane 
/ Et2O (9/1, 300 mL). The filtrate was concentrated under vacuum at 40 °C. To a solution of the 
crude mixture product in DCM (140 mL) under argon, Grubbs I (1.08 g, 1.3 mmol) was added 
in one portion. The resulting mixture was stirred at room temperature during 20 min and then 
concentrated under vacuum at 40 °C until the half volume was evaporated. After, NaOH (10.5 
g, 262.6 mmol) and benzyltriethylammonium chloride (500 mg, 2.19 mmol) was added to the 
resulting mixture followed by CHBr3 (7.7 mL, 87.5 mmol). The resulting mixture was placed 
in ultrasonic bath during 6 hours. After, the brown solid was removed by filtration through a 
pad of sand and rinced with DCM. The filtrate was concentrated under vacuum at 40 °C and 
absorbed on a pad of silica gel (diameter 7 cm, length 10 cm) and filtered off using a mixture 
of pentane / Et2O (9/1, 2 L). The filtrate was concentrated under vacuum at 40 °C. The crude 
mixture product was then heated neat at 45 °C during 6 hours and then at 130 °C during 1 hour.  
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The resulting mixture was then dissolved in DMF (100 mL) and K2CO3 (6.4 g, 46.6 mmol) was 
added followed by (S)-1-((tert-butyldimethylsilyl)oxy)propan-2-amine181 (2.23) (32.1 g, 169.5 
mmol). The resulting mixture was stirred at room temperature during 16 hours and then 90 °C 
during 6 hours. After, the mixture was quenched with an aqueous solution of NaHCO3 saturated 
and then extracted three times with ethyl acetate. The combined organic layers were washed 
with water, brine, dried over MgSO4, filtered and concentrated at 40 °C under vacuum. Finally, 
the crude mixture mixture of diastereoisomer was purified by column chromatography (SiO2, 
pentane / Et2O 1/0 to 95/5) which gave the compound 2.24a (8 g, 33 %) as slightly yellow oil. 
[α]D= – 18.9 ° (CHCl3, c 0.95). 1H NMR (300 MHz, CDCl3) d = 0.1 (s, 6 H) 0.9 (s, 9 H) 1.0 
(d, J=6.4 Hz, 3 H) 1.1 (s, 9 H) 1.34 (br. s, 1H) 1.8 - 1.9 (m, 2 H) 2.1 (dddd, J=17.3, 7.5, 3.4, 1.5 
Hz, 1 H) 2.3 (dt, J=17.3, 4.9 Hz, 1 H) 2.5 - 2.6 (m, 1 H) 3.3 (dd, J=9.5, 5.7 Hz, 1 H) 3.4 (dd, 
J=9.5, 4.6 Hz, 1 H) 3.5 (t, J=4.4 Hz, 1 H) 4.1 - 4.3 (m, 1 H) 5.9 (dd, J=4.6, 3.5 Hz, 1 H) 7.3 - 
7.5 (m, 6 H) 7.6 - 7.8 (m, 4 H). 13C NMR (75 MHz, CDCl3) d = -5.4, -5.4, 16.7, 18.2, 19.1, 
25.9, 26.9, 37.0, 38.5, 52.0, 56.3, 64.6, 68.0, 125.5, 127.5, 127.6, 128.4, 129.6, 129.6, 134.2, 
134.3, 135.7, 135.7. HRMS (ESI): calculated for C31H49BrNO2Si2 602.2480 found 602.2498. 
 
To a solution of 2.24a (7.5 g, 12.42 mmol) and pyridine (3 mL, 37.25 mmol) in DCM (180 
mL), trifluoroacetic anhydride (5.2 mL, 37.25 mmol) was added dropwise at 0°C. The mixture 
was then stirred 16 hours at room temperature and quenched with a saturated aqueous solution 
of NaHCO3. The resulting mixture was extracted with ethyl acetate three times and the 
combined organic layers were washed with water, brine, filtered, dried over MgSO4 and 
concentrated in vacuo. The crude mixture mixture was purified by column chromatography 
(SiO2, pentane / Et2O, 1/0 to 95/5) to give the compound 2.10 (8.7 g, 100%) as colorless oil. 
[α]D= – 40.7 ° (CHCl3, c 1.33). 1H NMR (300 MHz, CDCl3) complex mixture of rotamers. 13C 
NMR (75 MHz, CDCl3) complex mixture of rotamers. 19F NMR (282 MHz, CDCl3, major 
rotamer) d =– 69.2 HRMS (ESI): calculated for C33H48BrF3NO3Si2 698.2303 found 698.2310. 
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A flame dried schlenk tube was introduced in a glovebox and was charged with Pd(PCy3)2 (754 
mg, 1.13 mmol), potassium pivalate (475 mg, 3.39 mmol) and K2CO3 (3.12 g, 22.6 mmol). The 
schlenk was then removed from the glovebox and a solution of 2.10 (7.89 g, 11.3 mmol) in 
distilled toluene (57 mL) was added in the schlenk tube under argon. The resulting mixture was 
then heated at 120 °C during 24 hours. The brownish mixture was then filtered through a pad 
of celite and concentrated in vacuo. Purification by column chromatography (SiO2, pentane/ 
Et2O, 1/0 to 98/2) gave the compound 2.25 (4.77 g, 68 %) as slightly yellow solid. m.p. = 113.2 
°C. [α]D= + 21.5 ° (CHCl3, c 1.13). 1H NMR (300 MHz, CDCl3, major rotamer) d = 0.03 (s, 
6 H) 0.86 - 0.92 (m, 9 H) 0.90 - 0.99 (m, 1 H) 1.10 (s, 9 H) 2.12 - 2.24 (m, 2 H) 2.58 - 2.74 (m, 
2 H) 2.84 (dt, J=12.0, 4.5 Hz, 1 H) 3.20 (t, J=9.8 Hz, 1 H) 3.58 (dd, J=9.6, 4.1 Hz, 1 H) 4.15 - 
4.34 (m, 2 H) 4.74 - 4.91 (m, 1 H) 5.56 - 5.66 (m, 1 H) 7.31 - 7.54 (m, 6 H) 7.56 - 7.82 (m, 4 
H). 13C NMR (75 MHz, CDCl3, major rotamer) d = 136.0, 135.8, 134.5, 134.3, 133.5, 129.8, 
129.6, 127.7, 127.6, 120.0, 116.3 (q, JC-F =288 Hz), 66.1, 63.2, 60.6, 59.4 (q, JC-F =2.7 Hz), 
55.1, 34.9, 34.1, 34.0, 27.0, 25.8, 19.3, 18.3, -5.4, -5.5 CO is missing. 19F NMR (282 MHz, 
CDCl3, major rotamer) d =- 70.57. HRMS (ESI): calculated for C33H47F3NO3Si2 618.3041 
found 618.3030. 
 
To a solution of 2.25 (4.4 g, 7.28 mmol) in EtOAc (36 mL), Rh/C (5 % wt) (3 g, 1.48 mmol) 
was added and the atmosphere was replaced by H2 via vacuum / H2 cycle (three times). The 
resulting mixture was stirred 16 hours at room temperature and then was filtered through a pad 
of celite. The filtrate was concentrated in vacuo and the residue was dissolved in CHCl3 (40 
mL). At 0°C, a solution 0.5% HCl methanolic (prepared from 226 mL of MeOH and 1.7 mL of 
Acetyl chloride) was added and stirred during 1 hour at room temperature. The reaction was 
quenched with a saturated aqueous solution of NaHCO3. The resulting mixture was extracted 
three times with ethyl acetate and the combined organic layers were washed with brine, dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
pentane/ AcOEt, 1/0 to 98/2) gave the compound 2.27 (3.5 g, 95%) as a colorless oil.   
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[α]D= + 1.17 ° (CHCl3, c 1). 1H NMR (300 MHz, CDCl3) d = 1.1 (s, 9 H) 1.3 - 1.7 (m, 4 H) 
1.7 - 2.1 (m, 3 H) 2.2 - 2.5 (m, 2 H) 3.6 (dd, J=10.9, 5.5 Hz, 1 H) 3.7 - 3.9 (m, 2 H) 4.1 - 4.2 
(m, 1 H) 4.2 - 4.3 (m, 1 H) 4.6 (dt, J=11.3, 5.5 Hz, 1 H) 7.3 - 7.5 (m, 6 H) 7.6 - 7.8 (m, 4 H). 
13C NMR (75 MHz, CDCl3) d = 157.2 (q, JC-F =37 Hz), 135.8, 135.7, 134.1, 133.7, 129.8, 
129.8, 127.7, 127.7, 116.6 (q, JC-F =288 Hz), 67.5, 64.5, 62.7, 56.3 (q, JC-F =2.3 Hz), 36.6, 34.3, 
28.1, 27.0, 26.2, 19.4, 19.2. 19F NMR (282 MHz, CDCl3) d =– 70.6. HRMS (ESI): calculated 
for C27H35F3NO3Si 506.2333 found 506.2326. 
 
To a solution of 2.27 (3.5 g, 6.92 mmol) in acetone (53 mL) at 0°C, Jones reagent (8 mL, 21.56 
mmol, 2.7 M) was added dropwise. After 3 hours at 0 °C, isopropanol (13 mL) was added and 
the resulting mixture was stirred 1 hour at room temperature. The reaction was then extracted 
with ethyl acetate three times and the combined organic layers were washed with water and 
brine, dried over MgSO4, filtered and dried in vacuo. Purification by column chromatography 
(SiO2, pentane/ AcOEt / AcOH (1 %), 9/1 to 6/4) gave the compound 2.28 (3.1 g, 86 %) as a 
colorless oil. [α]D= – 23.2 ° (CHCl3, c 1.55). 1H NMR (300 MHz, CDCl3) d = 1.1 (s, 9 H) 1.3 
- 1.5 (m, 2 H), 1.5 - 1.7 (m, 2 H), 2.0 - 2.2 (m, 2 H), 2.2 - 2.5 (m, 2 H), 2.5 - 2.7 (m, 1 H), 4.1 
(br. s., 1 H), 4.6 (t, J=9.2 Hz, 1 H), 4.7 (dt, J=11.1, 5.5 Hz, 1 H), 7.3 - 7.5 (m, 6 H), 7.6 - 7.8 
(m, 4 H), 11.3 (br. s., 1 H). 13C NMR (75 MHz, CDCl3) d = 19.3, 19.3, 26.1, 27.0, 29.2, 33.9, 
37.6, 56.4 (br), 60.0, 67.4, 116.2 (q, JC-F=286.5 Hz), 127.7, 127.8, 129.8, 129.9, 133.6, 134.0, 
135.7, 135.7, 155.9 (q, JC-F= 38.4 Hz) 176.8. 19F NMR (282 MHz, CDCl3) d =– 71.0. HRMS 
(ESI): calculated for C27H33F3NO4Si 520.2125 found 520.2124. 
 
To a solution of 2.28 (1.7 g, 3.27 mmol) in MeOH (16 mL) at 0 °C, a solution of TMSCHN2 in 
hexane (2M, 8.2 mL, 16.96 mmol) was added dropwise. After 30 min at 0 °C, acetic acid (1.7 
mL) was added and the resulting mixture was concentrated in vacuo. Purification by column 
chromatography (SiO2, pentane/ AcOEt, 9/1 to 6/4) gave the compound 2.28’(1.7 g, 97 %) as 
a colorless oil. [α]D= – 17.6 (CHCl3, c 1.72). 
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1H NMR (300 MHz, CDCl3) d = 1.15 (s, 9 H), 1.30 - 1.48 (m, 2 H), 1.48 - 1.69 (m, 2 H), 1.90 
- 2.15 (m, 2 H), 2.21 - 2.46 (m, 2 H), 2.46 - 2.62 (m, 1 H), 3.75 (s, 3 H), 4.15 (br. s., 1 H), 4.58 
(t, J=9.3 Hz, 1 H), 4.67 (dt, J=11.6, 5.9 Hz, 1 H), 7.36 - 7.51 (m, 6 H), 7.67 – 7.75 (m, 4 H). 
13C NMR (75 MHz, CDCl3) d = 171.5, 155.6 (q, JC-F = 37.3 Hz), 135.57, 135.53, 133.85, 
133.39, 129.71, 129.62, 127.56, 127.50, 116.1(q, JC-F = 286.5 Hz),, 67.3, 59.9, 56.0 (q, JC-F = 
2.2 Hz), 52.3, 37.4, 33.8, 29.2, 26.8, 26.0, 19.2, 19.1. 19F NMR (282 MHz, CDCl3) d = – 71.0. 
HRMS (ESI): calculated for C28H35F3NO4Si 534.2282 found 534.2271. 
 
To a solution of 2.28’ (1.68 g, 3.15mmol) in MeOH (31 mL) at 0°C, NaBH4 (715 mg, 18.89 
mmol) was added in one portion. After 2 hours at 0 °C, a spatula of silica gel was added and 
the resulting mixture was concentrated in vacuo. Purification by column chromatography (SiO2, 
pentane/ AcOEt / Et3N (1 %), 9/1 to 1/1) gave the compound 2.6 (1.15 g, 83 %) as a colorless 
oil. [α]D= – 10.35 ° (CHCl3, c 1.25). 1H NMR (300 MHz, CDCl3) d = 1.08 (s, 9 H) 1.16 - 1.46 
(m, 3 H) 1.52 - 1.80 (m, 4 H) 2.00 - 2.22 (m, 2 H) 2.52 (br. s., 1 H) 3.36 (q, J=5.6 Hz, 1 H) 3.69 
(s, 3 H) 3.77 (dd, J=9.5, 6.3 Hz, 1 H) 3.92 - 4.03 (m, 1 H) 7.33 - 7.47 (m, 6 H) 7.64 - 7.72 (m, 
4 H). 13C NMR (75 MHz, CDCl3) d = 176.0, 135.6, 134.5, 134.3, 129.5, 129.4, 127.5, 127.4, 
67.9, 58.4, 57.6, 52.0, 37.4, 36.3, 34.8, 31.7, 26.9, 24.0, 19.1. HRMS (ESI): calculated for 
C26H36NO3Si 438.2459 found 438.2450. 
 
To a solution of 2.28 (198 mg, 0.381 mmol, 1 equiv) in THF (4 mL9 at 0°C under inert 
atmosphere, N-methylmorpholine (76 µL, 0.457 mmol, 1.2 equiv) was added followed by 
isobutyl chloroformate (60 µL, 0.457 mmol, 1.2 equiv) and the resulting mixture was stirred at 
0°C during one hour. The, ammonia was bubbled into the resulting mixture during 15 minutes 
and the resulting mixture was stirred at room temperature overnight. The crude mixture was 
concentrated under reduce pressure and extracted with ethyl acetate, driedd over MgSO4, 
filtered and concentrated under reduce pressure to afford the desired compound 2.28’’ without 
further purification (163 mg, 0.314 mmol, 83%). 
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1H NMR (300 MHz, CDCl3) d =  7.77 – 7.57 (m, 4H), 7.47 – 7.35 (m, 6H), 6.72 (br s, 1H), 
6.07 (br s, 1H), 4.73 – 4.44 (m, 2H), 4.18 – 4.06 (m, 1H), 2.53 – 2.38 (m, 1H), 2.36 – 2.21 (m, 
2H), 2.15 – 2.04 (m, 1H), 1.98 – 1.81 (m, 1H), 1.69 – 1.56 (m, 2H), 1.54 – 1.37 (m, 2H), 1.11 
(s, 9H). 19F NMR (282 MHz, CDCl3) d = –70.73. 13C NMR (75 MHz, CDCl3) d = 172.6, 
156.5 (q, J = 37.4 Hz), 135.8, 135.7, 134.1, 133.7, 129.9, 129.8, 127.7, 127.7, 116.4 (q, J = 
287.0 Hz), 67.5, 60.9, 56.8, 37.3, 33.7, 28.6, 27.0, 26.1, 19.4, 19.3. 
To a solution of 2.28’’ (163 mg, 0.314 mmol) in MeOH (3.1 mL) at 0°C, NaBH4 (35.7 mg, 
0.943 mmol, 3 equiv) was added in one portion. After 2 hours at 0 °C, a spatula of silica gel 
was added and the resulting mixture was concentrated in vacuo. Purification by column 
chromatography (SiO2, pentane/ AcOEt / Et3N (1 %), 9/1 to 1/1) gave the compound 2.29 
(118.2 mg, 0.28 mmo, 89 %) as a colorless oil. 
1H NMR (300 MHz, CDCl3) d = 7.73 – 7.65 (m, 4H), 7.47 – 7.31 (m, 6H), 7.10 (br s, 1H), 
5.79 (br s, 1H), 3.97 – 3.84 (m, 1H), 3.61 (dd, J = 10.9, 4.6 Hz, 1H), 3.46 (q, J = 4.8 Hz, 1H), 
2.24 (ddd, J = 13.1, 10.9, 7.0 Hz, 1H), 2.04 (s, 1H), 1.97 – 1.85 (m, 1H), 1.77 – 1.52 (m, 4H), 
1.43 – 1.16 (m, 3H), 1.07 (s, 9H). 
2.3. Synthesis of the C-termini 
 
To a solution of N-Boc L-orthinine 2.30 (1.14 g, 4.91 mmol) and Et3N (0.82 mL, 5.89 mmol) 
in DCM (10 mL), N-methyl-N-trimethylsilyltrifluoroacetamide (2.15 g, 10.8 mmol) was added 
and heated until a clear solution was obtained. After cooling at room temperature, N,N’-di-Cbz-
N’’-trifluoromethanesulfonyl-guanidine88 2.31 (2.7 g, 5.89 mmol) was added in one portion and 
the reaction was stirred at room temperature during 16 hours. The reaction was then quenched 
with an aqueous solution of NaHSO4 (2M) and extracted with DCM three times. The combined 
organic layers were washed with an aqueous solution of NaHSO4 (2M) and water, dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
pentane / AcOEt / 1% AcOH, 8/2 to 1/1) gave the compound 2.32 (2.02 g, 76 %) as a colourless 
oil. [α]D= + 14 ° (CHCl3, c 1). 1H NMR (300 MHz, CDCl3) d = 11.25 (br. s., 2 H) 8.29 (br. s., 
1 H) 7.11 - 7.35 (m, 10 H) 5.24 (br. d., J=7.9 Hz, 1 H) 5.07 (s, 2 H) 5.03 (s, 2 H) 4.24 (br. s., 1 
H) 3.34 (br. s., 2 H) 1.70 - 1.87 (m, 1 H) 1.46 - 1.69 (m, 3 H) 1.34 (s, 9 H)  
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13C NMR (75 MHz, CDCl3) d = 163.4, 155.9, 153.7, 136.5, 134.4, 128.6, 128.5, 128.3, 128.3, 
127.9, 127.8, 68.1, 67.1, 40.4, 28.2. HRMS (ESI): calculated for C27H35N4O8 543.2449 found 
543.2440. 
 
To a solution of 2.32 (1.7 g, 3.13 mmol) and N-methyl-morpholine (344 µL, 3.13 mmol) in 
THF (10 mL) at – 10 °C, isobutyl chloroformate (408 µL, 3.13 mmol) was added dropwise. 
After 30 min, the reaction was filtered through a celite pad and rinced with THF (1 mL). The 
filtrate was added to a solution NaBH4 (355 mg, 9.4 mmol) in a mixture H2O (2 mL) and THF 
(8 mL) at 0°C. After 4 hours at room temperature, the reaction was quenched with an aqueous 
solution of HCl (1N) and the resulting mixture was concentrated in vacuo. The resulting 
aqueous solution was extracted with EtOAc three times and the combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, pentane / AcOEt, 1/1 to 3/7) gave the compound 2.33 (1.22 g, 74 %) as a colourless oil. 
[α]D= – 3.3 ° (CHCl3, c 1.25). 1H NMR (300 MHz, CDCl3) d = 11.66 (br. s., 1 H) 8.27 (t, J=5.2 
Hz, 1 H) 7.11 - 7.37 (m, 10 H) 5.09 (s, 2 H) 5.04 (s, 2 H) 4.80 (d, J=7.5 Hz, 1 H) 3.40 - 3.59 
(m, 3 H) 3.35 (q, J=6.6 Hz, 2 H) 2.75 (br. s., 1 H) 1.42 - 1.64 (m, 3 H) 1.35 (s, 9 H). 13C NMR 
(75 MHz, CDCl3) d = 163.6, 156.0, 153.8, 136.6, 134.5, 128.7, 128.6, 128.4, 128.3, 128.0, 
127.9, 68.1, 67.1, 40.8, 28.3, 25.7. HRMS (ESI): calculated for C27H37N4O7 529.2657 found 
529.2648. 
 
To a solution of 2.33 (1.22 g, 2.31 mmol) in DCM (18 mL), imidazole (630 mg, 9.23 mmol) 
followed by TBSCl (1.39 g, 9.23 mmol) were added at 0 °C. The resulting mixture was stirred 
at room temperature during 16 hours. The reaction was quenched with an aqueous saturated 
solution of NaHCO3 and extracted with EtOAC three times. The combined organic layers were 
washed with water and brine, dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (SiO2, pentane / AcOEt, 8/2 to 1/1) gave the compound 
2.34 (1.47 g, 99 %) as a colorless oil. [α]D= – 5.4 ° (CHCl3, c 1.1). 1H NMR (300 MHz, CDCl3) 
d = 11.72 (s, 1 H) 8.30 (t, J=5.2 Hz, 1 H) 7.18 - 7.39 (m, 10 H) 5.12 (s, 2 H) 5.08 (s, 2 H) 4.66 
(d, J=7.3 Hz, 1 H) 3.47 - 3.62 (m, 3 H) 3.34 - 3.47 (m, 2 H) 1.45 - 1.68 (m, 3 H) 1.40 (s, 9 H) 
0.84 (s, 9 H) 0.00 (s, 6 H).  
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13C NMR (75 MHz, CDCl3) d = 163.6, 155.8, 155.4, 153.7, 136.7, 128.6, 128.5, 128.3, 128.2, 
127.9, 127.7, 67.9, 66.9, 64.6, 40.8, 28.2, 25.7, 18.1, -5.6. HRMS (ESI): calculated for 
C33H51N4O7Si 643.3522 found 643.3505. 
 
To a solution of 2.34 (1.47 g, 2.3 mmol) and 2,6-lutidine (2.1 mL, 18.4 mmol) in DCM (23 mL) 
at – 78 °C, TMSOTf (2.5 mL, 13.8 mmol) was added dropwise and the resulting mixture was 
allowed to warm to room temperature. After 1 hour, the reaction was quenched with an aqueous 
saturated solution of NaHCO3 and extracted with EtOAC three times. The combined organic 
layers were washed with water and brine, dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (SiO2, CHCl3 / MeOH (NH3, 7N), 1/0 to 95/5) gave 
the compound 2.7a (1.25 g, 100 %) as a colorless oil. [α]D= + 2.1 ° (CHCl3, c 1.1). 1H NMR 
(300 MHz, CDCl3) d = 7.16 - 7.40 (m, 10 H) 5.11 (s, 2 H) 5.06 (s, 2 H) 3.64 (dd, J=10.5, 4.0 
Hz, 1 H) 3.50 (dd, J=10.5, 6.2 Hz, 1 H) 3.32 (t, J=6.1 Hz, 2 H) 3.04 - 3.15 (m, 1 H) 1.45 - 1.73 
(m, 4 H) 0.82 (s, 9 H) 0.00 (s, 6 H). 13C NMR (75 MHz, CDCl3) d = 163.1, 156.1, 153.5, 136.4, 
134.4, 128.7, 128.5, 128.3, 128.1, 127.9, 68.1, 67.1, 63.7, 53.0, 40.1, 26.7, 25.6, 24.8, 18.0, -
5.8. HRMS (ESI): calculated for C28H43N4O5Si 543.2997 found 543.2999. 
 
To a solution of N-Boc butan-1,4-diamine 2.35 (1 mL, 5.23 mmol) and Et3N (727 µL, 5.23 
mmol) in DCM (20 mL), N,N’-di-Cbz-N’’-trifluoromethanesulfonyl-guanidine 2.31 (2.2 g, 4.7 
mmol) was added in one portion and the reaction was stirred at room temperature during 16 
hours. The reaction was then quenched with an aqueous solution of NaHSO4 (2M) and extracted 
with DCM three times. The combined organic layers were washed with an aqueous solution of 
NaHSO4 (2M) and water, dried over MgSO4, filtered and concentrated in vacuo. Purification 
by column chromatography (SiO2, pentane / AcOEt, 8/2 to 1/1) gave the compound 2.36 (2.34 
g, 100 %) as a colourless oil. 1H NMR (300 MHz, CDCl3) d = 11.65 (s, 1 H) 8.22 (t, J=5.4 Hz, 
1 H) 7.11 - 7.36 (m, 10 H) 5.04 (s, 2 H) 5.02 (s, 2 H) 4.72 (br. s., 1 H) 3.25 - 3.36 (m, 2 H) 2.93 
- 3.08 (m, 2 H) 1.36 - 1.56 (m, 4 H) 1.33 (s, 9 H). 13C NMR (75 MHz, CDCl3) d = 163.4, 155.7, 
153.5, 136.5, 134.3, 128.5, 128.4, 128.2, 128.1, 127.8, 127.6, 78.7, 67.8, 66.8, 40.4, 39.7, 28.1, 
27.0, 26.0. 
  
124 
 
 
To a solution of 2.36 (1.03 g, 2.07 mmol) and 2,6-lutidine (1.9 mL, 16.53 mmol) in DCM (20 
mL) at – 78 °C, TMSOTf (2.3 mL, 12.4 mmol) was added dropwise and the resulting mixture 
was allowed to warm to room temperature. After 1 hour, the reaction was quenched with an 
aqueous saturated solution of NaHCO3 and extracted with EtOAC three times. The combined 
organic layers were washed with water and brine, dried over MgSO4, filtered and concentrated 
in vacuo. Purification by column chromatography (SiO2, CHCl3 / MeOH (NH3, 7N), 1/0 to 
95/5) gave the compound 2.7b (823 mg, 100 %) as a colorless oil. 1H NMR (300 MHz, CDCl3) 
d = 8.23 (s, 1H), 7.32 - 7.08 (m, 10H), 5.02 (s, 2H), 5.01 (s, 2H), 4.49 (br. s., 2H), 3.36 - 3.21 
(m, 2H), 2.54 (t, J = 6.8 Hz, 2H), 1.52 - 1.39 (m, 2H), 1.39 - 1.24 (m, 2H). 13C NMR (75 MHz, 
CDCl3) d = 163.7, 155.9, 153.8, 136.8, 134.7, 128.7, 128.6, 128.4, 128.4, 128.1, 127.9, 68.0, 
67.0, 41.7, 40.9, 30.8, 26.3. 
2.4. Synthesis of HPLA fragments 
 
To a solution of (R)-2-(benzyloxy)propanoic acid 2.39 (4 g, 22.2 mmol), 2-pyridinylisopropyl 
(4.5 g, 33.3 mmol), DIPEA (14.7 mL, 89 mmol) in DMF (150 mL) at 0 °C, HBTU (12.6 g, 33.3 
mmol) was added in one portion and the resulting mixture was stirred at room temperature 
during 16 hours. The reaction was then quenched with an aqueous saturated solution of 
NaHCO3 and extracted three times with ethyl acetate. The combined organic layers were 
washed three times with water and finally with brine. The organic layer was then dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
pentane/ AcOEt, 9/1 to 1/1) gave the compound 2.13 (6 g, 92 %) as a colorless oil. [α]D= + 17.8 
° (CHCl3, c 1.3). 1H NMR (300 MHz, CDCl3) d = 8.87 (br. s., 1 H) 8.48 - 8.54 (m, 1 H) 7.72 
(td, J=7.7, 1.9 Hz, 1 H) 7.45 - 7.52 (m, 2 H) 7.31 - 7.42 (m, 4 H) 7.20 (ddd, J=7.3, 4.9, 0.9 Hz, 
1 H) 4.64 - 4.71 (m, 1 H) 4.57 - 4.64 (m, 1 H) 3.96 (q, J=6.8 Hz, 1 H) 1.78 (s, 3 H) 1.78 (s, 3 
H) 1.47 (d, J=6.8 Hz, 3 H). 13C NMR (75 MHz, CDCl3) d = 172.1, 164.2, 147.4, 137.4, 136.8, 
128.2, 127.7, 127.6, 121.6, 119.0, 76.9, 71.9, 55.8, 27.4, 27.1, 18.6. HRMS (ESI): calculated 
for C18H23N2O2 299.1754 found 299.1763.  
  
125 
 
 
A solution of 2.13 (1.2 g, 4.02 mmol), 4-iodophenoxytris(propane-2-yl)silane 2.14a (6.05 g, 
16.1 mmol), Pd(OAc)2 (90 mg, 0.4 mmol) and K2CO3 (1.39 g, 10.1 mmol) in MeCN (8 mL) 
was heated at 110 °C during 24 hours. The cooled mixture was filtered through a pad of celite 
and concentrated in vacuo. Purification by column chromatography (SiO2, Pentane / EtOAc, 
1/0 to 1/1) gave the compound 2.40a (1.39 g, 63 %) as a slightly brownish oil. [α]D= + 22 ° 
(CHCl3, c 1). HPLC analysis on a chiral stationary phase (SHIMADZU LC-20AD, 
Phenomenex Lux Cellulose-1, 5µm 150 x 4,6 mm) showed an e.e. > 99% (Hexane/i-PrOH : 
99.5/0.05 during 40 min; RT (R) = 23.1 min; RT (S) = 27 min). 1H NMR (300 MHz, CDCl3) 
d = 8.68 (s, 1H), 8.30 (d, J = 4.2 Hz, 1H), 7.50 (td, J = 7.9, 1.6 Hz, 1H), 7.23 ‒ 7.11 (m, 7H), 
7.07 – 6.96 (m, 3H), 6.68 (d, J = 8.4 Hz, 2H), 4.44 (d, J = 11.3 Hz, 1H), 4.30 (d, J = 11.3 Hz, 
1H), 3.90 (dd, J = 8.0, 3.3 Hz, 1H), 3.07 (dd, J = 14.1, 3.2 Hz, 1H), 2.80 (dd, J = 14.1, 8.1 Hz, 
1H), 1.62 (s, 3H), 1.56 (s, 3H), 1.18 – 1.06 (m, 4H), 0.99 – 0.91 (m, 18H).13C NMR (75 MHz, 
CDCl3) d = 170.7, 164.3, 154.5, 147.5, 137.5, 136.8, 130.6, 130.2, 128.2, 128.0, 127.7, 121.6, 
119.4, 119.1, 81.2, 73.0, 56.1, 38.3, 27.4, 27.3, 17.8, 12.5. HRMS (ESI): calculated for 
C33H46N2O3Si 547.3356 found 547.3359. 
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To a solution of 2.40a (400 mg, 0.73 mmol) in pyridine (16 mL) at – 30 °C, NOBF4 (855 mg, 
7.32 mmol) was added in one portion and the resulting mixture was stirred 3 hours at – 30 °C 
then 16 hours at room temperature. The reaction was quenched with an aqueous solution of HCl 
(6M) until the pH was around 1, then the mixture was extracted with ethyl acetate three time. 
The combined organic layers were washed with an aqueous solution of HCl (1M) two times, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, pentane / AcOEt / AcOH (1%), 9/1 to 7/3) gave the compound 2.9a (215 mg, 69 %) as 
a slightly yellow oil. [α]D= +24.2 ° (CHCl3, c 1.4). 1H NMR (300 MHz, CDCl3) d = 7.36 – 
7.27 (m, 3H), 7.23 – 7.15 (m, 2H), 7.10 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.5 Hz, 2H), 4.58 (d, J 
= 11.5 Hz, 1H), 4.42 (d, J = 11.5 Hz, 1H), 4.16 (dd, J = 8.3, 4.0 Hz, 1H), 3.12 (dd, J = 14.2, 4.0 
Hz, 1H), 2.96 (dd, J = 14.2, 8.3 Hz, 1H), 1.31 – 1.18 (m, 3H), 1.10 (m, 18H).13C NMR (75 
MHz, CDCl3) d = 155.1, 137.0, 130.6, 129.2, 128.5, 128.1, 128.1, 119.9, 119.7, 79.0, 72.9, 
38.4, 18.1, 12.8.HRMS (ESI): calculated for C25H36NaO4Si 451.2281 found 451.2292.  
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To a solution of 2.9a (190 mg, 0.44 mmol), D-Leucine methyl ester hydrochloride 2.8a (121 
mg, 0.66 mmol), DIPEA (0.3 mL, 1.8 mmol) in DMF (3 mL) at 0 °C, HBTU (252 mg, 0.66 
mmol) was added in one portion and the resulting mixture was stirred at room temperature 
during 16 hours. The reaction was then quenched with an aqueous saturated solution of 
NaHCO3 and extracted three times with ethyl acetate. The combined organic layers were 
washed three times with water and finally with brine. The organic layer was then dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
pentane/ AcOEt, 9/1 to 1/1) gave the compound 2.42 (177 g, 72 %) as a colorless oil. [α]D= + 
29 ° (CHCl3, c 1.15). 1H NMR (300 MHz, CDCl3) d = 7.29 – 7.13 (m, 5H), 7.01 (d, J = 8.5 
Hz, 2H), 6.80 (d, J = 9.0 Hz, 1H), 6.75 – 6.68 (m, 2H), 4.62 – 4.52 (m, 1H), 4.50 (d, J = 11.3 
Hz, 1H), 4.32 (d, J = 11.3 Hz, 1H), 3.97 (dd, J = 7.8, 3.5 Hz, 1H), 3.66 (s, 3H), 3.03 (dd, J = 
14.2, 3.4 Hz, 1H), 2.77 (dd, J = 14.2, 7.8 Hz, 1H), 1.55 – 1.42 (m, 1H), 1.42 – 1.27 (m, 2H), 
1.24 – 1.10 (m, 3H), 1.07 – 0.98 (m, 18H), 0.85 – 0.77 (m, 6H). 13C NMR (75 MHz, CDCl3) 
d = 173.4, 171.8, 154.9, 137.2, 130.7, 129.7, 128.6, 128.2, 128.1, 119.7, 81.1, 73.1, 52.3, 50.0, 
41.6, 38.4, 24.7, 22.9, 21.8, 18.0, 12.7. HRMS (ESI): calculated for C32H50NO5Si 556.3458 
found 556.3453. 
 
A solution of 2.13 (1.5 g, 5.03 mmol), 1-(benzyloxy)-4-iodobenzene 2.14b (6.24 g, 20.11 
mmol), Pd(OAc)2 (113 mg, 0.5 mmol) and K2CO3 (1.74 g, 12.6 mmol) in MeCN (10 mL) was 
heated at 110 °C during 24 hours. The cooled mixture was filtered through a pad of celite and 
concentrated in vacuo. Purification by column chromatography (SiO2, toluene / Et2O, 1/0 to 
6/4) gave the compound 2.40b (1.88 g, 78 %) as a slightly brownish oil. [α]D= + 45 ° (CHCl3, 
c 0.7). HPLC analysis on a chiral stationary phase (SHIMADZU LC-20AD, Phenomenex Lux 
Cellulose-1, 5µm 150 x 4,6 mm) showed an e.e. > 99% (Hexane/i-PrOH : 90/10 during 20 min; 
RT (R) = 10.19 min; RT (S) = 7.25 min). 
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1H NMR (300 MHz, CDCl3) d = 8.64 (s, 1 H), 8.28 - 8.34 (m, 1 H), 7.45 - 7.55 (m, 1 H), 7.06 
- 7.32 (m, 13 H), 6.99 (ddd, J=7.5, 4.9, 1.0 Hz, 1 H), 6.74 - 6.81 (m, 2 H), 4.89 (s, 2 H), 4.46 
(d, J=11.4 Hz, 1 H), 4.30 (d, J=11.4 Hz, 1 H), 3.89 (dd, J=8.1, 3.5 Hz, 1 H), 3.06 (dd, J=14.1, 
3.5 Hz, 1 H), 2.82 (dd, J=14.2, 8.2 Hz, 1 H), 1.62 (s, 3 H), 1.56 (s, 3 H). 13C NMR (75 MHz, 
CDCl3) d = 170.7, 164.2, 157.2, 147.5, 137.3, 137.0, 136.7, 130.6, 130.1, 128.3, 128.1, 127.9, 
127.7, 127.6, 127.2, 121.6, 119.0, 114.4, 81.8, 72.9, 69.7, 56.0, 38.2, 27.4, 27.2. HRMS (ESI): 
calculated for C31H33N2O3 481.2486 found 481.2477. 
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A solution of 2.13 (310 mg, 1.04 mmol), 1-(benzyloxy)-2-chloro-4-iodobenzene 2.14c (1.43 g, 
4.16 mmol), Pd(OAc)2 (23 mg, 0.1 mmol) and K2CO3 (360 mg, 2.6 mmol) in MeCN (2 mL) 
was heated at 110 °C during 24 hours. The cooled mixture was filtered through a pad of celite 
and concentrated in vacuo. Purification by column chromatography (SiO2, toluene / Et2O, 1/0 
to 6/4) gave the compound 2.40c (265 mg, 50 %) as a slightly brownish oil. [α]D= + 27.9 ° 
(CHCl3, c 1.1). 1H NMR (300 MHz, CDCl3) d = 8.69 (s, 1 H) 8.29 - 8.36 (m, 1 H) 7.52 (td, 
J=7.8, 1.8 Hz, 1 H) 7.27 - 7.36 (m, 2 H) 7.07 - 7.26 (m, 9 H) 6.92 - 7.07 (m, 3 H) 6.72 (d, J=8.3 
Hz, 1 H) 4.97 (s, 2 H) 4.49 (d, J=11.1 Hz, 1 H) 4.31 (d, J=11.3 Hz, 1 H) 3.88 (dd, J=7.7, 3.6 
Hz, 1 H) 3.00 (dd, J=14.2, 3.5 Hz, 1 H) 2.80 (dd, J=14.2, 7.8 Hz, 1 H) 1.63 (s, 3 H) 1.56 (s, 3 
H). 13C NMR (75 MHz, CDCl3) d = 170.5, 164.4, 152.8, 147.7, 137.3, 137.0, 136.7, 131.7, 
131.5, 129.0, 128.6, 128.5, 128.3, 128.0, 128.0, 127.1, 122.8, 121.9, 119.3, 113.9, 81.6, 73.1, 
70.9, 56.3, 38.0, 27.6, 27.4. HRMS (ESI): calculated for C31H32ClN2O3 515.2096 found 
515.2085.  
 
A solution of 2.13 (264 mg, 0.89 mmol), 1-(benzyloxy)-2-bromo-4-iodobenzene 2.14d (1.38 g, 
3.54 mmol), Pd(OAc)2 (20 mg, 0.09 mmol) and K2CO3 (306 mg, 2.21 mmol) in MeCN (2 mL) 
was heated at 110 °C during 24 hours. The cooled mixture was filtered through a pad of celite 
and concentrated in vacuo. Purification by column chromatography (SiO2, toluene / Et2O, 1/0 
to 6/4) gave the compound 2.40d (302 mg, 61 %) as a slightly brownish oil. [α]D= +25.8 ° 
(CHCl3, c 1.2). 1H NMR (300 MHz, CDCl3) d = 8.76 (s, 1 H) 8.39 - 8.45 (m, 1 H) 7.63 (td, 
J=7.7, 1.8 Hz, 1 H) 7.51 (d, J=2.0 Hz, 1 H) 7.40 - 7.46 (m, 2 H) 7.18 - 7.36 (m, 8 H) 7.07 - 7.17 
(m, 3 H) 6.79 (d, J=8.4 Hz, 1 H) 5.08 (s, 2 H) 4.59 (d, J=11.2 Hz, 1 H) 4.40 (d, J=11.2 Hz, 1 
H) 3.96 (dd, J=7.9, 3.5 Hz, 1 H) 3.09 (dd, J=14.1, 3.5 Hz, 1 H) 2.89 (dd, J=14.2, 7.8 Hz, 1 H) 
1.71 (s, 3 H) 1.64 (s, 3 H). 13C NMR (75 MHz, CDCl3) d = 170.4, 164.2, 153.5, 147.6, 137.2, 
136.9, 136.6, 134.5, 131.8, 129.6, 128.4, 128.3, 128.1, 127.8, 127.8, 126.9, 121.7, 119.1, 113.5, 
112.0, 81.4, 73.0, 70.7, 56.1, 37.8, 27.4, 27.3. HRMS (ESI): calculated for 
C31H32BrN2O3 559.1591 found 559.1580.  
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A solution of 2.13 (399.5 mg, 1.34 mmol), 2-(benzyloxy)-1,3-dichloro-5-iodobenzene 2.14e 
(2.03 g, 5.36 mmol), Pd(OAc)2 (30 mg, 0.13 mmol) and K2CO3 (463 mg, 3.35 mmol) in MeCN 
(2.7 mL) was heated at 110 °C during 24 hours. The cooled mixture was filtered through a pad 
of celite and concentrated in vacuo. Purification by column chromatography (SiO2, toluene / 
Et2O, 1/0 to 6/4) gave the compound 2.40e (432 mg, 59 %) as a slightly brownish oil. [α]D= 
+22.8 ° (CHCl3, c 1.3). 1H NMR (300 MHz, CDCl3) d = 8.80 (s, 1 H) 8.30 - 8.37 (m, 1 H) 7.53 
(td, J=7.8, 1.8 Hz, 1 H) 7.37 - 7.45 (m, 2 H) 7.07 - 7.30 (m, 9 H) 6.98 - 7.07 (m, 2 H) 4.83 (s, 
2 H) 4.54 (d, J=11.3 Hz, 1 H) 4.33 (d, J=11.3 Hz, 1 H) 3.90 (dd, J=7.3, 3.7 Hz, 1 H) 2.98 (dd, 
J=14.0, 3.7 Hz, 1 H) 2.82 (dd, J=14.0, 7.3 Hz, 1 H) 1.64 (s, 3 H) 1.56 (s, 3 H). 13C NMR (75 
MHz, CDCl3) d = 169.8, 164.0, 149.3, 147.5, 136.9, 136.8, 136.2, 135.3, 130.1, 128.8, 128.3, 
128.3, 128.2, 128.0, 127.9, 121.7, 119.0, 80.6, 74.6, 72.9, 56.1, 37.7, 27.3, 27.2. HRMS (ESI): 
calculated for C31H31Cl2N2O3 549.1706 found 549.1693. 
 
To a solution of 2.40b (1.8 g, 3.75 mmol) in pyridine (55 mL) at – 30 °C, NOBF4 (4.38 g, 37.5 
mmol) was added in one portion and the resulting mixture was stirred 3 hours at – 30 °C then 
16 hours at room temperature. The reaction was quenched with an aqueous solution of HCl 
(6M) until the pH was around 1, then the mixture was extracted with ethyl acetate three time. 
The combined organic layers were washed with an aqueous solution of HCl (1M) two times, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, pentane / AcOEt / AcOH (1%), 9/1 to 7/3) gave the compound 2.9b (1.25 g, 92 %) as a 
slightly yellow oil. [α]D= +24.2 ° (CHCl3, c 1.4). 1H NMR (300 MHz, CDCl3) d = 11.10 (s,1H), 
7.61 - 7.26 (m, 12H), 7.06 (d, J = 8.5 Hz, 2H), 5.16 (s, 2H), 4.83 (d, J = 11.8 Hz, 1H), 4.54 (d, 
J = 11.8 Hz, 1H), 4.30 (dd, J = 8.1, 4.2 Hz, 1H), 3.25 (dd, J = 14.1, 4.1 Hz, 1H), 3.16 (dd, J = 
14.1, 8.3 Hz, 1H). 13C NMR (75 MHz, CDCl3) d = 177.8, 157.9, 137.2, 137.1, 130.8, 129.2, 
128.7, 128.6, 128.1, 127.6, 114.9, 78.9, 72.8, 70.1, 38.3. HRMS (ESI): calculated for 
C23H22NaO4 385.1410 found 385.1411. 
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To a solution of 2.40c (213 mg, 0.41 mmol) in pyridine (8 mL) at – 30 °C, NOBF4 (484 mg, 
4.14 mmol) was added in one portion and the resulting mixture was stirred 3 hours at – 30 °C 
then 16 hours at room temperature. The reaction was quenched with an aqueous solution of HCl 
(6M) until the pH was around 1, then the mixture was extracted with ethyl acetate three time. 
The combined organic layers were washed with an aqueous solution of HCl (1M) two times, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, pentane / AcOEt / AcOH (1%), 9/1 to 7/3) gave the compound 2.9c (125 mg, 76 %) as a 
slightly yellow oil. [α]D= +19.7 ° (CHCl3, c 1). 1H NMR (300 MHz, CDCl3) d = 9.70 (br. s., 1 
H) 7.32 - 7.40 (m, 2 H) 7.19 - 7.31 (m, 3 H) 7.12 - 7.19 (m, 4 H) 7.03 - 7.10 (m, 2 H) 6.94 (dd, 
J=8.4, 2.2 Hz, 1 H) 6.76 (d, J=8.5 Hz, 1 H) 5.02 (s, 2 H) 4.60 (d, J=11.7 Hz, 1 H) 4.28 (d, 
J=11.7 Hz, 1 H) 4.01 (dd, J=8.4, 4.1 Hz, 1 H) 2.95 (dd, J=14.2, 4.1 Hz, 1 H) 2.85 (dd, J=14.3, 
8.5 Hz, 1 H). 13C NMR (75 MHz, CDCl3) d = 177.2, 153.0, 136.6, 136.5, 131.2, 130.2, 128.7, 
128.5, 128.3, 128.0, 127.9, 127.9, 127.0, 122.9, 113.9, 78.1, 72.7, 70.8, 37.7. HRMS (ESI): 
calculated for C23H21ClNaO4 419.1021 found 419.1022. 
 
To a solution of 2.40d (290 mg, 0.52 mmol) in pyridine (10 mL) at – 30 °C, NOBF4 (606 mg, 
5.2 mmol) was added in one portion and the resulting mixture was stirred 3 hours at – 30 °C 
then 16 hours at room temperature. The reaction was quenched with an aqueous solution of HCl 
(6M) until the pH was around 1, then the mixture was extracted with ethyl acetate three time. 
The combined organic layers were washed with an aqueous solution of HCl (1M) two times, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, pentane / AcOEt / AcOH (1%), 9/1 to 7/3) gave the compound 2.9d (159 mg, 70 %) as 
a slightly yellow oil. [α]D= + 24.2 (CHCl3, c 1.5). 1H NMR (300 MHz, CDCl3) d = 9.13 (br. 
s., 1 H) 7.32 - 7.41 (m, 3 H) 7.19 - 7.32 (m, 3 H) 7.10 - 7.19 (m, 3 H) 7.05 (dd, J=6.5, 2.9 Hz, 
2 H) 6.98 (dd, J=8.4, 2.0 Hz, 1 H) 6.72 (d, J=8.5 Hz, 1 H) 5.01 (s, 2 H) 4.59 (d, J=11.7 Hz, 1 
H) 4.27 (d, J=11.7 Hz, 1 H) 4.00 (dd, J=8.5, 4.0 Hz, 1 H) 2.95 (dd, J=14.1, 3.8 Hz, 1 H) 2.84 
(dd, J=14.1, 8.5 Hz, 1 H). 
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13C NMR (75 MHz, CDCl3) d = 177.1, 153.8, 136.6, 136.5, 134.2, 130.7, 129.4, 128.5, 128.3, 
127.9, 127.9, 127.8, 126.9, 113.6, 112.1, 78.2, 72.6, 70.7, 37.6. HRMS (ESI): calculated for 
C23H21BrNaO4 463.0515 found 463.0519. 
 
To a solution of 2.40e (343 mg, 0.62 mmol) in pyridine (12 mL) at – 30 °C, NOBF4 (729 mg, 
6.2 mmol) was added in one portion and the resulting mixture was stirred 3 hours at – 30 °C 
then 16 hours at room temperature. The reaction was quenched with an aqueous solution of HCl 
(6M) until the pH was around 1, then the mixture was extracted with ethyl acetate three time. 
The combined organic layers were washed with an aqueous solution of HCl (1M) two times, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, pentane / AcOEt / AcOH (1%), 9/1 to 7/3) gave the compound 2.9e (208 mg, 77 %) as a 
slightly yellow oil. [α]D= +21.3 ° (CHCl3, c 1.1). 1H NMR (300 MHz, CDCl3) d = 8.87 (br. s., 
1 H) 7.42 - 7.55 (m, 2 H) 7.24 - 7.38 (m, 3 H) 7.17 - 7.24 (m, 3 H) 7.03 - 7.13 (m, 4 H) 4.94 (s, 
2 H) 4.66 (d, J=11.7 Hz, 1 H) 4.30 (d, J=11.9 Hz, 1 H) 4.03 (dd, J=8.7, 3.8 Hz, 1 H) 2.96 (dd, 
J=14.1, 3.8 Hz, 1 H) 2.85 (dd, J=14.1, 8.7 Hz, 1 H). 13C NMR (75 MHz, CDCl3) d = 176.7, 
149.8, 136.4, 136.2, 134.5, 129.9, 129.2, 128.5, 128.4, 128.4, 128.4, 128.2, 128.1, 77.5, 74.9, 
72.8, 37.7. HRMS (ESI): calculated for C23H20Cl2NaO4 453.0631 found 453.0628. 
 
To a solution of 2.9b (1.25 g, 3.44 mmol) and DIPEA (2.3 mL, 13.74 mmol) in DCM (34 mL) 
at 0 °C, PyBOP (226 mg, 0.43 mmol) was added in one portion and stirred 20 min at 0 °C. D-
Leucine methyl ester hydrochloride 2.8a (94.6 mg, 0.52 mmol) was then added in one portion 
at 0 °C. The resulting mixture was stirred at room temperature during 16 hours. The reaction 
was quenched with a saturated aqueous solution of NaHCO3. The resulting mixture was 
extracted three times with ethyl acetate and the combined organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (SiO2, pentane/ AcOEt, 9/1 to 1/1) gave the compound 2.43b (1.384 g, 82 %) 
as a colorless oil. [α]D= + 40.4 (CHCl3, c 1.1).   
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1H NMR (300 MHz, CDCl3) d = 7.14 - 7.37 (m, 10 H) 7.07 (d, J=8.7 Hz, 2 H) 6.79 (d, J=8.7 
Hz, 3 H) 4.93 (s, 2 H) 4.48 - 4.59 (m, 2 H) 4.35 (d, J=11.5 Hz, 1 H) 3.97 (dd, J=7.2, 3.6 Hz, 1 
H) 3.62 (s, 3 H) 3.01 (dd, J=14.3, 3.6 Hz, 1 H) 2.80 (dd, J=14.2, 7.3 Hz, 1 H) 1.38 - 1.52 (m, 1 
H) 1.13 - 1.38 (m, 3 H) 0.77 (d, J=6.4 Hz, 3 H) 0.75 (d, J=6.4 Hz, 3 H). 13C NMR (75 MHz, 
CDCl3) d = 173.1, 171.5, 157.5, 137.0, 136.9, 130.6, 129.3, 128.4, 128.4, 127.9, 127.9, 127.8, 
127.3, 114.4, 80.7, 72.7, 69.8, 52.1, 49.7, 41.2, 37.8, 24.4, 22.7, 21.6. HRMS (ESI): calculated 
for C30H36NO5 490.2588 found 490.2584. 
 
To a solution of 2.9b (150 mg, 0.41 mmol) and DIPEA (274 µL, 1.66 mmol) in DCM (4 mL) 
at 0 °C, PyBOP (215 mg, 0.41 mmol) was added in one portion and stirred 20 min at 0 °C. D-
allo-isoleucine methyl ester hydrochloride182 2.8b (94.6 mg, 0.52 mmol) was then added in one 
portion at 0 °C. The resulting mixture was stirred at room temperature during 16 hours. The 
reaction was quenched with a saturated aqueous solution of NaHCO3. The resulting mixture 
was extracted three times with ethyl acetate and the combined organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (SiO2, pentane/ AcOEt, 9/1 to 1/1) gave the compound 2.43c (156 mg, 77 %) 
as a colorless oil. [α]D= + 32.7 (CHCl3, c 0.84). 1H NMR (300 MHz, CDCl3) d = 7.12 - 7.38 
(m, 10 H) 7.08 (m, J=8.7 Hz, 2 H) 6.92 (d, J=9.4 Hz, 1 H) 6.80 (m, J=8.9 Hz, 2 H) 4.95 (s, 2 
H) 4.51 - 4.61 (m, 2 H) 4.35 (d, J=11.3 Hz, 1 H) 3.98 (dd, J=7.4, 3.5 Hz, 1 H) 3.64 (s, 3 H) 3.04 
(dd, J=14.2, 3.5 Hz, 1 H) 2.80 (dd, J=14.2, 7.4 Hz, 1 H) 1.72 - 1.88 (m, 1 H) 1.07 (dd, J=13.7, 
6.5 Hz, 1 H) 0.82 - 0.94 (m, 1 H) 0.74 - 0.80 (m, 3 H) 0.62 (d, J=6.8 Hz, 3 H). 13C NMR (75 
MHz, CDCl3) d = 172.6, 171.9, 157.7, 137.2, 137.10, 130.8, 129.6, 128.6, 128.5, 128.1, 128.0, 
128.0, 127.4, 114.6, 81.1, 72.9, 70.0, 54.7, 52.2, 38.2, 37.5, 26.1, 14.4, 11.8. HRMS (ESI): 
calculated for C30H36NO5 490.2588 found 490.2580. 
 
To a solution of 2.9c (115 mg, 0.29 mmol) and DIPEA (191 µL, 1.15 mmol) in DCM (3 mL) 
at 0 °C, PyBOP (150 mg, 0.29 mmol) was added in one portion and stirred 20 min at 0 °C.  
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D-allo-isoleucine methyl ester hydrochloride 2.8b (63 mg, 0.35 mmol) was then added in one 
portion at 0 °C. The resulting mixture was stirred at room temperature during 16 hours. The 
reaction was quenched with a saturated aqueous solution of NaHCO3. The resulting mixture 
was extracted three times with ethyl acetate and the combined organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (SiO2, pentane/ AcOEt, 9/1 to 1/1) gave the compound 2.43d (111 mg, 74 %) 
as a colorless oil. [α]D= + 21.6 (CHCl3, c 0.85). 1H NMR (300 MHz, CDCl3) d = 7.14 - 7.42 
(m, 11 H) 6.87 - 7.01 (m, 2 H) 6.77 (d, J=8.5 Hz, 1 H) 5.05 (s, 2 H) 4.53 - 4.61 (m, 2 H) 4.36 
(d, J=11.3 Hz, 1 H) 3.96 (dd, J=7.2, 3.6 Hz, 1 H) 3.65 (s, 3 H) 2.99 (dd, J=14.2, 3.5 Hz, 1 H) 
2.77 (dd, J=14.2, 7.3 Hz, 1 H) 1.70 - 1.87 (m, 1 H) 1.01 - 1.14 (m, 1 H) 0.82 - 0.93 (m, 1 H) 
0.74 - 0.81 (m, 3 H) 0.62 (d, J=6.8 Hz, 3 H). 13C NMR (75 MHz, CDCl3) d = 172.6, 171.6, 
153.1, 136.9, 136.7, 131.7, 130.8, 129.0, 128.7, 128.6, 128.3, 128.2, 128.0, 127.1, 120, 113.9, 
80.6, 73.1, 70.9, 54.8, 52.3, 37.8, 37.5, 26.2, 14.4, 11.8. HRMS (ESI): calculated for 
C30H35ClNO5 524.2198 found 524.2190. 
 
To a solution of 2.9d (133 mg, 0.3 mmol) and DIPEA (200 µL, 1.21 mmol) in DCM (3 mL) at 
0 °C, PyBOP (157 mg, 0.3 mmol) was added in one portion and stirred 20 min at 0 °C. D-allo-
isoleucine methyl ester hydrochloride 2.8b (66 mg, 0.36 mmol) was then added in one portion 
at 0 °C. The resulting mixture was stirred at room temperature during 16 hours. The reaction 
was quenched with a saturated aqueous solution of NaHCO3. The resulting mixture was 
extracted three times with ethyl acetate and the combined organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (SiO2, pentane/ AcOEt, 9/1 to 1/1) gave the compound 2.43e (107 mg, 63 %) 
as a colorless oil. [α]D= + 19.1 (CHCl3, c 0.82). 1H NMR (300 MHz, CDCl3) d = 7.35 - 7.43 
(m, 3 H) 7.15 - 7.35 (m, 8 H) 7.02 (dd, J=8.4, 2.2 Hz, 1 H) 6.93 (d, J=9.4 Hz, 1 H) 6.75 (d, 
J=8.5 Hz, 1 H) 5.05 (s, 2 H) 4.54 - 4.62 (m, 2 H) 4.36 (d, J=11.5 Hz, 1 H) 3.96 (dd, J=7.3, 3.6 
Hz, 1 H) 3.65 (s, 3 H) 2.99 (dd, J=14.2, 3.5 Hz, 1 H) 2.77 (dd, J=14.2, 7.4 Hz, 1 H) 1.74 - 1.88 
(m, 1 H) 1.01 - 1.15 (m, 1 H) 0.82 - 0.96 (m, 1 H) 0.74 - 0.82 (m, 3 H) 0.63 (d, J=7.0 Hz, 3 H).  
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13C NMR (75 MHz, CDCl3) d = 172.6, 171.6, 153.9, 136.9, 136.7, 134.7, 131.3, 129.8, 128.7, 
128.3, 128.2, 128.0, 127.1, 113.6, 112.3, 80.6, 73.1, 70.9, 54.8, 52.3, 37.8, 37.5, 26.2, 14.4, 
11.9. HRMS (ESI): calculated for C30H35BrNO5 568.1693 found 568.1704. 
2.5. Fragment coupling and completion of total syntheses 
 
To a solution of 2.28 (226 mg, 0.44 mmol) and DIPEA (220 µL, 1.31 mmol) in DCM (4.5 mL) 
was added followed by PyBOP (227 mg, 0.44 mmol) at 0 °C. After 30 min at 0 °C, a solution 
of 2.7a (260 mg, 0.48 mmol) in DCM (2x2 mL) was added. The resulting mixture was stirred 
at room temperature during 16 hours. The reaction was then quenched with an aqueous 
saturated solution of NaHCO3 and extracted with AcOEt three times. The combined organic 
layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (SiO2, pentane/ AcOEt, 9/1 to 1/1) gave the compound 
2.44 (350 mg, 77 %). [α]D= – 19.5 (CHCl3, c 1.1). 1H NMR (400 MHz, CDCl3) d = 11.76 (s, 
1H), 8.36 (t, J = 5.6 Hz, 1H), 7.70 – 7.53 (m, 4H), 7.42 – 7.23 (m, 15H), 7.13 (d, J = 8.7 Hz, 
1H), 5.20 – 4.97 (m, 4H), 4.60 – 4.46 (m, 1H), 4.41 (t, J = 8.6 Hz, 1H), 4.07 (s, 1H), 3.99 – 
3.82 (m, 1H), 3.71 (dd, J = 13.4, 6.6 Hz, 1H), 3.50 (ddd, J = 14.7, 10.2, 4.0 Hz, 2H), 3.33 (dd, 
J = 13.5, 5.3 Hz, 1H), 2.32 – 2.15 (m, 2H), 2.14 – 1.64 (m, 4H), 1.64 – 1.50 (m, 3H), 1.51 – 
1.38 (m, 3H), 1.38 – 1.29 (m, 1H), 1.07 (s, 9H), 0.85 (s, 9H), -0.00 (s, 6H). 13C NMR (100 
MHz, CDCl3) d = 169.9, 163.7, 156.5, 156.2 (q, JC-F = 37 Hz), 153.8, 152.9, 136.8, 135.7, 
135.7, 134.7, 134.1, 133.6, 129.8, 129.7, 128.8, 128.7, 128.5, 128.5, 128.1, 128.0, 127.7, 127.6, 
116.4 (q, JC-F = 287 Hz), 68.1, 67.6, 67.1, 64.9, 61.7, 56.4, 51.2, 40.7, 37.3, 33.8, 29.7, 28.8, 
27.1, 27.0, 26.3, 26.1, 25.9, 19.4, 19.2, 18.2, -5.5. 19F NMR (282 MHz, CDCl3) d = – 70.6. 
HRMS (ESI): calculated for C55H73F3N5O8Si2 1044.4944 found 1044.4942. 
 
To a solution of 2.28 (262 mg, 0.51 mmol), 2.7b (436 mg, 1.09 mmol) and DIPEA (668 µL, 
4.04 mmol) in DCM (5 mL) was added HBTU (421 mg, 1.11 mmol) at 0 °C. The resulting 
mixture was stirred at room temperature during 16 hours.   
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The reaction was then quenched with an aqueous saturated solution of NaHCO3 and extracted 
with AcOEt three times. The combined organic layers were washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
pentane/ AcOEt, 9/1 to 1/1) gave the compound 2.45 (308 mg, 68 %). [α]D= – 3.8 (CHCl3, c 
1.13). 1H NMR (400 MHz, CDCl3) d = 11.66 (s, 1H), 8.28 (t, J = 5.4 Hz, 1H), 7.61 – 7.50 (m, 
4H), 7.36 – 7.17 (m, 15H), 6.85 (t, J = 5.5 Hz, 1H), 5.07 (s, 2H), 5.04 (s, 2H), 4.50 – 4.37 (m, 
1H), 4.33 (t, J = 8.0 Hz, 1H), 4.01 (s, 1H), 3.46 – 3.25 (m, 2H), 3.17 (dd, J = 11.9, 6.0 Hz, 2H), 
2.28 – 2.10 (m, 3H), 1.84 – 1.71 (m, 2H), 1.60 (d, J = 12.0 Hz, 1H), 1.56 – 1.27 (m, 7H), 1.00 
(s, 9H). 13C NMR (100 MHz, CDCl3) d = (CF3 coupling are missing) 170.0, 163.7, 156.3, 
153.9, 136.8, 135.8, 135.7, 134.7, 134.2, 133.7, 129.9, 129.8, 128.9, 128.8, 128.5, 128.5, 128.2, 
128.0, 127.7, 127.7, 68.3, 67.6, 67.2, 61.3, 56.6, 40.6, 39.5, 37.2, 33.7, 28.2, 27.0, 26.7, 26.1, 
26.0, 19.5, 19.3. 19F NMR (282 MHz, CDCl3) d = – 70.7. HRMS (ESI): calculated for 
C48H56F3N5O7Si 899.3901 found 899.3905. 
 
To a solution of 2.43b (1.07 g, 2.18 mmol) in a mixture of THF (23 mL) and MeOH (7.5 mL), 
an aqueous solution of LiOH (7.6 mL, 7.57 mmol, 1M) was added dropwise at 0 °C. After 3 
hours, the reaction was acidified with an aqueous solution of HCl (1M). The resulting mixture 
was extracted with DCM three times and the combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude mixture product was dissolved in DCM (10 mL) 
and DIPEA (1.1 mL, 6.55 mmol) was added followed by PyBOP (1.15 g, 2.18 mmol) at 0 °C. 
After 30 min at 0 °C, a solution of 2.6 (1.15 g, 2.62 mmol) in DCM (2x6 mL) was added. The 
resulting mixture was stirred at room temperature during 16 hours. The reaction was then 
quenched with an aqueous saturated solution of NaHCO3 and extracted with AcOEt three times. 
The combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (SiO2, pentane/ AcOEt, 9/1 to 
1/1) gave the compound 2.47 (1.49 g, 76 %) as a colorless oil and as a mixture of conformers 
(85:15). [α]D= + 16.8 (CHCl3, c 1.0).  
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1H NMR (400 MHz, CDCl3, major conformer) d = 7.60 - 7.71 (m, 4 H) 7.33 - 7.38 (m, 6 H) 
7.26 - 7.33 (m, 6 H) 7.14 - 7.25 (m, 7 H) 7.05 - 7.14 (m, 3 H) 6.81 (d, J=8.8 Hz, 2 H) 4.96 (s, 2 
H) 4.87 (td, J=9.9, 3.9 Hz, 1 H) 4.47 (d, J=11.0 Hz, 1 H) 4.27 - 4.33 (m, 1 H) 4.23 (d, J=11.2 
Hz, 1 H) 3.97 (dd, J=7.8, 3.7 Hz, 1 H) 3.54 (s, 3 H) 3.06 (dd, J=14.2, 3.4 Hz, 1 H) 2.85 (dd, 
J=14.2, 8.1 Hz, 1 H) 2.45 - 2.54 (m, 1 H) 2.35 - 2.45 (m, 1 H) 2.16 - 2.31 (m, 1 H) 2.01 - 2.11 
(m, 1 H) 1.81 (td, J=12.9, 10.4 Hz, 1 H) 1.61 (t, J=11.9 Hz, 1 H) 1.37 - 1.51 (m, 2 H) 1.23 - 
1.36 (m, 3 H) 1.04 (s, 9 H) 0.83 (d, J=6.4 Hz, 3 H) 0.78 (d, J=6.4 Hz, 3 H). 13C NMR (100 
MHz, CDCl3, major conformer) d = 172.6, 171.0, 170.7, 157.5, 137.1, 137.1, 135.9, 135.8, 
134.2, 133.4, 130.7, 129.9, 129.7, 129.6, 128.5, 128.4, 128.3, 127.8, 127.8, 127.7, 127.6, 127.4, 
114.4, 81.1, 72.8, 69.9, 67.4, 59.2, 54.8, 52.0, 48.0, 42.6, 38.3, 37.2, 34.3, 30.2, 29.6, 27.1, 25.9, 
24.4, 23.4, 22.0, 19.2. HRMS (ESI): calculated for C55H67N2O7Si 895.4712 found 895.4703. 
 
To a solution of 2.47 (1.49 g, 1.66 mmol) in THF (10 mL), Olah’s reagent (HF•pyridine, 7/3) 
(10 mL) was added in plastic tube at 0 °C. After 16 hours at room temperature, the reaction was 
quenched with an aqueous saturated solution of NaHCO3 and the resulting mixture was 
extracted with CHCl3 three times. The combined organic layers were washed with an aqueous 
saturated solution of NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (SiO2, CHCl3 / MeOH, 1/0 to 97/3) gave the compound 
2.47’ (1.08 g, 99 %) as a colorless oil. [α]D= + 12.1 (CHCl3, c 3.7). 1H NMR (300 MHz, CDCl3) 
d = 8.5 (d, J=3.7 Hz, 1 H ) 7.10 - 7.40 (m, 10 H) 7.07 (d, J=8.7 Hz, 2 H) 6.80 (d, J=8.7 Hz, 2 
H) 4.95 (s, 2 H) 4.79 (td, J=9.5, 4.1 Hz, 1 H) 4.46 (d, J=11.3 Hz, 1 H) 4.13 - 4.39 (m, 3 H) 4.06 
- 4.12 (m, 1 H) 3.94 (dd, J=7.5, 3.6 Hz, 1 H) 3.59 (s, 3 H) 3.00 (dd, J=14.1, 3.4 Hz, 1 H) 2.78 
(dd, J=14.2, 7.6 Hz, 1 H) 2.30 - 2.43 (m, 1 H) 2.18 - 2.30 (m, 1 H) 2.03 - 2.17 (m, 2 H) 1.81 - 
1.94 (m, 1 H) 1.65 - 1.72 (m, 1 H) 1.34 - 1.64 (m, 7 H) 0.84 (d, J=5.8 Hz, 3 H) 0.78 (d, J=6.0 
Hz, 3 H). 13C NMR (75 MHz, CDCl3) d = 172.8, 171.3, 170.3, 157.6, 149.7, 137.2, 137.1, 
130.8, 129.7, 128.6, 128.5, 128.4, 127.9, 127.5, 114.5, 80.8, 72.9, 70.0, 65.4, 59.1, 54.5, 52.1, 
48.1, 42.6, 38.2, 37.2, 34.2, 30.4, 25.8, 24.5, 23.5, 21.9, 19.3. HRMS (ESI): calculated for 
C39H48N2NaO7 679.3354 found 679.3373. 
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To a solution of 2.47’ (1.08 g, 1.65 mmol) in a mixture of THF (9 mL) and MeOH (4.6 mL), 
an aqueous solution of LiOH (5 mL, 5 mmol, 1M) was added dropwise at 0 °C. After 3 hours, 
the reaction was acidified with an aqueous solution of HCl (1M). The resulting mixture was 
extracted with DCM three times and the combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude mixture product was dissolved in DMF (8 mL) 
and DIPEA (0.8 mL, 5 mmol) was added followed by a solution of 2.7a (1.07 g, 2 mmol) in 
DMF (8 mL). To the resulting mixture at 0 °C, HBTU (750 mg, 2 mmol) was added in one 
portion and stirred at room temperature during 16 hours. The reaction was then quenched with 
an aqueous saturated solution of NaHCO3 and extracted with AcOEt three times. The combined 
organic layers were washed with water three times and one time with brine, dried over MgSO4, 
filtered and concentrated in vacuo. Purification by column chromatography (SiO2, CHCl3 / 
MeOH, 1/0 to 98/2) gave the compound 2.48 (1.93 g, 100 %) as a colorless oil. [α]D= + 7.2 
(CHCl3, c 3.3).  1H NMR (500 MHz, CDCl3) d = 11.71 (s, 1 H) 8.37 (t, J=5.6 Hz, 1 H) 7.26 - 
7.47 (m, 16 H) 7.17 - 7.26 (m, 4 H) 7.14 (m, J=8.5 Hz, 2 H) 6.87 (m, J=8.5 Hz, 2 H) 6.84 (d, 
J=9.2 Hz, 1 H) 5.13 (dd, J=7.8, 3.5 Hz, 4 H) 5.02 (s, 2 H) 4.73 - 4.81 (m, 1 H) 4.60 (d, J=11.3 
Hz, 1 H) 4.39 (d, J=11.6 Hz, 1 H) 4.32 - 4.37 (m, 1 H) 4.23 (dt, J=11.4, 5.8 Hz, 1 H) 4.18 (br. 
s., 1 H) 4.03 (dd, J=7.2, 3.5 Hz, 1 H) 3.92 - 4.01 (m, 1 H) 3.59 (dd, J=9.9, 3.8 Hz, 1 H) 3.44 - 
3.52 (m, 2 H) 3.23 - 3.32 (m, 1 H) 3.08 (dd, J=14.2, 3.5 Hz, 1 H) 2.88 (dd, J=14.2, 7.2 Hz, 1 
H) 2.20 - 2.35 (m, 5 H) 2.13 - 2.19 (m, 1 H) 1.97 - 2.04 (m, 1 H) 1.81 - 1.91 (m, 1 H) 1.50 - 
1.70 (m, 7 H) 1.40 - 1.50 (m, 1 H) 1.25 - 1.36 (m, 2 H) 0.94 (d, J=5.8 Hz, 3 H) 0.89 (s, 9 H) 
0.87 (d, J=6.1 Hz, 3 H) 0.04 (s, 6 H). 13C NMR (126 MHz, CDCl3) d = 171.5, 171.1, 170.8, 
163.7, 157.6, 156.0, 153.6, 137.1, 137.1, 136.8, 134.6, 130.7, 129.5, 128.7, 128.7, 128.5, 128.4, 
128.4, 128.3, 128.1, 127.9, 127.4, 114.4, 80.8, 77.3, 77.0, 76.8, 72.7, 69.9, 68.0, 67.0, 65.8, 
65.0, 60.3, 54.7, 50.5, 48.5, 41.9, 40.8, 37.9, 36.7, 33.7, 29.7, 27.8, 25.8, 25.6, 25.6, 24.4, 23.4, 
21.7, 19.3, 18.23, -5.4, -5.5. HRMS (ESI): calculated for C66H87N6O11Si 1167.6197 found 
1167.6149. 
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The compound 2.48 (1.925 g, 1.65 mmol) was dissolved in CHCl3 (10 mL) at 0 °C, then a 
cooled solution of HCl / MeOH (0.5 %, 50 mL) was added slowly and the reaction was stirred 
2 hours at 0 °C. The reaction was quenched with an aqueous saturated solution of NaHCO3 and 
extracted with AcOEt three times. The combined organic layers were washed with brine, dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
CHCl3 / MeOH, 95/5) gave the compound 2.49 (1.355 g, 78 %) as a colorless oil. [α]D= + 2.5 
(CHCl3, c 1.8). 1H NMR (500 MHz, CDCl3) d = 11.76 (br. s., 1 H) 8.37 (t, J=5.5 Hz, 1 H) 7.44 
- 7.48 (m, 2 H) 7.26 - 7.44 (m, 16 H) 7.16 (m, J=8.9 Hz, 2 H) 6.91 (m, J=8.5 Hz, 2 H) 6.87 (d, 
J=5.8 Hz, 1 H) 6.78 (d, J=8.9 Hz, 1 H) 5.17 (s, 2 H) 5.14 (s, 2 H) 5.05 (s, 2 H) 4.65 (d, J=11.6 
Hz, 1 H) 4.43 - 4.51 (m, 2 H) 4.31 - 4.37 (m, 1 H) 4.18 - 4.26 (m, 2 H) 4.05 (dd, J=7.2, 3.5 Hz, 
1 H) 3.91 - 4.00 (m, 1 H) 3.58 - 3.72 (m, 2 H) 3.42 - 3.53 (m, 4 H) 3.09 (dd, J=14.3, 3.4 Hz, 1 
H) 2.86 (dd, J=14.2, 7.2 Hz, 1 H) 2.49 (dt, J=13.8, 4.2 Hz, 1 H) 2.28 - 2.41 (m, 2 H) 2.12 - 2.24 
(m, 1 H) 2.00 - 2.11 (m, 2 H) 1.93 (br. s., 1 H) 1.55 - 1.70 (m, 5 H) 1.19 - 1.42 (m, 5 H) 0.90 
(d, J=2.7 Hz, 3 H) 0.89 (d, J=2.7 Hz, 3 H). 13C NMR (126 MHz, CDCl3) d = 173.8, 171.7, 
171.5, 163.7, 157.7, 156.0, 153.8, 137.1, 137.0, 136.8, 134.6, 130.7, 129.2, 128.7, 128.6, 128.6, 
128.5, 128.4, 128.1, 128.0, 127.9, 127.9, 127.4, 114.5, 80.7, 73.0, 70.0, 68.1, 67.1, 65.7, 64.0, 
60.9, 54.8, 51.4, 50.3, 41.0, 39.9, 38.1, 36.8, 33.3, 30.5, 29.7, 27.8, 26.3, 25.9, 24.6, 23.3, 21.3, 
19.1. HRMS (ESI): calculated for C60H73N6O11 1053.5332 found 1053.5300. 
 
The compound 2.49 (1.1 g, 1.04 mmol) was dissolved in a mixture of AcOEt (22 mL) and 
MeOH (22 mL) and Pd(OH)2/C (20 %) (3.67 g, 5.22 mmol) was added in one portion.   
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The atmosphere was replaced by hydrogen (1 atm.) by three cycles of vacuum / H2. After 6 
hours, the resulting mixture was filtered through a pad of celite and rinced with EtOAc (200 
mL) followed by MeOH (200 mL). The filtrate was concentrated in vacuo. The crude mixture 
was dissolved in MeOH (4 mL) then TFA (0.6 mL) was added at 0°C. Purification by column 
chromatography (C18, H2O / MeCN / 1% TFA, 9/1 to 1/1) gave aeruginosin 298A as TFA salt 
(700 mg, 93 %) as a white amorphous solid and as a mixture of conformers (85:15). [α]D= + 
17.3 ° (H2O, c 1.2), Lit.71 [α]D= + 22.3 ° (H2O, c 0.36). 1H NMR (400 MHz, DMSO d6, major 
conformer) d = 7.56 (d, J = 8.6 Hz, 1H), 7.52 (t, J = 5.7 Hz, 1H), 7.46 (d, J = 8.3 Hz, 1H), 6.98 
(d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.5 Hz, 2H), 4.57 – 4.45 (m, 1H), 4.16 (t, J = 8.9 Hz, 1H), 4.08 
– 3.96 (m, 2H), 3.91 (br. s, 1H), 3.69 – 3.57 (m, 1H), 3.30 (dd, J = 10.7, 5.0 Hz, 1H), 3.21 (dd, 
J = 10.7, 6.2 Hz, 1H), 3.12 – 2.99 (m, 2H), 2.85 (dd, J = 14.0, 3.4 Hz, 1H), 2.63 (dd, J = 13.9, 
7.5 Hz, 1H), 2.36 – 2.18 (m, 1H), 2.12 – 1.92 (m, 3H), 1.88 – 1.73 (m, 1H), 1.65 (t, J = 13.0 
Hz, 1H), 1.60 – 1.24 (m, 10H), 1.20 (t, J = 11.1 Hz, 1H), 0.87 (d, J = 6.4 Hz, 3H), 0.81 (d, J = 
6.4 Hz, 3H). 13C NMR (101 MHz, DMSO d6, major conformer) d = 172.85, 171.31, 169.76, 
158.54 (q, JC-F = 36.0 Hz), 156.75, 155.78, 130.48, 128.12, 115.88 (q, JC-F = 292.1 Hz), 114.70, 
72.15, 63.89, 63.30, 59.92, 54.02, 50.20, 48.10, 41.90, 40.80, 39.39, 36.02, 33.50, 30.54, 28.00, 
26.03, 25.08, 23.98, 23.40, 21.39, 19.00 (2 C). HRMS (ESI): calculated for C30H49N6O7 
605.3657 found 605.3646. 
 
To a solution of 2.43c (148 mg, 0.30 mmol) in a mixture of THF (3.1 mL) and MeOH (1.0 mL), 
an aqueous solution of LiOH (1.0 mL, 1.0 mmol, 1M) was added dropwise at 0 °C. After 3 
hours, the reaction was acidified with an aqueous solution of HCl (1M). The resulting mixture 
was extracted with DCM three times and the combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude mixture product was dissolved in DCM (3 mL) 
and DIPEA (150 µL, 0.90 mmol) was added followed by PyBOP (157 mg, 0.30 mmol) at 0 °C. 
After 30 min at 0 °C, a solution of 2.6 (159 mg, 0.36 mmol) in DCM (1 mL) was added. The 
resulting mixture was stirred at room temperature during 16 hours. The reaction was then 
quenched with an aqueous saturated solution of NaHCO3 and extracted with AcOEt three times.   
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The combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (SiO2, pentane/ AcOEt, 9/1 to 
1/1) gave the compound 2.43c’ (161 mg, 60 %) as a colorless oil. [α]D= + 7.8 (CHCl3, c 1.1). 
1H NMR (400 MHz, CDCl3) d = 7.56 - 7.73 (m, 4 H) 7.07 - 7.39 (m, 18 H) 6.81 (d, J=8.7 Hz, 
2 H) 4.96 (s, 2 H) 4.72 (dd, J=9.4, 5.7 Hz, 1 H) 4.46 (d, J=11.1 Hz, 1 H) 4.27 - 4.40 (m, 2 H) 
4.19 (d, J=11.1 Hz, 1 H) 4.02 (br. s., 1 H) 3.95 (dd, J=8.2, 3.3 Hz, 1 H) 3.53 (s, 3 H) 3.08 (dd, 
J=14.1, 3.2 Hz, 1 H) 2.83 (dd, J=14.2, 8.2 Hz, 1 H) 2.34 - 2.49 (m, 2 H) 2.17 – 2.31 (m, 1H)  
2.00 - 2.13 (m, 1 H) 1.74 - 1.90 (m, 2 H) 1.50 - 1.66 (m, 2 H) 1.44 (d, J=14.3 Hz, 1 H) 1.28 – 
1.34 (m, 1H) 1.06 (s, 9 H) 0.82 (t, J=7.2 Hz, 3 H) 0.70 (d, J=6.6 Hz, 3 H). 13C NMR (100 MHz, 
CDCl3) d = 172.8, 171.3, 170.0, 157.6, 137.3, 137.3, 136.0, 135.8, 134.4, 133.3, 130.8, 130.2, 
129.8, 129.7, 128.6, 128.5, 128.4, 127.9, 127.9, 127.8, 127.7, 127.5, 114.6, 81.5, 72.9, 70.0, 
67.6, 59.2, 54.8, 53.7, 52.1, 38.8, 38.7, 37.3, 34.4, 30.3, 29.7, 27.2, 26.6, 26.2, 19.4, 14.0, 12.2. 
HRMS (ESI): calculated for C55H67N2O7Si 895.4712 found 895.4714. 
 
To a solution of 2.43c’ (147 mg, 0.164 mmol) in THF (2 mL), Olah’s reagent (HF•pyridine, 
7/3) (2 mL) was added in plastic tube at 0 °C. After 16 hours at room temperature, the reaction 
was quenched with an aqueous saturated solution of NaHCO3 and the resulting mixture was 
extracted with CHCl3 three times. The combined organic layers were washed with an aqueous 
saturated solution of NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (SiO2, CHCl3 / MeOH, 1/0 to 97/3) gave the compound 
2.50a (102 mg, 95%) as a colorless oil. [α]D= + 7.3 (CHCl3, c 1.1). 1H NMR (300 MHz, CDCl3) 
d = 7.13 - 7.39 (m, 10 H) 7.09 (m, J=8.8 Hz, 2 H) 6.81 (m, J=8.8 Hz, 2 H) 4.97 (s, 2 H) 4.60 
(dd, J=9.9, 7.2 Hz, 1 H) 4.45 (d, J=11.0 Hz, 1 H) 4.31 (dd, J=10.0, 8.1 Hz, 1 H) 4.25 (dd, 
J=11.9, 6.0 Hz, 1 H) 4.21 (d, J=11.0 Hz, 1 H) 4.10 (br. s., 1 H) 3.93 (dd, J=8.1, 3.4 Hz, 1 H) 
3.58 (s, 3 H) 3.08 (br. s., 1 H) 3.02 (dd, J=14.2, 3.4 Hz, 1 H) 2.78 (dd, J=14.2, 8.1 Hz, 1 H) 
2.55 (br. s., 1 H) 2.38 (dq, J=12.6, 6.1 Hz, 1 H) 2.17 - 2.28 (m, 1 H) 2.06 - 2.17 (m, 2 H) 1.90 
(td, J=12.8, 10.3 Hz, 1 H) 1.66 - 1.79 (m, 1 H) 1.53 - 1.64 (m, 1 H) 1.37 - 1.53 (m, 2 H) 1.14 - 
1.29 (m, 1 H) 0.92 - 1.07 (m, 1 H) 0.82 (t, J=7.3 Hz 3 H) 0.69 (d, J=6.6 Hz, 3 H). 
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13C NMR (75 MHz, CDCl3) d = 172.8, 171.6, 169.7, 157.5, 137.1, 136.9, 130.7, 129.7, 128.5, 
128.4, 128.3, 127.8, 127.4, 114.5, 81.1, 72.9, 69.9, 65.5, 58.9, 54.4, 53.6, 52.1, 38.5, 38.4, 37.2, 
34.0, 30.3, 25.9, 25.6, 19.2, 14.1, 11.8. HRMS (ESI): calculated for C49H49N2O7 657.3534 
found 657.3535. 
 
To a solution of 2.43d (103 mg, 0.20 mmol) in a mixture of THF (2 mL) and MeOH (0.7 mL), 
an aqueous solution of LiOH (0.7 mL, 0.7 mmol, 1M) was added dropwise at 0 °C. After 3 
hours, the reaction was acidified with an aqueous solution of HCl (1M). The resulting mixture 
was extracted with DCM three times and the combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude mixture product was dissolved in DCM (2 mL) 
and DIPEA (97 µL, 0.59 mmol) was added followed by PyBOP (102 mg, 0.20 mmol) at 0 °C. 
After 30 min at 0 °C, a solution of 2.6 (103 mg, 0.23 mmol) in DCM (1 mL) was added. The 
resulting mixture was stirred at room temperature during 16 hours. The reaction was then 
quenched with an aqueous saturated solution of NaHCO3 and extracted with AcOEt three times. 
The combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (SiO2, pentane/ AcOEt, 9/1 to 
1/1) gave the compound 2.43d’ (161 mg, 60 %) as a colorless oil. [α]D= + 4.2 (CHCl3, c 0.88). 
1H NMR (400 MHz, CDCl3) d = 7.59 - 7.73 (m, 4 H) 7.12 - 7.43 (m, 18 H) 7.00 (dd, J=8.4, 
2.2 Hz, 1 H) 6.78 (d, J=8.5 Hz, 1 H) 5.06 (s, 2 H) 4.72 (dd, J=9.4, 5.7 Hz, 1 H) 4.49 (d, J=11.1 
Hz, 1 H) 4.27 - 4.40 (m, 2 H) 4.20 (d, J=11.3 Hz, 1 H) 3.93 (dd, J=8.0, 3.5 Hz, 1 H) 3.54 (s, 3 
H) 3.02 (dd, J=14.1, 3.4 Hz, 1 H) 2.81 (dd, J=14.2, 8.0 Hz, 1 H) 2.34 - 2.47 (m, 2 H) 2.17 - 
2.33 (m, 1 H) 2.01 - 2.14 (m, 1 H) 1.73 - 1.92 (m, 2 H) 1.51 - 1.66 (m, 2 H) 1.45 (d, J=16.4 Hz, 
1 H) 1.21 - 1.34 (m, 3 H) 1.06 (s, 9 H) 0.82 (t, J=7.1 Hz, 3 H) 0.69 (d, J=6.8 Hz, 3 H). 13C 
NMR (100 MHz, CDCl3) d = 172.9, 171.0, 170.1, 153.0, 137.1, 136.8, 136.1, 135.9, 134.5, 
133.4, 131.7, 131.4, 129.9, 129.8, 129.0, 128.7, 128.5, 128.0, 128.0, 127.7, 127.2, 122.9, 114.0, 
81.0, 73.1, 71.0, 67.7, 59.3, 54.9, 53.8, 52.2, 38.9, 38.3, 37.4, 34.4, 30.4, 27.3, 26.7, 26.2, 19.7, 
19.4, 14.0, 12.3. HRMS (ESI): calculated for C55H66ClN2O7Si 929.4322 found 929.4302. 
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To a solution of 2.43d’ (136 mg, 0.146 mmol) in THF (2 mL), Olah’s reagent (HF•pyridine, 
7/3) (2 mL) was added in plastic tube at 0 °C. After 16 hours at room temperature, the reaction 
was quenched with an aqueous saturated solution of NaHCO3 and the resulting mixture was 
extracted with CHCl3 three times. The combined organic layers were washed with an aqueous 
saturated solution of NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (SiO2, CHCl3 / MeOH, 1/0 to 97/3) gave the compound 
2.50b (89 mg, 88 %) as a colorless oil. [α]D= + 4.6 (CHCl3, c 0.81). 1H NMR (400 MHz, 
CDCl3) d = 7.36 - 7.42 (m, 2 H) 7.28 - 7.34 (m, 2 H) 7.12 - 7.27 (m, 8 H) 6.96 (dd, J=8.4, 2.1 
Hz, 1 H) 6.78 (d, J=8.6 Hz, 1 H) 5.06 (s, 2 H) 4.60 (dd, J=10.0, 7.1 Hz, 1 H) 4.48 (d, J=11.0 
Hz, 1 H) 4.31 (dd, J=10.0, 8.1 Hz, 1 H) 4.22 (d, J=11.2 Hz, 2 H) 4.11 (br. s., 1 H) 3.91 (dd, 
J=8.1, 3.4 Hz, 1 H) 3.59 (s, 3 H) 2.99 (br. s., 1 H) 2.97 (dd, J=14.3, 3.3 Hz, 1 H) 2.76 (dd, 
J=14.3, 7.9 Hz, 1 H) 2.46 (br. s., 1 H) 2.38 (dq, J=12.6, 6.3 Hz, 1 H) 2.17 - 2.27 (m, 1 H) 2.06 
- 2.17 (m, 2 H) 1.90 (td, J=12.8, 10.3 Hz, 1 H) 1.68 - 1.78 (m, 1 H) 1.53 - 1.64 (m, 1 H) 1.39 - 
1.53 (m, 2 H) 1.14 - 1.27 (m, 1 H) 0.92 - 1.06 (m, 1 H) 0.80 - 0.86 (m, 3 H) 0.68 (d, J=6.6 Hz, 
3 H). 13C NMR (100 MHz, CDCl3) d = 172.8, 171.3, 169.6, 152.9, 136.7, 136.6, 131.5, 130.9, 
128.8, 128.5, 128.4, 128.0, 127.9, 127.0, 122.8, 113.8, 80.5, 73.0, 70.8, 65.5, 58.9, 54.4, 53.6, 
52.1, 38.5, 38.0, 37.2, 34.0, 30.3, 26.0, 25.6, 19.2, 14.1, 11. HRMS (ESI): calculated for 
C39H48ClN2O7 691.3145 found 691.3129. 
 
To a solution of 2.43e (99 mg, 0.175 mmol) in a mixture of THF (2 mL) and MeOH (0.6 mL), 
an aqueous solution of LiOH (0.6 mL, 0.61 mmol, 1M) was added dropwise at 0 °C. After 3 
hours, the reaction was acidified with an aqueous solution of HCl (1M). The resulting mixture 
was extracted with DCM three times and the combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude mixture product was dissolved in DCM (2 mL) 
and DIPEA (87 µL, 0.52 mmol) was added followed by PyBOP (91 mg, 0.175 mmol) at 0 °C.   
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After 30 min at 0 °C, a solution of 2.6 (92 mg, 0.21 mmol) in DCM (1 mL) was added. The 
resulting mixture was stirred at room temperature during 16 hours. The reaction was then 
quenched with an aqueous saturated solution of NaHCO3 and extracted with AcOEt three times. 
The combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. Purification by column chromatography (SiO2, pentane/ AcOEt, 9/1 to 
1/1) gave the compound 2.43e’ (136 mg, 80 %) as a colorless oil. [α]D= + 5.2 (CHCl3, c 1.21). 
1H NMR (400 MHz, CDCl3) d = 7.59 - 7.71 (m, 4 H) 7.13 - 7.46 (m, 18 H) 7.05 (dd, J=8.3, 
2.1 Hz, 1 H) 6.75 (d, J=8.5 Hz, 1 H) 5.06 (s, 2 H) 4.72 (dd, J=9.5, 5.7 Hz, 1 H) 4.49 (d, J=11.1 
Hz, 1 H) 4.27 - 4.40 (m, 2 H) 4.20 (d, J=11.1 Hz, 1 H) 3.94 (d, J=3.6 Hz, 1 H) 3.55 (s, 3 H) 
3.03 (dd, J=14.3, 3.4 Hz, 1 H) 2.80 (dd, J=14.2, 8.0 Hz, 1 H) 2.33 - 2.49 (m, 2 H) 2.15 - 2.33 
(m, 1 H) 2.07 (td, J=13.3, 6.4 Hz, 1 H) 1.83 (td, J=12.8, 10.5 Hz, 1 H) 1.50 - 1.72 (m, 3 H) 1.45 
(d, J=13.8 Hz, 1 H) 1.22 - 1.36 (m, 3 H) 1.03 - 1.09 (m, 9 H) 0.83 (t, J=7.3 Hz, 3 H) 0.70 (d, 
J=6.8 Hz, 3 H). 13C NMR (100 MHz, CDCl3) d = 172.9, 171.0, 170.1, 153.9, 137.1, 136.8, 
136.1, 135.9, 134.7, 134.5, 133.4, 131.9, 129.9, 129.8, 128.7, 128.7, 128.5, 128.0, 128.0, 128.0, 
127.7, 127.1, 113.7, 112.2, 81.1, 73.1, 71.0, 67.7, 59.3, 54.9, 53.8, 52.2, 38.9, 38.2, 37.4, 34.4, 
30.4, 29.8, 27.3, 26.7, 26.2, 19.7, 19.4, 14.1, 12.3. HRMS (ESI): calculated for 
C55H66BrN2O7Si 973.3817 found 973.3807. 
 
To a solution of 28e’ (123 mg, 0.126 mmol) in THF (2 mL), Olah’s reagent (HF•pyridine, 7/3) 
(2 mL) was added in plastic tube at 0 °C. After 16 hours at room temperature, the reaction was 
quenched with an aqueous saturated solution of NaHCO3 and the resulting mixture was 
extracted with CHCl3 three times. The combined organic layers were washed with an aqueous 
saturated solution of NaHCO3 and brine, dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (SiO2, CHCl3 / MeOH, 1/0 to 97/3) gave the compound 
43c (84 mg, 90 %) as a colorless oil. [α]D= + 1.6 (CHCl3, c 0.78).  
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1H NMR (400 MHz, CDCl3) d = 7.36 - 7.44 (m, 3 H) 7.27 - 7.35 (m, 2 H) 7.13 - 7.27 (m, 7 H) 
7.02 (dd, J=8.4, 2.1 Hz, 1 H) 6.75 (d, J=8.3 Hz, 1 H) 5.06 (s, 2 H) 4.60 (dd, J=9.8, 7.1 Hz, 1 H) 
4.47 (d, J=11.2 Hz, 1 H) 4.32 (dd, J=10.0, 8.3 Hz, 1 H) 4.22 (d, J=11.0 Hz, 1 H) 4.11 (br. s., 1 
H) 3.91 (dd, J=8.1, 3.4 Hz, 1 H) 3.59 (s, 3 H) 2.97 (dd, J=14.3, 3.3 Hz, 1 H) 2.92 (br. s., 1 H) 
2.75 (dd, J=14.2, 8.1 Hz, 1 H) 2.33 - 2.45 (m, 1 H) 2.30 (br. s., 1 H) 2.17 - 2.26 (m, 1 H) 2.06 
- 2.17 (m, 2 H) 1.90 (td, J=12.8, 10.3 Hz, 1 H) 1.67 - 1.79 (m, 1 H) 1.53 - 1.66 (m, 2 H) 1.38 - 
1.53 (m, 2 H) 1.13 - 1.28 (m, 1 H) 0.92 - 1.08 (m, 1 H) 0.79 - 0.87 (m, 3 H) 0.68 (d, J=6.6 Hz, 
3 H). 13C NMR (101 MHz, CDCl3) d = 173.0, 171.5, 170.0, 153.9, 136.9, 136.8, 134.7, 131.6, 
129.8, 128.7, 128.7, 128.6, 128.2, 128.0, 127.1, 113.7, 112.3, 80.8, 73.2, 71.0, 65.7, 59.1, 54.6, 
53.8, 52.3, 38.6, 38.1, 37.3, 34.2, 30.4, 26.2, 25.8, 19.3, 14.3, 12.0. HRMS (ESI): calculated 
for C39H48BrN2O7 735.2639 found 735.2627. 
 
To a solution of 2.50a (63 mg, 0.096 mmol) in a mixture of THF (0.5 mL) and MeOH (0.25 
mL), an aqueous solution of LiOH (0.29 mL, 0.29 mmol, 1M) was added dropwise at 0 °C. 
After 3 hours, the reaction was acidified with an aqueous solution of HCl (1M). The resulting 
mixture was extracted with DCM three times and the combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude mixture product was dissolved in DMF 
(1 mL) and DIPEA (48 µL, 0.29 mmol) was added followed by a solution of 2.7b (46 mg, 0.12 
mmol) in DMF (1 mL). To the resulting mixture at 0 °C, HBTU (44 mg, 0.12 mmol) was added 
in one portion and stirred at room temperature during 16 hours. The reaction was then quenched 
with an aqueous saturated solution of NaHCO3 and extracted with AcOEt three times. The 
combined organic layers were washed with water three times and one time with brine, dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
pentane/ AcOEt, 7/3 to 1/9) gave the compound 2.51 (98.6 mg, 100 %) as a colorless oil. [α]D= 
-3.4 (CHCl3, c 0.9). 
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1H NMR (300 MHz, CDCl3) d = 11.62 (s, 1 H) 8.19 (t, J=5.4 Hz, 1 H) 7.10 - 7.40 (m, 20 H) 
6.99 - 7.10 (m, 3 H) 6.92 (t, J=5.6 Hz, 1 H) 6.79 (d, J=8.6 Hz, 2 H) 5.04 (s, 2 H) 5.02 (s, 2 H) 
4.93 (s, 2 H) 4.41 - 4.49 (m, 2 H) 4.30 - 4.36 (m, 1 H) 4.26 (d, J=11.2 Hz, 1 H) 4.15 - 4.23 (m, 
1 H) 4.07 (br. s., 1 H) 3.91 (dd, J=7.6, 3.4 Hz, 1 H) 3.25 (q, J=6.0 Hz, 2 H) 3.16 (dq, J=13.1, 
6.5 Hz, 1 H) 2.96 - 3.07 (m, 2 H) 2.88 (br. s., 1 H) 2.77 (dd, J=14.2, 7.6 Hz, 1 H) 1.94 - 2.24 
(m, 5 H) 1.33 - 1.64 (m, 10 H) 0.93 - 1.06 (m, 1 H) 0.81 (t, J=7.3 Hz, 3 H) 0.67 (d, J=6.8 Hz, 3 
H). 13C NMR (75 MHz, CDCl3) d = 172.1, 171.5, 170.5, 163.7, 157.6, 156.0, 153.8, 137.1, 
137.0, 136.8, 134.6, 130.8, 129.6, 128.8, 128.7, 128.6, 128.5, 128.4, 128.4, 128.1, 128.1, 128.0, 
127.9, 127.4, 114.6, 81.0, 72.8, 70.0, 68.1, 67.1, 65.7, 60.0, 55.0, 54.2, 40.7, 39.1, 38.2, 37.6, 
36.6, 33.4, 29.7, 29.4, 26.5, 26.3, 26.1, 19.3, 14.3, 11.9. HRMS (ESI): calculated for 
C59H71N6O10 1023.5226 found 1023.5215. 
 
In a test tube, 2.51 (103.2 mg, 0.1 mmol) was dissolved in pyridine (3.6 mL) and SO3•pyridine 
complex (69 mg, 0.43 mmol) was added in one portion and stirred at 50 °C during 3 hours. To 
the resulting mixture, water was added and the reaction was extracted with EtOAc three times. 
The combined organic layers were washed with an aqueous solution of HCl (1N) two times, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, CHCl3 / MeOH, 9/1) gave the compound 2.52 (89.1 mg, 80 %) as a colorless oil. [α]D= 
-2.7 (CHCl3, c 0.6). 1H NMR (300 MHz, DMSO-d6) d = 11.59 (s, 1 H) 8.38 (t, J=5.6 Hz, 1 H) 
7.82 (t, J=5.4 Hz, 1 H) 7.18 - 7.48 (m, 20 H) 7.13 (d, J=8.8 Hz, 2 H) 6.91 (d, J=8.6 Hz, 2 H) 
5.19 (s, 2 H) 5.06 (s, 2 H) 5.03 (s, 2 H) 4.45 - 4.54 (m, 2 H) 4.35 - 4.44 (m, 2 H) 4.21 (t, J=8.9 
Hz, 1 H) 4.05 (dd, J=7.1, 4.2 Hz, 1 H) 3.22 - 3.31 (m, 1 H) 3.00 - 3.08 (m, 2 H) 2.98 (d, J=2.9 
Hz, 1 H) 2.80 - 2.89 (m, 1 H) 2.23 - 2.38 (m, 2 H) 1.96 - 2.09 (m, 2 H) 1.92 (d, J=12.2 Hz, 1 
H) 1.71 - 1.86 (m, 2 H) 1.51 - 1.65 (m, 2 H) 1.33 - 1.51 (m, 6 H) 1.15 - 1.27 (m, 1 H) 0.92 - 
1.04 (m, 1 H) 0.83 - 0.90 (m, 3 H) 0.68 (d, J=6.6 Hz, 3 H). 13C NMR (101 MHz, DMSO-d6) 
d = 171.3, 170.5, 169.0, 163.1, 157.0, 155.0, 152.7, 137.6, 137.3, 136.9, 135.13, 130.5, 128.6, 
128.4, 128.3, 128.1, 128.0, 127.7, 127.6, 114.3, 80.3, 79.2, 71.3, 69.1, 67.6, 66.3, 60.0, 54.0, 
53.0, 40.2, 38.1, 37.3, 37.1, 36.0, 31.6, 30.6, 29.0, 26.2, 25.8, 23.3, 19.4, 14.0, 11.8. HRMS 
(ESI): calculated for C59H71N6O13S 1103.4794 found 1103.4755.  
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To a solution of 2.50b (66 mg, 0.095 mmol) in a mixture of THF (0.5 mL) and MeOH (0.25 
mL), an aqueous solution of LiOH (0.28 mL, 0.28 mmol, 1M) was added dropwise at 0 °C. 
After 3 hours, the reaction was acidified with an aqueous solution of HCl (1M). The resulting 
mixture was extracted with DCM three times and the combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude mixture product was dissolved in DMF 
(1 mL) and DIPEA (47 µL, 0.28 mmol) was added followed by a solution of 2.7b (45 mg, 0.11 
mmol) in DMF (1 mL). To the resulting mixture at 0 °C, HBTU (43 mg, 0.11 mmol) was added 
in one portion and stirred at room temperature during 16 hours. The reaction was then quenched 
with an aqueous saturated solution of NaHCO3 and extracted with AcOEt three times. The 
combined organic layers were washed with water three times and one time with brine, dried 
over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
pentane/ AcOEt, 7/3 to 1/9) gave the compound 2.51b (88.5 mg, 89 %) as a colorless oil. [α]D= 
– 1.3 (CHCl3, c 0.78). 1H NMR (400 MHz, CDCl3) d = 11.69 (s, 1 H) 8.26 (t, J=5.4 Hz, 1 H) 
7.40 - 7.49 (m, 2 H) 7.18 - 7.40 (m, 18 H) 7.11 (d, J=8.6 Hz, 1 H) 6.98 - 7.02 (m, 1 H) 6.94 - 
6.98 (m, 1 H) 6.82 (d, J=8.6 Hz, 1 H) 5.12 (s, 2 H) 5.09 (s, 4 H) 4.56 (d, J=11.2 Hz, 1 H) 4.51 
(dd, J=8.4, 6.5 Hz, 1 H) 4.32 - 4.42 (m, 2 H) 4.25 (dt, J=11.1, 5.3 Hz, 1 H) 4.14 (br. s., 1 H) 
3.97 (dd, J=7.2, 3.5 Hz, 1 H) 3.28 - 3.36 (m, 2 H) 3.23 (dq, J=13.1, 6.4 Hz, 1 H) 3.11 (dt, 
J=12.8, 6.4 Hz, 1 H) 3.01 (dd, J=14.3, 3.5 Hz, 1 H) 2.82 (dd, J=14.2, 7.3 Hz, 1 H) 2.24 - 2.33 
(m, 2 H) 2.15 - 2.24 (m, 2 H) 1.99 - 2.09 (m, 1 H) 1.72 (t, J=12.2 Hz, 1 H) 1.55 - 1.67 (m, 4 H) 
1.42 - 1.55 (m, 5 H) 1.16 - 1.31 (m, 3 H) 0.98 - 1.12 (m, 1 H) 0.88 (t, J=7.2 Hz, 3 H) 0.73 (d, 
J=6.8 Hz, 3 H). 13C NMR (101 MHz, CDCl3) d = 171.7, 171.5, 170.5, 163.7, 156.0, 153.8, 
153.0, 136.9, 136.7, 134.7, 131.6, 130.8, 129.0, 128.8, 128.7, 128.6, 128.6, 128.5, 128.4, 128.3, 
128.2, 128.1, 128.0, 128.0, 127.1, 122.9, 113.9, 80.5, 72.9, 70.9, 68.1, 67.1, 65.7, 60.0, 55.0, 
54.1, 40.7, 39.1, 37.8, 37.7, 36.7, 33.5, 29.4, 26.5, 26.4, 26.2, 25.8, 19.3, 14.3, 11.9. HRMS 
(ESI): calculated for C59H70ClN6O10 1057.4836 found 1057.4834. 
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In a test tube, 2.51b (87 mg, 0.083 mmol) was dissolved in pyridine (3 mL) and SO3•pyridine 
complex (56 mg, 0.35 mmol) was added in one portion and stirred at 50 °C during 3 hours. To 
the resulting mixture, water was added and the reaction was extracted with EtOAc three times. 
The combined organic layers were washed with an aqueous solution of HCl (1N) two times, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, CHCl3 / MeOH, 9/1) gave the compound 2.52b (77.5 mg, 83 %) as a colorless oil. [α]D= 
– 0.06 (CHCl3, c 3.88). 1H NMR (400 MHz, DMSO-d6, major rotamer) d = 11.59 (br. s., 1 
H) 8.38 (t, J=5.5 Hz, 1 H) 8.33 (s, 1 H) 7.84 (t, J=5.5 Hz, 1 H) 7.20 - 7.50 (m, 21 H) 7.05 - 7.18 
(m, 2 H) 5.19 (s, 2 H) 5.17 (s, 2 H) 5.03 (s, 2 H) 4.53 (d, J=6.1 Hz, 1 H) 4.47 - 4.51 (m, 1 H) 
4.37 - 4.45 (m, 2 H) 4.21 (t, J=8.9 Hz, 1 H) 4.00 - 4.10 (m, 2 H) 3.27 (q, J=6.5 Hz, 2 H) 2.96 - 
3.10 (m, 3 H) 2.81 - 2.90 (m, 1 H) 2.23 - 2.36 (m, 2 H) 1.97 - 2.09 (m, 2 H) 1.92 (d, J=12.5 Hz, 
1 H) 1.72 - 1.87 (m, 2 H) 1.54 - 1.62 (m, 1 H) 1.31 - 1.52 (m, 6 H) 1.17 (dd, J=13.6, 6.5 Hz, 1 
H) 0.95 (td, J=14.3, 6.8 Hz, 1 H) 0.83 - 0.89 (m, 3 H) 0.67 (d, J=6.6 Hz, 3 H). 13C NMR (101 
MHz, DMSO-d6, major rotamer) d = 171.3, 170.3, 168.9, 163.1, 155.1, 152.7, 152.2, 137.6, 
136.9, 136.8, 135.1, 130.9, 130.9, 129.3, 128.6, 128.5, 128.4, 128.3, 128.3, 128.2, 128.0, 127.9, 
127.8, 127.7, 127.6, 127.4, 127.3, 121.0, 113.9, 79.8, 71.2, 69.9, 67.6, 66.3, 60.0, 54.0, 52.9, 
40.2, 38.1, 37.3, 36.5, 36.0, 31.7, 30.6, 26.2, 25.8, 23.3, 19.4, 13.9, 11.8. HRMS (ESI): 
calculated for C59H70ClN6O13S 1137.4405 found 1137.4361. 
 
To a solution of 2.50c (57.5 mg, 0.078 mmol) in a mixture of THF (0.4 mL) and MeOH (0.2 
mL), an aqueous solution of LiOH (0.23 mL, 0.23 mmol, 1M) was added dropwise at 0 °C. 
After 3 hours, the reaction was acidified with an aqueous solution of HCl (1M). The resulting 
mixture was extracted with DCM three times and the combined organic layers were dried over   
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MgSO4, filtered and concentrated in vacuo. The crude mixture product was dissolved in DMF 
(0.8 mL) and DIPEA (39 µL, 0.23 mmol) was added followed by a solution of 2.7b (37 mg, 
0.094 mmol) in DMF (1 mL). To the resulting mixture at 0 °C, HBTU (35.6 mg, 0.094 mmol) 
was added in one portion and stirred at room temperature during 16 hours. The reaction was 
then quenched with an aqueous saturated solution of NaHCO3 and extracted with AcOEt three 
times. The combined organic layers were washed with water three times and one time with 
brine, dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (SiO2, pentane/ AcOEt, 7/3 to 1/9) gave the compound 2.51c (83 mg, 96 %) 
as a colorless oil. [α]D= – 3 (CHCl3, c 0.88). 1H NMR (400 MHz, CDCl3) d = 11.63 (s, 1 H) 
8.19 (t, J=5.4 Hz, 1 H) 7.34 - 7.45 (m, 3 H) 7.11 - 7.34 (m, 17 H) 7.03 (d, J=8.6 Hz, 1 H) 6.99 
(dd, J=8.3, 2.0 Hz, 1 H) 6.90 (t, J=5.9 Hz, 1 H) 6.74 (d, J=8.3 Hz, 1 H) 5.06 (s, 2 H) 5.03 (s, 2 
H) 5.03 (s, 2 H) 4.49 (d, J=11.5 Hz, 1 H) 4.43 (dd, J=8.6, 6.6 Hz, 1 H) 4.25 - 4.36 (m, 2 H) 4.14 
- 4.23 (m, 1 H) 4.08 (br. s., 1 H) 3.90 (dd, J=7.2, 3.5 Hz, 1 H) 3.21 - 3.30 (m, 2 H) 3.11 - 3.21 
(m, 1 H) 3.00 - 3.11 (m, 1 H) 2.94 (dd, J=14.3, 3.3 Hz, 1 H) 2.75 (dd, J=14.2, 7.3 Hz, 1 H) 2.47 
(br. s., 2 H) 2.17 - 2.29 (m, 2 H) 1.97 - 2.17 (m, 4 H) 1.66 (t, J=12.1 Hz, 1 H) 1.36 - 1.60 (m, 8 
H) 1.10 - 1.24 (m, 3 H) 0.91 - 1.05 (m, 1 H) 0.79 - 0.84 (m, 3 H) 0.67 (d, J=6.8 Hz, 3 H). 13C 
NMR (101 MHz, CDCl3) d = 171.7, 171.5, 170.5, 163.8, 156.0, 153.9, 153.9, 136.9, 136.7, 
134.7, 131.2, 129.8, 128.9, 128.8, 128.7, 128.6, 128.5, 128.5, 128.2, 128.2, 128.0, 127.1, 113.6, 
112.2, 80.6, 72.9, 70.9, 68.2, 67.2, 65.8, 60.0, 55.1, 54.2, 40.7, 39.1, 37.7, 36.7, 33.6, 29.8, 29.4, 
26.6, 26.4, 26.3, 25.8, 19.4, 14.3, 12.0. HRMS (ESI): calculated for C59H70BrN6O10 1101.4331 
found 1101.4318. 
 
In a test tube, 2.51c (82 mg, 0.074 mmol) was dissolved in pyridine (2.6 mL) and SO3•pyridine 
complex (51 mg, 0.32 mmol) was added in one portion and stirred at 50 °C during 3 hours. To 
the resulting mixture, water was added and the reaction was extracted with EtOAc three times. 
The combined organic layers were washed with an aqueous solution of HCl (1N) two times, 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(SiO2, CHCl3 / MeOH, 9/1) gave the compound 2.52c (66 mg, 75 %) as a colorless oil. [α]D= – 
23.7 (CHCl3, c 0.47).  
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1H NMR (400 MHz, DMSO-d6) d = 11.59 (s, 1 H) 8.38 (t, J=5.7 Hz, 1 H) 8.33 (s, 1 H) 7.83 
(t, J=5.5 Hz, 1 H) 7.44 - 7.52 (m, 3 H) 7.21 - 7.44 (m, 17 H) 7.00 - 7.20 (m, 2 H) 5.19 (s, 2 H) 
5.17 (s, 2 H) 5.03 (s, 2 H) 4.44 - 4.56 (m, 2 H) 4.36 - 4.44 (m, 2 H) 4.20 (t, J=8.9 Hz, 1 H) 3.99 
- 4.14 (m, 2 H) 3.26 (q, J=6.5 Hz, 2 H) 2.95 - 3.09 (m, 3 H) 2.79 - 2.90 (m, 1 H) 2.24 - 2.37 (m, 
2 H) 1.95 - 2.08 (m, 2 H) 1.91 (d, J=12.7 Hz, 1 H) 1.70 - 1.86 (m, 2 H) 1.52 - 1.64 (m, 1 H) 
1.29 - 1.52 (m, 7 H) 1.10 - 1.21 (m, 1 H) 0.89 - 1.01 (m, 1 H) 0.81 - 0.89 (m, 3 H) 0.67 (d, J=6.6 
Hz, 3 H). 13C NMR (101 MHz, DMSO-d6) d = 171.3, 170.2, 168.9, 163.0, 155.0, 153.0, 152.7, 
137.6, 136.9, 136.8, 135.1, 133.9, 131.4, 130.0, 128.6, 128.5, 128.4, 128.3, 128.2, 128.2, 128.0, 
127.8, 127.7, 127.6, 127.3, 127.2, 113.8, 110.7, 79.8, 71.2, 71.1, 69.9, 67.6, 66.3, 60.0, 54.0, 
52.9, 40.2, 38.1, 37.3, 36.4, 36.0, 31.7, 30.6, 29.0, 26.2, 25.8, 23.3, 19.4, 13.9, 11.8. HRMS 
(ESI): calculated for C59H70BrN6O13S 1181.3899 found 1181.3854. 
 
The compound 2.52a (83 mg, 0.075 mmol) was dissolved in a mixture of AcOEt (2 mL) and 
MeOH (2 mL) and Pd(OH)2/C (20 %) (264 mg, 0.38 mmol) was added in one portion. The 
atmosphere was replaced by hydrogen (1 atm.) by three cycles of vacuum / H2. After 6 hours, 
the resulting mixture was filtered through a pad of celite and rinced with EtOAc (50 mL) 
followed by MeOH (50 mL). The filtrate was concentrated in vacuo. Purification by HPLC 
(Interchim Puriflash 4250, Waters X-Bridge Prep C18, 5µm 19 x 50 mm, H2O/MeCN : 1/0 to 
0/1 during 10 min; RT = 1 min) gave aeruginosin 98B  (37 mg, 75 %) as a mixture of 
conformers (84:16). [α]D= ‒ 10.3 ° (H2O, c 0.1) Lit. 72a [α]D= ‒ 5.24 ° (H2O, c 0.25). 1H NMR 
(300 MHz, CDCl3) d = 9.23 (s, 1H), 8.43 (s, 2H), 8.33 (s, 1H), 7.90 (t, J = 5.3 Hz, 1H), 7.60 – 
7.41 (m, 3H), 7.35 (d, J = 8.5 Hz, 1H), 7.00 (d, J = 8.3 Hz, 2H), 6.64 (d, J = 8.3 Hz, 2H), 5.87 
(s, 1H), 4.47 (dd, J = 8.3, 4.6 Hz, 1H), 4.39 – 4.31 (m, 1H), 4.17 (t, J = 8.9 Hz, 1H), 4.09 – 4.03 
(m, 1H), 4.04 – 3.98 (m, 1H), 3.11 – 3.03 (m, 3H), 3.02 – 2.95 (m, 1H), 2.88 (dd, J = 14.2, 3.2 
Hz, 1H), 2.63 (dd, J = 14.0, 7.4 Hz, 1H), 2.32 – 2.18 (m, 2H), 2.06 – 1.93 (m, 2H), 1.86 (d, J = 
13.1 Hz, 1H), 1.82 – 1.72 (m, 1H), 1.72 – 1.64 (m, 1H), 1.58 – 1.51 (m, 1H), 1.49 – 1.38 (m, 
5H), 1.37 – 1.29 (m, 1H), 1.23 – 1.14 (m, 1H), 1.03 – 0.92 (m, 1H), 0.85 (t, J = 7.3 Hz, 3H), 
0.67 (d, J = 6.6 Hz, 3H).  
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13C NMR (75 MHz, CDCl3) d = 172.8, 171.5, 168.9, 157.3, 155.7, 130.5, 128.1, 114.7, 72.2, 
71.0, 59.9, 54.0, 52.5, 40.3, 39.2, 38.0, 37.7, 35.9, 31.7, 30.7, 26.2, 25.8, 23.4, 19.4, 13.8, 11.8. 
HRMS (ESI): calculated for C29H47N6O9S 655.3120 found 655.3115. 
 
The compound 2.52b (33.8 mg, 30 µmol) was dissolved in acetonitrile (2 mL) and Pd/C (10 %) 
(158 mg, 0.15 mmol) and ZnBr2 (33.5 mg, 0.15 mmol) were added in one portion. The 
atmosphere was replaced by hydrogen (1 atm.) by three cycle of vacuum / H2. After 6 hours, 
silica gel was added and the resulting mixture was filtered through a pad of celite and rinced 
with MeOH (50 mL). The filtrate was concentrated in vacuo. The 1H NMR analysis in MeOH-
d4 of the crude mixture showed a total conversion (See spectrum below). Purification by column 
chromatography (C18, H2O / MeCN / 1% TFA, 9/1 to 1/1) gave aeruginosin 98A (10 mg, 50 
%) as a mixture of conformers (80:20) 1H NMR (500 MHz, DMSO-d6) d = 9.94 – 9.84 (m, 
1H), 8.37 – 8.21 (m, 1H), 7.84 (br s, 1H), 7.63 (br s, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.17 (br s, 
1H), 6.96 (d, J = 8.0 Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H), 5.88 (br s, 1H), 4.46 (dd, J = 8.3, 4.0 
Hz, 1H), 4.38 – 4.32 (m, 1H), 4.16 (t, J = 8.9 Hz, 1H), 4.09 (br s, 1H), 4.06 – 3.97 (m, 1H), 3.18 
– 3.03 (m, 3H), 3.03 – 2.95 (m, 1H), 2.89 – 2.82 (m, 1H), 2.70 – 2.62 (m, 1H), 2.32 – 2.18 (m, 
2H), 2.04 – 1.92 (m, 2H), 1.91 – 1.81 (m, 1H), 1.81 – 1.71 (m, 1H), 1.73 – 1.64 (m, 1H), 1.56 
– 1.49 (m, 1H), 1.49 – 1.34 (m, 5H), 1.36 – 1.24 (m, 3H), 1.19 – 1.11 (m, 2H), 0.97 – 0.88 (m, 
1H), 0.84 (t, J = 7.1 Hz, 3H), 0.64 (d, J = 6.6 Hz, 3H). .13C NMR (126 MHz, DMSO-d6) 
d = 172.5, 171.7, 169.1, 156.7, 151.5, 130.8, 129.7, 129.4, 119.0, 116.2, 71.8, 71.7, 59.9, 54.1, 
52.6, 40.4, 38.8, 38.0, 37.6, 36.0, 31.7, 30.8, 26.3, 26.0, 25.9, 23.5, 19.4, 13.8, 11.9. HRMS 
(ESI): calculated for C29H46ClN6O9S 689.2736 found 689.2718. 
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The compound 44c (36.2 mg, 31 µmol) was dissolved in acetonitrile (2 mL) and Pd/C (10 %) 
(163 mg, 0.15 mmol) and ZnBr2 (35 mg, 0.15 mmol) were added in one portion. The 
atmosphere was replaced by hydrogen (1 atm.) by three cycle of vacuum / H2. After 6 hours, 
silica gel was added and the resulting mixture was filtered through a pad of celite and rinced 
with MeOH (50 mL). The filtrate was concentrated in vacuo. The 1H NMR analysis in MeOH-
d4 of the crude mixture showed a total conversion of 1:1 mixture of aeruginosin 98B and 98C. 
(See spectrum below). The mixture was purified by HPLC (Waters , Sunfire Waters Prep C18, 
5 µm 19 x 150 mm, H2O/MeCN 0.1% Formic acid; isocratic 8:2; 20 mL/min; RT = 8.72 min)  
and aeruginosin 98C72f (1d) (2 mg) was obtained as a mixture of conformers (82:18) with 
unexpected 9 % yield due to loss of material during the purification.  
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1H NMR (500 MHz, DMSO-d6) d = 10.01 (br s, 1H), 8.40 (br s, 1H), 7.95 (br s, 1H), 7.89 – 
7.78 (m, 1H), 7.44 (d, J = 8.9 Hz, 1H), 7.35 (s, 1H), 7.33 (d, J = 1.7 Hz, 1H), 7.29 (d, J = 1.8 
Hz, 2H), 7.00 (dd, J = 8.2, 1.7 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 5.89 (br s, 1H), 4.49 – 4.42 
(m, 1H), 4.36 (br s, 1H), 4.16 (t, J = 8.9 Hz, 1H), 4.08 (br s, 1H), 4.06 – 3.98 (m, 1H), 3.15 – 
2.95 (m, 4H), 2.86 (dd, J = 14.0, 3.1 Hz, 1H), 2.67 (dd, J = 14.0, 7.1 Hz, 1H), 2.36 – 2.17 (m, 
2H), 2.06 – 1.92 (m, 2H), 1.91 – 1.82 (m, 1H), 1.82 – 1.72 (m, 1H), 1.72 – 1.63 (m, 1H), 1.57 
– 1.50 (m, 1H), 1.51 – 1.35 (m, 5H), 1.37 – 1.29 (m, 1H), 1.19 – 1.10 (m, 1H), 0.99 – 0.90 (m, 
1H), 0.85 (t, J = 7.2 Hz, 3H), 0.65 (d, J = 6.5 Hz, 3H).13C NMR (126 MHz, DMSO-d6) 
d = 172.3, 171.5, 169.0, 156.9, 152.4, 133.6, 130.0, 130.0, 115.8, 108.6, 71.7, 70.8, 59.9, 54.0, 
52.5, 40.4, 38.8, 37.9, 37.5, 35.9, 31.7, 30.7, 26.2, 25.8, 23.4, 19.4, 13.8, 11.9. HRMS (ESI): 
calculated for C29H46BrN6O9S 733.2230 found 733.2204. 
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3. Synthesis of Strained g-Lactams by Palladium(0)-Catalyzed C(sp3)–
H Alkenylation and Application to Alkaloid Synthesis 
3.1. General procedures 
General procedure A: General procedure for the C(sp3)-H activation 
In the glovebox, palladium allyl chloride (5 mol%.), PPh3 (20 mol%), cesium carbonate (1.5 
equiv) and pivalic acid (30 mol%) were added to a reaction tube containing a magnetic stir bar. 
The protected amide (1 equiv) was added to second, dried reaction tube, which was evacuated 
and backfilled with argon three times. Then, mesitylene (1 mL) was added and the solution was 
transferred to the first tube containing the catalyst under argon. The reaction was placed in a 
pre-heated oil batch or metal block and stirred overnight (12 h) at 160°C. The mixture was 
diluted with ethyl acetate, filtered over Celite and concentrated under reduced pressure. The 
crude product was purified by preparative thin layer chromatography or by flash 
chromatography. 
General procedure B: Amide formation 
A carboxylic acid (1 equiv) was dissolved under exclusion of moisture in DCM. Oxalyl chloride 
(1.3 equiv) and a catalytic quantity of DMF were added. The mixture was stirred for 1h at room 
temperature and disappearance of the starting material was checked by GCMS. Then, the amine 
(2-6 equiv) and a solution of NaOH (1M, 8 equiv) were added at 0°C. The reaction mixture was 
allowed to warm up to room temperature and was stirred vigorously overnight. After quenching 
with brine, the aq. phase was extracted three times with DCM. The unified organic phase was 
dried over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
flash chromatography. 
General procedure C: Amide protection 
To a stirred solution of amide (1 equiv), in THF under argon atmosphere, a solution of 
NaHMDS (2 equiv) in THF was added dropwise at 0°C. The mixture was stirred for 30 minutes 
and allowed to warm up to room temperature. Then, the electrophile (2 equiv) was added 
dropwise. The reaction was stirred for at least two hours, then quenched with a sat. solution of 
NaHCO3 and extracted with ethyl acetate. The organic layer was separated, washed with brine, 
dried over MgSO4 and concentrated under reduced pressure. The crude product was purified by 
flash chromatography. 
  
155 
 
3.2. Synthesis of bromoalkenes 
2-Bromo-3-methylbut-2-enoic acid 3.17183 
 
Small scale synthesis : To a stirred solution of 3-methylbut-2-enoic acid (200 mg, 2.00 mmol, 
1.0 equiv) in DCM (2 mL), was added bromine (351 mg, 2.20 mmol, 1.1 equiv) dropwise at 
0°C. The mixture was stirred 12 hours. Then quenched with saturated solution of Na2S2O3 to 
remove excess of bromine and extracted three times with DCM. The organic layer was dried 
over MgSO4 and concentrated to give the dibrominated acid. The product was dissolved in THF 
and piperidine (967 µL, 9.80 mmol, 4.9 equiv) was added in one portion at 0°C. The solution 
was stirred for 24 h at room temperature and then quenched with aq. HCl (5 M). The product 
was extracted with ethyl acetate. The collected organic layers were dried over MgSO4 and 
concentrated to give the 2-bromo-3-methylbut-2-enoic acid 3.17 as a yellow powder (319 mg, 
1.78 mmol, 89% yield). 
Gram scale synthesis : To a stirred solution of 3-methylbut-2-enoic acid (10 g, 99.9 mmol, 1.0 
equiv) in DCM (70 mL), was added bromine (5.64 mL, 109.9 mmol, 1.1 equiv) dropwise at 
0°C. The mixture was stirred 12 hours. Then quenched with saturated solution of Na2S2O3 to 
remove excess of bromine and extracted three times with DCM. The organic layer was dried 
over MgSO4 and concentrated to give the dibrominated acid. The product was dissolved in THF 
(100 mL) and piperidine (48 mL, 490 mmol, 4.9 equiv) was added in one portion at 0°C. The 
solution was stirred for 24 h at room temperature and then HCl gas was bubbled in the organic 
phase during 2 hours. The crude product was filtrated on a pad of celite and concentrated to 
give the 2-bromo-3-methylbut-2-enoic acid 3.17 as a brown oil (10 g, 55.86 mmol, 56% yield). 
1H NMR (CDCl3, 300 MHz): δ = 10.7 (s, 1 H), 2.20 (s, 3 H), 2.10 (s, 3 H). 13C NMR (CDCl3, 
75 MHz): δ = 169.4, 153.7, 108.7, 28.5, 23.8. MS (EI, 70 eV, 200 °C):  m/z (%) = 178.1 [M] 
+· IR (neat): ν = 1620 cm-1 Melting point: 73-75 °C 
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(Z)-2-Bromobut-2-enoic acid 
 
Methyl (2Z)-2-bromobut-2-enoate was prepared as described previously184.  
Methyl (2Z)-2-bromobut-2-enoate (1.4 g, 7.82 mmol, 1 equiv) was dissolved in THF (7 ml) and 
a solution of LiOH (562 mg, 23.46 mmol, 3 equiv) in water (8 ml) was added. The solution was 
stirred at overnight at room temperature. The solution was acidified with an aq. solution of HCl 
(1 N) until pH < 3 and then three times extracted with DCM. The unified org. phase was washed 
with brine, dried over Na2SO4 and concentrated under reduced pressure affording 750 mg (4.55 
mmol, 58%) of a white solid. 
1H NMR (CDCl3, 300 MHz): δ = 11.38 (br. s., 1 H), 7.55 (q, J=6.8 Hz, 1 H), 1.99 (d, J=7.0 
Hz, 3 H). 13C136 NMR (CDCl3, 101 MHz): δ = 168.1, 144.9, 116.7, 18.3. LRMS (ESI) calcd 
for C4H9BrO2 ([M-H]-): 162.9; found: 162.9; IR(neat): ν = 2821, 2645, 2522, 1673, 1615, 1283 
cm-1. Mp = 106-108 °C. HRMS(ESI): calcd for C4H6BrO2 ([M+H]+): 164.9546; found: 
164.9544; 
(Z)-2-bromo-3-phenylacrylaldehyde  
 
To a stirred solution of cinnamaldehyde (8.0 g, 60.5 mmol, 1.0 equiv) in DCM (64 mL), was 
added bromine (11.6 g, 72.6 mmol, 1.2 equiv) dropwise at 0°C. The mixture was stirred 30 min. 
Then triethylamine (18.4 g, 181.6 mmol, 3.0 equiv) was added and the reaction was stirred for 
1 hour. Quenched with saturated solution of Na2S2O3 to remove excess of bromine and extracted 
three times with DCM. The organic layer was dried over MgSO4 and concentrated to give (Z)-
2-bromo-3-phenylacrylaldehyde as a white powder (8.4 g, 39.8 mmol, 66% yield). 
Spectroscopic data are consistent with those previously reported.  
1H NMR (CDCl3, 300 MHz):  δ = 7.40 - 7.54 (m, 3 H), 7.91 (s, 1 H), 7.96 - 8.07 (m, 2 H), 
9.36 (d, J=0.4 Hz, 1 H) ppm. MS (EI, 70 eV, 200 °C): 209.9 [M] +· 
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(Z)-2-bromo-3-phenylacrylic acid 
 
A solution of NaClO2 (4.8 g, 53.1 mmol, 1.4 equiv) in water was added dropwise to a stirred solution 
of (Z)-2-bromo-3-phenyl-propenal (8.0 g, 37.9 mmol, 1.0 equiv), an aq. solution of NaH2PO4 (1.1 
g, 15 mL, 9.5 mmol, 0.25 equiv) and an aq. solution of H2O2 (30%, 3.55 mL, 45.5 mmol, 1.2 equiv) 
in MeCN (38 mL), at 0°C. The mixture was stirred 2 hours and then quenched with Na2CO3 in water 
until pH=10 was reached. The reaction mixture was extracted with Et2O (3x 60 mL) and the aq. 
phase was acidified with aq. HCl (1M), until the pH=1 was reached. The precipitate formed was 
filtered and washed with cold water. The white powder was collected and dried overnight to give 
the (Z)-2-bromo-3-phenylacrylic acid (7.1 g, 31.3 mmol, 59 %). Spectroscopic data are consistent 
with those previously reported. 
1H NMR (CDCl3, 300 MHz):  δ = 7.39 - 7.52 (m, 3 H), 7.84 - 7.97 (m, 2 H), 8.37 (s, 1 H) ppm. 
MS (EI, 70 eV, 200 °C): 226.1 [M] +· 
2-Bromo-N,N-diisopropyl-3-methylbut-2-enamide 3.13a 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (200 mg, 1.12 mmol, 
1.0 equiv) was reacted with oxalyl chloride (124 µL, 1.45 mmol, 1.3 equiv), DMF (2 drops), 
diisopropylamine (947 µL, 6.70 mmol, 6.0 equiv) and aq. NaOH (1 M, 8.9 mL, 8.90 mmol, 8.0 
equiv) in DCM (8.9 mL) for 12 hours. The crude product was purified by flash chromatography 
(eluent: CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N,N-diisopropyl-3-methylbut-2-
enamide 3.13a (234 mg, 0.89 mmol, 80%) as a white solid. 
1H NMR (CDCl3, 300 MHz): δ = 4.00 (sep., J=6.7 Hz, 1 H), 3.38 (sep., J=6.7 Hz, 1 H), 1.87 
(s, 3 H), 1.81 (s, 3 H), 1.41 (d, J=6.7 Hz, 3 H), 1.44 (d, J=6.7 Hz, 3 H), 1.18 (d, J=6.7 Hz, 3 H), 
1.13 (d, J=6.7 Hz, 3 H). 13C136 NMR (CDCl3, 75 MHz): δ = 165.6, 133.2, 110.1, 51.2, 45.7, 
22.8, 21.4, 21.0, 20.4, 20.3, 19.7. IR (neat): ν = 2971, 1620 cm-1. MS (EI, 70 eV, 200 °C): m/z 
(%) = 260.9 [M]+·. Melting point: 71-73 °C 
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2-Bromo-N-isopropyl-3-methylbut-2-enamide 3.19 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (319 mg, 1.78 mmol, 
1.0 equiv), oxalyl chloride (199 µL, 2.32 mmol, 1.3 equiv), DMF (2 drops), isopropylamine 
(1.5 mL, 10.69 mmol, 6.0 equiv) and aq. NaOH (1 M) (14.3 mL, 14.26 mmol, 8.0 equiv) in 
DCM (14,5 mL) were allowed to react for 12 hours. The obtained oil was purified by flash 
chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2). The 2-bromo-N-isopropyl-3-
methylbut-2-enamide 3.19 was obtained as a white solid (350 mg, 1.59 mmol, 89%). 
1H NMR (CDCl3, 300 MHz): δ = 5.94 (s, 1 H), 4.06 (sept, J=6.6 Hz, 1 H), 2.07 (s, 3 H), 1.95 
(s, 3 H), 1.18 (d, J=6.6 Hz, 6 H). 13C136 NMR (CDCl3, 75 MHz): δ = 164.0, 142.6, 111.3, 42.1, 
26.3, 22.7, 22.6 (2C). IR (neat): ν = 3251, 2971, 1627, 697 cm-1. MS (EI, 70 eV, 200 °C): m/z 
(%) = 219.1 [M]+·. Melting point: 64-66 °C 
Tert-butyl (2-bromo-3-methylbut-2-enoyl)(isopropyl)carbamate 3.13b 
 
To a solution of 2-bromo-3-methyl-N-(propan-2-yl)but-2-enamide 3.19 (200 mg, 0.91 mmol, 1 
equiv) in acetonitrile (2 mL) was added Boc2O (218 mg, 0.21 mL, 1.00 mmol, 1.1 equiv). The 
solution was warmed to 70°C then DMAP (16 mg, 0.13 mmol, 14 mol%) was added. The 
reaction was monitored by TLC every 30 min and portions of Boc2O (0.5 equiv) and DMAP (5 
mol%) were added until after 3h the conversion was complete. The reaction was quenched with 
a sat. aq. NaHCO3, extracted with DCM and dried over MgSO4. The crude product was purified 
by flash chromatography (eluent: Cyclohex/EtOAC/Et3N 96:4:2) affording Tert-butyl (2-
bromo-3-methylbut-2-enoyl)(isopropyl)carbamate 3.13b (260 mg 0.81 mmol, 89 %) as a 
colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.64 (sep, J=6.9 Hz, 1 H), 1.86 (s, 3 H), 1.82 (s, 3 H), 1.43 
(s, 9 H), 1.29 (d, J=6.9 Hz, 6 H). 13C 136 NMR (CDCl3, 75 MHz): δ = 167.5, 152.3, 137.0, 
111.7, 83.3, 48.1, 27.9 (3 C), 24.2, 21.8 (2 C), 20.0. IR (neat): ν = 2976, 2935, 1734, 1667 cm-
1. MS (EI, 70 eV, 200 °C): m/z (%) = 262.0 [M - C4H9]+· 
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2-Bromo-N-(ethoxymethyl)-N-isopropyl-3-methylbut-2-enamide 3.13c 
 
Following general procedure C, 2-bromo-N-isopropyl-3-methylbut-2-enamide 3.19 (200 mg, 
0.91 mmol, 1.0 equiv) was reacted with NaHMDS (364 µL, 1.82 mmol, 2 equiv), ethoxymethyl 
chloride (170 µL, 1.82 mmol, 2.0 equiv) in THF (4 mL). The obtained oil was purified by flash 
chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) affording 2-bromo-N-(ethoxymethyl)-
N-isopropyl-3-methylbut-2-enamide 3.13c as a colorless oil (215 mg, 0.77 mmol, 85%). 
1H NMR (CDCl3, 300 MHz, mixture of two conformers, ratio = 0.55/0.45): δ= 4.64, 4.90 (2 
m, J=3 Hz, together 2 H), 4.08, 4.46 (2 sep., J=6.7 Hz, together 1 H), 3.36, 3.57 (2 q, J=7 Hz, 
together 2 H), 1.77-1.86 (d, J=9.0 Hz, d, J=5.9 Hz, together 6 H), 1.22 (s, 3 H), 1.20 (s, 3 H), 
1.13 (m, 3 H). 13C {1H} NMR (CDCl3, 75 MHz): δ = 168.0-167.2, 136.1-134.9, 108.23-108.17, 
76.1-70.2, 64.4-63.2, 50.1-46.1, 23.1-23.0, 21.9-21.8, 22.3-21.4, 15.3, 15.0. IR (neat): ν = 
2957, 2933, 1644, 1076 cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 277.0 [M]+· 
2-Bromo-N-isopropyl-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13e 
 
Following general procedure C, 2-bromo-N-isopropyl-3-methylbut-2-enamide 3.19 (200 mg, 
0.909 mmol, 1.0 equiv) was reacted with NaHMDS (364 µL, 1.817 mmol, 2 equiv), 2-
(trimethylsilyl)ethoxymethyl chloride (322 µL, 1.817 mmol, 2.0 equiv) in THF (4 mL). The 
crude product was purified  by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) 
affording 2-Bromo-N-isopropyl-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-enamide 
3.13e as a colorless oil (285 mg, 0.813 mmol, 90% yield). 
1H NMR (CDCl3, 300 MHz, mixture of two conformers, ratio = 0.57/0.43): δ = 5.03 – 4.81 
(m, 1H), 4.66 (d, J = 9.7 Hz, 1H), 4.56 – 4.02 (m, 1H), 3.70 – 3.55 (m, 1H), 3.67-3.40 (m, 1H), 
1.90 (d, J = 5.0 Hz, 3H), 1.81 (d, J = 9.7 Hz, 3H), 1.25 (d, J = 8.3 Hz, 6H), 0.99 – 0.77 (m, 2H), 
0.00 (d, J = 3.3 Hz, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 167.8, 135.3, 108.2, 77.2, 69.7, 
65.9-65.2, 49.9-46.1, 22.9, 21.7, 20.3, 18.1, 0 (3 C). IR (neat): ν = 2890, 1645, 1044 cm-1. MS 
(EI, 70 eV, 200 °C): m/z (%) = 349.1 [M]+·  
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2-Bromo-N-isopropyl-3-methyl-N-(2,4,6-trimethoxybenzyl)but-2-enamide 3.13f 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (524 mg, 2.93 mmol, 
1.0 equiv) was reacted with oxalyl chloride (327 µL, 3.81 mmol, 1.3 equiv), DMF (2 drops), N-
(2,4,6-trimethoxybenzyl)propan-2-amine (2.1 g, 8.79 mmol, 3.0 equiv) and aq. NaOH (1 M, 
23.4 mL, 23.4 mmol, 8.0 equiv) in DCM (15 mL) for 12 hours. The crude product was purified 
by flash chromatography (eluent: CyHex/EtOAc 90:10) affording 2-Bromo-N-isopropyl-3-
methyl-N-(2,4,6-trimethoxybenzyl)but-2-enamide 3.13f (973 mg ,2.43 mmol, 83%) as a yellow 
oil. 
1H NMR (CDCl3, 300 MHz, mixture of two conformers, ratio = 0.50/0.50): δ= 6.12 – 6.05 
(m, 2H), 4.93 – 4.64 (m, 1H), 4.56 – 4.38 (m, 1H), 4.18 – 4.06 (m, 0.5H), 3.84 – 3.76 (m, 9H), 
3.77 – 3.70 (m, 0.5H), 1.90 – 1.87 (m, 3H), 1.87 – 1.83 (m, 3H), 1.18 – 1.10 (m, 3H), 1.08 – 
0.93 (m, 3H). 13C {1H} NMR (CDCl3, 75 MHz): δ = 166.8, 166.1, 161.3, 160.9, 160.0, 159.7, 
134.9, 133.5, 111.7, 110.0, 107.6, 104.8, 90.4, 90.3, 55.7, 55.5, 55.4, 55.4, 51.0, 48.9, 41.0, 
32.1, 23.6, 23.1, 21.7, 21.4, 21.3, 20.5, 19.6, 19.1. IR (neat): ν = 2937, 1630, 1606, 1418, 1204 
cm-1. HRMS(ESI): calcd for C18H27BrNO4 ([M+H]+): 400.1118; found: 400.1125; 
2-Bromo-N-ethyl-3-methylbut-2-enamide 3.19g 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1 equiv) was reacted with oxalyl chloride (311 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
ethylamine (1.03 mL, 16.76 mmol, 6.0 equiv) and aq. NaOH (1M, 22 mL, 22.00 mmol, 8.0 
equiv) in DCM (22 mL). The crude product was purified by flash chromatography (eluent: 
CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-ethyl-3-methylbut-2-enamide 3.19g (523 
mg, 2.54 mmol, 91%) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 6.23 (s, 1H), 3.61 – 3.09 (m, 2H), 2.08 (s, 3H), 2.04 (s, 3H), 
1.45 – 1.10 (t, J=10.2 Hz, 3H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 164.7, 142.9, 111.0, 35.0,  
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26.3, 22.8, 14.7. IR (neat): ν = 3269, 1519,1296 cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 
206.2 [M]+· 
 
2-Bromo-N-ethyl-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13g 
 
Following general procedure C, 2-bromo-N-ethyl-3-methylbut-2-enamide  3.19g (200 mg, 0.97 
mmol, 1.0 equiv) was reacted with NaHMDS (389 µL, 1.94 mmol, 2.0 equiv) and 2 
(trimethylsilyl)ethoxymethyl chloride (344 µL, 1.94 mmol, 2.0 equiv) in THF (3 mL). The 
crude product was purified by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) 
affording 2-Bromo-N-ethyl-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-enamide 
3.13g (278 mg, 0.83 mmol, 85% yield) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.93 – 4.54 (m, 2H), 3.57 – 3.33 (m, 4H), 1.92 – 1.68 (m, 
6H), 1.17 – 1.05 (m, 3H), 0.91 – 0.79 (m, 2H), -0.04 – -0.10 (m, 9H). 13C{1H} NMR (CDCl3, 
75 MHz): δ = 166.4, 136.3, 107.6, 78.4, 65.6, 38.8, 23.1, 21.7, 18.0, 12.4,-1.4. IR (neat): ν = 
2950, 1646, 1419 cm-1. HRMS (ESI): calcd for C13H27BrNO2Si ([M+H]+) : 336.0989; found: 
336.0990; 
2-Bromo-N-(tert-butyl)-3-methylbut-2-enamide 3.19h 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid  3.17 (500 mg, 2.79 mmol, 
1.0 equiv) was reacted with oxalyl chloride (311 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
tert-butylamine (1.77 mL, 16.76 mmol, 6.0 equiv) and aq. NaOH (1M, 22 mL, 22 mmol, 8.0 
equiv) in DCM (22 mL). The crude product was purified by flash chromatography (eluent: 
CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-(tert-butyl)-3-methylbut-2-enamide 3.19h 
(582 mg, 2.49 mmol, 89%) as a white solid 
1H NMR (CDCl3, 300 MHz): δ = 5.83 (s, 1H), 2.05 (s, 3H), 1.93 (s, 3H), 1.38 (s, 9H). 13C{1H} 
NMR (CDCl3, 75 MHz): δ = 164.4, 140.9, 111.9, 51.8, 28.7, 25.8, 22.5. IR (neat): ν = 2971, 
1620 cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 233.1 [M]+·. Melting point: 70-72 °C 
  
162 
 
2-Bromo-N-(tert-butyl)-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-enamide 
3.13h 
 
Following general procedure C, 2-bromo-N-(tert-butyl)-3-methylbut-2-enamide  3.17 (200 mg, 
0.85 mmol, 1.0 equiv) was reacted with NaHMDS (342 µL, 1.72 mmol, 2.0 equiv) and 2 
(trimethylsilyl)ethoxymethyl chloride (303 µL, 1.718 mmol, 2.0 equiv) in THF (3 mL). After 
the addition of SEM chloride the reaction was heated at 60°C overnight. The crude product was 
purified by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-
(tert-butyl)-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13h (274 mg, 0.75 
mmol, 88% yield) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.70 (m, 2H), 3.50 (m, 2H), 1.87 (s, 3H), 1.81 (s, 3H), 1.46 
(s, 9H), 0.87 (m, 2H), 0.00 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 169.4, 136.5, 111.6, 
61.1, 78.0, 58.6, 29.5 (3 C), 24.7, 23.2, 19.5, 0.0 (3 C). IR (neat): ν = 2987, 1663 cm-1. MS 
(EI, 70 eV, 200 °C): m/z (%) = 362.2 [M]+· 
(R)-2-Bromo-N-(1-cyclohexylethyl)-3-methylbut-2-enamide 3.19i 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1.0 equiv) was reacted with oxalyl chloride (311 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
(R)-1-cyclohexylethanamine (2.49 mL, 16.76 mmol, 6.0 equiv) and aq. NaOH (1M, 22 mL, 
22.00 mmol, 8.0 equiv) in DCM (22 mL). The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) affording (R)-2-Bromo-N-(1-
cyclohexylethyl)-3-methylbut-2-enamide 3.19i (531 mg, 1.84 mmol, 66%) as a white solid. 
1H NMR (CDCl3, 300 MHz): δ = 5.94 (s, 1H), 3.89 (m, 1H), 2.12 (s, 3H), 1.99 (s, 3H), 1.68 
(d, J = 10.7 Hz, 3H), 1.31 – 1.10 (m, 11H). 13C{1H} NMR (CDCl3, 75 MHz): 164.9, 141.2, 
111.2, 50.0, 43.1, 29.1, 29.0, 26.3, 26.2 (2 C), 22.7, 18.1, 17.8. IR (neat): ν = 3277, 2980, 2950, 
1629 cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 287.0 [M]+· Melting point: 79-81 °C. Optical 
rotation: [ ]20Da  = +2.7 (c = 1.01, CHCl3)  
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(R)-2-Bromo-N-(1-cyclohexylethyl)-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-
enamide 3.13i 
 
Following general procedure C, (R)-2-bromo-N-(1-cyclohexylethyl)-3-methylbut-2-enamide  
3.19i(200 mg, 0.69 mmol, 1.0 equiv) was reacted with NaHMDS (278 µL, 1.39 mmol, 2.0 
equiv), 2 (trimethylsilyl)ethoxymethyl chloride (246 µL, 1.39 mmol, 2.0 equiv) in THF (2 mL). 
The crude product was purified by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) 
affording (R)-2-Bromo-N-(1-cyclohexylethyl)-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13i (267 mg, 0.64 mmol, 92%) as a colorless 
oil. 
1H NMR (CDCl3, 300 MHz): δ = 5.18 – 4.36 (m, 2H), 3.99 (m, 1H), 3.70 – 3.44 (m, 1H), 3.40 
(t, J = 7.8 Hz, 1H), 1.90 (s, 3H), 1.82 (s, 3H), 1.74 (d, J = 13.9 Hz, 3H), 1.64 (m, 2H), 1.22 (m, 
4H), 0.88 (m, 6H), -0.00 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): complex mixture of 
rotamers IR (neat): ν = 2921, 1645 cm-1. Optical rotation: [ ]20Da  = -11.6 (c = 0.97, CHCl3) 
MS (EI, 70 eV, 200 °C): m/z (%) = 417.0 [M]+· 
(R)-2-Bromo-N-(3,3-dimethylbutan-2-yl)-3-methylbut-2-enamide 3.19j 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1.0 equiv) was reacted with oxalyl chloride (311 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
(R)-3,3-dimethylbutan-2-amine (1.14 mL, 8.38 mmol, 3.0 equiv) and aq. NaOH (1M, 22 mL, 
22.00 mmol, 8.0 equiv) in DCM (22 mL). The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) affording (R)-2-Bromo-N-(3,3-
dimethylbutan-2-yl)-3-methylbut-2-enamide 3.19j (451 mg, 2.07 mmol, 74%) as a white solid. 
1H NMR (CDCl3, 300 MHz): δ = 6.05 (d, J = 9.2 Hz, 1H), 3.70 (q, J = 6.8 Hz, 1H), 1.89 (s, 
3H), 1.78 (s, 3H), 0.92 (d, J = 6.9 Hz, 3H), 0.76 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 
163.9, 141.2, 111.2, 53.1, 34.3, 26.0 (3 C), 25.6, 22.4, 15.7. IR (neat): ν = 3271, 2967, 1631 
cm-1. Optical rotation: [ ]20Da  = -31.5 (c = 0.93, CHCl3). MS (EI, 70 eV, 200 °C): m/z (%) = 
261.3 [M]+·. Melting point: 83-85 °C 
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(R)-2-Bromo-N-(3,3-dimethylbutan-2-yl)-3-methyl-N-((trimethylsilyl)ethoxy)methyl)but-
2-enamide 3.13j 
 
Following general procedure C, (R)-2-bromo-N-(3,3-dimethylbutan-2-yl)-3-methylbut-2-
enamide 3.19j (200 mg, 0.76 mmol, 1.0 equiv) was reacted with NaHMDS (305 µL, 1.53 mmol, 
2.0 equiv), 2 (trimethylsilyl)ethoxymethyl chloride (271 µL, 1.53 mmol, 2.0 equiv) in THF (3 
mL). The crude product was purified by flash chromatography (eluent: CyHex/EtOAc/Et3N 
90:10:2) affording (R)-2-Bromo-N-(3,3-dimethylbutan-2-yl)-3-methyl-
N((trimethylsilyl)ethoxy) methyl)but-2-enamide 3.13j (240 mg, 0.61 mmol, 80%) as a colorless 
oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.86 – 4.25 (m, 2H), 3.86 – 3.25 (m, 2H), 3.32 (s, 1H), 1.90 
(s, 3H), 1.82 (s, 3H), 1.32 – 1.06 (m, 3H), 0.93 (s, 9H), 0.85 (m, 2H), -0.00 (s, 9H). 13C{1H} 
NMR (CDCl3, 75 MHz): complex mixture of rotamers. IR (neat): ν = 2952, 1642 cm-1. 
Optical rotation: [ ]20Da  = -29.3 (c = 0.98, CHCl3). MS (EI, 70 eV, 200 °C): m/z (%) = 392.4 
[M]+· 
2-Bromo-3-methyl-N-(4-phenylbutan-2-yl)but-2-enamide 3.19k 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (400 mg, 2.23 mmol, 
1.0 equiv) was reacted with oxalyl chloride (250 µL, 2.91 mmol, 1.3 equiv), DMF (2 drops), 2-
amino-4-phenylbutane (1.09 mL, 6.70 mmol, 3.0 equiv) and aq. NaOH (1M, 18 mL, 18.00 
mmol, 8.0 equiv) in DCM (18 mL) overnight. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) to afford 2-Bromo-3-methyl-N-(4-
phenylbutan-2-yl)but-2-enamide 3.19k (495 mg 1.60 mmol, 72%) as a white solid 
1H NMR (CDCl3, 300 MHz): δ = 7.57 – 7.07 (m, 5H), 5.89 (d, J = 6.9 Hz, 1H), 4.25 – 3.94 
(m, 1H), 2.83 – 2.57 (m, 2H), 2.09 (s, 3H), 1.96 (s, 3H), 1.93 – 1.71 (m, 2H), 1.32 – 0.99 (d, J= 
10.8, 3H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 168.8, 136.2, 131.2, 129.6 (2 C), 129.5 (2 C), 
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128.7, 128.3, 50.9, 45.2, 34.4, 23.8, 21.8, 19.5. IR (neat): ν = 3277, 2929, 2850, 1629 cm-1. 
MS (EI, 70 eV, 200 °C): m/z (%) = 309.1 [M]+·. Melting point: 77-79 °C 
2-Bromo-3-methyl-N-(4-phenylbutan-2-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-
enamide 3.13k 
 
Following general procedure C, 2-bromo-3-methyl-N-(4-phenylbutan-2-yl)but-2-enamide  
3.19k (200 mg, 0.65 mmol, 1.0 equiv) was reacted with NaHMDS (258 µL, 1.29 mmol, 2.0 
equiv), 2-(trimethylsilyl)ethoxymethyl chloride (229 µL, 1.29 mmol, 2.0 equiv) in THF (2 mL). 
The crude product was purified by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) 
affording 2-Bromo-3-methyl-N-(4-phenylbutan-2-yl)-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2 enamide 3.13k (201 mg 0.47 mmol, 73% yield) as a 
colorless oil 
1H NMR (CDCl3, 300 MHz, mixture of two conformers, ratio = 0.60/0.40): δ = 7.51 – 6.77 
(m, 5H), 5.10 – 4.83 (m, 1H), 4.80-4.30 (m, 2H), 3.99– 3.31 (m, 2H), 2.87 – 2.38 (m, 2H), 2.15-
1.6 (m, 8H), 1.40-1.20 (m, 3H), 0.99 – 0.79 (m, 2H), 0.00 (s, 9H). 13C{1H} NMR (CDCl3, 75 
MHz): complex mixture of rotamers. IR (neat): ν = 2950, 1645 cm-1. MS (EI, 70 eV, 200 °C): 
m/z (%) = 439.5 [M]+· 
2-Bromo-N-(cyclopropylmethyl)-3-methylbut-2-enamide 3.19l 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1.0 equiv) was reacted with oxalyl chloride (311 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
aminomethylcyclopropane (1.45 mL, 16.76 mmol, 6.0 equiv) and aq. NaOH (1M, 22 mL, 22 
mmol, 8.0 equiv) in DCM (22 mL). The crude product was purified by flash chromatography 
(eluent: CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-(cyclopropylmethyl)-3-methylbut-
2-enamide 3.19l (467 mg, 2.01 mmol, 72%) as a yellow solid. 
1H NMR (CDCl3, 300 MHz): δ = 6.6-6.2 (s, 1H), 2.91 (m, 2H), 1.81 (s, 3H), 1.71 (s, 3H), 0.98 
– 0.57 (m, 1H), 0.38 – 0.13 (m, 2H), 0.07 – 0.00 (m, 2H). 13C{1H} NMR (CDCl3, 75 MHz): δ 
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= 164.9, 141.1, 110.9, 44.5, 25.6, 22.4, 10.5, 3.3 (2 C). IR (neat): ν = 3273, 2917, 1625 cm-1. 
MS (EI, 70 eV, 200 °C): m/z (%) = 232.3 [M]+·. Melting point: 75-77 °C 
2-Bromo-N-(cyclopropylmethyl)-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-
enamide 3.13l 
 
Following general procedure C, 2-bromo-N-(cyclopropylmethyl)-3-methylbut-2-enamide 3.19l 
(200 mg, 0.86 mmol, 1.0 equiv) was reacted with NaHMDS (345 µL, 1.72 mmol, 2.0 equiv) 
and 2 (trimethylsilyl)ethoxymethyl chloride (306 µL, 1.72 mmol, 2.0 equiv) in THF (3 mL). 
The crude product was purified by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) 
affording 2-Bromo-N-(cyclopropylmethyl)-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-
2-enamide 3.13l (240 mg, 0.66 mmol, 77%) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 5.05 – 4.54 (m, 2H), 3.48 – 3.28 (m, 2H), 3.28 – 3.03 (m, 
2H), 1.79 (s, 3H), 1.75 – 1.64 (m, 3H), 1.05 – 0.70 (m, 3H), 0.48 – 0.31 (m, 2H), 0.23 – 0.04 
(m, 2H), -0.08 – -0.17 (m, 9H). 13C{1H} NMR (CDCl3, 75 MHz, major rotamers): δ = 166.5, 
136.0, 107.6, 78.2, 72.8, 65.5, 47.5, 22.9, 21.6, 17.9, 9.3, 3.4, -1.5. IR (neat): ν = 2952, 1648 
cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 361.5 [M]+· 
2-Bromo-N-cyclopropyl-3-methylbut-2-enamide 3.19m 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1 equiv) was reacted with oxalyl chloride (311 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
cyclopropylamine (1.16 mL, 16.76 mmol, 6.0 equiv) and aq. aq. NaOH (1M, 22 mL, 22 mmol, 
8.0 equiv) in DCM (22 mL). The crude product was purified by flash chromatography (eluent: 
CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-cyclopropyl-3-methylbut-2-enamide 
3.19m (463 mg, 2.12 mmol, 76%) as a yellow oil. 
1H NMR (CDCl3, 300 MHz): δ = 6.34 (s, 1H), 2.82-2.62 (m, 1H), 2.11 (s, 3H), 1.96 (s, 3H), 
0.99 – 0.72 (m, 2H), 0.68 – 0.49 (m, 2H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 166.0, 143.7, 
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110.6, 26.4, 23.0, 22.8, 6.6 (2 C). IR (neat): ν = 3277, 2930, 2860, 1517 cm-1. MS (EI, 70 eV, 
200 °C): m/z (%) = 217.1 [M]+· 
2-Bromo-N-cyclopropyl-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-enamide 
3.13m 
 
Following general procedure C, 2-bromo-N-cyclopropyl-3-methylbut-2-enamide 3.19m (200 
mg, 0.92 mmol, 1.0 equiv) was reacted with NaHMDS (367 µL, 1.83 mmol, 2.0 equiv), 2 
(trimethylsilyl)ethoxymethyl chloride (325 µL, 1.83 mmol, 2.0 equiv) in THF (3 mL). The 
crude product was purified by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) 
affording 2-Bromo-N-cyclopropyl-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-
enamide 3.13m (256 mg, 0.73 mmol, 80%) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.77 (m, 2H), 3.78 – 3.41 (m, 2H), 2.79 (m, 1H), 1.95-1.85 
(s, 3H), 1.85-1.75 (s, 3H), 1.02 – 0.6 (m, 6H), 0.01 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): 
δ = 170.9, 136.8, 110.9, 80.9, 76.8, 67.3, 31.1, 24.6, 23.3, 19.5, 8.2, 0.0 (3 C). IR (neat): ν = 
2950, 1652 cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 347.3 [M]+· 
2-Bromo-N-cyclohexyl-3-methylbut-2-enamide 3.19n 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1.0 equiv) was reacted with oxalyl chloride (311 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
cyclohexanamine (1.19 mL, 16.76 mmol, 6.0 equiv) and aq. NaOH (1M, 22 mL, 22 mmol, 8.0 
equiv) in DCM (22 mL). The crude product was purified by flash chromatography (eluent: 
CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-cyclohexyl-3-methylbut-2-enamide 3.19n 
(661 mg, 2.54 mmol, 91%) as a white solid. 1H NMR (CDCl3, 300 MHz): δ = 6.07 (s, 1H), 
3.85 – 3.61 (m, 1H), 2.02 (s, 3H), 1.90 (s, 3H), 1.90-1.8 (m, 2H), 1.76 – 1.52 (m, 3H), 1.44 – 
1.25 (m, 2H), 1.25 – 1.08 (m, 3H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 163.9, 142.0, 111.2, 
48.7, 32.7, 26.0, 25.5, 24.7(2 C), 22.6 (2 C).  
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IR (neat): ν = 3281, 2935, 1546 cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 259.1 [M]+·. Melting 
point: 71-73 °C 
2-Bromo-N-cyclohexyl-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-enamide 
3.13n 
 
Following general procedure C, 2-bromo-N-cyclohexyl-3-methylbut-2-enamide 3.19n (200 
mg, 0.769 mmol, 1.0 equiv) was reacted with NaHMDS (309 µL, 1.54 mmol, 2.0 equiv), 2-
(trimethylsilyl)ethoxymethyl chloride (273 µL, 1.54 mmol, 2.0 equiv) in THF (2 mL). The 
crude product was purified by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) 
affording 2-Bromo-N-cyclohexyl-3-methyl-N-((2-(trimethylsilyl)ethoxy)methyl)but-2-
enamide 3.13n (267 mg, 0.684 mmol, 89% yield) as a colorless oil. 
1H NMR (CDCl3, 300 MHz, ): δ = 4.97 – 4.5 (m, 2H), 4.13 (m, 1H), 3.67 – 3.54 (m, 1H), 3.47 
– 3.35 (m, 1H), 1.90 (m, 3H), 1.84-.1.70 (m, 6H), 1.68 – 1.00 (m, 7H), 1.01 – 0.81 (m, 2H), 
0.00 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 168.5, 137.2, 109.6, 77.4, 71.6, 67.3, 66.6, 
66.3, 60.1, 55.5, 27.3, 26.9–26.7, 24.4–23.2, 19.6, 0.0 (3 C). IR (neat): ν = 2930, 2854, 1646 
cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 389.1 [M]+· 
(Z)-2-Bromo-N,N-diisopropyl-3-phenylacrylamide 3.13o and (E)-2-bromo-N,N-
diisopropyl-3-phenylacrylamide 3.13p 
An isomeric mixture of E/Z-2-bromo-3-phenylideneprop-2-enoic acid (1.17 g, 5.18 mmol, 1.0 
equiv) was reacted with thionyl chloride (2.50 mL, 34.5 mmol, 6.7 equiv) at 80 °C for 45 min. 
Then, all volatiles were evaporated under high vacuum and the resulting yellow liquid was 
taken up in DCM (15 mL) and cooled to 0 °C. Et3N (0.86 mL, 6.21 mmol, 1.2 equiv) and 
diisopropylamine (1.46 mL, 10.4 mmol, 2 equiv) were added, the reaction mixture was allowed 
to warm up to rt and was stirred overnight. After quenching with sat. solution of NH4Cl, the aq. 
phase was extracted three times with DCM. The unified org. phase was washed with brine, 
dried over Na2SO4 and was concentrated under reduced pressure. From the crude mixture, the 
two isomers were isolated by column chromatography (4% to 10% EtOAc in CyHex) giving 
(Z)-2-Bromo-N,N-diisopropyl-3-phenylacrylamide 3.13o (550 mg, 1.77 mmol, 34 %) and E)-
2-bromo-N,N-diisopropyl-3-phenylacrylamide 3.13p (385 mg, 1.24 mmol, 24 %). 
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(Z)-2-Bromo-N,N-diisopropyl-3-phenylacrylamide 3.13o 
 
1H NMR (CDCl3, 300 MHz): δ = 7.71 - 7.64 (m, 2 H), 7.43 - 7.30 (m, 3 H), 6.96 (s, 1 H), 4.41 
– 3.96 (m, 1 H), 3.70 - 3.24 (m, 1 H), 1.63 - 1.10 (m, 12 H). 13C{1H} NMR (CDCl3, 75 MHz): 
δ =166.0, 134.1, 129.0, 128.7, 128.3, 115.9, 51.3, 45.9, 20.2 (4 C).  IR (neat): ν = 2972, 2931, 
1627, 763, 684cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 309.2 [M]+·. Mp: 62-64°C 
(E)-2-Bromo-N,N-diisopropyl-3-phenylacrylamide 3.13p 
 
1H NMR (CDCl3, 300 MHz): δ =7.43 - 7.34 (m, 2 H), 7.34 - 7.21 (m, 3 H), 6.92 (s, 1 H), 4.07 
(sept, J=6.7 Hz, 1 H), 3.34 (sept, J=6.8 Hz, 1 H), 1.46 (dd, J=6.6, 1.0 Hz, 6 H), 1.17 (d, J=6.6 
Hz, 3 H), 0.66 (d, J=6.8 Hz, 3 H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 164.9, 134.7, 131.7, 
128.5, 127.8, 115.1, 51.3, 45.9, 20.4, 20.1, 19.8, 19.6.  IR (neat): ν = 2968, 2930, 1625, 751, 
669cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 309.2  [M]+·. Mp: 62-64°C 
 
(Z)-2-Bromo-N,N-diisopropylbut-2-enamide 3.13q 
 
Following general procedure B, (2Z)-2-bromobut-2-enoic acid (400 mg, 2.42 mmol, 1.2 equiv) 
was reacted with oxalyl chloride (0.21 mL, 2.42 mmol, 1.2 equiv), DMF (2 drops), 
diisopropylamine (0.29 mL, 2.02 mmol, 1.0 equiv) and NaOH (1 M, 21 mL, 21 mmol, 10.4 
equiv) in DCM (21 mL). The crude product was purified by flash chromatography (eluent: 0% 
to 5% EA in CyHex) affording (Z)-2-Bromo-N,N-diisopropylbut-2-enamide 3.13q (432 mg, 
1.74 mmol, 86 %) as a colorless oil. 
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1H NMR (CDCl3, 400 MHz, mixture of two conformers, ratio = 0.75/0.25): δ = 6.05 and 
4.30 (2 q, J=6.6 Hz and J=7.1 Hz, together 1 H), 4.30-3.11 (m, 2 H), 1.80 (d, J=6.6 Hz, 3 H), 
1.52 - 1.02 (m, 12 H). 13C{1H} NMR (CDCl3, 101 MHz, major rotamer): δ = 165.9, 126.6, 
119.2, 50.7, 46.0, 20.8, 20.4, 20.1, 16.4, 14.1. IR(neat) ν: 2969, 2933, 1737, 1632, 1328 cm-1. 
LRMS (EI) calcd for C10H18BrNO ([M]+·): 247.1; found: 247.1; 
2-bromo-N-ethyl-N-isopropyl-3-methylbut-2-enamide 3.13r 
 
Following general procedure B, 2-bromo-3-methylbut-2- enoic acid 3.17 (180 mg, 1.00 mmol, 
1.0 equiv) was reacted with oxalyl chloride (111 µL, 1.31 mmol, 1.3 equiv), DMF (2 drops), 
ethyl(propan-2-yl)amine (175 mg, 2.00 mmol, 2.0 equiv) and aq. NaOH (1M, 8 mL, 8.00 mmol, 
8.0 equiv) in DCM (8 mL). The crude product was purified by flash chromatography (gradient 
0% to 10% EtOAc in CyHex) affording 2-bromo-N-ethyl-N-isopropyl-3-methylbut-2-enamide 
3.13r (240 mg, 0.97 mmol, 96%).as a colorless oil.  
1H NMR (CDCl3, 300 MHz, mixture of two conformers, ratio = 0.79/0.21): δ = 3.90- 4.40 
(m, 1H), 3.43 – 2.91 (m, 2H), 1.74 (s, 3H), 1.65 (s, 3H), 1.18 – 0.87 (m, 9H) ppm. 13C{1H} 
NMR (CDCl3, 75 MHz): δ = 165.8, 134.7, 108.8, 50.5, 46.6, 35.4, 22.8, 21.6, 20.6, 13.9 ppm.  
IR (neat): ν = 1420, 1627, 2956 cm-1. MS (EI, 70 eV, 200 °C): m/z (%) = 247.2 (1.6) [M+.] 
2-Bromo-N-(tert-butyl)-N,3-dimethylbut-2-enamide 3.13s 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1.0 equiv) was reacted with oxalyl chloride (288 µL, 3.35 mmol, 1.2 equiv), DMF (2 drops) 2-
bromo-N-(tert-butyl)-N,3-dimethylbut-2-enamide (2.07 g, 16.76 mmol, 6.0 equiv) and aq. 
NaOH (1M, 29 mL, 29.00 mmol, 10.4 equiv) in DCM (29 mL). The crude product was purified 
by flash chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-(tert-
butyl)-N,3-dimethylbut-2-enamide 3.13s (385 mg, 1.54 mmol, 55%) as a yellow oil. 
1H NMR (CDCl3, 300 MHz): δ = 2.92 (s, 3H), 1.87 (s, 3H), 1.80 (s, 3H), 1.45 (s, 9H). 13C{1H} 
NMR (CDCl3, 75 MHz): δ =167.3, 133.3, 111.7, 57.0, 33.3, 27.9, 23.0, 21.1.  
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IR (neat): ν = 2920, 1665, 1400, 1260 cm-1. HRMS(ESI): calcd for C10H19BrNO ([M+H]+) : 
248.0648; found: 248.0645; 
2-Bromo-N-isopropyl-N,3-dimethylbut-2-enamide 3.13t 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1.0 equiv) was reacted with oxalyl chloride (312 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
methyl(propan-2-yl)amine (729 µL, 6.90 mmol, 2.5 equiv) and aq. NaOH (1 M, 22 mL, 22.3 
mmol, 8.0 equiv) in DCM (22 mL) for 12 hours. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-isopropyl-N,3-
dimethylbut-2-enamide 3.13t (580 mg 2.47 mmol, 89%) as a slightly yellow oil. 
1H NMR (CDCl3, 300 MHz, mixture of rotamers): δ = 4.78 – 3.83 (m, 1H), 2.73 – 2.64 (m, 
3H), 1.82 – 1.72 (m, 3H), 1.70 – 1.62 (m, 3H), 1.13 – 1.03 (m, 3H), 1.03 – 0.97 (m, 3H). 13C{1H} 
NMR (CDCl3, 75 MHz, mixture of rotamers): δ = 166.1, 166.0, 134.6, 134.2, 108.9, 108.1, 
49.7, 47.6, 43.9, 42.3, 28.7, 26.2, 25.4, 25.3, 24.3, 22.7, 22.6, 21.4, 21.3, 20.9, 20.5, 20.0, 19.7, 
19.0, 18.7. IR (neat): ν = 2980, 1645 cm-1. HRMS(ESI): calcd for C9H17BrNO ([M+H]+): 
234.0494; found: 234.0490; 
N-((1R,2S)-1-(Benzyloxy)-1-phenylpropan-2-yl)-2-bromo-N,3-dimethylbut-2-enamide 
3.13u 
 
To a solution of 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 1.0 equiv) and 
DIPEA (1.38 mL, 8.38 mmol, 3.0 equiv) in DCM (28 mL) at 0 °C, PyBOP (1.45 g, 2.79 mmol, 
1.0 equiv) was added in one portion and stirred 20 min at 0 °C. (1R,2S)-1-(benzyloxy)-N-
methyl-1-phenylpropan-2-amine (713 mg, 2.79 mmol, 1.0 equiv) was then added in one portion 
at 0 °C. The resulting mixture was stirred at room temperature during 16 hours. The reaction 
was quenched with a saturated aqueous solution of NaHCO3. The resulting mixture was 
extracted three times with ethyl acetate and the combined organic layers were washed with 
brine, dried over MgSO4, filtered and concentrated in Vacuo.   
172 
 
Purification by column chromatography (SiO2, pentane/ AcOEt, 9/1 to 1/1 affording N-
((1R,2S)-1-(Benzyloxy)-1-phenylpropan-2-yl)-2-bromo-N,3-dimethylbut-2-enamide 3.13u 
(942 mg, 2.26 mmol, 81 %) as a colorless oil. 
1H NMR (CDCl3, 300 MHz, complex mixture of rotamers): δ = 7.46 – 7.06 (m, 10H), 4.81 
– 3.88 (m, 4H), 3.07 – 2.59 (m, 3H), 2.01 – 1.48 (m, 4H), 1.36 – 0.97 (m, 6H). 13C{1H} NMR 
(CDCl3, 75 MHz): δ = 166.5, 139.1, 138.9, 138.2, 134.5, 128.8, 128.4, 128.4, 128.3, 127.8, 
127.7, 127.6, 126.8, 83.5, 83.3, 77.4, 70.9, 68.3, 60.3, 59.5, 54.0, 31.9, 28.8, 22.7, 21.6, 20.4, 
20.3, 14.2, 13.4, 12.9, 12.8, 11.8, 11.7. HRMS(ESI): calcd for C22H27BrNO2 ([M+H]+): 
416.1225; found: 416.1231; IR(neat) ν: 2932, 2866, 1690, 1650, 1512, 1254 cm-1. 
2-Bromo-N-cyclohexyl-N,3-dimethylbut-2-enamide 3.13v 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (600 mg, 3.35 mmol, 
1.0 equiv) was reacted with oxalyl chloride (375 µL, 4.35 mmol, 1.3 equiv), DMF (2 drops), N-
methylcyclohexanamine (947 µL, 6.70 mmol, 6.0 equiv) and aq. NaOH (1 M, 26 mL, 26  mmol, 
8.0 equiv) in DCM (27 mL) for 12 hours. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-N-cyclohexyl-N,3-
dimethylbut-2-enamide 3.13v (643 mg, 2.35 mmol, 70%) as a slightly yellow oil. 
1H NMR (CDCl3, 300 MHz, mixture of rotamers): δ = 4.23 – 3.30 (m, 1H), 2.68 – 2.58 (m, 
3H), 1.74 – 1.66 (m, 3H), 1.65 – 1.54 (m, 5H), 1.52 – 0.77 (m, 8H). 13C{1H} NMR (CDCl3, 75 
MHz, mixture of rotamers): δ =165.9, 134.3, 133.8, 108.9, 108.0, 58.1, 51.9, 30.8, 29.9, 29.8, 
29.1, 26.6, 25.4, 25.1, 25.1, 24.8, 22.5, 22.3, 21.2, 20.7. IR (neat): ν = 2945, 1390 cm-1 
HRMS(ESI): calcd for C12H20BrNaNO ([M+Na]+): 296.0620; found: 296.0623; 
2-(4-Hydroxyphenyl)-N-(pentan-2-yl)acetamide 3.40 
 
To a stirred solution of pentan-2-amine (5.73 g, 65.7 mmol, 1.0 equiv), 4-hydroxyphenylacetic 
acid (10 g, 65.7 mmol, 1.0 equiv) and DIPEA (13.0 mL, 78.9 mmol, 1.2 equiv) in DMF (500 
mL) was added EDCI (12.2 g, 78.9 mmol, 1.2 equiv) in one portion at 0°C.   
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The reaction was stirred at 0°C for 1 h and 2 h at room temperature. The reaction was quenched 
by adding 50 mL of HCl (1 N). The aq. phase was extracted with DCM (2 x 50 mL), then the 
org. phase was washed with an sat. aq. solution of NaHCO3 (2x150 mL) and dried over MgSO4, 
before being concentrated. The crude product was purified by flash chromatography (gradient: 
30% to 65% EtOAc in CyHex) affording 2-(4-Hydroxyphenyl)-N-(pentan-2-yl)acetamide 3.40 
(9.63 g, 43.52 mmol, 66%) as a white solid. 
1H NMR (CDCl3, 300 MHz): δ = 8.10-7.64 (m, 1 H), 7.04 (m , 2 H), 6.83 (m, 2 H), 5.35 (br. 
s., 1 H), 4.06 – 3.88 (m, 1 H), 3.49 (s, 2 H),  1.38 - 1.15 (m, 4 H), 1.04 (d, J=6.6 Hz, 3 H), 0.85 
(t, J=7.0 Hz, 3 H).  13C{1H} NMR (CDCl3, 75 MHz): δ = 172.2, 156.4, 130.6 (2C), 125.5, 
116.3 (2C), 45.5, 43.0, 38.8, 20.8, 19.2, 14.0. IR (neat): ν = 3313, 2963, 2932, 2876, 1622, 
1548, 1512, 1159 cm-1. Mp = 105-106 °C. HRMS(ESI): calcd for C13H20NO2 ([M+H]+) : 
222.1494; found: 222.1493; 
N-(Pentan-2-yl)-2-(4-((triisopropylsilyl)oxy)phenyl)acetamide 3.41 
 
To a stirred solution of 2-(4-hydroxyphenyl)-N-(pentan-2-yl)acetamide 3.40 (1.26 g, 5.69 
mmol, 1.0 equiv), imidazole (775 mg, 11.40 mmol, 2.0 equiv) in DMF (20 mL) was added 
TIPSCl (1.58 mL, 7.40 mmol, 1.3 equiv) in one portion. The solution was stirred for 18 h at 
20°C before being quenched with an sat. aq. solution of NH4Cl (50 mL). The aq. phase was 
extracted with EtOAc (2 x 50 mL), washed with brine (2 x 75 mL) and dried over MgSO4 before 
being concentrated. The crude product was purified by flash chromatography (gradient: 0% to 
40% EtOAc in CyHex) affording N-(Pentan-2-yl)-2-(4-
((triisopropylsilyl)oxy)phenyl)acetamide 3.41 (1.80 g, 4.75 mmol, 83%) as a yellow oil. 
1H NMR (CDCl3, 300 MHz): δ = 7.15 - 7.02 (m, 2 H), 6.92 - 6.80 (m, 2 H), 5.26 – 4.87 (m, 1 
H), ), 4.01 – 3.85 (m, 1 H), 3.47 (s, 2 H), 1.36 - 1.16 (m, 7 H), 1.09 (d, J=6.8 Hz, 18 H), 1.00 
(d, J=6.4 Hz, 3 H), 0.84 (t, J=7.0 Hz, 3 H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 170.8, 155.5, 
130.6 (2C), 127.7, 120.7 (2C), 45.1, 43.4, 39.0, 20.9, 19.2, 14.0, 12.7 (3 C). IR (neat): ν = 
3279, 2944, 2866, 1639, 1550, 1507, 1260 cm-1. HRMS(ESI): calcd for C22H40NO2Si 
([M+H]+) : 378.2828; found: 378.2814; 
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N-(4-((Triisopropylsilyl)oxy)phenethyl)pentan-2-amine 3.42 
 
N-(pentan-2-yl)-2-(4-{[tris(propan-2-yl)silyl]oxy}phenyl)acetamide 3.41 (12.50 g, 33.0 mmol, 
1.0 equiv) was dissolved in THF (75 mL) and BH3●THF (1 M, 65.9 mL, 65.9 mmol, 2.0 equiv) 
was added dropwise at room temperature. The reaction mixture was refluxed for 5 h. After 
cooling it down to 0°C, the solution was quenched by adding first MeOH (20 mL) and then 
conc. H2SO4 (10 mL). The mixture was stirred at room temperature for 30 min before 
neutralization with an aq. solution of NaOH (4 M). The aq. phase was extracted with EtOAc, 
washed with water, dried over MgSO4 and concentrated. The crude product was purified by 
flash chromatography (gradient: 0% to 5% NH3 (7 M in MeOH) in DCM) affording N-(4-
((Triisopropylsilyl)oxy)phenethyl)pentan-2-amine 3.42 (10.29 g, 28.3 mmol, 86%) as a yellow 
oil. 
1H NMR (CDCl3, 300 MHz): δ =7.10 – 6.97 (m, 2 H), 6.86- 6.71 (m, 2 H), 2.92 - 2.53 (m, 5 
H), 1.43 - 1.19 (m, 8 H), 1.14 - 1.04 (m, 18 H), 1.00 (d, J=6.2 Hz, 3 H), 0.90 - 0.82 (m, 3 H).  
13C{1H} NMR (CDCl3, 75 MHz): δ = 154.3, 132.4, 129.5, 119.8, 52.8, 48.7, 39.4, 35.6, 20.3, 
19.1, 17.9, 14.2, 12.6. IR (neat): ν = 2944, 2866, 1608, 1508, 1463, 1260 cm-1. HRMS(ESI): 
calcd for C22H42NOSi ([M+H]+): 364.3036; found: 364.3026; 
2-Bromo-3-methyl-N-(pentan-2-yl)-N-(4-((triisopropylsilyl)oxy)phenethyl)but-2-enamide 
3.13w 
 
Oxalyl chloride (2.52 mL, 29.3 mmol, 1.3 equiv) was added to a solution of 2-bromo-3-
methylbut-2-enoic acid 3.17 (5.25 g, 29.3 mmol, 1.3 equiv) in DCM (75 mL) at room 
temperature followed by DMF (52 µL, 676 µmol, 3 mol%). The resulting solution was stirred 
for 2 h (gas evolution stoped) at room temperature before being added to a solution of DIPEA 
(11.20 mL, 67.6 mmol, 3.0 equiv) and (pentan-2-yl)[2-(4-{[tris(propan-2-
yl)silyl]oxy}phenyl)ethyl]amine 3.42 (8.20 g, 22.5 mmol, 1.0 equiv) in DCM (75 mL) stirred 
at 0°C. The reaction mixture was stirred for 15 h at room temperature. Then it was washed with 
HCl (1 N, 75 mL), a sat. aq. solution of NaHCO3 (75 mL), dried over MgSO4 and the solvent   
175 
 
was removed in vacuo. The crude product was purified by flash chromatography (gradient: 0% 
to 10% EtOAc in CyHex) affording 2-Bromo-3-methyl-N-(pentan-2-yl)-N-(4-
((triisopropylsilyl)oxy)phenethyl)but-2-enamide 3.13w (10.37 g , 19.77 mmol, 88%) as an 
orange oil. 
1H NMR (CDCl3, 300 MHz): δ = 7.17 – 6.91 (m, 2 H), 6.86 - 6.71 (m, 2 H), 4.54 - 3.74 (m, 1 
H), 3.53 - 3.14 (m, 2 H), 3.00 – 2.60 (m, 2 H), 2.01 – 1.72 (m, 6 H), 1.49 - 1.12 (m, 10 H), 1.12 
- 1.04 (m, 18 H), 0.95 - 0.81 (m, 3 H), 13C{1H} NMR (CDCl3, 75 MHz, complex mixture of 
rotamers): δ = 166.6, 166.4, 154.6, 154.3, 135.3, 134.5, 131.8, 130.7, 129.6, 129.2, 119.9, 
119.6, 109.5, 109.0, 108.6, 54.5, 43.3, 43.2, 37.1, 36.4, 33.8, 33.5, 22.9, 22.8, 22.7, 21.9, 21.7, 
21.6, 19.8, 19.5, 18.9, 17.8, 17.7, 13.9, 13.7, 12.9, 12.7, 12.5, 12.3, 12.1. IR (neat): ν = 2942, 
2866, 1633, 1509, 1261 cm-1. HRMS(ESI): calcd for C27H47BrNO2Si ([M+H]+): 524.2559; 
found: 524.2517; 
2-Bromo-3-methyl-1-(2,2,6,6-tetramethylpiperidin-1-yl)but-2-en-1-one 3.13x 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (500 mg, 2.79 mmol, 
1.0 equiv) was reacted with oxalyl chloride (311 µL, 3.63 mmol, 1.3 equiv), DMF (2 drops), 
tretramethylpiperidine (2.85 mL, 16.76 mmol, 6.0 equiv) and aq. NaOH (1M, 22 mL, 22.00 
mmol, 8.0 equiv) in DCM (22 mL). The crude product was purified by flash chromatography 
(eluent: CyHex/EtOAc/Et3N 90:10:2) affording 2-Bromo-3-methyl-1-(2,2,6,6-
tetramethylpiperidin-1-yl)but-2-en-1-one 3.13x (735 mg, 2.43 mmol, 87%) as a yellow oil. 
1H NMR (CDCl3, 300 MHz): δ = 1.88 (2s, 3H each), 1.75 (m, 6H), 1.53 (s, 6H), 1.48 (s, 6H ). 
13C{1H} NMR (CDCl3, 75 MHz): δ = 169.2, 134.2, 116.3, 57.7 (2 C), 39.4 (2 C) , 30.4 (2 C), 
29.3(2 C), 24.4, 22.8, 15.3. IR (neat): ν = 2890, 2935, 3281 cm-1. MS (EI, 70 eV, 200 °C): 
m/z (%) = 301.3 [M]+· 
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2-Bromo-3-methyl-1-(2-methylpiperidin-1-yl)but-2-en-1-one 3.13y 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid 3.17 (3 g, 16.8 mmol, 1 
equiv) was reacted with oxalyl chloride (1.87 mL, 21.8 mmol, 1.3 equiv), DMF (2 drops), 2-
methylpiperidine (11.8 mL, 101 mmol, 6 equiv) and NaOH (1 M, 134 mL, 134 mmol, 8 equiv) 
in DCM (90 mL). The crude product was purified by flash chromatography (eluent: 0% to 20% 
EA in CyHex) affording 2-Bromo-3-methyl-1-(2-methylpiperidin-1-yl)but-2-en-1-one 3.13y 
(3.565 g, 13.71 mmol, 82 %) as a colorless oil. 
1H NMR (CDCl3, 400 MHz, mixture of two conformers, ratio = 0.55/0.45, 323 K): δ = 4.82 
and 4.10 (2 m, together 1 H), 4.40 and 3.58 (2 m, together 1 H), 3.04 and 2.72 (2 m, together 1 
H), 1.60 (m, 15 H). 13C{1H} NMR (CDCl3, 101 MHz, , 323 K): δ = 165.3, 165.1, 164.9, 134.6, 
134.4, 108.8, 108.5, 108.3, 108.1, 50.3, 43.9, 43.7, 42.3, 41.9, 36.5, 31.4, 30.3, 29.8, 29.5, 26.6, 
25.9, 25.4, 22.9, 22.8, 21.7, 21.5, 18.8, 17.1, 16.2, 15.7, 15.0. IR (neat): ν = 2986, 2935, 2863, 
1626, 1422, 1272 cm-1. LRMS (EI) calcd for C11H18BrNO ([M]+·): 259.1; found: 259.1; 
2-Bromo-3-methyl-1-(2-methylpyrrolidin-1-yl)but-2-en-1-oneone 3.13z 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid  3.17 (750 mg, 4.19 mmol, 
1 equiv) was reacted with oxalyl chloride (0.47 mL, 5.45 mmol, 1.3 equiv), DMF (2 drops), 2-
methylpyrrolidine (1.22 mL, 12.6 mmol, 3 equiv) and NaOH (1 M, 33.5 mL, 33.5 mmol, 8 
equiv) in DCM (34 mL). The crude product was purified by flash chromatography (eluent: 0% 
to 30% EA in CyHex) affording 2-Bromo-3-methyl-1-(2-methylpyrrolidin-1-yl)but-2-en-1-
oneone 3.13z (875 mg, 3.55 mmol, 85 %) as a colorless oil. 
1H NMR (CDCl3, 300 MHz, mixture of two conformers, ratio = 0.7/0.3, 298 K): δ = 4.03 – 
3.62 (m, together 1H), 3.37 – 3.05 (m, together 2H), 1.87 – 1.63 (m, 3H), 1.63 – 1.57 (m, 3H), 
1.54 (s, 3H), 1.44 – 1.29 (m, 1H), 0.93 (d, J = 6.4 Hz, together 3H). 
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 13C{1H} NMR (CDCl3, 75 MHz, mixture of rotamers, major rotamer): δ = 164.0, 133.7, 
109.4, 52.2, 46.9, 31.86, 23.39, 22.24, 20.55, 18.51. IR (neat): ν = 2960, 2935, 1640, 1443, 
1253 cm-1. HRMS(ESI): calcd for C10H16BrNaNO([M+Na]+): 268.0307; found: 268.0303; 
2-Bromo-3-methyl-1-(2-methylazepan-1-yl)but-2-en-1-one 3.13aa 
 
Following general procedure B, 2-bromo-3-methylbut-2-enoic acid  3.17 (750 mg, 4.19 mmol, 
1 equiv) was reacted with oxalyl chloride (0.47 mL, 5.45 mmol, 1.3 equiv), DMF (2 drops), 2-
methylazepan-1-ium chloride (2.25 g, 15 mmol, 3.6 equiv) and NaOH (1 M, 33.5 mL, 33.5 
mmol, 8 equiv) in DCM (34 mL). The crude product was purified by flash chromatography 
(eluent: 0% to 30% EA in CyHex) affording 2-Bromo-3-methyl-1-(2-methylazepan-1-yl)but-
2-en-1-one 3.13aa (751 mg, 2.74 mmol, 65 %) as a colorless oil. 
1H NMR (CDCl3, 300 MHz, complex mixture rotamers): δ = 4.28 – 2.28 (m, 3H), 1.94 – 
0.58 (m, 17H). 13C{1H} NMR (CDCl3, 75 MHz, complex mixture of rotamers): δ = 166.5, 
166.3, 166.1, 165.9, 165.5, 165.1, 134.3, 134.0, 133.8, 133.5, 133.4, 108.7, 108.3, 108.1, 107.9, 
77.4, 53.3, 53.0, 50.9, 50.0, 49.8, 48.4, 45.3, 42.9, 39.6, 39.2, 36.4, 36.0, 34.8, 29.5, 28.9, 27.9, 
27.3, 26.6, 26.3, 24.8, 24.1, 23.9, 22.4, 22.3, 22.3, 21.6, 21.4, 20.4, 19.9, 19.5, 18.2, 17.8. IR 
(neat): ν = 2923, 2856, 1627, 1419 cm-1. HRMS(ESI): calcd for C12H21BrNO ([M+H]+): 
274.0801; found: 274.0804; 
3.3. Scope of the C(sp3)-H alkenylation 
1-Isopropyl-5-methyl-3-(propan-2-ylidene)pyrrolidin-2-one 3.14a 
 
Following general procedure A, 2-bromo-N,N-diisopropyl-3-methylbut-2-enamide 3.13a (50 
mg, 0.19 mmol, 1.0 equiv) was reacted with cesium carbonate (93.2 mg, 0.29 mmol, 1.5 equiv), 
palladium allyl chloride (3.5 mg, 10 µmol, 5 mol%), PPh3 (10.0 mg, 38 µmol, 20 mol%) and 
pivalic acid (6.8 mg, 57 µmol, 30 mol%) in mesitylene (1 mL) at 160°C overnight. The crude 
product was purified by preparative thin layer chromatography (eluent CyHex/EA 9:1) 
affording 1-Isopropyl-5-methyl-3-(propan-2-ylidene)pyrrolidin-2-one 3.14a (26.3 mg, 0.14 
mmol, 78 %) as a colorless oil. 1H NMR (CDCl3, 300 MHz): δ = 4.15 (m, 1 H), 3.68 (m, 1 H), 
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2.85-2.65 (m, 1 H), 2.23 (s, 3 H), 2.23-2.15 (m, 1H), 1.73 (s, 3 H), 1.19-1.28 (m, 9 H). 13C{1H} 
NMR (CDCl3, 75 MHz): δ = 167.3, 136.9, 111.6, 48.0, 28.0, 27.9, 27.8, 24.1, 21.7, 19.9. IR 
(neat): ν = 2978, 2936, 1678, 1355 cm-1. HRMS(APCI): calcd for C11H19NO ([M]+): 
181.1467; found: 181.1453; 
1-(Ethoxymethyl)-5-methyl-3-(propan-2-ylidene)pyrrolidin-2-one 3.14d 
 
Following general procedure A, starting with 2-bromo-N-(ethoxymethyl)-N-isopropyl-3-
methylbut-2-enamide 3.13d (50.0 mg, 0.18 mmol, 1.0 equiv), was reacted with cesium 
carbonate (87.8 mg, 0.27 mmol, 1.5 equiv), palladium allyl chloride (3.3 mg, 9 µmol, 5 mol%.), 
Ethyldiphenylphosphine (7.7 mg, 36 µmol, 20 mol%.) and pivalic acid (5.5 mg, 54 µmol, 30 
mol%) in mesitylene (1 mL) at 160°C overnight. The crude product was purified by preparative 
thin layer chromatography affording 1-(Ethoxymethyl)-5-methyl-3-(propan-2-
ylidene)pyrrolidin-2-one 3.14d (21.3 mg 0.11 mmol, 60%) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.93 (d, J=10.8 Hz, 1 H), 4.64 (d, J=10.8 Hz, 1 H), 3.69 (m, 
1H), 3.47 (m, 2 H), 2.85 (dd, J=15.6, 8.3 Hz, 1 H), 2.23 (s, 3 H), 2.17 (m, 1 H), ), 1.75 (s, 3 H), 
1.21 (d, J=6.2 Hz, 3 H), 1.14 (t, J=7.0 Hz, 3 H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 169.8, 
143.5, 123.6, 70.8, 63.8, 49.0, 33.5, 23.8, 21.1, 19.4, 15.2. IR (neat): ν = 2932, 1683, 1044 cm-
1. HRMS(ESI): calcd for C11H20NNaO2 ([M+Na]+): 220.1308; found: 220.1300; 
5-Methyl-3-(propan-2-ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)-pyrrolidine-2-one 
3.14e 
 
Racemic reaction: Following general procedure A, 2-bromo-N-isopropyl-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13e (50.0 mg, 0.14 mmol, 1.0 equiv) was 
reacted with cesium carbonate (69.7 mg, 0.21 mmol, 1.5 equiv), palladium allyl chloride (2.6 
mg, 7 µmol, 5 mol%.), PPh3 (7.5 mg, 29 µmol, 20 mol%) and pivalic acid (4.4 mg, 42 µmol, 
30 mol%.) in mesitylene (1 mL) at 160°C overnight. The crude product was purified by flash 
chromatography (gradient: CyHex to CyHex/EtOAc 90:10) affording 5-Methyl-3-(propan-2- 
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ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)-pyrrolidine-2-one 3.14e (31.2 mg, 0.12 mmol, 
81%) asa colorless oil. 
Asymmetric catalysis: Following general procedure A, 2-bromo-N-isopropyl-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide  3.13e (100.0 mg, 0.29 mmol, 1.0 equiv) was 
reacted with cesium carbonate (139.0 mg, 0.43 mmol, 1.5 equiv), palladium allyl chloride (2.6 
mg, 7 µmol, 2.5 mol%.), phosphine185 L1 (15.4 mg, 29 µmol, 10 mol%) and pivalic acid (8.7 
mg, 86 µmol, 30 mol%.) in mesitylene (2 mL) at 160°C overnight. The crude product was 
purified by flash chromatography (gradient: CyHex to CyHex/EtOAc 90:10) affording 5-
Methyl-3-(propan-2-ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)-
pyrrolidine-2-one 3.14e (43.0 mg, 0.16 mmol, 56%) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ 4.96 (d, J = 10.6 Hz, 1H), 4.63 (d, J = 10.6 
Hz, 1H), 3.78 – 3.66 (m, 1H), 3.59 – 3.42 (m, 2H), 2.92 – 2.80 (m, 1H), 
2.31 – 2.23 (m, 3H), 2.23 – 2.13 (m, 1H), 1.78 (s, 3H), 1.24 (d, J = 6.3 Hz, 3H), 0.95 – 
0.85 (m, 2H), -0.01 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 168.9, 142.4, 123.2, 69.8, 
64.9, 48.4, 32.9, 23.2, 20.5, 18.8, 17.5, -1.7. IR (neat): ν = 2952, 1634, 1060 cm-1 
HRMS(ESI): calcd for C14H27NO2Si ([M]+): 270.1884; found: 270.1881; HPLC separation: 
Lux Cellulose 1, 4.6 x 150 mm; 99:1 (n-heptane/i-PrOH), 0.8 mL/min, 226 nm; tr(major) = 5.2 
min, tr(minor) = 5.7 min, 79:21 e.r. 
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5-Methyl-3-(propan-2-ylidene)-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 3.14f 
 
Following general procedure A, starting with 2-bromo-N-isopropyl-3-methyl-N-(2,4,6-
trimethoxybenzyl)but-2-enamide 3.13f (200.0 mg, 0.5 mmol, 1.0 equiv), was reacted with 
cesium carbonate (244 mg, 0.75 mmol, 1.5 equiv), palladium allyl chloride (9.3 mg, 0.025 
mmol, 5 mol%.), PPh3 (26 mg, 100 µmol, 20 mol%.) and pivalic acid (15 mg, 150 µmol, 30 
mol%) in mesitylene (3.25 mL) at 160°C overnight. The crude product was purified by 
preparative thin layer chromatography affording 5-Methyl-3-(propan-2-ylidene)-1-(2,4,6-
trimethoxybenzyl)pyrrolidin-2-one 3.14f (100 mg, 0.31 mmol, 63 %) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 6.08 (s, 2H), 4.97 (d, J = 14.1 Hz, 1H), 4.13 (d, J = 14.1 Hz, 
1H), 3.78 (s, 3H), 3.75 (s, 6H), 3.30 – 3.14 (m, 1H), 2.67 – 2.55 (m, 1H), 2.27 (t, J = 1.9 Hz, 
3H), 2.12 – 2.04 (m, 1H), 1.70 (s, 3H), 1.08 (d, J = 6.2 Hz, 3H). 13C{1H} NMR (CDCl3, 75 
MHz): δ = 168.0, 160.9, 160.1, 139.8, 124.7, 105.1, 90.4, 55.8, 55.3, 48.6, 33.3, 32.6, 23.5, 
20.7, 19.0. IR (neat): ν = 3054, 2968, 1689, 1658, 1265 cm-1 HRMS(ESI): calcd for 
C18H26NO4 ([M+H]+): 320.1856; found: 320.1861; 
5-Methyl-3-(propan-2-ylidene)pyrrolidin-2-one 3.22 
 
To a solution of 5-methyl-3-(propan-2-ylidene)-1-(2,4,6-trimethoxybenzyl)pyrrolidin-2-one 
3.14f (50 mg, 0.15 mmol, 1 equiv) in anisole (1.2 mL) was added TFA (2.5 mL, 34 mmol, 217 
equiv). The mixture was stirred at room temperature until completion of the reaction (monitored 
by TLC). The crude mixture was evaporated under vaccum and the mixture was purified by 
colum chromatography eluant 1/1 pentane/EtOAc to pure EtOAc affording 5-Methyl-3-
(propan-2-ylidene)pyrrolidin-2-one 3.22 (20.5  mg 0.15 mmol, 94 %) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 6.45 (s, 1H), 3.78 – 3.61 (m, 1H), 2.97 – 2.82 (m, 1H), 2.30 
– 2.22 (m, 1H), 2.22 (s, 3H), 1.74 (s, 3H), 1.18 (d, J = 6.2 Hz, 3H). 13C{1H} NMR (CDCl3, 75 
MHz): δ = 171.9, 142.4, 123.8, 46.0, 35.3, 23.7, 23.5, 19.1. IR (neat): ν = 3172, 2924, 1685, 
1653, 1437 cm-1. HRMS(ESI): calcd for C8H14NO ([M+H]+): 140.1070; found: 140.1072; 
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3-(Propan-2-ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-one 3.14g 
 
Following general procedure A, 2-bromo-N-ethyl-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13g (100 mg, 0.27 mmol, 1.0 equiv) was 
reacted with cesium carbonate (134 mg, 0.41 mmol, 1.5 equiv), palladium allyl chloride (5.0 
mg, 13 µmol, 5 mol%), PPh3 (14.4 mg, 55 µmol, 20 mol%) and pivalic acid (8.3 mg, 83 µmol, 
30 mol%) in mesitylene (2 mL) at 160°C overnight. The crude product was analyzed by GC/MC 
analysis showing a ratio 14/86 desired product/dehalogenated by-product which is not purified. 
5,5-Dimethyl-3-(propan-2-ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-one 
3.14h 
 
Following general procedure A, 2-bromo-N-(tert-butyl)-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13h (100 mg, 0.27 mmol, 1.0 equiv) was 
reacted with cesium carbonate (134 mg, 0.41 mmol, 1.5 equiv), palladium allyl chloride (5.0 
mg, 13 µmol, 5 mol%), PPh3 (14.4 mg, 55 µmol, 20 mol%) and pivalic acid (8.3 mg, 83 µmol, 
30 mol%) in mesitylene (2 mL) at 160°C overnight. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc 90:10) affording 5,5-Dimethyl-3-(propan-2-ylidene)-
1-((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-one 3.14h (72 mg, 0.25 mmol, 92% yield) as 
a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.75 (s, 2H), 3.62 (m, 2H), 2.5 (s, 2H), 2.25 (s, 3H), 1.78 (s, 
3H), 1.32 (s, 6H), 0.88 (m, 2H), 0.00 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 169.3, 
143.4, 123.5, 69.2, 65.4, 56.40, 41.6, 30.3, 28.3, 23.8, 19.54, 18.3, -1.2. IR (neat): ν = 2945, 
1688 cm-1. HRMS(ESI) calcd for C15H29NNaO2Si ([M+Na]+): 306.4818; found: 306.4807; 
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(R)-5-Cyclohexyl-3-(propan-2-ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-
one 3.14i 
 
Following general procedure A, 2-bromo-N-(1-cyclohexylethyl)-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13i (100 mg, 0.24 mmol, 1.0 equiv) was reacted 
with cesium carbonate (117 mg, 0.36 mmol, 1.5 equiv), palladium allyl chloride (4.4 mg, 12 
µmol, 5 mol%), PPh3 (12.5 mg, 48 µmol, 20 mol%) and pivalic acid (7.3 mg, 72 µmol, 30 
mol%) in mesitylene (2 mL) at 160°C overnight. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc 90:10) affording (R)-5-Cyclohexyl-3-(propan-2-
ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-one 3.14i (57 mg, 0.17 mmol, 70%) 
as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 5.00 (d, J = 5.5 Hz, 1H), 4.58 (d, J = 10.7 Hz, 1H), 3.66 – 
3.37 (m, 2H), 2.53 (m, 1H), 2.25 (m, 2H), 1.91 (m, 1H), 1.84 (m, 2H), 1.81 (s, 3H), 1.67 (s, 
3H), 1.59 – 0.82 (m, 10H), 0.01 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 170.1, 142.6, 
123.9, 71.0, 65.5, 57.1, 38.9, 29.1, 26.6, 26.4, 26.1, 25.9, 24.3, 23.6, 19.2, 18.1, 0 (3 C). IR 
(neat): ν = 2952, 2823, 1618 cm-1. HRMS(ESI): calcd for C19H35NNaO2Si ([M+Na]+) : 
360.2329; found: 360.2333; Optical rotation: [ ]20Da  = -9.2 (c = 1.03, CHCl3) 
(R)-5-(Tert-butyl)-3-(propan-2-ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-
one 3.14j 
 
Following general procedure A, (S)-2-bromo-N-(3,3-dimethylbutan-2-yl)-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13j (100.0 mg, 0.25 mmol, 1.0 equiv) was 
reacted with cesium carbonate (124 mg, 0.38 mmol, 1.5 equiv), palladium allyl chloride (4.7 
mg, 13 µmol, 5 mol%), PPh3 (13.4 mg, 51 µmol, 2 mol%) and pivalic acid (7.8 mg, 76 µmol, 
30 mol%) in mesitylene (2 mL) at 160°C overnight. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc 90:10) affording (R)-5-(Tert-butyl)-3-(propan-2-
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ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-one 3.14j (60.9 mg, 0.20 mmol, 77% 
yield) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.96 (d, J = 10.5 Hz, 1H), 4.75 (d, J = 10.5 Hz, 1H), 3.55 – 
3.46 (m, 2H), 3.39 (dd, J = 8.9, 3.5 Hz, 1H), 2.67 – 2.52 (m, 1H), 2.52 – 2.40 (m, 1H), 2.23 (s, 
3H), 1.78 (s, 3H), 0.93 – 0.89 (m, 11H), -0.02 (s, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 
171.8, 142.4, 124.3, 73.8, 65.6, 62.5, 35.8, 28.9, 26.4, 23.7, 19.5, 18.1, -1.3. IR (neat): ν = 
1688, 2945 cm-1 HRMS (ESI) calcd for C17H33NNaO2Si ([M+Na]+): 334.2172; found: 
334.2166; Optical rotation: [ ]20Da  = +21.3 (c = 1.02, CHCl3). 
5-Phenethyl-3-(propan-2-ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-one 
3.14k 
 
 Following general procedure A, 2-bromo-3-methyl-N-(4-phenylbutan-2-yl)-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13k (100 mg, 0.23 mmol, 1.0 equiv) was 
reacted with cesium carbonate (111 mg, 0.34 mmol, 1.5 equiv), palladium allyl chloride (4.2 
mg, 12 µmol, 5 mol%), PPh3 (11.9 mg, 45 µmol, 20mol%) and pivalic acid (6.9 mg, 68 µmol, 
30 mol%) in mesitylene (2 mL) at 160°C overnight. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc 90:10) affording 5-Phenethyl-3-(propan-2-ylidene)-1-
((2-(trimethylsilyl)ethoxy)methyl)pyrrolidin-2-one 3.14k (50 mg, 0.14 mmol, 61%) as a 
colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 7.35- 7.10 (m, 5H), 4.98 (d, J = 10.7 Hz, 1H), 4.66 (d, J = 
10.7 Hz, 1H), 3.75-3.60 (m, 1H), 3.52 (m, 2H), 2.9-2.8 (m, 1H), 2.75 -2.5 (m, 2 H), 2,29 (s, 
3H), 2.25-2.10 (m, 1 H), 1.82 (s, 3H), 1.5-1.15 (m, 2H), 1.02 – 0.78 (m, 2H), 0.00 (s, 9H) 
13C{1H} NMR (CDCl3, 75 MHz): δ = 171.1, 144.9, 142.7, 129.9 (2 C), 129.7 (2 C), 127.4, 
124.8, 72.0, 66.9, 54.1, 36.9, 32.1 (2 C), 25.1, 20.7, 19.4, 0.0 (3 C). IR (neat): ν = 1688, 2945 
cm-1. HRMS(ESI) calcd for C21H33NNaO2Si ([M+Na]+): 382.2173; found: 382.2162; 
7-(Propan-2-ylidene)-5-((2-(trimethylsilyl)ethoxy)methyl)-5-azaspiro[2.4]heptan-6-one 
3.14l 
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Following general procedure A, 2-bromo-N-(cyclopropylmethyl)-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13l (200 mg, 0.55 mmol, 1.0 equiv) was reacted 
with cesium carbonate (269 mg, 0.83 mmol, 1.5 equiv), palladium allyl chloride (10.1 mg, 28 
µmol, 5 mol%), PPh3 (29 mg, 110 µmol, 20 mol%) and pivalic acid (17 mg, 165 µmol, 30 
mol%) in mesitylene (4 mL) at 160°C overnight. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc 90:10) affording 7-(Propan-2-ylidene)-5-((2-
(trimethylsilyl)ethoxy)methyl)-5-azaspiro[2.4]heptan-6-one 3.14l (82 mg, 0.29 mmol, 53% 
yield) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 4.75 (s, 2H), 3.59 – 3.41 (m, 2H), 3.21 (s, 2H), 2.23 (s, 3H), 
1.62 (s, 3H), 1.40 (dt, J = 6.1, 3.1 Hz, 2H), 0.92 – 0.83 (m, 2H), 0.72 (q, J = 5.1 Hz, 2H), 0.02 
– -0.10 (m, 9H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 169.9, 141.3, 126.2, 72.3, 65.5, 53.9, 
21.8, 21.0, 20.3, 18.0, 14.8, -1.3. IR (neat): ν = 2952, 1689 cm-1. HRMS(ESI) calcd for 
C15H27NNaO2Si ([M+Na]+) : 304.1709; found: 304.1716; 
4-(Propan-2-ylidene)-2-((2-(trimethylsilyl)ethoxy)methyl)-2-azabicyclo[3.1.0]hexan-3-
one 3.14m 
 
Following general procedure A, 2-bromo-N-cyclopropyl-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide 3.13m (100 mg, 0.29 mmol, 1.0 equiv) was 
reacted with cesium carbonate (140 mg, 0.43 mmol, 1.5 equiv), palladium allyl chloride (5.8 
mg, 15 µmol, 5 mol%), PPh3 (15.1 mg, 57 µmol, 20 mol%) and pivalic acid (8.8 mg, 86 µmol, 
30 mol%) in mesitylene (2 mL) at 160°C overnight. The crude product was purified by flash 
chromatography (eluent: CyHex/EtOAc 90:10) affording 4-(Propan-2-ylidene)-2-((2-
(trimethylsilyl)ethoxy)methyl)-2-azabicyclo[3.1.0]hexan-3-one 3.14m (53 mg, 0.20 mmol, 
69% yield) as a colorless oil 
The stereochemistry of the product was confirmed by NOE-spectroscopy. 
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1H NMR (CDCl3, 300 MHz): δ = 4.82 (d, J = 10.5 Hz, 1H, H10), 4.73 (d, J = 10.5 Hz, 1H, H10), 
3.71 – 3.39 (m, 2H, H13), 3.21 (ddd, J = 7.2, 5.0, 2.4 Hz, 1 H, H2), 2.24 (s, 3H, H7), 2.11 (m, 
1H, H1), 1.95 (s, 3H, H8), 1.01-0.93 (m, 1 H, H11b), 0.99-0.88 (m, 2 H, H15), 0.43 (ddd, J=5.3, 
4.5, 2.4 Hz, 1 H, H11a), 0.0 (s, 9H, H16). 13C{1H} NMR (CDCl3, 75 MHz): δ = 169.0 (C4), 145.0 
(C6), 126.9 (C5), 73.0 (C10), 65.8 (C13), 32.5 (C2), 24.0 (C8), 19.2 (C7), 18.2 (C14), 18.0 (C11), 
13.1 (C1), -1.2 (3 C, C16). HRMS(ESI): calcd for C14H25NNaO2Si ([M+Na]+): 290.1552; 
found: 290.1550; 
3-(Propan-2-ylidene)-1-((2-(trimethylsilyl)ethoxy)methyl)hexahydro-1H-indol-2(3H)-one 
3.14n 
 
Following general procedure A, 2-bromo-N-cyclohexyl-3-methyl-N-((2-
(trimethylsilyl)ethoxy)methyl)but-2-enamide  3.13n (100 mg, 0.27 mmol, 1.0 equiv) was 
reacted with cesium carbonate (134 mg, 0.41 mmol, 1.5 equiv), palladium allyl chloride (5.0 
mg, 13 µmol, 5 mol%), PPh3 (14.4 mg, 55 µmol, 20 mol%) and pivalic acid (8.3 mg, 83 µmol, 
30 mol%) in mesitylene (2 mL) at 160°C overnight. The crude product was analyzed by GC/MC 
analysis showing complete conversion for dehalogenated by-product. 
(E)-3-Benzylidene-1-isopropyl-5-methylpyrrolidin-2-one 3.14o 
 
Following general procedure A, (Z)-2-bromo-N,N-diisopropyl-3-phenylacrylamide 3.13o 
(100.0 mg, 0.32 mmol, 1.0 equiv) was reacted with cesium carbonate (157.5 mg, 0.48 mmol, 
1.5 equiv), palladium allyl chloride (5.9 mg, 16 µmol, 5 mol%), PPh3 (16.9 mg, 64 µmol, 20 
mol%) and pivalic acid (9.9 mg, 96 µmol, 30 mol%) in mesitylene (2 mL) at 160°C overnight. 
The crude product was purified by preparative TLC (eluent: CyHex/EtOAc 90:10) affording 
(E)-3-Benzylidene-1-isopropyl-5-methylpyrrolidin-2-one 3.14o (51.7 mg, 0.23 mmol, 70%) as 
a colorless oil. 
The stereochemistry of the product was confirmed by NOE-spectroscopy. 
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1H NMR (CDCl3, 400 MHz): δ = 7.50 – 7.27 (m, 5H), 4.25 (sept, J = 6.9 Hz, 1H, H7), 3.99 – 
3.86 (m, 1H, H5), 3.25 (ddd, J = 17.4, 8.1, 3.0 Hz, 1H, H4a), 2.62 (dt, J = 17.4, 2.8 Hz, 1H, H4b), 
1.41 – 1.30 (m, 9H, H8, H9, H10). 13C{1H} NMR (CDCl3, 75 MHz): δ = 168.8, 136.0, 131.5, 
129.5, 129.0 (2 C), 128.6 (2 C), 128.2, 50.8, 45.1, 34.3, 23.6, 21.7, 19.4. IR (neat): ν = 2946, 
1678 cm-1. HRMS(ESI) calcd for C15H20NO ([M+H]+·) : 230.1545; found: 230.1555; 
(E)-3-Ethylidene-1-isopropyl-5-methylpyrrolidin-2-one 3.14q 
 
Following general procedure A, (2Z)-2-bromo-N,N-bis(propan-2-yl)but-2-enamide 3.13q (100 
mg, 0.40 mmol, 1 equiv) was reacted with cesium carbonate (196 mg, 0.60 mmol, 1.5 equiv) 
palladium allyl chloride (3.7 mg, 10 µmol, 2.5 mol%), PPh3 (10.6 mg, 40 µmol, 10 mol%) and 
pivalic acid (12.3 mg, 0.12 mmol, 30 mol%) in mesitylene (2.8 mL) at 160°C overnight. The 
crude product was purified by flash chromatography (CyHex to 50% EtOAc) affording (E)-3-
Ethylidene-1-isopropyl-5-methylpyrrolidin-2-one 3.14q (52 mg, 0.31 mmol, 77 %) as a 
colorless oil. 
The stereochemistry of the product was confirmed by NOE-spectroscopy. 
1H NMR (CDCl3, 400 MHz): δ = 6.51 - 6.31 (m, 1 H, H10), 4.11 (m, 1 H, H7), 3.85 - 3.69 (m, 
1 H, H5), 2.85 - 2.69 (m, 1 H, H4a), 2.21 - 2.09 (m, 1 H, H4b), 1.76 - 1.65 (m, 3 H, H11), 1.30 - 
1.19 (m, 9 H, H8, H9, H12). 13C{1H} NMR (CDCl3, 101 MHz): δ = 168.0, 132.6, 126.8, 50.4, 
44.7, 31.6, 23.6, 21.7, 19.4, 14.5. IR (neat): ν = 2968, 2931, 1692, 1664, 1409, 720 cm-1. 
HRMS (ESI): calcd for C10H18NO ([M+H]+): 168.1388; found: 168.1284; 
1-ethyl-5-methyl-3-(propan-2-ylidene)pyrrolidin-2-one 3.14r 
 
Following general procedure A, 2-bromo-N-ethyl-N-isopropyl-3-methylbut-2-enamide 3.13r 
(50.0 mg, 0.20 mmol, 1.0 equiv) was reacted with cesium carbonate (98.5 mg, 0.30 mmol, 1.5 
equiv), palladium allyl chloride (3.7 mg, 10 µmol, 5mol%), PPh3 (10.6 mg, 40 µmol, 20 mol%) 
and pivalic acid (6.2 mg, 60 µmol, 30 mol%) in mesitylene (1 mL) at 160°C overnight. The 
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crude product was purified by preparative TLC (eluent: CyHex/EtOAc 90:10) affording 1-
ethyl-5-methyl-3-(propan-2-ylidene)pyrrolidin-2-one 3.14r (22.0 mg, 0.14 mmol, 67%) as a 
colorless oil.  
1H NMR (CDCl3, 300 MHz): δ = 3.61 (spt, 1H), 3.24 (m, 2H), 2.75 (m, 2H), 2.31 (s, 3H), 1.85 
(s, 3H), 1.27 (m, 6H) ppm. 13C{1H} NMR (CDCl3, 75 MHz): δ = 166.1, 134.7, 109.1, 50.5, 
46.6, 35.4, 22.8, 21.6, 20.6, 13.9 ppm. IR (neat): ν = 1637, 2934 cm-1. HRMS(ESI) calcd (for 
C10H17NO) : 167.2111; found: 167.2123; 
1,5,5-Trimethyl-3-(propan-2-ylidene)pyrrolidin-2-one 3.14s 
 
Following general procedure A, 2-bromo-N-(tert-butyl)-N,3-dimethylbut-2-enamide 3.13s 
(100 mg, 0.4 mmol, 1.0 equiv) was reacted with cesium carbonate (197 mg, 0.60 mmol, 1.5 
equiv), palladium allyl chloride (7.4 mg, 20 µmol, 5 mol%), PPh3 (21.1 mg, 80 µmol, 20 mol%) 
and pivalic acid (12.4 mg, 120 µmol, 30 mol%) in mesitylene (2 mL) at 160°C overnight. The 
crude product was purified by flash chromatography (eluent: CyHex/EtOAc 90:10) affording 
1,5,5-Trimethyl-3-(propan-2-ylidene)pyrrolidin-2-one 3.14s (62 mg, 0.37 mmol, 92% yield) of 
a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 2.70 (s, 3H), 2.43 – 2.33 (m, 2H), 2.19 (t, J = 2.0 Hz, 3H), 
1.67 (s, 3H), 1.14 (s, 6H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 168.4, 140.8, 123.7, 56.1, 
40.8, 26.7, 24.0, 23.4, 19.1. IR (neat): ν = 2930, 1660, 1390, 1240 cm-1. HRMS(ESI): calcd 
for C10H18NO ([M+H]+) : 168.1386; found: 168.1383; 
Following general procedure A, 2-bromo-N-isopropyl-N,3-dimethylbut-2-enamide (200 mg, 
0.85 mmol, 1.0 equiv) was reacted with cesium carbonate (361 mg, 1.1 mmol, 1.5 equiv), 
palladium allyl chloride (15.6 mg, 42 µmol, 5 mol%), PPh3 (45 mg, 170 µmol, 20 mol%) and 
pivalic acid (26 mg, 256 µmol, 30 mol%) in mesitylene (5.5 mL) at 160°C overnight. GC/MS 
ratio 2s/4s/3s - 53:22:25 The crude product was purified by preparative thin layer 
chromatography (eluent CyHex/EA 9:1) affording (50 mg,  0.326 mmol, 38 %) of 3.14t as a 
slightly yellow oil and 3.14t’ (15 mg, 0.098 mmol, 11 %) as a slightly yellow oil. 
 
 
189 
 
1,5-Dimethyl-3-(propan-2-ylidene)pyrrolidin-2-oneone 3.14t 
 
1H NMR (CDCl3, 300 MHz): δ = 3.54 – 3.38 (m, 1H), 2.88 – 2.68 (m, 4H), 2.20 (s, 3H), 2.17 
– 2.07 (m, 1H), 1.69 (s, 3H), 1.15 (d, J = 6.3 Hz, 3H). 
13C{1H} NMR (CDCl3, 75 MHz): δ = 169.1, 140.9, 123.7, 51.9, 33.2, 27.5, 23.5, 20.6, 18.9. 
IR (neat): ν = 2916, 1684, 1658, 1426, 1395, 1291 cm-1. HRMS(ESI): calcd for C9H15NNaO 
([M+Na]+·): 176.1046; found: 176.1045; 
 
1-Isopropyl-3-(propan-2-ylidene)azetidin-2-one 3.14t’ 
 
1H NMR (CDCl3, 300 MHz): δ = 4.01 (sept, J = 6.7 Hz, 1H), 3.60 (s, 2H), 2.02 (s, 3H), 1.68 
(s, 3H), 1.18 (d, J = 6.7 Hz, 6H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 163.9, 134.0, 130.5, 
43.6, 42.9, 20.9, 20.7, 19.8. IR (neat): ν = 2968, 1670, 1642, 1405, 1270 cm-1. HRMS(ESI): 
calcd for C9H15NNaO ([M+Na]+·): 176.1046; found: 176.1048; 
1-((1R,2S)-1-(Benzyloxy)-1-phenylpropan-2-yl)-3-(propan-2-ylidene)azetidin-2-one 
3.14u’ 
 
Following general procedure A, N-((1R,2S)-1-(benzyloxy)-1-phenylpropan-2-yl)-2-bromo-
N,3-dimethylbut-2-enamide 3.13u (200 mg, 0.48 mmol, 1 equiv) was reacted with cesium 
carbonate (235 mg, 0.72 mmol, 1.5 equiv) palladium allyl chloride (8.9 mg, 24 µmol, 2.5 
mol%), PPh3 (25 mg, 96 µmol, 10 mol%) and pivalic acid (15 mg, 0.14 mmol, 30 mol%) in 
mesitylene (3.1 mL) at 160°C overnight. The crude product was purified by flash 
chromatography (CyHex to 50% EtOAc) affording 1-((1R,2S)-1-(Benzyloxy)-1-phenylpropan-
2-yl)-3-(propan-2-ylidene)azetidin-2-one 3.14u’ (75 mg, 0.22 mmol, 47 %) asa yellow oil. 
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1H NMR (CDCl3, 300 MHz): δ = 7.41 – 7.27 (m, 10H), 4.61 (d, J = 5.0 Hz, 1H), 4.51 (d, J = 
11.7 Hz, 1H), 4.31 (d, J = 11.7 Hz, 1H), 4.06 – 3.92 (m, 1H), 3.60 (d, J = 6.9 Hz, 1H), 3.48 (d, 
J = 6.9 Hz, 1H), 2.00 (s, 3H), 1.63 (s, 3H), 1.24 (d, J = 6.9 Hz, 3H). 13C{1H} NMR (CDCl3, 75 
MHz): δ = 164.0, 139.2, 138.4, 134.2, 130.9, 128.6, 128.5, 128.0, 127.7, 127.2, 83.6, 71.0, 
53.0, 46.4, 20.9, 19.8, 12.7. IR (neat): ν = 2935, 2874, 1726, 1605, 1449, 1371, 1063 cm-1 
HRMS(ESI): calcd for C22H26NO2 ([M+H]+): 336.1958; found: 336.1950; 
1-Cyclohexyl-3-(propan-2-ylidene)azetidin-2-one 3.14v 
 
Following general procedure A, 2-bromo-N-cyclohexyl-N,3-dimethylbut-2-enamide 3.13v 
(200 mg, 0.73 mmol, 1.0 equiv) was reacted with cesium carbonate (357 mg, 1.09 mmol, 1.5 
equiv), palladium allyl chloride (13 mg, 36 µmol, 5 mol%), PPh3 (38 mg, 145 µmol, 20 mol%) 
and pivalic acid (22 mg, 220 µmol, 30 mol%) in mesitylene (4.7 mL) at 160°C overnight. The 
crude product was purified by preparative thin layer chromatography (eluent CyHex/EA 9:1 to 
1;1) affording 1-Cyclohexyl-3-(propan-2-ylidene)azetidin-2-one 3.14v’ (56 mg, 0.29 mmol, 40 
%) of a slightly yellow oil. 
1H NMR (CDCl3, 300 MHz): δ = 3.65 – 3.53 (m, 3H), 2.00 (s, 3H), 1.89 – 1.78 (m, 2H), 1.78 
– 1.69 (m, 2H), 1.66 (s, 3H), 1.64 – 1.55 (m, 1H), 1.40 – 1.22 (m, 4H), 1.19 – 1.02 (m, 1H). 
13C{1H} NMR (CDCl3, 75 MHz): δ = 163.9, 133.8, 130.6, 50.5, 44.3, 31.0, 25.5, 25.0, 20.9, 
19.7. IR (neat): ν = 2935, 2856, 1716, 1390 cm-1 HRMS(ESI): calcd for C12H19NNaO 
([M+Na]+·): 216.1359; found: 216.1353; 
3-(Propan-2-ylidene)-5-propyl-1-(4-((triisopropylsilyl)oxy)phenethyl)pyrrolidin-2-one 
3.14w 
 
Following general procedure A, 2-bromo-3-methyl-N-(pentan-2-yl)-N-[2-(4-{[tris(propan-2-
yl)silyl]oxy}phenyl)ethyl]but-2-enamide  3.13w (5.93 g, 11.3 mmol, 1.0 equiv) was dissolved 
in mesitylene (75 mL) and was transferred to a Schlenk-flask containing Cs2CO3 (5.52 g, 16.95 
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mmol, 1.5 equiv), [Pd(Cl)(C3H5)]2 (103 mg, 282 µmol, 2.5 mol%,), PPh3 (296 mg, 1.13 mmol, 
10 mol%) and PivOH (346 mg, 3.39 mmol, 30 mol%) and the reaction was heated using a 
preheated oil bath at 160°C for 15 h. The solution was cooled at room temperature, filtered over 
celite with EtOAc and concentrated. The crude product was purified by flash chromatography 
(CyHex/EtOAc 90:10) affording 3-(Propan-2-ylidene)-5-propyl-1-(4-
((triisopropylsilyl)oxy)phenethyl)pyrrolidin-2-one 3.14w (3.49 g, 7.86 mmol, 70%) as a yellow 
oil. 
1H NMR (CDCl3, 300 MHz): δ = 7.11 - 7.01 (m, 2 H), 6.84 - 6.75 (m, 2 H), 3.90 - 3.77 (m, 1 
H), 3.38 - 3.23 (m, 1 H), 3.19 - 3.03 (m, 1 H), 2.91 - 2.77 (m, 1 H), 2.77 - 2.56 (m, 2 H), 2.30 - 
2.14 (m, 4 H), 1.74 (s, 3 H), 1.34 - 1.14 (m, 7 H), 1.12 - 1.05 (m, 18 H), 0.91 (t, J=7.0 Hz, 3 H). 
13C{1H} NMR (CDCl3, 75 MHz): δ = 169.1, 154.6, 140.8, 131.8, 129.7, 124.0, 119.9, 54.1, 
42.6, 36.1, 33.3, 30.9, 23.6, 19.0, 18.0, 18.0, 17.6, 14.2, 12.7. IR (neat): ν = 2942, 2866, 1682, 
1661, 1508, 1261 cm-1. HRMS(ESI): calcd for C27H46NO2Si ([M+H]+): 444.3298; found: 
444.3280; 
5,5,8a-Trimethyl-2-(propan-2-ylidene)hexahydroindolizin-3(2H)-one 3.14x 
 
Following general procedure A, 2-bromo-3-methyl-1-(2,2,6,6-tetramethylpiperidin-1-yl)but-2-
en-1-one  3.13x (100 mg, 0.33 mmol, 1.0 equiv) was reacted with cesium carbonate (162 mg, 
0.50 mmol, 1.5 equiv), palladium allyl chloride (6.1 mg, 17 µmol, 5 mol%), PPh3 (17.4 mg, 66 
µmol, 20 mol%) and pivalic acid (10.1 mg, 99 µmol, 30 mol%) in mesitylene (2 mL) at 160°C 
overnight. The crude product was purified by flash chromatography (eluent: CyHex/EtOAc 
90:10) affording 5,5,8a-Trimethyl-2-(propan-2-ylidene)hexahydroindolizin-3(2H)-one 3.14x 
(61 mg, 0.28 mmol, 83% yield) as a colorless oil. 
1H NMR (CDCl3, 300 MHz): δ = 2.43 – 2.39 (m, 2H), 2.18 (s, 3H), 1.76  (s, 3H), 1.70 – 1.50 
(m, 6H), 1.40 (s, 3H), 1.37 (s, 3H), 1.16 (s, 3H). 13C NMR (CDCl3, 75 MHz): δ = 169.1, 140.5, 
124.8, 57.4, 53.6, 44.3, 39.8, 37.3, 30.1, 27.7, 25.9, 23.6, 19.0, 17.0. IR (neat): ν = 2930, 1651, 
1609 cm-1. HRMS(ESI): calcd for C14H24NO ([M+H]+) : 222.1852; found: 222.1858; 
2-(Propan-2-ylidene)hexahydroindolizin-3(2H)-one 3.14y 
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Following general procedure A, 2-bromo-3-methyl-1-(2-methylpiperidin-1-yl)but-2-en-1-one  
3.13y (2.3 g, 8.84 mmol, 1 equiv) was reacted with cesium carbonate (4.3 g, 13.3 mmol, 1.5 
equiv), palladium allyl chloride (160 mg, 0.44 mmol, 5 mol%,), PPh3 (463 mg, 1.77 mmol, 20 
mol%) and PivOH (270 mg, 2.65 mmol, 30 mol%) in mesitylene (57 mL) at 160°C overnight. 
The crude product was purified by flash chromatography (CyHex to 20% EtOAc) affording 2-
(Propan-2-ylidene)hexahydroindolizin-3(2H)-one 3.14y (1.109 g,  6.18 mmol, 70 %) as a 
yellow solid. 
1H NMR (CDCl3, 400 MHz): δ = 4.23 - 4.12 (m, 1 H), 3.35 (dddd, J=11.3, 8.1, 4.9, 3.2 Hz, 1 
H), 2.86 - 2.74 (m, 1 H), 2.62 (td, J=12.7, 3.5 Hz, 1 H), 2.28 - 2.23 (m, 3 H), 2.22 - 2.11 (m, 1 
H), 1.90 - 1.79 (m, 2 H), 1.770 - 1.70 (m, 3 H), 1.70 - 1.62 (m, 1 H), 1.50 - 1.26 (m, 2 H), 1.18 
- 1.05 (m, 1 H).13C{1H} NMR (CDCl3, 101 MHz): δ = 167.7, 141.0, 123.9, 53.8, 40.1, 34.1, 
32.0, 24.8, 24.1, 23.7, 19.0. IR (neat): ν = 2934, 2851, 1680, 1658, 1421, 1298 cm-1. Mp = 41-
42 °C. . HRMS(ESI): calcd for C11H17NNaO ([M+Na]+): 202.1205; found: 202.1202; 
2-(Propan-2-ylidene)tetrahydro-1H-pyrrolizin-3(2H)-one 3.14z 
 
Following general procedure A, 2-bromo-3-methyl-1-(2-methylpyrrolidin-1-yl)but-2-en-1-one 
3.13z (200 mg, 0.81 mmol, 1 equiv) was reacted with cesium carbonate (397 mg, 1.2 mmol, 
1.5 equiv), palladium allyl chloride (15 mg, 41 µmol, 5 mol%,), PPh3 (42 mg, 160 µmol, 20 
mol%) and PivOH (25 mg, 240 µmol, 30 mol%) in mesitylene (5.3 mL) at 160°C overnight. 
The crude product was purified by flash chromatography (CyHex to 40% EtOAc) affording 2-
(Propan-2-ylidene)tetrahydro-1H-pyrrolizin-3(2H)-one 3.14z (30 mg, 0.18 mmol, 22 %) asa 
yellow oil. 
1H NMR (CDCl3, 300 MHz): δ = 3.72 – 3.65 (m, 1H), 3.65 – 3.59 (m, 1H), 3.16 – 3.05 (m, 
1H), 2.87 (m, 1H), 2.45 – 2.32 (m, 1H), 2.21 (m, 3H), 2.06 – 1.84 (m, 3H), 1.73 (s, 3H), 1.31 – 
1.11 (m, 2H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 170.5, 141.6, 127.1, 57.6, 42.1, 32.8, 31.6, 
26.0, 23.5, 19.1. IR (neat): ν = 2917, 2842, 1675, 1421, 1298 cm-1. HRMS(ESI): calcd for 
C10H15NNaO ([M+Na]+·): 188.1051; found: 188.1058; 
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2-(Propan-2-ylidene)hexahydro-1H-pyrrolo[1,2-a]azepin-3(2H)-one 3.14aa 
 
Following general procedure A, 2-bromo-3-methyl-1-(2-methylazepan-1-yl)but-2-en-1-one 
3.13aa (200 mg, 0.73 mmol, 1 equiv) was reacted with cesium carbonate (356 mg, 1.09 mmol, 
1.5 equiv), palladium allyl chloride (13.3 mg, 36 µmol, 5 mol%,), PPh3 (38 mg, 145 µmol, 20 
mol%) and PivOH (22 mg, 220 µmol, 30 mol%) in mesitylene (4.7 mL) at 160°C overnight. 
The crude product was purified by flash chromatography (CyHex to 40% EtOAc) affording 2-
(Propan-2-ylidene)hexahydro-1H-pyrrolo[1,2-a]azepin-3(2H)-one 3.14aa (84 mg, 0.43 mmol, 
60 %) of a yellow oil. 
1H NMR (CDCl3, 300 MHz): δ = 3.76 – 3.65 (m, 1H), 3.65 – 3.54 (m, 1H), 2.98 (m, 1H), 2.71 
(m, 1H), 2.16 (m, 3H), 2.15 – 2.05 (m, 1H), 1.89 – 1.69 (m, 2H), 1.67 (s, 3H), 1.63 – 1.40 (m, 
6H). 13C{1H} NMR (CDCl3, 75 MHz): δ = 169.0, 139.7, 124.5, 55.3, 42.7, 36.6, 33.0, 29.5, 
27.3, 25.0, 23.3, 18.8. IR (neat): ν = 2925, 2857, 1683, 1659, 1443, 1414, 1297 cm-1. 
HRMS(ESI): calcd for C12H20NNaO ([M+Na]+·): 216.1359; found: 216.1355; 
3.4. Attempts toward a total synthesis of plakoridine A 
5-propyl-1-(4-((triisopropylsilyl)oxy)phenethyl)pyrrolidine-2,3-dione 3.43 
 
To a solution of 3.14w (1.564 g, 3.53 mmol, 1 equiv) in DCM was bubbled ozone at -78 °C 
until the solution was saturated in ozone. A flux of argon was used to removed excess of ozone 
and DMS (1.49 mL, 20.2 mmol, 5.7 equiv) is added dropwise at -78°C. The reaction was stirred 
during 30 min at -78°C, then the solution was allowed to warm up temperature. The crude 
mixture was evaporated under vacuo, diluted with DCM and water, extracted with DCM. The 
combined organic layers were dried over MgSO4 and evaparated under reduce pressure to 
afford the title compound (1.4 g, 3.35 mmol, 95%) without further purification (unstable on 
silica gel).  
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1H NMR (CDCl3, 300 MHz): δ = 7.00 – 6.96 (m, 2H), 6.76 – 6.72 (m, 2H), 4.07 – 3.91 (m, 
1H), 3.52 – 3.42 (m, 1H), 3.26 (dt, J = 14.1, 7.6 Hz, 1H), 2.96 – 2.84 (m, 1H), 2.81 – 2.71 (m, 
1H), 2.56 (dd, J = 19.7, 7.2 Hz, 1H), 2.23 (dd, J = 19.7, 2.5 Hz, 1H), 1.77 – 1.62 (m, 1H), 1.19 
– 1.12 (m, 6H), 1.02 – 0.97 (m, 18H), 0.85 (t, J = 7.2 Hz, 3H). 13C{1H} NMR (CDCl3, 75 
MHz): δ = 198.7, 159.9, 154.9, 130.4, 129.5, 120.1, 52.3, 43.8, 37.3, 35.4, 32.4, 17.9, 17.4, 
13.8, 12.6. 
3-((tert-butyldimethylsilyl)oxy)-5-propyl-1-(4-((triisopropylsilyl)oxy)phenethyl)-1,5-
dihydro-2H-pyrrol-2-one 3.52 
 
To a solution of 3.43 (45 mg, 0.11 mmol, 1 equiv) and 2,6-lutidine (15 mL, 0.13 mmol, 1.2 
equiv) in dichloromethane (0.5 mL) at -78°C was added dropwise TBSOTf (27.3 mL, 0.12 
mmol, 1.1 equiv). The reaction mixture was stirred at -78°C during 10 minutes and allowed to 
reach room temperature. Then, the reaction mixture was quench with a saturated solution of 
NaHCO3, extracted with DCM. The combined organic layers were dried over MgSO4, filtered 
and concentrated under reduce pressure. The crude mixture was puridifed by silica gel 
chromatography to afford the desired product as a yellow oil (30 mg, 0.056 mmol, 52%). 
1H NMR (CDCl3, 300 MHz): 7.06 – 6.99 (m, 2H), 6.85 – 6.76 (m, 2H), 5.74 (d, J = 2.2 Hz, 
1H), 3.95 (ddd, J = 14.1, 8.3, 5.8 Hz, 1H), 3.67 – 3.57 (m, 1H), 3.16 (dt, J = 14.3, 7.6 Hz, 1H), 
2.91 – 2.71 (m, 2H), 1.71 – 1.58 (m, 1H), 1.28 – 1.14 (m, 6H), 1.14 – 1.03 (m, 18H), 0.96 (s, 
9H), 0.89 (t, J = 7.2 Hz, 3H), 0.23 (s, 6H). 13C{1H} NMR (CDCl3, 75 MHz): δ =167.3, 154.7, 
147.4, 131.5, 129.7, 120.1, 117.3, 56.6, 42.1, 34.1, 33.1, 25.8, 18.5, 18.1, 17.4, 14.3, 12.8, -4.5. 
3.5. Total synthesis of (±)-d-Coniceine 
 
A solution of 2-(propan-2-ylidene)hexahydroindolizin-3(2H)-one 3.14y (208 mg, 1.16 mmol, 
1 equiv) in DCM (12 mL) was cooled down to -78°C and ozone was bubbled in the mixture 
solution until apparation of persistent blue coloration. Then, oxygene was bubbled to eliminate 
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excess of ozone and NaBH4 (131 mg, 3.48 mmol, 3 equiv) was added in one portion. The 
mixture was stirred 30 min at -78°C and then allowed to room temperature. Spatula of silica 
was added and the crude product was filtered on a pad of silica (CyHex to 100 % EtOAc) 
affording 150 mg of diastereoisomers 3.55 (0.962 mmol, 83 %) as a yellow oil. The product is 
enough pure to engage it directly in the next step. The crude alcohol (150 mg, 0.962 mmol, 1 
equiv) in dry dichloromethane (2 mL) under an argon atmosphere was treated with a solution 
of carbon tetrabromide (1.6 g, 4.8 mmol, 5 equiv) in dry dichloromethane (1.5 mL) followed 
by triphenylphosphine (1.26 g, 4.8 mmol, 5 equiv). The reaction mixture was stirred for 24 h, 
poured into saturated aqueous sodium hydrogencarbonate and extracted with dichloromethane. 
The combined organic extracts were dried over MgSO4, filtered and evaporated under reduced 
pressure. The residue was triturated with ethyl acetate and the organic solution was filtered and 
evaporated under reduced pressure. The residue was purified by flash chromatography on silica 
(CyHex to 50 % EtOAc) affording 209 mg of diastereoisomers (0.962 mmol, 99 %) as a yellow 
oil. Solution of the bromide (209 mg, 0.962 mmol, 1 equiv) in toluene (27 mL) was treated with 
tributyltin hydride (0.78 mL, 2.9 mmol, 3 equiv) and AIBN (16 mg, 0.096 mmol, 0.1 equiv), 
and the reaction mixture was heated at reflux under an argon atmosphere for 2 h. The reaction 
mixture was poured into saturated aqueous sodium hydrogen carbonate and extracted three 
times with ethyl acetate. The combined organic extracts were dried over MgSO4, filtered and 
evaporated under reduced pressure. The residue was purified by flash chromatography on silica 
(CyHex to 50 % EtOAc) affording 123 mg of the lactam 3.56 (0.88 mmol, 92%) as a slightly 
yellow oil. The physical data were in accordance to the litterature186. To a suspension of lithium 
aluminium hydride (65.5 mg, 1.72 mmol, 2 equiv) in anhydrous tetrahydrofuran (8 mL), under 
a nitrogen atmosphere at 0°C, a solution of lactam (123 mg, 0.88 mmol, 1 equiv) in anhydrous 
tetrahydrofuran (7 mL) was added slowly. The resulting mixture was stirred at room 
temperature for 2 hours. After hydrolysis with saturated aqueous ammonium chloride (10 mL), 
ethyl acetate (15 mL) was added and the mixture was stirred during 30 minutes. The organic 
phase was separated, dried over MgSO4, and HCl gas was bubbled in the organic phase during 
15 minutes. The crude product was purified by flash chromatography (EtOAc/MeOH 100:0 to 
90:10) affording 125 mg (0.77 mmol, 90 %) of a white solid. 
 1H NMR (DMSO-d6, 300 MHz): δ = 2.88 – 2.72 (m, 2H), 2.35 – 2.17 (m, 2H), 2.16 – 
2.05 (m, 1H), 1.53 – 1.42 (m, 1H), 1.42 – 1.34 (m, 1H), 1.33 – 1.25 (m, 1H), 1.25 – 
1.10 (m, 3H), 1.04 – 0.79 (m, 3H), 0.79 – 0.66 (m, 2H). 13C{1H} NMR (DMSO-d6, 101 
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MHz): δ = 58.4, 45.6, 44.6, 20.3, 19.6, 14.6, 14.3, 11.5. IR (neat): ν = 2930, 1650, 1555 
cm-1. HRMS(ESI): calcd for C8H16N ([M+H]+·): 126.1277; found: 126.1282;
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Synthesis of b-Lactams by Palladium(0)-Catalyzed C(sp3) Carbamoylation 
3.6. General procedure 
Amines’s synthesis 
Method A  
Amines (2 equiv), aldehyde (1 equiv) and 4Å molecular sieves were stirred for 4h in THF 
(0.1M). Then, a solution of NaBH4 (2 equiv) in EtOH (0.1 M) was carefully added to the 
mixture. The reaction was stirred at room temperature overnight, and was then filtered through 
celite. The crude was then acidified using a solution of HCl (0.1M) and stirred for 30 minutes. 
The mixture was then basified using NaOH solution (0.1M) and extracted three times using 
AcOEt. The combined organic layers were dried over sodium sulfate, filtered and evaporated 
under vacuum. The excess of starting material was removed under high vacuum to provide the 
amine. The amines were used without purification, or were purified by chromatography on 
silica gel using DCM/MeOH as eluent. 
Method B  
Amines (1 equiv), aldehyde (1 equiv), and AcOH (2 equiv) were stirred at room temperature in 
DCE (0.1 M) for 30 minutes. NaBH(OAc)3 (2 equiv) was then added to the turning solution, 
which was reacted overnight. Then, the mixture was quenched using a solution of NaOH (1M) 
and the crude was stirred for further 30 minutes. The crude was extracted twice with DCM, 
dried over sodium sulfate, filtered and evaporated under vacuum to give the desired amines. 
The amines were used without purification, or were purified by chromatography on silica gel 
using DCM/MeOH as eluent. 
Method C 
Amine (1 equiv), ketone/aldehyde (1 equiv) were dissolved in MeOH (0.7M) and purged with 
argon. Pd/C (10 mol%) was carefully added and the flask was purged with H2.  The mixture 
was stirred overnight under H2 balloon. The crude was then filtered through celite, and the 
solvent evaporated. The resulting amines were used without further purification or were 
purified by chromatography on silica gel using DCM/MeOH as eluent. 
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Phosphine’s synthesis  
TADDOL 
In a two-neck-flask equipped with magnetic stirring bar and reflux condenser were placed 
active magnesium turning (53 mmol, 5.3 equiv) and suspended in THF (30 mL). To this 
suspension a solution of the arylhalide (50 mmol, 5.0 equiv) in THF (10 mL) was added. If the 
exothermic reaction did not start after 5 minutes, iodine was added and the reaction mixture 
warmed by a oil bath. After the start of the exothermic reaction, the reaction mixture was 
refluxed for 30 minutes and afterwards cooled down to room temperature. A solution of 
dicarboxylate (10 mmol, 1.0 equiv) in THF or ether (40 mL) was added slowly, keeping the 
internal temperature below the boiling point of the solvent. After complete addition, the reaction 
mixture was refluxed for 8-14 h and afterwards cooled down to room temperature. Saturated 
ammonium chloride solution (40 mL), hydrochloric acid (1.0 M, 10 mL) and water (50 mL) 
were added carefully. The resulting biphasic mixture was extracted with ether (4x 50 mL). The 
combined organic extracts were washed with brine (30 mL) and dried over sodium sulfate. All 
volatiles were removed under reduced pressure. The crude product was purified by column 
chromatography (SiO2, Pentane: Et2O). 
Dichloroarylphosphine 
To a solution of chlorobis(diethylamino)phosphine (1.1 equiv) in dry Et2O (1 mL/mmol) at -
78°C was added a freshly prepared solution of a Grignard or an organolithium reagent (1.0 to 
1.5 equiv, 0.5 to 2 M in Et2O) slowly via a cannula. After complete addition, the reaction 
mixture was allowed to warm up to rt and stirred for an additional hour. In case an 
organolithium reagent was used the reaction, mixture was used as such for the next step. When 
Grignard reagent were used, the reaction mixture was filtered using a Schlenk-frit and the 
residue was washed with additional Et2O (~0.5 mL/mmol). The filtrate was concentrated with 
a rotary evaporator under N2-atmosphere and the obtained oil was redissolved in Et2O (~0.5 
mL/mmol). The reaction mixture was cooled to 0 °C and a solution of hydrogenchloride (4.4 to 
5 equiv equiv, 2M in Et2O) was added dropwise. After complete addition, the reaction mixture 
was allowed to warmup to rt and stirred for an additional hour. The white precipitate formed 
was filtered off (Schlenk-frit). The residue was washed with additional Et2O (~0.5 mL/mmol) 
and the filtrate was concentrated with a rotary evaporator under N2-atmosphere. The crude 
product was purified by distillation under high vacuum. 
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Phosphine 
To a mixture of TADDOL of (0.3 mmol, 1 equiv) and 4Å molecular sieves (75 mg) in THF 
(1.2 mL) at 0°C was added triethylamine (0.70 mmol, 2.34 equiv). Next, dichloroarylphosphine 
(0.33 mmol, 1.1 equiv)  was added dropwise. The reaction was allowed to warm to room 
temperature and stirred for 2 h. The reaction was diluted with Et2O, filtered through celite, and 
concentrated under reduced pressure. Column chromatography (SiO2, Pentane: Et2O) afforded 
phosphonite ligand as a white solid. 
Carbamoyl chloride’s synthesis 
The carbamoyl chloride was not submitted to heating. The carbamoyl chloride was freshly used 
and stocked in a freezer (-30 °C). The yield of the reaction didn’t show any loss of efficiency 
after sotcking in freezer for severals days. 
Amines (1 equiv) dissolved in dry benzene (0.4M) and Et3N (1.2 equiv) were slowly added to 
a stirred solution of triphosgene (0.34 equiv) in dry benzene (0.4M) at 0 °C. The mixture was 
then slowly allowed to reach room temperature and was stirred overnight. The crude was then 
quenched with HCl solution (1M) and extracted twice with DCM. The combined organic layers 
were dried over sodium sulfate, filtered and evaporated under vacuum. The excess of benzene 
was removed by coevaporation with CHCl3.  The desired carbamoyl chloride was used without 
further purification. 
Palladium-catalyzed C(sp3)-H activation 
Conditions A: Double-chamber system: 
General scale synthesis:  
Chamber A: CO generator: 
Chamber A, equipped with a stirring bar, was filled in a glovebox with Pd(OAc)2 (8.9 mg, 0.04 
mmol, 30 mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), and COgen (97 mg, 0.4 mmol, 
3.0 equiv).  
Chamber B: Substrate chamber: 
Chamber B, previously charged with substrate (0.133 mmol, 1 equiv) and stirring bar, was 
added PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 
mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 
3.0 equiv).   
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Both chambers were sealed with screwcap, and removed from the glovebox. Mesitylene (2.62 
mL) was added to chamber B, followed by addition of Cy2NMe (161 mg, 0.798 mmol, 6.0 
equiv)  in 0.5 mL of mesitylene in chamber A. The COware system was heated at 120 °C in an 
oil bath and stirred for 18h. The excess of mesitylene was removed by flushing cyclohexane on 
silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt 
as eluent. 
Conditions A: Double-chamber system: 
Tenfold scale synthesis:  
Chamber A: CO generator: 
Chamber A, equipped with a stirring bar, was filled in a glovebox with Pd(OAc)2 (89 mg, 0.4 
mmol, 30 mol%), P(t-Bu)3●HBF4 (120 mg, 0.4 mmol, 30 mol%), and COgen (970 mg, 4 mmol, 
3.0 equiv).  
Chamber B: Substrate chamber: 
Chamber B, previously charged with substrate (1.33 mmol, 1 equiv) and stirring bar, was added 
PdCl2 (24 mg, 0.133 mmol, 10 mol%), cataCXium AHI (120 mg, 0.266 mmol, 20 mol%), 
pivalic acid (41 mg, 0.4 mmol, 30 mol%) and cesium carbonate (1.3 g, 4 mmol, 3.0 equiv).  
Both chambers were sealed with screwcap, and removed from the glovebox. Mesitylene (26.2 
mL) was added to chamber B, followed by addition of Cy2NMe (161 mg, 0.798 mmol, 6.0 
equiv)  in 5 mL of mesitylene in chamber A. The double chamber system was heated at 120 °C 
in an oil bath and stirred for 18h. The excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent. 
Conditions B: CO atmosphere 
Standard scale synthesis: 
In a glovebox, a 10-mL vial, charged with carbamoyl chloride substrates (0.133 mmol) and 
stirring bar, was filled with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv). The vial was sealed, removed from the glovebox and purged 
with CO balloon. Mesitylene (2.62 mL) was added and the mixture placed in a preheated block 
at 120 °C. The solution was stirred for 18h, and the excess of mesitylene was removed by   
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flushing cyclohexane on silica gel. The resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent. 
3.7. Amine’s synthesis 
N-(2,4,6-trimethoxybenzyl)ethanamine 4.13b 
 
Following general procedure A, ethylamine (70 % in MeOH, 25.5 mmol, 5 equiv), 2,4,6-
trimethoxybenzaldehyde (1 g, 5.1 mmol,1 equiv), were reacted in THF (10 mL) for 4h with 4Å 
molecular sieves (2.5 g, 6.5 mmol.). NaBH4 (580 mg, 15.3 mmol, 3 equiv) in EtOH (6 mL) was 
carefully added and the mixture was stirred overnight. The crude was purified by 
chromatography on silica gel using DCM/MeOH as eluent to provide N-(2,4,6-
trimethoxybenzyl)ethanamine 4.13b as a yellowish oil (1.1 g, 4.90 mmol, 96 %). 
1H NMR (400 MHz, CDCl3) : δ =  6.11 (s, 2H), 3.79 (s, 3H), 3.78 (s, 6H), 3.76 (s, 2H), 2.59 
(q, J = 7.2 Hz, 2H), 1.65 (br. s, 1H), 1.08 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3, 101 MHz) :  δ 
= 160.3, 159.4, 109.5, 90.4, 55.7, 55.4, 43.2, 41.2, 15.5. IR (neat): ν = 2953, 1581, 1473 cm-1. 
HRMS (ESI): Calculated for C12H20NO3 ([M+H]+): 226.1438; found: 226.1440 
 
N-(2,4,6-trimethoxybenzyl)propan-2-amine 4.13a 
 
N-(2,4,6-trimethoxybenzyl)propan-2-amine was obtained according to a known procedure187. 
2-methyl-N-(2,4,6-trimethoxybenzyl)propan-2-amine 4.13c 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), 
tertbutylamine (0.541 mL, 5.1 mmol, 1 equiv), AcOH (0.583 mL, 10.2 mmol, 2 equiv) and. 
NaBH(OAc)3 (2.16 g, 10.2 mmol, 2 equiv) were reacted in DCE (25 mL) overnight.  
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The crude mixture was purified by chromatography on silica gel using DCM/MeOH as eluent, 
yielding 2-methyl-N-(2,4,6-trimethoxybenzyl)propan-2-amine 4.13c (1.25 g, 5.0 mmol, 97 %). 
1H NMR (400 MHz, CDCl3): δ = 6.10 (s, 2H), 3.79 (s, 6H), 3.78 (s, 3H), 3.70 (s, 2H), 1.43 
(br.ns, 1H), 1.16 (s, 9H). 13C NMR (CDCl3, 101 MHz) : δ = 160.2, 159.2, 110.3, 90.7, 55.7, 
55.4, 50.6, 35.1, 29.2. IR (neat): ν = 2960, 1598, 1463, 1205 cm-1. HRMS (ESI): Calculated 
for C14H24NO3 ([M+H]+): 254.1751; found: 254.1753 
2-phenyl-N-(2,4,6-trimethoxybenzyl)propan-2-amine 4.13d 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (700 mg, 3.57 mmol, 1 equiv), 
cumylamine (483 mg, 3.57 mmol, 1 equiv), AcOH (0.408 mL, 7.14 mmol, 2 equiv) and. 
NaBH(OAc)3 (1.51 g, 7.14 mmol, 2 equiv) were reacted in DCE (15 mL) overnight. The crude 
was purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 2-phenyl-
N-(2,4,6-trimethoxybenzyl)propan-2-amine 4.13d (1.02 g, 3.2 mmol, 90 %). 
1H NMR (400 MHz, CDCl3) δ = 7.57 – 7.47 (m, 2H), 7.33 (dd, J = 8.5, 7.0 Hz, 2H), 7.24 – 
7.17 (m, 1H), 6.07 (s, 2H), 3.75 (s, 3H), 3.75 (s, 6H), 3.45 (s, 2H), 1.52 (s, 6H). 13C NMR (101 
MHz, CDCl3) δ = 160.2, 159.1, 148.0, 127.8, 126.1, 125.9, 109.8, 90.6, 55.9, 55.6, 55.3, 35.5, 
29.8. IR (neat): ν = 2961, 1596, 1460, 1127 cm-1. HRMS (ESI): Calculated for C19H26NO3 
([M+H]+): 316.1913; found: 316.1917 
 
(R)-3,3-dimethyl-N-(2,4,6-trimethoxybenzyl)butan-2-amine 4.13e 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), (R)-
3,3-dimethylbutan-2-amine (0.7 mL, 5.1 mmol, 1 equiv), AcOH (0.583 mL, 10.2 mmol, 2 
equiv) and. NaBH(OAc)3 (2.16 g, 10.2 mmol, 2 equiv) were reacted in DCE (25 mL) overnight. 
The crude mixture was purified by chromatography on silica gel using DCM/MeOH as eluent, 
yielding (R)-3,3-dimethyl-N-(2,4,6-trimethoxybenzyl)butan-2-amine 4.13e (1.4 g, 5.0 mmol, 
98 %).  
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1H NMR (400 MHz, CDCl3) : δ = 6.11 (s, 2H), 3.88 – 3.71 (m, 11H), 2.09 (q, J = 6.4 Hz, 1H), 
1.83 (br. s, 1H), 0.97 (d, J = 6.3 Hz, 3H), 0.81 (s, 9H). 13C NMR (CDCl3, 101 MHz) : δ = 
160.1, 159.6, 109.6, 90.5, 60.4, 55.7, 55.4, 40.1, 34.1, 26.6, 14.8. IR (neat): ν = 2954, 1607, 
1140, 1204 cm-1. HRMS (ESI): Calculated for C16H28NO3 ([M+H]+): 282.2064; found: 
282.2062 
 
(S)-N-(2,4,6-trimethoxybenzyl)octan-2-amine 4.13f  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1.38  g, 7.03 mmol, 1 equiv), 
(S)-octan-2-amine (1 g, 7.03 mmol, 1 equiv), AcOH (0.804 mL, 14.06 mmol, 2 equiv) and. 
NaBH(OAc)3 (2.98 g, 14.06 mmol, 2 equiv) were reacted in DCE (14 mL) overnight. The crude 
mixture was purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 
(S)-N-(2,4,6-trimethoxybenzyl)octan-2-amine 4.13f  (1.8 g, 5.8 mmol, 83 %). 
1H NMR (400 MHz, CDCl3) : δ =  6.08 (s, 2H), 3.84 – 3.72 (m, 11H), 2.71 – 2.62 (m, 1H), 
2.55 – 2.46 (m, 1H), 1.52 – 1.38 (m, 1H), 1.32 – 1.17 (m, 10H), 1.04 (d, J = 6.3 Hz, 3H), 0.84 
(t, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 101 MHz) : δ = 160.3, 159.4, 108.8, 90.4, 55.6, 55.3, 
51.7, 38.7, 36.8, 32.0, 29.5, 26.0, 22.7, 20.2, 14.2. IR (neat): ν = 2933, 2820, 1623, 1156 cm-
1. HRMS (ESI): Calculated for C18H32NO3 ([M+H]+): 310.2382; found: 310.2387 
(R)-1-cyclohexyl-N-(2,4,6-trimethoxybenzyl)ethan-1-amine 4.13g 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1.38 g, 7.03 mmol, 1 equiv), 
R-(-)-Cyclohexylethylamine (0.95 mL, 7.03 mmol, 1 equiv), AcOH (0.804 mL, 14.06 mmol, 2 
equiv) and. NaBH(OAc)3 (2.98 g, 14.06 mmol, 2 equiv) were reacted in DCE (14 mL) 
overnight. The crude mixture was purified by chromatography on silica gel using DCM/MeOH 
as eluent, yielding (R)-1-cyclohexyl-N-(2,4,6-trimethoxybenzyl)ethan-1-amine 4.13g (1.95 g, 
6.33 mmol, 90 %).  
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1H NMR (400 MHz, CDCl3) : δ = 6.11 (s, 2H), 3.83 – 3.72 (m, 11H), 2.37 – 2.29 (m, 1H), 
1.76 – 1.61 (m, 5H), 1.40 – 1.29 (m, 1H), 1.27 – 1.07 (m, 3H), 1.00 (d, J = 6.4 Hz, 3H), 0.97 – 
0.84 (m, 2H). 13C NMR (CDCl3, 101 MHz) : δ = 160.3, 159.5, 90.5, 56.5, 55.8, 55.4, 42.7, 
39.1, 29.9, 28.3, 26.9, 26.8, 26.7, 16.7. IR (neat): ν = 2923, 2850, 1603, 1149 cm-1. HRMS 
(ESI): Calculated for C18H30NO3 ([M+H]+): 308.2220; found: 308.2222 
 
(R)-2-((2,4,6-trimethoxybenzyl)amino)propan-1-ol  
 
Following general procedure C, 2,4,6-trimethoxybenzaldehyde (1.5 g, 7.63 mmol, 1 equiv), L-
alanilol (573 mg, 7.63 mmol, 1 equiv) and Pd/C (812 mg, 10% w/w, 10 mol%) were reacted in 
MeOH (11 mL) and stirred overnight under H2 atmosphere. The crude mixture was purified by 
chromatography on silica gel to provide (R)-2-((2,4,6-trimethoxybenzyl)amino)propan-1-ol 
(686 mg, 2.67 mmol, 35 %). 
1H NMR (400 MHz, CDCl3) δ = 6.10 (s, 2H), 3.81 (d, J = 12.5 Hz, 1H + NH), 3.78 – 3.77  (m, 
9H), 3.73 (d, J = 12.6 Hz, 1H), 3.59 (dd, J = 10.7, 4.0 Hz, 1H), 3.24 (dd, J = 10.7, 6.3 Hz, 1H), 
2.70 (td, J = 6.4, 4.0 Hz, 1H + OH), 1.02 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
= 160.4, 159.4, 108.9, 90.5, 65.1, 55.7, 55.4, 53.0, 38.5, 17.4. IR (neat): ν = 3132, 2925, 2840, 
1608, 1139 cm-1. HRMS (ESI): Calculated for C13H22NO4 ([M+H]+): 256.1543; found: 
256.1544 
 
(R)-2-((2,4,6-trimethoxybenzyl)amino)propyl pivalate 4.13h  
 
(R)-2-((2,4,6-trimethoxybenzyl)amino)propan-1-ol (300 mg, 1.18 mmol, 1 equiv) was 
dissolved in dichloromethane (6 mL) and cooled to 0 °C. Triethylamine (0.201 mL, 1.43 mmol, 
1.2 equiv) and DMAP (7.2 mg, 0.06 mmol, 5 mol%) were added, followed by drop-wise 
addition of pivaloyl chloride (0.163 mL, 1.3 mmol, 1.1 equiv). The reaction mixture was 
allowed to warm slowly to ambient temperature and stirred for 16 h. The reaction mixture was 
quenched with water (10 mL) and extracted with dichloromethane (2 x 10 mL).   
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The combined organic layers were dried over sodium sulfate, filtered and evaporated under 
vacuum. The residue was purified by chromatography on silica gel using DCM/MeOH as eluent 
to afford (R)-2-((2,4,6-trimethoxybenzyl)amino)propyl pivalate 4.13h as yellowish oil (200 mg, 
0.58 mmol, 50 %). 
1H NMR (400 MHz, CDCl3) δ = 6.11 (s, 2H), 4.05 – 4.00 (m, 1H), 3.92 – 3.86 (m, 1H), 3.82 
(d, J = 5.5 Hz, 2H), 3.80 (s, 3H), 3.78 (s, 6H), 3.33 (br. s, 1H), 2.90 – 2.80 (m, 1H), 1.17 (s, 
9H), 1.09 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 178.2, 160.4, 159.3, 108.6, 
90.3, 68.3, 55.6, 55.3, 50.5, 38.8, 38.5, 27.1, 16.9. IR (neat): ν = 2957, 1729, 1608, 1150 cm-
1. HRMS (ESI): Calculated for C18H30NO5 ([M+H]+): 340.2118; found: 340.2119 
(S)-1-phenyl-N-(2,4,6-trimethoxybenzyl)ethan-1-amine 4.13i  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1.38  g, 7.03 mmol, 1 equiv), 
(S)-1-phenylethan-1-amine (900 mg, 7.03 mmol, 1 equiv), AcOH (0.804 mL, 14.06 mmol, 2 
equiv) and. NaBH(OAc)3 (2.98 g, 14.06 mmol, 2 equiv) were reacted in DCE (14 mL) 
overnight. The crude mixture was purified by chromatography on silica gel using DCM/MeOH 
as eluent, yielding (S)-1-phenyl-N-(2,4,6-trimethoxybenzyl)ethan-1-amine 4.13i (1.75 g, 5.8 
mmol, 82 %). 
1H NMR (400 MHz, CDCl3) : δ =  7.40 – 7.27 (m, 4H), 7.27 – 7.17 (m, 1H), 6.10 (s, 2H), 3.79 
(s, 3H), 3.75 (s, 6H), 3.66 (s, 2H), 2.15 (s, 1H), 1.33 (d, J = 6.6 Hz, 3H). 13C NMR (CDCl3, 
101 MHz) : δ =  160.4, 159.5, 146.3, 128.2, 127.0, 126.7, 109.3, 90.5, 57.3, 55.6, 55.4, 39.5, 
24.5. IR (neat): ν = 2923, 2857, 1613 cm-1. HRMS (ESI): Calculated for C18H24NO3 
([M+H]+): 302.1756; found: 302.1758 
N-(cyclopentylmethyl)propan-2-amine 4.13k  
 
Following general procedure C, cyclopentanecarboxaldehyde (1 g, 10.2 mmol, 1 equiv), 
isopropylamine (0.874 mL, 10.2 mmol, 1 equiv) and Pd/C (1.09 g, 10% w/w, 10 mol%) were 
reacted in MeOH (25 mL) and stirred overnight under H2 atmosphere. The crude was then   
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filtered through celite, and the solvent evaporated to provide N-(cyclopentylmethyl)propan-2-
amine 4.13k as a yellowish oil (1.30 g, 9.18 mmol, 90 %). 
1H NMR (400 MHz, CDCl3) : δ = 2.78 (hept, J = 6.2 Hz, 1H), 2.52 (d, J = 7.1 Hz, 2H), 2.08 – 
1.89 (m, 1H), 1.85 – 1.68 (m, 3H), 1.65 – 1.48 (m, 4H), 1.22 – 1.09 (m, 2H), 1.06 (d, J = 6.2 
Hz, 6H). 13C NMR (CDCl3, 101 MHz): δ = 53.3, 48.9, 40.1, 30.9, 25.2, 22.8. IR (neat): ν = 
2953, 2867, 1452, 730 cm-1. HRMS (ESI): Calculated for C9H20N ([M+H]+): 142.1590; found: 
142.1592 
N-(2,4,6-trimethylbenzyl)propan-2-amine 4.13l  
 
Following general procedure B, mesitaldehyde (500 mg, 3.37 mmol, 1 equiv), isopropylamine 
(0.577 mL, 6.74 mmol, 2 equiv), AcOH (0.385 mL, 6.74 mmol, 2 equiv) and. NaBH(OAc)3 
(1.58 g, 6.74 mmol, 2 equiv) were reacted in DCE (10 mL) overnight. The crude was purified 
by chromatography on silica gel using DCM/MeOH as eluent, yielding N-(2,4,6-
trimethylbenzyl)propan-2-amine 4.13l (505 mg, 2.64 mmol, 78 %). 
1H NMR (400 MHz, CDCl3): δ = 6.85 (s, 2H), 4.48 (d, J = 14.7 Hz, 1H), 4.34 (d, J = 14.7 Hz, 
1H), 3.47 – 3.40 (m, 1H), 3.01 (dd, J = 14.4, 5.0 Hz, 1H), 2.48 – 2.42 (m, 1H), 2.33 (s, 6H), 
2.26 (s, 3H), 1.06 (d, J = 6.1 Hz, 3H). 13C NMR (CDCl3, 101 MHz):  δ = 166.8, 137.6, 137.4, 
129.4, 128.5, 47.6, 44.1, 38.9, 21.0, 20.1, 19.4. IR (neat): ν = 2965, 2361 cm-1. HRMS (ESI): 
Calculated for C13H22N ([M+H]+): 192.1747; found: 192.1749 
N-benzylpropan-2-amine 4.13n 
 
Following general procedure A, isopropylamine (3.62 mL, 42.3 mmol, 3 equiv), benzaldehyde 
(1.5 g, 14.1 mmol, 1 equiv), were reacted in THF (10 mL) for 4h with 4Å molecular sieves (5 
g, 14 mmol). NaBH4 (1.6 g, 42.3 mmol, 3 equiv) in EtOH (10 mL) was carefully added and the 
mixture was stirred overnight. The crude was purified by chromatography on silica gel using 
DCM/MeOH as eluent to provide N-benzylpropan-2-amine 4.13n as a yellowish oil (400 mg, 
2.68 mmol, 19 %).  
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1H NMR (400 MHz, CDCl3): δ = 7.36 – 7.20 (m, 5H), 3.78 (s, 2H), 2.86 (hept, 1H), 1.46 (br. 
s, 1H), 1.10 (d, J = 6.3 Hz, 6H). 13C NMR (CDCl3, 101 MHz):  δ = 140.9, 128.5, 128.2, 127.0, 
51.8, 48.2, 23.0 IR (neat): ν = 2964, 2362, 1453, 1171 cm-1. HRMS (ESI): Calculated for 
C10H16N ([M+H]+): 150.1283; found: 150.1284 
N-phenethylpropan-2-amine 4.13o 
 
Following general procedure C, acetone (1.17 mL, 15.9 mmol, 1 equiv), 2-phenylethan-1-
amine (2 mL, 15.9 mmol, 1 equiv) and Pd/C (1.69 g, 10% w/w, 10 mol%) were reacted in 
MeOH (15 mL) and stirred overnight under H2 atmosphere. The crude was then filtered through 
celite, and the solvent evaporated to provide N-phenethylpropan-2-amine 4.13o (2.4 g, 14.6 
mmol, 92 %). 
1H NMR (400 MHz, CDCl3): δ = 7.36 – 7.11 (m, 5H), 2.93 – 2.68 (m, 5H), 1.10 (br. s, 1H), 
1.03 (d, J = 6.3 Hz, 6H). 13C NMR (CDCl3, 101 MHz):  δ = 140.0, 128.6, 128.4, 126.0, 48.7, 
48.5, 36.5, 22.9. IR (neat): ν = 2962, 2825, 1473, 1173, 697 cm-1. HRMS (ESI): Calculated 
for C11H18N ([M+H]+): 164.1434; found: 164.1437 
N-isopropyl-3-phenylpropan-1-amine 4.13p  
 
Following general procedure B, 3-phenylpropionaldehyde (2 g, 14.9 mmol, 1 equiv), 
isopropylamine (3.83 mL, 44.7 mmol, 3 equiv), AcOH (1.7 mL, 29.8 mmol, 2 equiv) and. 
NaBH(OAc)3 (6.32 g, 29.8 mmol, 2 equiv) were reacted in DCE (75 mL) overnight. The crude 
mixture was purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 
N-isopropyl-3-phenylpropan-1-amine 4.13p (2 g, 11.3 mmol, 76 %). 
1H NMR (400 MHz, CDCl3): δ = 7.34 – 7.26 (m, 2H), 7.21 (d, J = 7.3 Hz, 3H), 2.80 (hept, J 
= 6.3 Hz, 1H), 2.72 – 2.62 (m, 4H), 1.90 – 1.79 (m, 2H), 1.20 (br. s, 1H), 1.07 (d, J = 6.3 Hz, 
6H). 13C NMR (CDCl3, 101 MHz):  δ = 142.3, 128.5, 128.4, 125.9, 48.8, 47.3, 34.0, 32.2, 23.1. 
IR (neat): ν = 2964, 2861, 1473, 699 cm-1. HRMS (ESI): Calculated for C12H20N ([M+H]+): 
178.1590; found: 178.1592 
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Ethyl 3-(isopropylamino)propanoate 4.13q 
 
To a solution of isopropylamine (20 mmol, 1.18 g, 2.0 equiv) in ethanol (13 mL) at 0°C was 
added, via addition funnel, a solution of ethyl acrylate (10 mmol, 1 g, 1.0 equiv) in ethanol (7 
mL). The reaction mixture was allowed to warm to ambient temperature then stirred at ambient 
temperature for 24 h, concentrated under vacuum. The excess of amine was removed under 
high vacuum to provide Ethyl 3-(isopropylamino)propanoate 4.13q (1.59 g, 10 mmol, 100 %).  
1H NMR (400 MHz, CDCl3) : δ = 4.14 (q, J = 7.1 Hz, 2H), 2.92 – 2.72 (m, 3H), 2.49 (t, J = 
6.6 Hz, 2H), 1.33 – 1.21 (m, 4H), 1.05 (d, J = 6.2 Hz, 6H). 13C NMR (CDCl3, 101 MHz):  δ = 
172.8, 60.3, 48.4, 42.5, 35.0, 22.9, 14.2. IR (neat): ν = 1732 1191 cm-1. HRMS (ESI): 
Calculated for C8H18NO2 ([M+H]+): 160.1332; found: 160.1331 
2-(3-(isopropylamino)propyl)isoindoline-1,3-dione 4.13r  
 
 
3-Phthalimidopropionaldehyde was prepared following an analogous procedure described by 
T. Livinghouse. Acroleine (561 mg, 10 mmol, 1 equiv) and phtalimid (1.47 g, 10 mmol, 1 
equiv) were suspended in AcOEt (6.5 mL) and stirred at 65 °C for 10 minutes. Then, Triton B 
(40 % solution of benzyltrimethylammonium hydroxide in MeOH, 90 µL, 0.2 mmol, 2 mol%) 
was added to the solution, which was further stirred for 20 minutes. The mixture was then 
cooled to room temperature, the solvent removed under vacuum and the resulting yellowish 
solid triturated with Et2O. The resulting solid was then filtered to provide 3-
Phthalimidopropionaldehyde (2.02 g, 10 mmol, 100 %). Then, following general procedure C, 
3-Phthalimidopropionaldehyde (2.02 g, 10 mmol, 1 equiv), isopropylamine (0.852 mL, 10 
mmol, 1 equiv) and Pd/C (1.06 g, 10% w/w, 10 mol%) were reacted in MeOH (25 mL) and 
stirred overnight under H2 atmosphere. The crude was then filtered through celite, and the 
solvent evaporated to provide 2-(3-(isopropylamino)propyl)isoindoline-1,3-dione 4.13r as a 
yellowish oil (1.84 g, 7.5 mmol, 75 %). Prepared according to the described literature 188. 
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1H NMR (400 MHz, CDCl3) : δ = 7.88 – 7.81 (m, 2H), 7.76 – 7.66 (m, 2H), 3.76 (t, J = 6.8 
Hz, 2H), 2.75 (hept, J = 6.2 Hz, 1H), 2.62 (t, J = 7.0 Hz, 2H), 1.94 – 1.79 (m, 3H), 1.03 (d, J = 
6.2 Hz, 6H). 13C NMR (CDCl3, 101 MHz) : δ = 168.5, 133.9, 132.2, 123.2, 48.7, 44.3, 36.0, 
29.2, 22.9. IR (neat): ν = 1773, 1705, 1468, 1442 cm-1. HRMS (ESI): Calculated for 
C14H19N2O2 ([M+H]+): 247.1441; found: 247.1442 
2-methyl-N-(3-phenylpropyl)butan-2-amine 4.13s  
 
Following general procedure B, 3-phenylpropionaldehyde (1 g, 7.45 mmol, 1 equiv), tert-
amylamine (2.61 mL, 22.4 mmol, 3 equiv), AcOH (0.852 mL, 14.9 mmol, 2 equiv) and. 
NaBH(OAc)3 (3.16 g, 14.9 mmol, 2 equiv) were reacted in DCE (37 mL) overnight. The crude 
mixture was purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 2-
methyl-N-(3-phenylpropyl)butan-2-amine 4.13s (1.35 g, 6.57 mmol, 88 %). 
1H NMR (400 MHz, CDCl3): δ = 7.34 – 7.13 (m, 5H), 3.73 (s, 1H), 2.72 – 2.62 (m, 2H), 2.60 
– 2.47 (m, 2H), 1.86 – 1.69 (m, 2H), 1.47 – 1.32 (m, 2H), 1.01 (s, 6H), 0.82 (t, J = 7.5 Hz, 3H). 
13C NMR (CDCl3, 101 MHz) : δ =  142.2, 128.3, 128.2, 125.6, 52.3, 41.5, 33.8, 33.0, 32.6, 
26.5, 8.2. IR (neat): ν = 3028, 2935, 1475, 1442 cm-1. HRMS (ESI): Calculated for C14H24N 
([M+H]+): 206.1903; found: 206.1902 
3-phenyl-N-(2-phenylpropan-2-yl)propan-1-amine 4.13t  
 
Following general procedure B, phenylpropionaldehyde (500 mg, 3.73 mmol, 1 equiv), 
cumylamine (504 mg, 3.73 mmol, 1 equiv), AcOH (0.427 mL, 7.46 mmol, 2 equiv) and. 
NaBH(OAc)3 (1.58 g, 7.1 mmol, 2 equiv) were reacted in DCE (19 mL) overnight. The crude 
mixture was purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 3-
phenyl-N-(2-phenylpropan-2-yl)propan-1-amine 4.13t (832 mg, 3.28 mmol, 88 %). 
1H NMR (400 MHz, CDCl3) : δ =  7.46 – 7.41 (m, 2H), 7.36 – 7.30 (m, 2H), 7.27 – 7.19 (m, 
3H), 7.18 – 7.10 (m, 3H), 2.62 – 2.55 (m, 2H), 2.38 (t, J = 7.1 Hz, 2H), 1.82 – 1.70 (m, 2H), 
1.47 (s, 6H).   
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13C NMR (CDCl3, 101 MHz) : δ = 142.3, 128.5, 128.4, 128.3, 126.4, 125.9, 125.8, 56.2, 42.8, 
33.8, 32.5, 29.6. IR (neat): ν = 3026, 2928, 1495, 1452, 699 cm-1. HRMS (ESI) : Calculated 
for C18H24N ([M+H]+): 254.1903; found: 254.1908 
N-(tert-butyl)-3,7-dimethyloct-6-en-1-amine 4.13u 
 
Following general procedure B, (±)-citronellal (1.66 g, 10 mmol, 1 equiv), tert-butylamine 
(1.06 mL, 10 mmol, 1 equiv), AcOH (1.14 mL, 20 mmol, 2 equiv) and. NaBH(OAc)3 (4.23 g, 
20 mmol, 2 equiv) were reacted in DCE (25 mL) overnight. The crude was purified by 
chromatography on silica gel using DCM/MeOH as eluent, yielding N-(tert-butyl)-3,7-
dimethyloct-6-en-1-amine 4.13u (1.77 g, 8.4 mmol, 84 %). 
1H NMR (400 MHz, CDCl3) : δ = 5.08 – 4.99 (m, 1H), 2.59 – 2.38 (m, 2H), 1.99 – 1.85 (m, 
2H), 1.62 (d, J = 1.3 Hz, 3H), 1.53 (s, 3H), 1.48 – 1.07 (m, 6H), 1.04 (s, 9H), 0.83 (d, J = 6.3 
Hz, 3H). 13C NMR (CDCl3, 101 MHz) : δ = 131.1, 124.9, 50.3, 40.4, 38.3, 37.3, 30.8, 29.1, 
25.8, 25.5, 19.7, 17.7. IR (neat): ν = 2964, 2917, 2362, 1449, 731 cm-1. HRMS (ESI): 
Calculated for C14H30N ([M+H]+): 212.2378; found: 212.2379 
N-(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-3-yl)methyl)-2-methylpropan-2-amine 
4.13v  
 
Following general procedure B, (-)-Myrtenal (800 mg, 5.33 mmol, 1 equiv), tert-butylamine 
(0.565 mL, 5.33 mmol, 1 equiv), AcOH (0.610 mL, 10.7 mmol, 2 equiv) and. NaBH(OAc)3 
(2.26 g, 10.7 mmol, 2 equiv) were reacted in DCE (25 mL) overnight. The crude was purified 
by chromatography on silica gel using DCM/MeOH as eluent, yielding N-(((1S,5R)-6,6-
dimethylbicyclo[3.1.1]hept-2-en-3-yl)methyl)-2-methylpropan-2-amine 4.13v (970 mg, 4.69 
mmol, 88 %). 
1H NMR (400 MHz, CDCl3): δ = 5.41 – 5.35 (m, 1H), 3.12 – 3.02 (m, 2H), 2.36 (dt, J = 8.5, 
5.6 Hz, 1H), 2.30 – 2.15 (m, 2H), 2.06 (dd, J = 5.7, 1.6 Hz, 2H), 1.26 (s, 3H), 1.18 (d, J = 8.6 
Hz, 1H), 1.12 (s, 9H), 0.81 (s, 3H).  
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13C NMR (CDCl3, 101 MHz): δ = 146.6, 117.1, 50.9, 47.9, 45.1, 41.0, 38.2, 31.7, 31.3, 28.9, 
26.4, 21.2. IR (neat): ν = 2960, 2913, 1483, 733 cm-1. HRMS (ESI): Calculated for C14H26N 
([M+H]+): 208.2060; found: 208.2061 
(S)-2-methyl-N-((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)propan-2-amine 4.13w 
 
Following general procedure B, (-)-perillaldehyde (1.5 g, 10 mmol, 1 equiv), tert-butylamine 
(1.06 mL, 10 mmol, 1 equiv), AcOH (1.15 mL, 20 mmol, 2 equiv) and. NaBH(OAc)3 (4.23 g, 
20 mmol, 2 equiv) were reacted in DCE (25 mL) overnight. The crude was purified by 
chromatography on silica gel using DCM/MeOH as eluent, yielding (S)-2-methyl-N-((4-(prop-
1-en-2-yl)cyclohex-1-en-1-yl)methyl)propan-2-amine 4.13w (1.84 g, 8.9 mmol, 89 %). 
1H NMR (400 MHz, CDCl3): δ = 5.64 – 5.57 (m, 1H), 4.73 – 4.64 (m, 2H), 3.13 – 3.00 (m, 
2H), 2.19 – 2.04 (m, 4H), 2.00 – 1.89 (m, 1H), 1.87 – 1.76 (m, 1H), 1.75 – 1.70 (m, 3H), 1.59 
– 1.35 (m, 2H), 1.11 (s, 9H). 13C NMR (CDCl3, 101 MHz) : δ = 150.2, 136.7, 121.5, 108.6, 
50.6, 48.8, 41.4, 30.8, 29.1, 28.1, 20.9. IR (neat): ν = 2960, 2922, 1463, 790 cm-1. HRMS 
(ESI): Calculated for C14H26NO ([M+H]+): 208.2060; found: 208.2062 
 
1-cyclopropyl-N-(2,4,6-trimethoxybenzyl)methanamine 4.13y 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), 
cyclopropylmethanamine (0.445 mL, 5.1 mmol, 1 equiv), AcOH (0.583 mL, 10.2 mmol, 2 
equiv) and. NaBH(OAc)3 (2.16 g, 10.2 mmol, 2 equiv) were reacted in DCE (25 mL) overnight. 
The crude was purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 
1-cyclopropyl-N-(2,4,6-trimethoxybenzyl)methanamine 4.13y (1.25 g, 5.0 mmol, 98 %). 
1H NMR (400 MHz, CDCl3): δ = 6.10 (s, 2H), 3.81 – 3.75 (m, 11H), 2.44 (br. s, 1H), 2.41 (d, 
J = 7.0 Hz, 2H), 1.03 – 0.92 (m, 1H), 0.47 – 0.39 (m, 2H), 0.10 – 0.02 (m, 2H). 13C NMR 
(CDCl3, 101 MHz) : δ = 160.4, 159.4, 109.0, 90.5, 55.7, 55.4, 54.1, 41.3, 11.4, 3.5. 
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IR (neat): ν = 3000, 2362, 1604, 1459, 1130 cm-1. HRMS (ESI): Calculated for C14H22NO3 
([M+H]+): 252.1594; found: 252.1597 
1,1-dicyclopropyl-N-(2,4,6-trimethoxybenzyl)methanamine 4.13z 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (697 mg, 3.55 mmol, 1 equiv), 
dicyclopropylmethanamine (395 mg, 3.55 mmol, 1 equiv), AcOH (0.406 mL, 7.1 mmol, 2 
equiv) and NaBH(OAc)3 (1.5 g, 7.1 mmol, 2 equiv) were reacted in DCE (18 mL) overnight. 
The crude was purified by chromatography on silica gel using DCM/MeOH as eluent, yielding 
1,1-dicyclopropyl-N-(2,4,6-trimethoxybenzyl)methanamine 4.13z (847 mg, 2.91 mmol, 82 %). 
1H NMR (400 MHz, CDCl3) : δ =  6.08 (s, 2H), 3.86 (s, 2H), 3.81 – 3.75 (m, 9H), 1.04 (t, J = 
8.6 Hz, 1H), 0.96 – 0.85 (m, 2H), 0.48 – 0.37 (m, 4H), 0.20 – 0.07 (m, 4H). 13C NMR (CDCl3, 
101 MHz) : δ = 160.3, 159.3, 109.0, 90.4, 67.0, 55.6, 55.4, 40.2, 16.2, 2.8, 2.2 . IR (neat): ν = 
3001, 2939, 1604, 1459, 1149 cm-1. HRMS (ESI): Calculated for C17H26NO3 ([M+H]+): 
292.1907; found: 292.1911 
N-isopropyl-2,3-dihydro-1H-inden-2-amine 4.13aa  
 
Following general procedure C, acetone (0.276 mL, 3.75 mmol, 1 equiv), 2,3-dihydro-1H-
inden-2-amine (500 mg, 3.75 mmol, 1 equiv) and Pd/C (400 mg, 10% w/w, 10 mol%) were 
reacted in MeOH (7 mL) and stirred overnight under H2 atmosphere. The crude was then filtered 
through celite, and the solvent evaporated to provide N-isopropyl-2,3-dihydro-1H-inden-2-
amine 4.13aa (526 mg, 3 mmol, 80 %). 
1H NMR (400 MHz, CDCl3): δ = 7.22 – 7.17 (m, 2H), 7.17 – 7.11 (m, 3H), 3.74 (p, J = 7.1 
Hz, 1H), 3.18 (dd, J = 15.4, 7.1 Hz, 2H), 2.98 (hept, J = 6.2 Hz, 1H), 2.72 (dd, J = 15.4, 7.1 Hz, 
2H), 1.27 (br. s, 1H), 1.10 (d, J = 6.3 Hz, 6H). 13C NMR (CDCl3, 101 MHz) : δ = 141.9, 126.5, 
124.8, 57.1, 46.6, 40.5, 23.3. IR (neat): ν = 2962, 1475, 1175, 741cm-1. HRMS (ESI): 
Calculated for C12H18N ([M+H]+): 176.1434; found: 176.1437 
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N-(2,4,6-trimethoxybenzyl)-2,3-dihydro-1H-inden-2-amine 4.13ab  
 
Following general procedure C, 2,4,6-trimethoxybenzaldehyde (447 mg, 2.28 mmol, 1 equiv), 
2,3-dihydro-1H-inden-2-amine (304 mg, 2.28 mmol, 1 equiv) and Pd/C (243 mg, 10% w/w, 10 
mol%) were reacted in MeOH (10 mL) and stirred overnight under H2 atmosphere. The crude 
was purified by chromatography on silica gel to provide N-(2,4,6-trimethoxybenzyl)-2,3-
dihydro-1H-inden-2-amine 4.13ab (215 mg, 0.684 mmol, 30 %). 
1H NMR (400 MHz, CDCl3): δ = 7.21 – 7.07 (m, 4H), 6.12 (s, 2H), 3.84 (s, 2H), 3.81 (s, 9H), 
3.60 (p, J = 6.9 Hz, 1H), 3.15 (dd, J = 15.6, 7.1 Hz, 2H), 2.79 (dd, J = 15.6, 6.8 Hz, 2H), 1.73 
(br. s, 1H). 13C NMR (CDCl3, 101 MHz) : δ = 160.4, 159.4, 142.4, 126.3, 124.7, 109.4, 90.5, 
58.8, 55.8, 55.5, 40.4, 39.9. IR (neat): ν = 2937, 2361, 1597, 1131cm-1. HRMS (ESI): 
Calculated for C19H24NO3 ([M+H]+): 314.1751; found: 314.1754 
N-(2,4,6-trimethoxybenzyl)-1,2,3,4-tetrahydronaphthalen-1-amine 4.13ac  
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (691 mg, 3.52 mmol, 1 equiv), 
1,2,3,4-tetrahydronaphthalen-1-amine (518 mg, 3.52 mmol, 1 equiv), AcOH (0.403 mL, 7.04 
mmol, 2 equiv) and. NaBH(OAc)3 (1.49 g, 7.04 mmol, 2 equiv) were reacted in DCE (10 mL) 
overnight. The crude was extracted twice with DCM, dried over sodium sulfate, filtered, 
evaporated under vacuum, yielding N-(2,4,6-trimethoxybenzyl)-1,2,3,4-tetrahydronaphthalen-
1-amine 4.13ac (950 mg, 2.9 mmol, 83 %). 
1H NMR (250 MHz, CDCl3) δ = 7.11 – 7.02 (m, 4H), 6.15 (s, 2H), 3.88 (d, J = 1.8 Hz, 2H), 
3.82 (s, 9H), 3.72 – 3.66 (m, 1H), 2.90 – 2.61 (m, 2H), 2.12 – 1.95 (m, 3H), 1.87 – 1.61 (m, 
2H). 13C NMR (63 MHz, CDCl3) δ = 160.4, 159.6, 140.0, 137.8, 129.0, 128.8, 126.4, 125.7, 
109.7, 90.7, 55.8, 55.5, 54.2, 39.4, 29.7, 28.0, 19.0. IR (neat): ν = 2936, 2361, 1607, 1131 cm-
1. HRMS (ESI): Calculated for C20H26NO3 ([M+H]+): 328.1907; found: 328.1912  
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(R)-N-(2,4,6-trimethoxybenzyl)-1,2,3,4-tetrahydronaphthalen-1-amine (-)-4.13ac  
 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (2.67 g, 13.6 mmol, 1 equiv), 
(R)-1,2,3,4-tetrahydronaphthalen-1-amine (2 g, 13.6 mmol, 1 equiv), AcOH (1.56 mL, 27.2 
mmol, 2 equiv) and. NaBH(OAc)3 (5.76 g, 27.2 mmol, 2 equiv) were reacted in DCE (30 mL) 
overnight. Then, the mixture was quenched using a solution of NaOH (1M) and the crude was 
stirred for further 30 minutes. The crude was extracted twice with DCM, dried over sodium 
sulfate, filtered, evaporated under vacuum, yielding -(R)-N-(2,4,6-trimethoxybenzyl)-1,2,3,4-
tetrahydronaphthalen-1-amine (-)-4.13ac (4.45 g, 13.6 mmol, 100 %). 
1H NMR (250 MHz, CDCl3) δ = 7.13 – 7.00 (m, 4H), 6.15 (s, 2H), 3.88 (d, J = 1.8 Hz, 2H), 
3.82 (s, 9H), 3.72 – 3.65 (m, 1H), 2.94 – 2.59 (m, 2H), 2.22 – 1.93 (m, 3H), 1.88 – 1.51 (m, 
2H). 13C NMR (63 MHz, CDCl3) δ = 160.4, 159.6, 140.0, 137.8, 129.0, 128.8, 126.4, 125.7, 
109.7, 90.7, 55.8, 55.5, 54.2, 39.4, 29.7, 28.0, 19.0. IR (neat): ν = 2938, 2355, 1635, 1115 cm-
1. HRMS (ESI): Calculated for C20H26NO3 ([M+H]+): 328.1907; found: 328.1912. 
N-(2,4,6-trimethoxybenzyl)pentan-3-amine 4.11af 
 
Following general procedure B, 2,4,6-trimethoxybenzaldehyde (1 g, 5.1 mmol, 1 equiv), 
Pentan-3-amine(0.88 g, 10.2 mmol, 2 equiv), AcOH (0.58 mL, 10.2 mmol, 2 equiv) and 
NaBH(OAc)3 (2.16 g, 10.2 mmol, 2 equiv) were reacted in DCE (25mL) overnight. The crude 
mixture was extracted twice with DCM, dried over sodium sulfate, filtered, evaporated under 
vacuum, yielding N-(2,4,6-trimethoxybenzyl)pentan-3-amine 4.11af as a slighly yellow oil 
(1.02 g, 3.8 mmol, 75%). 
1H NMR (250 MHz, CDCl3) δ = 6.07 (s, 2H), 3.76 (s, 3H), 3.76 (s, 6H), 3.71 (s, 2H), 2.20 (p, 
J = 6.0 Hz, 1H), 1.91 (s, 1H), 1.46 –1.26 (m, 4H), 0.81 (t, J = 7.5 Hz, 6H).  
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13C NMR (63 MHz, CDCl3) δ = 160.2, 159.4, 109.7, 90.5, 59.3, 55.7, 55.4, 38.8, 26.1, 10.2. 
IR (neat): ν = 2928, 2840, 1623, 1139 HRMS (ESI): Calculated for C20H26NO3([M+H]+): 
269.1913; found: 269.1917 
3.8. Carbamoyl’s synthesis 
Isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11a 
 
Following general procedure carbamoyl chloride, N-(2,4,6-trimethoxybenzyl)propan-2-amine 
4.13a (800 mg, 3.34 mmol 1 equiv), Et3N (0.560 mL, 4.01 mmol, 1.2 equiv) and triphosgene 
(337 mg, 1.14 mmol, 0.34 equiv) were reacted in in dry benzene (16 mL) at 0 °C . The desired 
Isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11a was obtained as a grey solid (792 
mg, 2.74 mmol, 82 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 6.11 (s, 2H), 4.72 (s, 2H), 3.83 – 3.82 (m, 9H), 3.57 (sep, J 
= 6.8 Hz, 1H), 1.11 (d, J = 6.8 Hz, 6H). 
 
Ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11b 
 
Following general procedure carbamoyl chloride, N-(2,4,6-trimethoxybenzyl)ethanamine 
4.11b (401 mg, 1.78 mmol, 1 equiv), Et3N (0.301 mL, 2.14 mmol, 1.2 equiv) and triphosgene 
(180 mg, 0.60 mmol, 0.34 equiv) were reacted in dry benzene (9 mL) at 0 °C . The desired 
Ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11b was obtained as a white solid (472 mg, 
1.64 mmol, 92 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 6.11 (s, 2H), 4.69 – 4.66 (m, 2H), 3.82 (s, 3H), 3.81 (s, 6H), 
3.31 – 3.17 (m, 2H), 1.06 – 1.01 (m, 3H). 
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Tert-butyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11c 
 
Following general procedure carbamoyl chloride, 2-methyl-N-(2,4,6-
trimethoxybenzyl)propan-2-amine 4.13 c(400 mg, 1.58 mmol, 1 equiv), Et3N (0.267 mL, 1.90 
mmol, 1.2 equiv) and triphosgene (159 mg, 0.537 mmol, 0.34 equiv) were reacted in dry 
benzene (8 mL) at 0 °C . The desired Tert-butyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 
4.11c was obtained as a yellowish oil (229 mg, 0.73 mmol, 46 %) and used without further 
purification. 
1H NMR (250 MHz, CDCl3) δ = 6.07 (s, 2H), 4.12 – 4.04 (m, 2H), 3.87 (s, 6H), 3.78 (s, 3H), 
1.33 (s, 9H). 
(2-phenylpropan-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11d 
 
Following general procedure carbamoyl chloride, 2-phenyl-N-(2,4,6-
trimethoxybenzyl)propan-2-amine  4.13d (400 mg, 1.27 mmol, 1 equiv), Et3N (0.214 mL, 1.52 
mmol, 1.2 equiv) and triphosgene (128 mg, 0.432 mmol, 0.34 equiv) were reacted in dry 
benzene (7.6mL) at 0 °C . The desired (2-phenylpropan-2-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11d was obtained as an orange oil (341 mg, 0.9 mmol, 
71 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.70 – 7.61 (m, 2H), 7.41 – 7.36 (m, 3H), 5.93 (s, 2H), 3.81 
(s, 6H), 3.70 (s, 3H), 1.83 (s, 6H). 
 
(S)-(3,3-dimethylbutan-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11e 
 
Following general procedure carbamoyl chloride, (S)-3,3-dimethyl-N-(2,4,6-
trimethoxybenzyl)butan-2-amine 4.13e (300 mg, 1.07 mmol, 1 equiv), Et3N (0.180 mL, 1.28 
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mmol, 1.2 equiv) and triphosgene (108 mg, 0.367 mmol, 0.34 equiv) were reacted in dry 
benzene (5.4 mL) at 0 °C. The desired (S)-(3,3-dimethylbutan-2-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11e was obtained as a greenish solid (304 mg, 0.89 
mmol, 84 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 6.16 – 6.10 (m, 2H), 5.04 – 4.45 (m, 2H), 3.87 – 3.78 (m, 
9H), 3.16 – 2.35 (m, 1H), 1.42 – 1.02 (m, 3H), 0.99 – 0.90 (m, 9H). 
(S)-octan-2-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11f 
 
Following general procedure for the synthesis of carbamoyl chloride, (S)-N-(2,4,6-
trimethoxybenzyl)octan-2-amine 4.13f (400 mg, 2.45 mmol, 1 equiv), Et3N (0.413 mL, 2.94 
mmol, 1.2 equiv) and triphosgene (247 mg, 0.833 mmol, 0.34 equiv) were reacted in dry 
benzene (15 mL) at 0 °C . The desired (S)-octan-2-yl(2,4,6-trimethoxybenzyl)carbamoyl 
chloride 4.11f was obtained as a yellowish solid (515 mg, 2.28 mmol, 93 %) and used without 
further purification. 
1H NMR (400 MHz, CDCl3) δ = 6.12 – 6.10 (m, 2H), 4.78 – 4.64 (m, 2H), 3.82 (s, 3H), 3.82 
(s, 6H), 3.32 (dt, J = 8.1, 6.4 Hz, 1H), 1.84 – 1.72 (m, 1H), 1.46 – 1.33 (m, 1H), 1.30 – 1.10 (m, 
8H), 1.05 (d, J = 6.7 Hz, 3H), 0.86 (t, J = 7.0 Hz, 3H). 
(R)-(1-cyclohexylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11g 
 
Following general procedure carbamoyl chloride, (R)-1-cyclohexyl-N-(2,4,6-
trimethoxybenzyl)ethan-1-amine 4.13g (600 mg, 1.95 mmol, 1 equiv), Et3N (0.329 mL, 2.34 
mmol, 1.2 equiv) and triphosgene (197 mg, 0.663 mmol, 0.34 equiv) were reacted in dry 
benzene (10 mL) at 0 °C .   
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The desired (R)-(1-cyclohexylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11g was 
obtained as a red oil (528 mg, 1.42 mmol, 73 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 6.11 (s, 2H), 4.82 (d, J = 14.2 Hz, 1H), 4.57 (d, J = 14.1 Hz, 
1H), 3.82 (s, 3H), 3.81 (s, 6H), 2.89 (dq, J = 10.2, 6.7 Hz, 1H), 1.96 – 1.85 (m, 1H), 1.78 – 1.60 
(m, 4H), 1.26 – 1.04 (m, 4H), 1.00 (d, J = 6.8 Hz, 3H), 0.75 – 0.52 (m, 2H). 
(R)-2-((chlorocarbonyl)(2,4,6-trimethoxybenzyl)amino)propyl pivalate 4.11h 
 
Following general procedure carbamoyl chloride, (R)-2-((2,4,6-
trimethoxybenzyl)amino)propyl pivalate 4.13h (188 mg, 0.553 mmol, 1 equiv), Et3N (0.093 
mL, 0.66 mmol, 1.2 equiv) and triphosgene (56 mg, 0.188 mmol, 0.34 equiv) were reacted in 
dry benzene (2.8 mL) at 0 °C . The desired (R)-2-((chlorocarbonyl)(2,4,6-
trimethoxybenzyl)amino)propyl pivalate 4.11h was obtained as a brownish solid (190 mg, 0.47 
mmol, 85 %) and used without further purification. 
1H NMR (250 MHz, CDCl3) δ = 6.11 (s, 2H), 4.90 (d, J = 14.3 Hz, 1H), 4.62 (d, J = 14.3 Hz, 
1H), 4.33 (dd, J = 11.2, 9.1 Hz, 1H), 4.07 (dd, J = 11.2, 5.3 Hz, 1H), 3.82 (s, 3H), 3.81 (s, 6H), 
3.73 – 3.59 (m, 1H), 1.21 (s, 9H), 0.99 (d, J = 6.9 Hz, 3H). 
(S)-(1-phenylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11i 
 
Following general procedure carbamoyl chloride, (S)-1-phenyl-N-(2,4,6-
trimethoxybenzyl)ethan-1-amine 4.13i (300 mg, 0.995 mmol, 1 equiv), Et3N (0.167 mL, 1.19 
mmol, 1.2 equiv) and triphosgene (100 mg, 0.338 mmol, 0.34 equiv) were reacted in dry 
benzene (7.8 mL) at 0 °C . The desired (S)-(1-phenylethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride 4.11i was obtained as a brownish solid (325 mg, 0.9 mmol, 90 %) and used without 
further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.24 – 7.16 (m, 5H), 6.09 – 5.98 (m, 2H), 4.89 – 4.80 (m, 
2H), 4.74 – 4.64 (m, 1H), 3.81 (s, 3H), 3.78 (s, 6H), 1.50 (d, J = 7.1 Hz, 3H).  
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(cyclopentylmethyl)(isopropyl)carbamoyl chloride 4.11k 
 
Following general procedure carbamoyl chloride, N-(cyclopentylmethyl)propan-2-amine 
4.13k (400 mg, 2.83 mmol, 1 equiv), Et3N (0.477 mL, 3.40 mmol, 1.2 equiv) and triphosgene 
(286 mg, 0.962 mmol, 0.34 equiv) were reacted in dry benzene (17 mL) at 0 °C . The desired 
(cyclopentylmethyl)(isopropyl)carbamoyl chloride 4.11k was obtained as a yellowish oil (507 
mg, 2.49 mmol, 88 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 4.55 – 3.77 (m, 1H), 3.40 – 3.20 (m, 2H), 2.28 – 2.15 (m, 
1H), 1.82 – 1.50 (m, 8H), 1.37 – 1.19 (m, 6H). 
 
Isopropyl(2,4, 6-trimethylbenzyl)carbamoyl chloride 4.11l 
 
Following general procedure carbamoyl chloride, N-isopropyl-3-phenylpropan-1-amine 4.13l 
(400 mg, 2.09 mmol, 1 equiv), Et3N (0.352 mL, 2.51 mmol, 1.2 equiv) and triphosgene (211 
mg, 0.711 mmol, 0.34 equiv) were reacted in dry benzene (10.4 mL) at 0 °C The desired 
Isopropyl(2,4, 6-trimethylbenzyl)carbamoyl chloride 4.11l was obtained as a brownish solid 
(418 mg, 1.65 mmol, 79 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 6.87 (s, 2H), 4.76 (s, 2H), 3.23 – 3.10 (m, 1H), 2.33 (s, 6H), 
2.28 (s, 3H), 1.20 (d, J = 6.8 Hz, 6H). 
 
Isopropyl(phenyl)carbamoyl chloride 4.11m 
 
 
Following general procedure A, aniline (130 mg, 1.4 mmol, 1 equiv), acetone (0.103 mL, 1.4 
mmol, 1 equiv) and 4Å molecular sieves (200 mg) were stirred for 4h in THF (14 mL). Then, 
a solution of NaBH4 (106 mg, 2.8 mmol, 2 equiv) in EtOH (5 mL) was carefully added to the 
mixture. The reaction was stirred at room temperature overnight, and was then filtered through   
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celite. The crude was then acidified using a solution of HCl (0.1M) and stirred for 30 minutes. 
The mixture was then basified using NaOH solution (0.1M) and extracted three times using 
AcOEt. The combined organic layers were dried over sodium sulfate, filtered and evaporated 
under vacuum.  Following general procedure carbamoyl chloride, N-isopropylaniline (189 mg, 
1.4 mmol, 1 equiv), Et3N (0.236 mL, 1.36 mmol, 1.2 equiv) and triphosgene (141 mg, 2.01 
mmol, 0.34 equiv) were reacted in dry benzene (7 mL) at 0 °C. The desired 
Isopropyl(phenyl)carbamoyl chloride 4.11m was obtained as a yellowish solid (218 mg, 1.1 
mmol, 79 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.45 – 7.39 (m, 2H), 7.18 – 7.14 (m, 2H), 4.68 (sep, J = 6.8 
Hz, 1H), 1.17 (d, J = 6.8 Hz, 6H). 
Benzyl(isopropyl)carbamoyl chloride 4.11n 
 
Following general procedure carbamoyl chloride, N-benzylpropan-2-amine 4.13n (150 mg, 
1.1 mmol, 1 equiv), Et3N (0.170 mL, 1.21 mmol, 1.2 equiv) and triphosgene (102 mg, 0.343 
mmol, 0.34 equiv)  were reacted in dry benzene (5 mL) at 0 °C. The desired 
Benzyl(isopropyl)carbamoyl chloride 4.11n was obtained as a yellowish solid (64 mg, 0.33 
mmol, 30 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.39 – 7.27 (m, 5H), 4.67 (s, 2H), 4.30 – 4.20 (m, 1H), 1.20 
(d, J = 6.8 Hz, 6H). 
Isopropyl(phenethyl)carbamoyl chloride 4.11o 
 
Following general procedure carbamoyl chloride, N-phenethylpropan-2-amine 4.13o (400 
mg, 2.45 mmol, 1 equiv), Et3N (0.413 mL, 2.94 mmol, 1.2 equiv) and triphosgene (247 mg, 
0.833 mmol, 0.34 equiv) were reacted in dry benzene (15 mL) at 0 °C. The desired 
Isopropyl(phenethyl)carbamoyl chloride 4.11o was obtained as a yellowish solid (515 mg, 2.28 
mmol, 93 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.37 – 7.18 (m, 5H), 4.61 – 4.27 (m, 1H), 3.55 – 3.37 (m, 
2H), 3.02 – 2.89 (m, 2H), 1.29 – 1.18 (m, 6H).  
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Isopropyl(3-phenylpropyl)carbamoyl chloride 4.11p 
 
Following general procedure carbamoyl chloride, N-isopropyl-3-phenylpropan-1-amine 
4.13p (302 mg, 0.916 mmol, 1 eq), Et3N (0.154 mL, 1.1 mmol, 1.2 equiv) and triphosgene (96 
mg, 0.311 mmol, 0.34 equiv) were reacted in dry benzene (4.8 mL) at 0 °C. The desired 
Isopropyl(3-phenylpropyl)carbamoylchloride 4.11p was obtained as a brownish solid (298 mg, 
0.76 mmol, 83 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.33 – 7.27 (m, 2H), 7.25 – 7.16 (m, 3H), 4.56 – 4.16 (m 1H), 
3.35 – 3.09 (m, 2H), 2.71 – 2.49 (m, 2H), 2.08 – 1.87 (m, 2H), 1.22 – 1.14 (m, 6H). 
Ethyl 3-((chlorocarbonyl)(isopropyl)amino)propanoate 4.11q 
 
Following general procedure carbamoyl chloride, ethyl 3-(isopropylamino)propanoate 4.13q 
(400 mg, 2.52 mmol, 1 equiv), Et3N (0.425 mL, 3.02 mmol, 1.2 equiv) and triphosgene (254 
mg, 0.857 mmol, 0.34 equiv) were reacted in dry benzene (15 mL) at 0 °C . The desired Ethyl 
3-((chlorocarbonyl)(isopropyl)amino)propanoate 4.11q was obtained as an orange oil (465 mg, 
2.09 mmol, 83 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 4.60 – 4.26 (m, 1H), 4.21 – 4.11 (m, 2H), 3.67 – 3.49 (m, 
2H), 2.74 – 2.62 (m, 2H), 1.32 – 1.21 (m, 9H). 
(3-(1,3-dioxoisoindolin-2-yl)propyl)(isopropyl)carbamoyl chloride 4.11r 
 
Following general procedure carbamoyl chloride, 2-(3-(isopropylamino)propyl)isoindoline-
1,3-dione 4.13r (300 mg, 1.22 mmol 1 equiv), Et3N (0.206 mL, 1.46 mmol, 1.2 equiv) and  
triphosgene (123 mg, 0.415 mmol, 0.34 equiv) were reacted in dry benzene (6.2 mL) at 0 °C . 
The desired (3-(1,3-dioxoisoindolin-2-yl)propyl)(isopropyl)carbamoyl chloride 4.11r was 
obtained as a yellowish solid (302 mg, 1.0 mmol, 82 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 8.08 – 7.67 (m, 4H), 4.57 – 4.17 (m, 1H), 3.77 – 3.69 (m, 
2H), 3.54 – 3.26 (m, 2H), 2.08 – 2.00 (m, 2H), 1.28 – 1.22 (m, 6H).  
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Tert-pentyl(3-phenylpropyl)carbamoyl chloride 4.11s 
 
Following general procedure carbamoyl chloride, 2-methyl-N-(3-phenylpropyl)butan-2-
amine 4.13s (400 mg, 1.95 mmol, 1 equiv), Et3N (0.329 mL, 2.34 mmol, 1.2 equiv) and 
triphosgene (197 mg, 0.663 mmol, 0.34 equiv) were reacted in dry benzene (5 mL, 0.4M) at 0 
°C . The desired Tert-pentyl(3-phenylpropyl)carbamoyl chloride 4.11s was obtained as a 
yellowish oil (400 mg, 1.53 mmol, 77 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.33 – 7.17 (m, 5H), 3.45 (t, J = 8.4 Hz, 2H), 2.61 (t, J = 7.6 
Hz, 2H), 2.03 – 1.93 (m, 2H), 1.83 (q, J = 7.5 Hz, 2H), 1.34 (s, 6H), 0.80 (t, J = 7.5 Hz, 3H). 
(2-phenylpropan-2-yl)(3-phenylpropyl)carbamoyl chloride 4.11t 
 
Following general procedure carbamoyl chloride, 3-phenyl-N-(2-phenylpropan-2-yl)propan-
1-amine 4.13t (250 mg, 0.987 mmol 1 equiv), Et3N (0.166 mL, 1.18 mmol, 1.2 equiv) and 
triphosgene (100 mg, 0.336 mmol, 0.34 equiv) were reacted in dry benzene (5 mL) at 0 °C . 
The desired (2-phenylpropan-2-yl)(3-phenylpropyl)carbamoyl chloride 4.11t was obtained as 
a white solid  (290 mg, 0.91 mmol, 92 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.34 – 7.26 (m, 5H), 7.25 – 7.18 (m, 5H), 3.65 – 3.58 (m, 
1H), 2.65 (t, J = 7.6 Hz, 2H), 2.19 – 2.11 (m, 2H), 1.68 (s, 6H).  
Tert-butyl(3,7-dimethyloct-6-en-1-yl)carbamoyl chloride 4.11u 
 
Following general procedure carbamoyl chloride, N-(tert-butyl)-3,7-dimethyloct-6-en-1-
amine 4.13u (400 mg, 1.89 mmol, 1 equiv), Et3N (0.319 mL, 2.27 mmol, 1.2 equiv) and 
triphosgene (191 mg, 0.643 mmol, 0.34 equiv) were reacted in dry benzene (11.2 mL, 0.4M) at 
0 °C. The desired Tert-butyl(3,7-dimethyloct-6-en-1-yl)carbamoyl chloride 4.11u was obtained 
as a yellowish solid (404 mg, 1.47 mmol, 78 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 5.07 (dtd, J = 7.1, 3.5, 2.7, 1.4 Hz, 1H), 3.59 – 3.40 (m, 2H), 
1.99 (dq, J = 14.3, 7.3 Hz, 2H), 1.68 (d, J = 1.4 Hz, 3H), 1.71 – 1.62 (m, 1H), 1.60 (s, 3H), 1.45 
(s, 9H), 1.38 – 1.13 (m, 3H) 0.92 (d, J = 6.4 Hz, 3H).  
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Tert-butyl(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-3-yl)methyl)carbamoyl chloride 
4.11v 
 
Following general procedure carbamoyl chloride, dimethylbicyclo[3.1.1]hept-2-en-2-
yl)methyl)-2-methylpropan-2-amine 4.13v (280 mg, 1.35 mmol, 1 equiv), Et3N (0.228 mL, 1.62 
mmol, 1.2 equiv) and triphosgene (136 mg, 0.459 mmol, 0.34 equiv) were reacted in dry 
benzene (7 mL) at 0 °C . The desired Tert-butyl(((1S,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-
3-yl)methyl)carbamoyl chloride 4.11v was obtained as a yellowish solid (270 mg, 1.0 mmol, 
74 %) and used without further purification 
1H NMR (400 MHz, CDCl3) δ = 5.39 – 5.35 (m, 1H), 4.12 – 3.92 (m, 2H), 2.44 – 2.21 (m, 
4H), 2.13 (dtd, J = 5.8, 2.9, 1.3 Hz, 1H), 1.95 (td, J = 5.6, 1.6 Hz, 1H), 1.46 (s, 9H), 1.29 (s, 
3H), 0.86 (s, 3H). 
(S)-tert-butyl((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)carbamoyl chloride 4.11w 
 
Following general procedure carbamoyl chloride, (S)-2-methyl-N-((4-(prop-1-en-2-
yl)cyclohex-1-en-1-yl)methyl)propan-2-amine 4.13w (259 mg, 1.25 mmol 1 equiv), Et3N 
(0.211 mL, 1.5 mmol, 1.2 equiv) and triphosgene (126 mg, 0.425 mmol, 0.34 equiv) were 
reacted in dry benzene (7.2 mL) at 0 °C .The desired (S)-tert-butyl((4-(prop-1-en-2-
yl)cyclohex-1-en-1-yl)methyl)carbamoyl chloride 4.11w was obtained as a reddish oil (300 mg, 
1.11 mol, 89 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 5.61 – 5.58 (m, 1H), 4.76 – 4.65 (m, 2H), 4.15 – 3.94 (m, 
2H), 2.23 – 2.11 (m, 2H), 2.07 – 1.81 (m, 2H), 1.74 (s, 3H), 1.44 (s, 9H).  
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3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carbamoyl chloride 4.11x 
 
Following general procedure carbamoyl chloride, 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane 
4.11x (1 g, 5.91 mmol, 1 equiv), Et3N (0.997 mL, 7.10 mmol, 1.2 equiv) and triphosgene (596 
mg, 2.01 mmol, 0.34 equiv) were reacted in dry benzene (30 mL) at 0 °C . The desired 3,3-
dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carbamoyl chloride 4.11x was obtained as a yellowish 
solid (1.29 g, 5.55 mmol, 94 %) and used without further purification. 
 1H NMR (400 MHz, CDCl3) δ = 3.79 – 3.71 (m, 2H), 2.57 – 2.29 (m, 2H), 1.73 – 1.55 (m, 
7H), 1.53 – 1.44 (m, 6H), 1.27 – 1.15 (m, 1H). 
(cyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11y 
 
Following general procedure carbamoyl chloride, 1-cyclopropyl-N-(2,4,6-
trimethoxybenzyl)methanamine 4.13y (400 mg, 1.59 mmol, 1 equiv), Et3N (0.268 mL, 1.91 
mmol, 1.2 equiv) and triphosgene (161 mg, 0.541 mmol, 0.34 equiv)  were reacted in dry 
benzene (8 mL) at 0 °C. The desired (cyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride 4.11y was obtained as a yellowish solid (428 mg, 1.36 mmol, 83 %) and used without 
further purification. 
1H NMR (250 MHz, CDCl3) δ = 6.10 (s, 2H), 4.78 (s, 1H), 4.69 (s, 1H), 3.81 – 3.78 (m, 9H), 
3.05 (dd, J = 18.5, 7.2 Hz, 2H), 1.26 – 1.16 (m, 1H), 0.55 – 0.32 (m, 2H), 0.29 – 0.12 (m, 2H). 
(dicyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11z 
 
Following general procedure carbamoyl chloride, 1,1-dicyclopropyl-N-(2,4,6-
trimethoxybenzyl)methanamine 4.13z (300 mg, 1.03 mmol, 1 equiv), Et3N (0.174 mL, 1.24 
mmol, 1.2 equiv) and triphosgene (104 mg, 0.350 mmol, 0.34 equiv) were reacted in dry 
benzene (6 mL) at 0 °C . The desired (dicyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl  
  
225 
 
chloride 4.11z was obtained as a yellowish solid (287 mg, 0.81mmol, 79 %) and used without 
further purification. 
1H NMR (400 MHz, CDCl3) δ = 6.09 (s, 2H), 4.80 (s, 2H), 3.82 (s, 3H), 3.79 (s, 6H), 1.31 – 
1.18(m, 1H), 0.57 – 0.41 (m, 4H), 0.26 – 0.18 (m, 4H), -0.07 – -0.21 (m, 2H). 
(2,3-dihydro-1H-inden-2-yl)(isopropyl)carbamoyl chloride 4.11aa 
 
Following general procedure carbamoyl chloride, N-isopropyl-2,3-dihydro-1H-inden-2-
amine 4.13aa (150 mg, 0.856 mmol 1 equiv), Et3N (0.144 mL, 1.03 mmol, 1.2 equiv) and 
triphosgene (86 mg, 0.291 mmol, 0.34 equiv) were reacted in dry benzene (4.2 mL) at 0 °C. 
The desired (2,3-dihydro-1H-inden-2-yl)(isopropyl)carbamoyl chloride 4.11aa was obtained as 
a yellowish oil (160 mg, 0.67 mmol, 78 %) and used without further purification. 
1H NMR (400 MHz, CDCl3) δ = 7.23 – 7.14 (m, 4H), 5.23 – 4.60 (m, 1H), 4.22 – 3.71 (m, 
1H), 3.69 – 3.38 (m, 2H), 3.31 – 2.88 (m, 2H), 1.26 – 1.40 (m, 6H). 
(2,3-dihydro-1H-inden-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11ab 
 
Following general procedure carbamoyl chloride, N-(2,4,6-trimethoxybenzyl)-2,3-dihydro-
1H-inden-2-amine 4.13ab (269 mg, 0.858 mmol 1 equiv), Et3N (0.144 mL, 1.03 mmol, 1.2 
equiv) and triphosgene (86 mg, 0.291 mmol, 0.34 equiv) were reacted in dry benzene (4.2 mL) 
at 0 °C. The desired (2,3-dihydro-1H-inden-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 
4.11ab was obtained as a white solid (290 mg, 0.77 mmol, 90 %) and used without further 
purification. 
1H NMR (250 MHz, CDCl3) δ = 7.07 (s, 4H), 6.10 (s, 2H), 4.83 (s, 2H), 4.15 – 3.99 (m, 1H), 
3.82 (s, 3H), 3.80 (s, 6H), 3.49 – 3.33 (m, 2H), 2.74 – 2.59 (m, 2H). 
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(1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11ac 
 
Following general procedure carbamoyl chloride, N-(2,4,6-trimethoxybenzyl)-1,2,3,4-
tetrahydronaphthalen-1-amine 4.13ac (490 mg, 1.50 mmol, 1 equiv), Et3N (0.253 mL, 1.80 
mmol, 1.2 equiv) and triphosgene (151 mg, 0.510 mmol, 0.34 equiv) were reacted in dry 
benzene (7.4 mL) at 0 °C. The desired (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11ac was obtained as a yellowish solid (480 mg, 1.23 
mmol, 82 %) and used without further purification. 
1H NMR (250 MHz, CDCl3) δ = 7.09 – 6.97 (m, 4H), 6.10 – 6.03 (m 2H), 5.03 – 4.83 (m, 2H), 
4.71 – 4.50 (m, 1H), 3.81 (s, 3H), 3.80 (s, 6H), 3.80 – 3.73 (m, 2H), 2.86 – 2.50 (m, 2H), 1.97 
– 1.66 (m, 2H). 
(R)-(1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride (-)-
4.11ac 
 
Following general procedure carbamoyl chloride, (R)-N-(2,4,6-trimethoxybenzyl)-1,2,3,4-
tetrahydronaphthalen-1-amine (-)-4.13ac (600 mg, 1.83 mmol, 1 equiv), Et3N (0.308 mL, 2.20 
mmol, 1.2 equiv) and triphosgene (185 mg, 0.622 mmol, 0.34 equiv) were reacted in dry 
benzene (10 mL) at 0 °C. The desired (R)-(1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride (-)-4.11ac was obtained as a yellowish solid (613 mg, 
1.53 mmol, 86 %) and used without further purification. 
1H NMR (250 MHz, CDCl3) δ = 7.09 – 6.95 (m, 4H), 6.10 – 6.03 (m, 2H), 5.03 – 4.82 (m, 
2H), 4.71 – 4.49 (m, 1H), 3.81 (s, 3H), 3.80 (s, 6H), 3.79 – 3.73 (m, 2H), 2.87 – 2.52 (m, 2H), 
1.99 – 1.67 (m, 2H). 
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(2,3-dihydro-1H-inden-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11ad 
 
Following general procedure B for the synthesis of amines, 2,3-dihydro-1H-inden-1-amine 
(200 mg, 1.5 mmol, 1 equiv), 2,4,6-trimethoxybenzaldehyde (294 mg, 1.5 mmol, 1 equiv), and 
AcOH (0.172 mL, 3 mmol 2 equiv) were stirred at room temperature in DCE (15 mL) for 30 
minutes. NaBH(OAc)3 (636 mg, 3 mmol, 2 equiv) was then added to the turning solution, which 
was reacted overnight. Then, the mixture was quenched using a solution of NaOH (1M) and the 
crude was stirred for further 30 minutes. The crude was extracted twice with DCM, dried over 
sodium sulfate, filtered and evaporated under vacuum.  
Following general procedure carbamoyl chloride, N-(2,4,6-trimethoxybenzyl)-2,3-dihydro-
1H-inden-1-amine (470 mg, 1.50 mmol, 1 equiv), Et3N (0.632 mL, 4.50 mmol, 1.2 equiv) and 
triphosgene (151 mg, 0.51 mmol, 0.34 equiv) were reacted in dry benzene (7.6 mL) at 0 °C. 
The desired (2,3-dihydro-1H-inden-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11ad 
was obtained as a yellowish solid (430 mg, 1.14 mmol, 76 %) and used without further 
purification. 
1H NMR (250 MHz, CDCl3) δ = 7.29 – 6.96 (m 4H), 6.11 – 5.93 (m, 2H), 5.07 – 4.75 (m, 2H), 
3.85 – 3.75 (m, 9H), 3.70 – 3.61 (m, 2H), 3.51 – 3.40 (m, 1H), 3.14 – 3.05 (m, 1H), 2.19 – 2.01 
(m, 1H). 
Dicyclohexylcarbamoyl chloride 4.11ae 
 
Following general procedure carbamoyl chloride, dicyclohexylamine (363 mg, 2.0 mmol 1 
equiv), Et3N (0.337 mL, 2.24 mmol, 1.2 equiv) and triphosgene (202 mg, 0.68 mmol, 0.34 
equiv) were reacted in dry benzene (10 mL) at 0 °C. The desired Dicyclohexylcarbamoyl 
chloride 4.11ae was obtained as a yellowish solid (450 mg, 1.84 mmol, 92 %) and used without 
further purification. 
1H NMR (400 MHz, CDCl3) δ = 4.12 (s, 1H), 3.10 (s, 1H), 2.19 (s, 2H), 1.85 – 1.80 (m, 6H), 
1.65 – 1.54 (m, 2H), 1.54 – 1.04 (m, 10H).  
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Pentan-3-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11af 
 
Following general procedure carbamoyl chlorides, N-(2,4,6-trimethoxybenzyl)pentan-3-
amine(400 mg, 1.5mmol 1 equiv), Et3N (0.250mL, 1.8mmol, 1.2 equiv) and triphosgene 
(151mg, 0.51mmol,  0.34 equiv) were reacted in  dry benzene (7 mL) at 0 °C. The desired 
Pentan-3-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11af was obtained as a yellowish 
solid (430 mg, 1.30 mmol, 87%) and used without further purification. 
1H NMR (250 MHz, CDCl3) δ = 6.16 –6.06 (m, 2H), 4.75 –4.60 (m, 2H), 3.88 –3.78 (m,9H), 
3.10–2.93 (m, 1H), 1.89 –1.64 (m, 2H), 1.54 –1.33 (m, 2H), 0.96 –0.52 (m, 6H). 
3.9. b-lactams’s synthesis 
4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12a 
 
Standard scale synthesis: Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11a (40 mg, 0.133 mmol, 
1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as 
eluent, providing 4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12a (32.5 mg, 0.122 
mmol, 92 %). 
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Standard scale synthesis: Conditions B: CO atmosphere 
Following general procedure B, isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11a 
(40 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed 
by flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-
one 4.12a (30.0 mg, 0.064 mmol, 85 %). 
Enantioselective conditions: CO atmosphere 
Following general procedure B, Isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11a 
(400 mg, 1.33 mmol, 1 equiv) was reacted with PdCl2 (24 mg, 0.133 mmol, 10 mol%), L ligand 
(332 mg , 0.266 mmol, 20 mol%), pivalic acid (41 mg, 0.4 mmol, 30 mol%) and cesium 
carbonate (650 mg, 2 mmol, 1.5 equiv) in mesitylene (26.2 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent, providing (R)-4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-
one 4.12a (266 mg, 1 mmol, 75 %, e.r.: 92:8). Optical rotation : [a]D20 = +71.8° (c = 1.0, 
CHCl3) 
Enantioselective conditions: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11a  (40 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), L ligand (33.2 mg , 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (65 
mg, 0.2 mmol, 1.5 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 
18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica gel, 
and the resulting crude was purified by chromatography using cyclohexane/AcOEt as eluent, 
providing (R)-4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12a (30.5 mg, 0.114 
mmol, 86 %, e.r.: 86:14). 
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Tenfold scale synthesis: 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (89 mg, 0.4 mmol, 30 
mol%), P(t-Bu)3●HBF4 (120 mg, 0.4 mmol, 30 mol%), COgen (970 mg, 4 mmol, 3.0 equiv), 
Cy2NMe (1.610 g, 7.98 mmol, 6.0 equiv) and mesitylene (5 mL). Chamber B, previously 
charged with isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11a (400 mg, 1.33 mmol, 
1 equiv) was reacted with PdCl2 (24 mg, 0.133 mmol, 10 mol%), cataCXium AHI (120 mg , 
0.266 mmol, 20 mol%), pivalic acid (41 mg, 0.4 mmol, 30 mol%) and cesium carbonate (1.30 
g, 4 mmol, 3.0 equiv) in mesitylene (26.2 mL). The two chambers system was reacted for 18h 
at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica gel, and 
the resulting crude was purified by chromatography using cyclohexane/AcOEt as eluent, 
providing 4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12a (337 mg, 1.26 mmol, 95 
%). 
Conditions A: Double-chamber system: Under air atmosphere: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (89 mg, 0.4 mmol, 30 
mol%), P(t-Bu)3●HBF4 (120 mg, 0.4 mmol, 30 mol%), COgen (970 mg, 4 mmol, 3.0 equiv), 
Cy2NMe (1.610 g, 7.98 mmol, 6.0 equiv) and mesitylene (commercial batch under argon 
atmosphere)  (5 mL). Chamber B, previously charged with isopropyl(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11a (400 mg, 1.33 mmol, 1 equiv) was reacted with 
PdCl2 (24 mg, 0.133 mmol, 10 mol%), cataCXium AHI (120 mg , 0.266 mmol, 20 mol%), 
pivalic acid (41 mg, 0.4 mmol, 30 mol%) and cesium carbonate (1.30 g, 4 mmol, 3.0 equiv) in 
mesitylene (commercial batch under argon atmosphere)  (26.2 mL). The two chambers system 
was reacted for 18h at 120 °C under air atmosphere. The excess of mesitylene was removed by 
flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-
one 4.12a (266 mg, 1.0 mmol, 75 %). 
1H NMR (400 MHz, CDCl3) : δ = 6.11 (s, 2H), 4.57 (d, J = 13.9 Hz, 1H), 4.13 (dd, J = 13.8, 
1.1 Hz, 1H), 3.81 (s, 9H), 3.41 – 3.33 (m, 1H), 2.90 (dd, J = 14.2, 4.9 Hz, 1H), 2.38 (ddd, J = 
14.2, 2.2, 1.0 Hz, 1H), 1.17 (d, J = 6.0 Hz, 3H). 13C NMR (CDCl3, 101 MHz) : δ = 166.5, 
161.2, 159.7, 104.6, 90.3, 55.8, 55.5, 47.0, 43.8, 32.4, 18.7. IR (neat): ν = 2946, 1739, 1600, 
1140cm-1. HRMS (ESI): Calculated for C14H19NNaO4 ([M+Na]+): 288.1206; found: 288.1208 
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1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12b 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11b (38.3 mg, 0.133 mmol, 1 
equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as 
eluent, providing 1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12b (16.0 mg, 0.064 mmol, 48 
%). 
Conditions B: CO atmosphere 
Following general procedure B, ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11b (38.3 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent, providing 1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12b (11.4 
mg, 0.045 mmol, 34 %). 
1H NMR (400 MHz, CDCl3) : δ = 6.12 (s, 2H), 4.38 (s, 2H), 3.82 (s, 3H), 3.81 (s, 6H), 3.01 
(t, J = 4.0 Hz, 2H), 2.79 (t, J = 4.0 Hz, 2H). 13C NMR (CDCl3, 101 MHz) : δ = 167.2, 161.2, 
159.7, 104.2, 90.4, 55.9, 55.5, 38.7, 36.2, 34.1. IR (neat): ν = 2939, 1737, 1596, 1145, 814 cm-
1. HRMS (ESI): Calculated for C13H17NNaO4 ([M+Na]+): 274.1050; found: 274.1051 
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(S)-4-(tert-butyl)-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12e 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (S)-(3,3-dimethylbutan-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11e 
(47.6 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two 
chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed by 
flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing (S)-4-(tert-butyl)-1-(2,4,6-
trimethoxybenzyl)azetidin-2-one 4.12e (30.7 mg, 0.100 mmol, 75 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-(3,3-dimethylbutan-2-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11e  (47.6 mg, 0.133 mmol, 1 equiv) was reacted with 
PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), 
pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) 
in mesitylene (2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, the 
excess of mesitylene was removed by flushing cyclohexane on silica gel, and the resulting crude 
was purified by chromatography using cyclohexane/AcOEt as eluent, providing (S)-4-(tert-
butyl)-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12e (15.5 mg, 0.051 mmol, 38 %). 
1H NMR (400 MHz, CDCl3): δ = 6.10 (s, 2H), 4.64 (d, J = 14.5 Hz, 1H), 4.21 (d, J = 14.5 Hz, 
1H), 3.82 (s, 3H), 3.78 (s, 6H), 2.97 (dd, J = 5.4, 2.6 Hz, 1H), 2.65 (dd, J = 14.6, 5.4 Hz, 1H), 
2.57 – 2.50 (m, 1H), 0.82 (s, 9H). 13C NMR (CDCl3, 101 MHz):  δ = 169.0, 161.0, 159.6, 
103.8, 90.3, 59.9, 55.7, 55.4, 37.8, 35.3, 32.4, 25.7. IR (neat): ν = 2975, 1739, 743 cm-1. 
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HRMS (ESI): Calculated for C17H26NO4 ([M+H]+): 308.1856; found: 308.1859 Optical 
rotation : [a]D20 = +50.1° (c = 0.7, CHCl3) 
(R)-4-hexyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12f 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (S)-octan-2-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11f (49.5 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 
mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as 
eluent, providing (R)-4-hexyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12f (41 mg, 0.122 
mmol, 92 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-octan-2-yl(2,4,6-trimethoxybenzyl)carbamoyl chloride 
4.11f (49.5 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed 
by flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing (R)-4-hexyl-1-(2,4,6-
trimethoxybenzyl)azetidin-2-one 4.12f (39.3 mg, 0.117 mmol, 88 %). 
1H NMR (400 MHz, CDCl3) : δ = 6.10 (s, 2H), 4.56 (d, J = 14.0 Hz, 1H), 4.13 (d, J = 13.9 Hz, 
1H), 3.81 – 3.78 (m, 9H), 3.26 – 3.20 (m, 1H), 2.81 (dd, J = 14.2, 5.0 Hz, 1H), 2.45 – 2.39 (m, 
1H), 1.80 – 1.69 (m, 1H), 1.28 – 1.18 (m, 9H), 0.86 (t, J = 6.9 Hz, 3H).  
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13C NMR (CDCl3, 101 MHz) : δ = 166.9, 161.2, 159.6, 104.5, 90.3, 55.8, 55.4, 51.2, 41.8, 
32.7, 32.5, 31.8, 29.3, 25.0, 22.7, 14.2. IR (neat): ν = 2962, 1739, 1608, 1140, 732 cm-1. HRMS 
(ESI): Calculated for C19H30NO4 ([M+H]+): 336.2169; found: 336.2167 Optical rotation : 
[a]D20 = +46.6° (c = 1.3, CHCl3) 
(S)-4-cyclohexyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12g 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (S)-(1-cyclohexylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11g (49.2 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system 
was reacted for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane 
on silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt 
as eluent, providing (S)-4-cyclohexyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12g (44.4 
mg, 0.133 mmol, 100 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-(1-cyclohexylethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride 4.11g (49.2 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 
10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 
30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under 
CO atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was 
removed by flushing cyclohexane on silica gel, and the resulting crude was purified by 
chromatography using cyclohexane/AcOEt as eluent, providing (S)-4-cyclohexyl-1-(2,4,6-
trimethoxybenzyl)azetidin-2-one 4.12g (39.1 mg, 0.117 mmol, 88 %).  
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1H NMR (400 MHz, CDCl3) : δ = 6.09 (s, 2H), 4.57 (d, J = 14.0 Hz, 1H), 4.16 (d, J = 14.0 Hz, 
1H), 3.80 (s, 3H), 3.79 (s, 6H), 3.13 – 3.08 (m, 1H), 2.65 (dd, J = 14.3, 5.1 Hz, 1H), 2.53 (d, J 
= 14.3 Hz, 1H), 1.70 – 1.46 (m, 5H), 1.19 – 1.04 (m, 4H), 0.91 – 0.72 (m, 2H). 13C NMR 
(CDCl3, 101 MHz) : δ =  167.7, 161.1, 159.6, 104.1, 90.3, 55.7, 55.4, 55.4, 39.2, 38.0, 33.7, 
29.5, 26.5, 26.3, 26.3, 26.0. IR (neat): ν = 2972, 1729, 1628, 1120, 734 cm-1. HRMS (ESI): 
Calculated for C19H28NO4 ([M+H]+): 334.2013; found: 334.2013 Optical rotation : [a]D20 = -
38.2° (c = 1.6, CHCl3) 
(S)-(4-oxo-1-(2,4,6-trimethoxybenzyl)azetidin-2-yl)methyl pivalate 4.12h  
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (S)-2-((chlorocarbonyl)(2,4,6-trimethoxybenzyl)amino)propyl pivalate 4.11h 
(53.5 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two 
chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed by 
flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing (S)-(4-oxo-1-(2,4,6-trimethoxybenzyl)azetidin-
2-yl)methyl pivalate 4.12h (48.6 mg, 0.133 mmol, 100 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-2-((chlorocarbonyl)(2,4,6-trimethoxybenzyl)amino)propyl 
pivalate 4.11h (53.5 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 
10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 
30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under 
CO atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was 
removed by flushing cyclohexane on silica gel, and the resulting crude was purified by   
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chromatography using cyclohexane/AcOEt as eluent, providing (S)-(4-oxo-1-(2,4,6-
trimethoxybenzyl)azetidin-2-yl)methyl pivalate 4.12h (42.7 mg, 0.117 mmol, 88 %). 
1H NMR (500 MHz, CDCl3) δ = 6.10 (s, 2H), 4.60 (d, J = 14.0 Hz, 1H), 4.25 (dd, J = 11.8, 
4.3 Hz, 1H), 4.11 – 4.04 (m, 2H), 3.81 – 3.78 (m, 9H), 3.54 – 3.49 (m, 1H), 2.83 (dd, J = 14.3, 
5.1 Hz, 1H), 2.70 (ddd, J = 14.2, 2.4, 1.0 Hz, 1H), 1.18 (s, 9H). 13C NMR (126 MHz, CDCl3) 
δ = 178.3, 166.2, 161.3, 159.5, 104.3, 90.4, 62.0, 55.8, 55.4, 49.4, 39.3, 39.1, 32.9, 27.2. IR 
(neat): ν = 1738, 1598, 904, 723cm-1. HRMS (ESI): Calculated for C19H27NNaO6 ([M+Na]+): 
388.1731; found: 388.1735 Optical rotation : [a]D20 = +41.3° (c = 1.2, CHCl3) 
(S)-4-phenyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12i and  
(S)-3-methyl-2-(2,4,6-trimethoxybenzyl)isoindolin-1-one 4.12j 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (S)-(1-phenylethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11i (48.4 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system 
was reacted for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane 
on silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt 
as eluent, providing (S)-4-phenyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12i and (S)-3-
methyl-2-(2,4,6-trimethoxybenzyl)isoindolin-1-one 4.12j as an unseparable mixture (29.6 mg, 
0.09 mmol, 68 %, 7/3). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-(1-phenylethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride4 11i (48.4 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 
10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol,   
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30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under 
CO atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was 
removed by flushing cyclohexane on silica gel, and the resulting crude was purified by 
chromatography using cyclohexane/AcOEt as eluent, providing (S)-4-phenyl-1-(2,4,6-
trimethoxybenzyl)azetidin-2-one 4.12i and (S)-3-methyl-2-(2,4,6-
trimethoxybenzyl)isoindolin-1-one 4.12j as an unseparable mixture (29.6 mg, 0.09 mmol, 68 
%, 7/3). 
(S)-4-phenyl-1-(2,4,6-trimethoxybenzyl)azetidin-4.12i: Beta-lactam product : 
1H NMR (400 MHz, CDCl3): δ = 7.34 – 7.22 (m, 3H), 7.22 – 7.16 (m, 2H), 5.99 (s, 2H), 4.67 
(d, J = 13.8 Hz, 1H), 4.27 (dd, J = 5.3, 2.4 Hz, 1H), 4.11 (dd, J = 13.8, 1.1 Hz, 1H), 3.79 (s, 
3H), 3.61 (s, 6H), 3.23 (dd, J = 14.4, 5.3 Hz, 1H), 2.72 (ddd, J = 14.4, 2.4, 1.0 Hz, 1H). 13C 
NMR (CDCl3, 101 MHz) : δ = 167.2, 161.2, 159.5, 139.8, 130.9, 127.8, 126.2, 104.0, 90.1, 
55.5, 55.4, 54.0, 46.7, 33.1. IR (neat): ν = 2950, 1737, 1680, 1595, 1150, 907, 727 cm-1. HRMS 
(ESI): Calculated for C19H21NNaO4 ([M+Na]+): 350.1363; found: 350.1365 
(S)-3-methyl-2-(2,4,6-trimethoxybenzyl)isoindolin-1-one 4.12j  : Oxindole product : 
1H NMR (400 MHz, CDCl3) : δ = 7.86 (dt, J = 7.4, 1.1 Hz, 1H), 7.48 (td, J = 7.4, 1.3 Hz, 1H), 
7.44 – 7.40 (m, 1H), 7.33 – 7.31 (m, 1H), 6.13 (s, 2H), 5.27 (d, J = 14.2 Hz, 1H), 4.44 (d, J = 
14.1 Hz, 1H), 4.19 (q, J = 6.7 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 6H), 1.44 (d, J = 6.6 Hz, 3H). 13C 
NMR (CDCl3, 101 MHz) : δ = 167.3, 161.2, 160.0, 147.6, 132.5, 128.4, 127.7, 123.6, 121.8, 
105.5, 90.4, 55.9, 55.5, 55.0, 32.5, 18.4.  
1-(cyclopentylmethyl)-4-methylazetidin-2-one 4.12k 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (cyclopentylmethyl)(isopropyl)carbamoyl chloride 4.11k (27.1 mg, 0.133 mmol, 
1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL).   
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The two chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed 
by flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 2k (16.7 mg, 0.100 mmol, 75 %). 
Conditions B: CO atmosphere 
Following general procedure B, (cyclopentylmethyl)(isopropyl)carbamoyl chloride 4.11k (27.1 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent, providing 1-(cyclopentylmethyl)-4-methylazetidin-2-one 4.12k 
(13.0 mg, 0.078 mmol, 59 %). 
1H NMR (400 MHz, CDCl3) : δ = 3.74 – 3.59 (m, 1H), 3.25 (dd, J = 13.9, 7.9 Hz, 1H), 3.04 
(dd, J = 14.4, 4.8 Hz, 1H), 2.87 (dd, J = 14.0, 7.1 Hz, 1H), 2.47 (d, J = 14.4 Hz, 1H), 2.19 – 
2.00 (m, 1H), 1.85 – 1.46 (m, 5H), 1.31 (d, J = 5.9 Hz, 3H), 1.26 – 1.14 (m, 3H). 13C NMR 
(CDCl3, 101 MHz) : δ = 167.1, 47.7, 45.5, 44.0, 38.9, 30.9, 30.8, 25.5, 25.2, 18.8. IR (neat): ν 
= 2956, 1731, 907, 729 cm-1. HRMS (ESI): Calculated for C10H17NNaO ([M+Na]+): 190.1202; 
found: 190.1202 
4-methyl-1-(2,4,6-trimethylbenzyl)azetidin-2-one 4.12l 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with isopropyl(2,4,6-trimethylbenzyl)carbamoyl chloride 4.11l  (33.8 mg, 0.133 mmol, 
1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as   
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eluent, providing 4-methyl-1-(2,4,6-trimethylbenzyl)azetidin-2-one 4.12l (20.2 mg, 0.093 
mmol, 70 %). 
Conditions B: CO atmosphere 
Following general procedure B, isopropyl(2,4,6-trimethylbenzyl)carbamoyl chloride 4.11l 
(33.8 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed 
by flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 4-methyl-1-(2,4,6-trimethylbenzyl)azetidin-2-
one 4.12l (19.4 mg, 0.078 mmol, 67 %). 
1H NMR (400 MHz, CDCl3) : δ = 6.85 (s, 2H), 4.48 (d, J = 14.7 Hz, 1H), 4.34 (d, J = 14.7 Hz, 
1H), 3.48 – 3.38 (m, 1H), 3.01 (dd, J = 14.4, 5.0 Hz, 1H), 2.48 – 2.40 (m, 1H), 2.33 (s, 6H), 
2.26 (s, 3H), 1.06 (d, J = 6.1 Hz, 3H). 13C NMR (CDCl3, 101 MHz) : δ =  166.8, 137.6, 137.4, 
129.4, 128.5, 47.6, 44.1, 38.9, 21.0, 20.1, 19.4. IR (neat): ν = 1733, 907, 731 cm-1. HRMS 
(ESI): Calculated for C14H19NNaO ([M+Na]+): 240.1359; found: 240.1360 
4-methyl-1-phenethylazetidin-2-one 4.12o 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with isopropyl(phenethyl)carbamoyl chloride 4.11o (30.0 mg, 0.133 mmol, 1 equiv) 
was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 
mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 
0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h 
at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica gel, and 
the resulting crude was purified by chromatography using cyclohexane/AcOEt as eluent, 
providing 4-methyl-1-phenethylazetidin-2-one 4.12o (13.5 mg, 0.071 mmol, 54 %).  
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Conditions B: CO atmosphere 
Following general procedure B, isopropyl(phenethyl)carbamoyl chloride 4.11o  (30.0 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent, providing 4-methyl-1-phenethylazetidin-2-one 4.12o (7 mg, 
0.037 mmol, 28 %). 
1H NMR (400 MHz, CDCl3) δ = 7.26 – 7.18 (m, 2H), 7.18 – 7.10 (m, 3H), 3.52 (dt, J = 14.6, 
7.4 Hz, 1H), 3.46 – 3.39 (m, 1H), 3.15 (dt, J = 14.4, 7.4 Hz, 1H), 2.91 (dd, J = 14.4, 4.9 Hz, 
1H), 2.80 (t, J = 7.4 Hz, 2H), 2.36 (dd, J = 14.4, 2.2 Hz, 1H), 1.11 (d, J = 6.2 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ = 167.0, 138.8, 128.7, 128.7, 126.7, 47.7, 44.0, 41.8, 34.7, 18.5. 
IR (neat): ν = 2960, 1740, 1399, 700 cm-1. HRMS (ESI): Calculated for C12H15NNaO 
([M+Na]+): 212.1246; found: 212.1246 
4-methyl-1-(3-phenylpropyl)azetidin-2-one 4.12p 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with isopropyl(3-phenylpropyl)carbamoyl chloride 4.11p (31.9 mg, 0.133 mmol, 1 
equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as 
eluent, providing 4-methyl-1-(3-phenylpropyl)azetidin-2-one 4.12p (21.9 mg, 0.108 mmol, 81 
%). 
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Conditions B: CO atmosphere 
Following general procedure B, isopropyl(3-phenylpropyl)carbamoyl chloride 4.11p (31.9 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent, providing 4-methyl-1-(3-phenylpropyl)azetidin-2-one 4.12p 
(16.0 mg, 0.078 mmol, 59 %). 
1H NMR (400 MHz, CDCl3) : δ = 7.26 – 7.17 (m, 2H), 7.15 – 7.07 (m, 3H), 3.60 – 3.52 (m, 
1H), 3.31 – 3.22 (m, 1H), 3.02 – 2.91 (m, 2H), 2.57 (t, J = 7.7 Hz, 2H), 2.40 (dd, J = 14.4, 2.2 
Hz, 1H), 1.84 – 1.74 (m, 2H), 1.23 (d, J = 6.1 Hz, 3H). 13C NMR (CDCl3, 101 MHz) : δ =  
167.1, 141.3, 128.6, 128.4, 126.1, 47.3, 43.9, 40.0, 33.5, 29.9, 18.8. IR (neat): ν = 2925, 1738, 
1400, 701 cm-1. HRMS (ESI): Calculated for C13H17NNaO4 ([M+Na]+): 226.1202; found: 
226.1203 
Methyl 3-(2-methyl-4-oxoazetidin-1-yl)propanoate 4.12q 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with methyl 3-((chlorocarbonyl)(isopropyl)amino)propanoate 4.11q (29.5 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 
mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as 
eluent, providing Methyl 3-(2-methyl-4-oxoazetidin-1-yl)propanoate 4.12q (12.5 mg, 0.065 
mmol, 50 %).  
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Conditions B: CO atmosphere 
Following general procedure B, methyl 3-((chlorocarbonyl)(isopropyl)amino)propanoate 4.11q 
(29.5 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed 
by flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing Methyl 3-(2-methyl-4-oxoazetidin-1-
yl)propanoate 4.12q (12 mg, 0.060 mmol, 49 %). 
1H NMR (400 MHz, CDCl3) : δ = 4.15 (q, J = 7.1 Hz, 2H), 3.72 – 3.64 (m, 1H), 3.60 (dt, J = 
14.5, 6.5 Hz, 1H), 3.33 – 3.23 (m, 1H), 3.03 (dd, J = 14.5, 4.9 Hz, 1H), 2.66 – 2.50 (m, 2H), 
2.47 (dd, J = 14.5, 2.3 Hz, 1H), 1.32 (d, J = 6.1 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR 
(CDCl3, 101 MHz) : δ = 171.6, 167.1, 60.1, 48.0, 44.2, 36.0, 33.6, 18.7, 14.3. IR (neat): ν = 
2923, 1737, 1396, 1183 cm-1. HRMS (ESI): Calculated for C9H15NNaO3 ([M+Na]+): 
208.0944; found: 208.0946 
2-(3-(2-methyl-4-oxoazetidin-1-yl)propyl)isoindoline-1,3-dione 4.12r 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (3-(1,3-dioxoisoindolin-2-yl)propyl)(isopropyl)carbamoyl chloride 4.11r (41.1 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system 
was reacted for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane 
on silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt 
as eluent, providing 2-(3-(2-methyl-4-oxoazetidin-1-yl)propyl)isoindoline-1,3-dione 4.12r 
(15.6 mg, 0.057 mmol, 43 %).  
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Conditions B: CO atmosphere 
Following general procedure B, (3-(1,3-dioxoisoindolin-2-yl)propyl)(isopropyl)carbamoyl 
chloride 4.11r (41.1 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 
10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 
30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under 
CO atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was 
removed by flushing cyclohexane on silica gel, and the resulting crude was purified by 
chromatography using cyclohexane/AcOEt as eluent, providing 2-(3-(2-methyl-4-oxoazetidin-
1-yl)propyl)isoindoline-1,3-dione 4.12r (8.0 mg, 0.029 mmol, 22 %). 
1H NMR (400 MHz, CDCl3) : δ = 7.87 – 7.80 (m, 2H), 7.76 – 7.69 (m, 2H), 3.82 – 3.66 (m, 
3H), 3.46 – 3.31 (m, 1H), 3.15 – 3.01 (m, 2H), 2.50 (dd, J = 14.5, 2.3 Hz, 1H), 2.01 – 1.85 (m, 
3H), 1.34 (d, J = 6.1 Hz, 3H). 13C NMR (CDCl3, 101 MHz) : δ = 168.4, 167.2, 134.2, 132.2, 
123.4, 47.6, 44.1, 38.1, 35.8, 27.3, 18.9. IR (neat): ν = 1711, 1742, 1397, 722 cm-1. HRMS 
(ESI): Calculated for C15H16N2NaO3 ([M+Na]+): 295.1059; found: 295.1057 
4-ethyl-4-methyl-1-(3-phenylpropyl)azetidin-2-one 4.12s 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with tert-pentyl(3-phenylpropyl)carbamoyl chloride 4.11s (35.6 mg, 0.133 mmol, 1 
equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as 
eluent, providing 4-ethyl-4-methyl-1-(3-phenylpropyl)azetidin-2-one 4.12s (22.5 mg, 0.097 
mmol, 73 %). 
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Conditions B: CO atmosphere 
Following general procedure B, tert-pentyl(3-phenylpropyl)carbamic chloride 4.11s (35.6 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent, providing 4-ethyl-4-methyl-1-(3-phenylpropyl)azetidin-2-one 
4.12s (22.2 mg, 0.096 mmol, 72 %). 
1H NMR (400 MHz, CDCl3): δ = 7.30 – 7.17 (m, 5H), 3.21 – 3.03 (m, 2H), 2.75 (d, J = 14.3 
Hz, 1H), 2.70 – 2.61 (m, 2H), 2.57 (d, J = 14.4 Hz, 1H), 1.95 – 1.85 (m, 2H), 1.76 – 1.67 (m, 
1H), 1.64 – 1.55 (m, 1H), 1.35 (s, 3H), 0.92 (t, J = 7.5 Hz, 3H). 13C NMR (CDCl3, 101 MHz) 
: δ = 167.1, 141.4, 128.5, 128.5, 126.1, 58.8, 47.1, 39.4, 33.7, 31.0, 30.8, 23.1, 9.1. IR (neat): 
ν = 2924, 1739, 1399, 733 cm-1. HRMS (ESI): Calculated for C15H22NO ([M+H]+): 232.1696; 
found: 232.1699 
4-methyl-4-phenyl-1-(3-phenylpropyl)azetidin-2-one 4.12t 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (2-phenylpropan-2-yl)(3-phenylpropyl)carbamoyl chloride 4.11t (42 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 
mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as 
eluent, providing 4-methyl-4-phenyl-1-(3-phenylpropyl)azetidin-2-one 4.12t (20.8 mg, 0.074 
mmol, 56 %). 
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Conditions B: CO atmosphere 
Following general procedure B, (2-phenylpropan-2-yl)(3-phenylpropyl)carbamoyl chloride 
4.11t (42 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed 
by flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 4-methyl-4-phenyl-1-(3-phenylpropyl)azetidin-
2-one 4.12t (21.2 mg, 0.076 mmol, 57 %). 
1H NMR (400 MHz, CDCl3) : δ = 7.42 – 7.07 (m, 10H), 3.32 – 3.24 (m, 1H), 3.03 (s, 2H), 
3.01 – 2.95 (m, 1H), 2.69 – 2.53 (m, 2H), 1.92 – 1.80 (m, 2H), 1.84 (s, 3H). 13C NMR (CDCl3, 
101 MHz) : δ = 167.7, 142.1, 141.3, 128.9, 128.5, 128.4, 127.9, 126.1, 125.6, 59.0, 53.9, 40.5, 
33.7, 30.4, 23.4. IR (neat): ν = 2926, 1743, 1395, 732 cm-1. HRMS (ESI): Calculated for 
C19H21NNaO ([M+Na]+): 302.1515; found: 302.1517 
1-(3,7-dimethyloct-6-en-1-yl)-4,4-dimethylazetidin-2-one 4.12u 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with tert-butyl(3,7-dimethyloct-6-en-1-yl)carbamoyl chloride 4.11u (36.4 mg, 0.133 
mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 
mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica 
gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt as 
eluent, providing 1-(3,7-dimethyloct-6-en-1-yl)-4,4-dimethylazetidin-2-one 4.12u (31.6 mg, 
0.133 mmol, 100 %). 
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Conditions B: CO atmosphere 
Following general procedure B, tert-butyl(3,7-dimethyloct-6-en-1-yl)carbamoyl chloride 4.11u  
(36.4 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed 
by flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 1-(3,7-dimethyloct-6-en-1-yl)-4,4-
dimethylazetidin-2-one 4.12u (24 mg, 0.101 mmol, 76 %).  
1H NMR (400 MHz, CDCl3): δ = 5.12 – 5.02 (m, 1H), 3.09 (t, J = 7.7 Hz, 2H), 2.68 (s, 2H), 
2.03 – 1.88 (m, 2H), 1.69 – 1.65 (m, 3H), 1.58 (s, 3H), 1.36 (s, 6H), 1.54 – 1.09 (m, 5H), 0.90 
(d, J = 6.3 Hz, 3H). 13C NMR (CDCl3, 101 MHz): δ = 166.5, 131.5, 124.7, 55.4, 50.4, 37.7, 
37.0, 36.1, 30.6, 25.8, 25.5, 25.3, 19.3, 17.8. IR (neat): ν = 2925, 1736, 1402, 911, 732cm-1. 
HRMS (ESI): Calculated for C15H27NNaO ([M+Na]+): 260.1985; found: 260.1985 
1-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)-4,4-dimethylazetidin-2-one 
4.12v 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with tert-butyl(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)carbamoyl 
chloride 4.11v (35.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 
10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 
30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The 
two chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed by 
flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 1-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-
en-2-yl)methyl)-4,4-dimethylazetidin-2-one 4.12v (16.5 mg, 0.07 mmol, 53 %).  
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Conditions B: CO atmosphere 
Following general procedure B, tert-butyl(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-
yl)methyl)carbamoyl chloride 4.11v (35.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 
(2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic 
acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in 
mesitylene (2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, the 
excess of mesitylene was removed by flushing cyclohexane on silica gel, and the resulting crude 
was purified by chromatography using cyclohexane/AcOEt as eluent, providing 1-(((1R,5S)-
6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)-4,4-dimethylazetidin-2-one 4.12v (15.5 mg, 
0.067 mmol, 50 %). 
1H NMR (400 MHz, CDCl3): δ = 5.46 – 5.40 (m, 1H), 3.82 (dq, J = 15.5, 2.2 Hz, 1H), 3.38 
(d, J = 15.5 Hz, 1H), 2.71 (s, 2H), 2.39 (dt, J = 8.6, 5.6 Hz, 1H), 2.29 – 2.18 (m, 2H), 2.17 – 
2.14 (m, 1H), 2.11 – 2.01 (m, 1H), 1.35 (d, J = 5.9 Hz, 6H), 1.27 (s, 3H), 1.13 (d, J = 8.6 Hz, 
1H), 0.81 (s, 3H). 13C NMR (CDCl3, 101 MHz): δ = 166.9, 144.1, 120.1, 55.7, 50.6, 44.3, 43.8, 
40.7, 38.2, 31.8, 31.4, 26.2, 26.0, 24.6, 21.0. IR (neat): ν = 1731, 907, 728 cm-1. HRMS (ESI): 
Calculated for C15H23NNaO ([M+Na]+): 256.1672; found: 256.1672 Optical rotation : [a]D20 
= -59.1° (c = 0.8, CHCl3) 
(S)-4,4-dimethyl-1-((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)azetidin-2-one 4.12w 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (S)-tert-butyl((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)carbamoyl chloride 
4.11w (35.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 
mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 
mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two 
chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed by 
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using cyclohexane/AcOEt as eluent, providing (S)-4,4-dimethyl-1-((4-(prop-1-en-2-
yl)cyclohex-1-en-1-yl)methyl)azetidin-2-one 4.12w (18.9 mg, 0.081 mmol, 68 %). 
Conditions B: CO atmosphere 
Following general procedure B, (S)-tert-butyl((4-(prop-1-en-2-yl)cyclohex-1-en-1-
yl)methyl)carbamoyl 4.11w (35.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 
0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 
mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene 
(2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, the excess of 
mesitylene was removed by flushing cyclohexane on silica gel, and the resulting crude was 
purified by chromatography using cyclohexane/AcOEt as eluent, providing (S)-4,4-dimethyl-
1-((4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methyl)azetidin-2-one 4.12w (18.3 mg, 0.078 mmol, 
59 %). 
1H NMR (400 MHz, CDCl3): δ = 5.66 – 5.60 (m, 1H), 4.74 – 4.67 (m, 2H), 3.70 (d, J = 15.0 
Hz, 1H), 3.57 (d, J = 15.0 Hz, 1H), 2.72 (s, 2H), 2.21 – 1.77 (m, 7H), 1.75 – 1.71 (m, 3H), 1.35 
(d, J = 6.4 Hz, 6H). 13C NMR (CDCl3, 101 MHz):  δ = 166.9, 149.7, 133.5, 124.9, 108.8, 55.9, 
50.8, 45.6, 41.0, 30.8, 27.6, 26.9, 25.2, 24.8, 20.9. IR (neat): ν = 2921, 1745, 1392, 732 cm-1. 
HRMS (ESI): Calculated for C15H23NNaO ([M+Na]+): 256.1672 found: 256.1672. Optical 
rotation : [a]D20 = -65.5° (c = 1.1, CHCl3) 
5-methyl-3-oxa-1-azaspiro[bicyclo[3.2.0]heptane-2,1'-cyclohexan]-7-one 4.12x 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carbamoyl chloride 4.11x  (30.8 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system 
was reacted for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane   
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on silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt 
as eluent, providing 2x (18.2 mg, 0.093 mmol, 70 %). 
Conditions B: CO atmosphere 
Following general procedure B, ethyl(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11x (30.8 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The 
mixture was stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent, providing 5-methyl-3-oxa-1-azaspiro[bicyclo[3.2.0]heptane-
2,1'-cyclohexan]-7-one 4.12x (18.2 mg, 0.093 mmol, 70 %). 
1H NMR (400 MHz, CDCl3) : δ = 3.89 (d, J = 9.0 Hz, 1H), 3.82 (d, J = 9.0 Hz, 1H), 2.91 (d, 
J = 15.9 Hz, 1H), 2.86 (d, J = 16.0 Hz, 1H), 2.21 (m, 1H), 1.88 – 1.56 (m, 6H), 1.55 (s, 3H), 
1.53 – 1.39 (m, 3H). 13C NMR (CDCl3, 101 MHz): δ = 175.4, 98.5, 73.9, 59.1, 47.7, 35.9, 32.7, 
25.2, 24.5, 23.9, 23.5. IR (neat): ν = 2935, 2859, 1768, 1450, 1264, 913, 731 cm-1. HRMS 
(ESI): Calculated for C11H17NNaO2 ([M+Na]+): 218.1151; found: 218.1150 
5-(2,4,6-trimethoxybenzyl)-5-azaspiro[2.3]hexan-4-one 4.12y 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (cyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11y (41.7 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system 
was reacted for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane  
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on silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt 
as eluent, providing 2y (27.6 mg, 0.100 mmol, 75 %). 
Conditions B: CO atmosphere 
Following general procedure B, ((cyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride 4.11y (41.7 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 
10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 
30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under 
CO atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was 
removed by flushing cyclohexane on silica gel, and the resulting crude was purified by 
chromatography using cyclohexane/AcOEt as eluent, providing 5-(2,4,6-trimethoxybenzyl)-5-
azaspiro[2.3]hexan-4-one 4.12y (27.7 mg, 0.102 mmol, 76 %). 
1H NMR (400 MHz, CDCl3): δ = 6.13 (s, 2H), 4.47 (s, 2H), 3.84 – 3.79 (m, 9H), 3.21 (s, 2H), 
1.14 – 1.06 (m, 2H), 0.86 – 0.79 (m, 2H). 13C NMR (CDCl3, 101 MHz): δ = 172.0, 161.2, 
159.7, 104.7, 90.5, 55.9, 55.5, 48.5, 34.4, 31.6, 7.3. IR (neat): ν = 2968, 1745, 1608, 1147, 669 
cm-1. HRMS (ESI): Calculated for C15H19NNaO4 ([M+Na]+): 300.1206; found: 300.1208 
6-cyclopropyl-5-(2,4,6-trimethoxybenzyl)-5-azaspiro[2.3]hexan-4-one 4.12z 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (dicyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11z (47.1 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system 
was reacted for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane 
on silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt   
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as eluent, providing 6-cyclopropyl-5-(2,4,6-trimethoxybenzyl)-5-azaspiro[2.3]hexan-4-one 
4.12z (34 mg, 0.107 mmol, 81 %). 
Conditions B: CO atmosphere 
Following general procedure B, (dicyclopropylmethyl)(2,4,6-trimethoxybenzyl)carbamoyl 
chloride 4.11z (47.1 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 
10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 
30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under 
CO atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was 
removed by flushing cyclohexane on silica gel, and the resulting crude was purified by 
chromatography using cyclohexane/AcOEt as eluent, providing 6-cyclopropyl-5-(2,4,6-
trimethoxybenzyl)-5-azaspiro[2.3]hexan-4-one 4.12z (34 mg, 0.107 mmol, 81 %). 
1H NMR (400 MHz, CDCl3) : δ = 6.10 (s, 2H), 4.59 (d, J = 14.0 Hz, 1H), 4.41 (d, J = 14.0 Hz, 
1H), 3.82 – 3.78 (m, 9H), 2.55 (d, J = 9.3 Hz, 1H), 1.16 – 0.98 (m, 1H), 0.95 – 0.85 (m, 1H), 
0.83 – 0.73 (m, 1H), 0.71 – 0.58 (m, 1H), 0.41 – 0.26 (m, 2H), -0.02 – -0.11 (m, 1H), -0.19 – -
0.28 (m, 1H). 13C NMR (CDCl3, 101 MHz):  δ = 172.4, 161.0, 159.7, 104.9, 90.3, 64.1, 55.7, 
36.6, 33.5, 11.6, 7.2, 5.9, 2.4, 0.1. IR (neat): ν = 2937, 1736, 1597, 1138, 728 cm-1. HRMS 
(ESI): Calculated for C18H23NNaO4 ([M+Na]+): 340.1519; found: 340.1523 
1-isopropyl-1,2a,7,7a-tetrahydro-2H-indeno[2,1-b]azet-2-one 4.12aa 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (2,3-dihydro-1H-inden-2-yl)(isopropyl)carbamoyl chloride 4.11aa (31.6 mg, 
0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium 
AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium 
carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system 
was reacted for 18h at 120 °C. The excess of mesitylene was removed by flushing cyclohexane 
on silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt   
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as eluent, providing 1-isopropyl-1,2a,7,7a-tetrahydro-2H-indeno[2,1-b]azet-2-one 4.12aa (20.9 
mg, 0.104 mmol, 78 %). 
Conditions B: CO atmosphere 
Following general procedure B, (2,3-dihydro-1H-inden-2-yl)(isopropyl)carbamoyl chloride 
4.11aa (31.6 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 
mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 
mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under 
CO atmosphere. The mixture was stirred for 18h at 120 °C, the excess of mesitylene was 
removed by flushing cyclohexane on silica gel, and the resulting crude was purified by 
chromatography using cyclohexane/AcOEt as eluent, providing 1-isopropyl-1,2a,7,7a-
tetrahydro-2H-indeno[2,1-b]azet-2-one 4.12aa  (20.9 mg, 0.104 mmol, 78 %). 
1H NMR (400 MHz, CDCl3): δ = 7.46 – 7.39 (m, 1H), 7.25 – 7.19 (m, 3H), 4.48 (d, J = 4.0 
Hz, 1H), 4.40 (ddd, J = 6.3, 4.0, 1.3 Hz, 1H), 3.83 (hept, J = 6.8 Hz, 1H), 3.24 – 2.99 (m, 3H), 
1.30 (d, J = 6.8 Hz, 3H), 1.23 (d, J = 6.8 Hz, 3H). 13C NMR (CDCl3, 101 MHz):  δ = 168.5, 
142.1, 137.7, 127.9, 127.4, 126.3, 125.2, 61.5, 53.6, 44.3, 35.4, 22.1, 20.7. IR (neat): ν = 2973, 
1742, 672 cm-1. HRMS (ESI): Calculated for C13H15NNaO ([M+Na]+): 224.1046; found: 
224.1043 
1-(2,4,6-trimethoxybenzyl)-1,2a,7,7a-tetrahydro-2H-indeno[2,1-b]azet-2-one 4.12ab 
 
 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (2,3-dihydro-1H-inden-2-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11ab 
(52 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two 
chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed by 
flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography   
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using cyclohexane/AcOEt as eluent, providing 1-(2,4,6-trimethoxybenzyl)-1,2a,7,7a-
tetrahydro-2H-indeno[2,1-b]azet-2-one 4.12ab (42 mg, 0.124mmol, 93 %). 
Conditions B: CO atmosphere 
Following general procedure B, (2,3-dihydro-1H-inden-2-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11ab (52 mg, 0.133 mmol, 1 equiv) was reacted with 
PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), 
pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) 
in mesitylene (2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, the 
excess of mesitylene was removed by flushing cyclohexane on silica gel, and the resulting crude 
was purified by chromatography using cyclohexane/AcOEt as eluent, providing 1-(2,4,6-
trimethoxybenzyl)-1,2a,7,7a-tetrahydro-2H-indeno[2,1-b]azet-2-one 4.12ab (30.6 mg, 0.09 
mmol, 68 %). 
1H NMR (400 MHz, CDCl3) : δ = 7.44 – 7.39 (m, 1H), 7.23 – 7.16 (m, 3H), 6.13 (s, 2H), 4.56 
(d, J = 13.9 Hz, 1H), 4.43 (d, J = 3.9 Hz, 1H), 4.20 (d, J = 13.9 Hz, 1H), 4.12 – 4.05 (m, 1H), 
3.83 (s, 3H), 3.80 (s, 6H), 3.06 (d, J = 17.6 Hz, 1H), 2.82 (dd, J = 17.5, 6.8 Hz, 1H). 13C NMR 
(CDCl3, 101 MHz) : δ = 168.3, 161.3, 159.6, 142.7, 138.1, 127.7, 127.1, 126.2, 125.2, 104.4, 
90.4, 62.0, 55.8, 55.5, 55.1, 33.3, 32.2. IR (neat): ν = 2939, 1737, 1596, 1459, 1131, 728 cm-
1. HRMS (ESI): Calculated for C20H21NNaO4 ([M+Na]+): 362.1363; found: 362.1365 
1-(2,4,6-trimethoxybenzyl)-2a,3,4,8b-tetrahydronaphtho[1,2-b]azet-2(1H)-one 4.12ac 
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 
4.11ac (51.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 
mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30   
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mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two 
chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed by 
flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 1-(2,4,6-trimethoxybenzyl)-2a,3,4,8b-
tetrahydronaphtho[1,2-b]azet-2(1H)-one 4.12ac (47.0 mg, 0.133 mmol, 100 %). 
Conditions B: CO atmosphere 
Following general procedure B, (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11ac (51.9 mg, 0.133 mmol, 1 equiv) was reacted with 
PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), 
pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) 
in mesitylene (2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, the 
excess of mesitylene was removed by flushing cyclohexane on silica gel, and the resulting crude 
was purified by chromatography using cyclohexane/AcOEt as eluent, providing 1-(2,4,6-
trimethoxybenzyl)-2a,3,4,8b-tetrahydronaphtho[1,2-b]azet-2(1H)-one 4.12ac (22.6 mg, 0.064 
mmol, 48 %). 
1H NMR (400 MHz, CDCl3): δ = 7.22 – 7.12 (m, 1H), 7.12 – 7.06 (m, 1H), 7.02 (s, 1H), 6.80 
(dd, J = 7.4, 1.3 Hz, 1H), 6.00 (s, 2H), 4.44 (d, J = 13.9 Hz, 1H), 4.31 (d, J = 4.9 Hz, 1H), 4.04 
(d, J = 13.8 Hz, 1H), 3.80 (s, 3H), 3.73 (s, 6H), 3.55 – 3.47 (m, 1H), 2.86 – 2.56 (m, 2H), 2.37 
– 2.24 (m, 1H), 1.57 – 1.36 (m, 1H). 13C NMR (CDCl3, 101 MHz):  δ = 169.4, 161.2, 159.6, 
139.9, 133.2, 130.6, 128.4, 127.8, 125.6, 103.8, 90.2, 55.6, 55.5, 53.6, 49.7, 33.0, 27.0, 23.0. 
IR (neat): ν = 2935, 1737, 1597, 1133 cm-1. HRMS (ESI): Calculated for C21H23NNaO4 
([M+Na]+): 376.1519; found: 376.1521 
2(aR,8bR)-1-(2,4,6-trimethoxybenzyl)-2a,3,4,8b-tetrahydronaphtho[1,2-b]azet-2(1H)- 
one (-)-4.12ac 
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Standard synthesis: 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 
4.11ac (51.9 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 
mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 
mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two 
chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed by 
flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 2(aR,8bR)-1-(2,4,6-trimethoxybenzyl)-
2a,3,4,8b-tetrahydronaphtho[1,2-b]azet-2(1H)- one (-)-4.12ac (46.0 mg, 0.130 mmol, 98 %). 
Conditions B: CO atmosphere 
Following general procedure B, (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11ac (51.9 mg, 0.133 mmol, 1 equiv) was reacted with 
PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), 
pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) 
in mesitylene (2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, the 
excess of mesitylene was removed by flushing cyclohexane on silica gel, and the resulting crude 
was purified by chromatography using cyclohexane/AcOEt as eluent, providing 2(aR,8bR)-1-
(2,4,6-trimethoxybenzyl)-2a,3,4,8b-tetrahydronaphtho[1,2-b]azet-2(1H)- one (-)-4.12ac (32 
mg, 0.09 mmol, 63 %).  
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Tenfold scale synthesis: 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (89 mg, 0.4 mmol, 30 
mol%), P(t-Bu)3●HBF4 (120 mg, 0.4 mmol, 30 mol%), COgen (970 mg, 4 mmol, 3.0 equiv), 
Cy2NMe (1.610 g, 7.98 mmol, 6.0 equiv) and mesitylene (5 mL). Chamber B, previously 
charged with (1,2,3,4-tetrahydronaphthalen-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 
4.11ac  (519 mg, 1.33 mmol, 1 equiv) was reacted with PdCl2 (24 mg, 0.133 mmol, 10 mol%), 
cataCXium AHI (120 mg , 0.266 mmol, 20 mol%), pivalic acid (41 mg, 0.4 mmol, 30 mol%) 
and cesium carbonate (1.30 g, 4 mmol, 3.0 equiv) in mesitylene (26.2 mL). The two chambers 
system was reacted for 18h at 120 °C. The excess of mesitylene was removed by flushing 
cyclohexane on silica gel, and the resulting crude was purified by chromatography using 
cyclohexane/AcOEt as eluent, providing 2(aR,8bR)-1-(2,4,6-trimethoxybenzyl)-2a,3,4,8b-
tetrahydronaphtho[1,2-b]azet-2(1H)- one (-)-4.12ac (385 mg, 1.09 mmol, 82 %). 
1H NMR (250 MHz, CDCl3) δ = 7.19 – 7.12 (m, 1H), 7.11 – 6.98 (m, 2H), 6.80 (dd, J = 7.4, 
1.3 Hz, 1H), 5.99 (s, 2H), 4.44 (d, J = 13.9 Hz, 1H), 4.31 (d, J = 4.9 Hz, 1H), 4.04 (d, J = 13.8 
Hz, 1H), 3.80 (s, 3H), 3.73 (s, 6H), 3.51 (t, J = 5.3 Hz, 1H), 2.85 – 2.58 (m, 2H), 2.37 – 2.22 
(m, 1H), 1.58 – 1.42 (m, 1H). 13C NMR (63 MHz, CDCl3) δ = 169.4, 161.2, 159.6, 139.9, 
133.2, 130.6, 128.4, 127.8, 125.6, 103.8, 90.2, 55.6, 55.5, 53.6, 49.7, 33.0, 27.0, 23.0. IR (neat): 
ν = 2935, 1737, 1597, 1133 cm-1. HRMS (ESI): Calculated for C21H23NNaO4 ([M+Na]+): 
376.1519; found: 376.1524 Optical rotation : [a]D20 = -38.8° (c = 1.3, CHCl3) 
1-(2,4,6-trimethoxybenzyl)-1,2a,3,7b-tetrahydro-2H-indeno[1,2-b]azet-2-one 4.12ad	
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with (2,3-dihydro-1H-inden-1-yl)(2,4,6-trimethoxybenzyl)carbamoyl chloride 4.11ad  
(50 mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%),  
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cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two 
chambers system was reacted for 18h at 120 °C. The excess of mesitylene was removed by 
flushing cyclohexane on silica gel, and the resulting crude was purified by chromatography 
using cyclohexane/AcOEt as eluent, providing 1-(2,4,6-trimethoxybenzyl)-1,2a,3,7b-
tetrahydro-2H-indeno[1,2-b]azet-2-one 4.12ad (21 mg, 0.062 mmol, 47 %). 
Conditions B: CO atmosphere 
Following general procedure B, (2,3-dihydro-1H-inden-1-yl)(2,4,6-
trimethoxybenzyl)carbamoyl chloride 4.11ad (50 mg, 0.133 mmol, 1 equiv) was reacted with 
PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 20 mol%), 
pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) 
in mesitylene (2.62 mL), under CO atmosphere. The mixture was stirred for 18h at 120 °C, the 
excess of mesitylene was removed by flushing cyclohexane on silica gel, and the resulting crude 
was purified by chromatography using cyclohexane/AcOEt as eluent, providing 1-(2,4,6-
trimethoxybenzyl)-1,2a,3,7b-tetrahydro-2H-indeno[1,2-b]azet-2-one 4.12ad (11 mg, 0.032 
mmol, 25 %). 
1H NMR (400 MHz, CDCl3) δ = 7.28 – 7.23 (m, 2H), 7.15 – 7.11 (m, 2H), 6.13 (s, 2H), 4.72 
(dd, J = 4.2, 1.0 Hz, 1H), 4.56 (d, J = 14.1 Hz, 1H), 4.04 (d, J = 14.1 Hz, 1H), 3.85 – 3.82 (m, 
10H), 3.36 – 3.27 (m, 1H), 2.97 (dd, J = 17.4, 10.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 
169.7, 161.3, 159.7, 145.2, 139.6, 128.7, 126.4, 126.4, 126.0, 104.7, 90.5, 62.0, 55.8, 55.5, 52.3, 
33.0, 30.2. IR (neat): ν = 1743, 670 cm-1. HRMS (ESI): Calculated for C20H21NNaO4 
([M+Na]+): 312.1368; found: 312.1369 
7-cyclohexyl-7-azabicyclo[4.2.0]octan-8-one 4.12ae  
 
Conditions A: Double-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg, 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with dicyclohexylcarbamoyl chloride 4.11ae (32.4 mg, 0.133 mmol, 1 equiv) was   
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reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 0.0266 mmol, 
20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (130 mg, 0.4 
mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h at 
120 °C. The excess of mesitylene was removed by flushing cyclohexane on silica gel, and the 
resulting crude was purified by chromatography using cyclohexane/AcOEt as eluent, providing 
7-cyclohexyl-7-azabicyclo[4.2.0]octan-8-one 4.12ae (8.5 mg, 0.041 mmol, 29 %). 
Conditions B: CO atmosphere 
Following general procedure B, dicyclohexylcarbamoyl chloride 4.11ae (32.4 mg, 0.133 mmol, 
1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate 
(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO atmosphere. The mixture 
was stirred for 18h at 120 °C, the excess of mesitylene was removed by flushing cyclohexane 
on silica gel, and the resulting crude was purified by chromatography using cyclohexane/AcOEt 
as eluent, providing 7-cyclohexyl-7-azabicyclo[4.2.0]octan-8-one 4.12ae  (7 mg, 0.034 mmol, 
25 %). 
1H NMR (250 MHz, CDCl3) δ = 3.78 (dt, J = 5.5, 3.6 Hz, 1H), 3.46 (ddt, J = 11.5, 7.8, 3.8 Hz, 
1H), 3.08 (td, J = 5.6, 4.1 Hz, 1H), 1.89 – 1.20 (m, 22H + H2O). 13C NMR (63 MHz, CDCl3) 
δ = 170.3, 51.5, 49.3, 46.1, 32.0, 30.7, 25.4, 25.3, 24.7, 19.6, 18.7, 16.9. IR (neat): ν = 2932, 
1732 cm-1. HRMS (ESI): Calculated for C13H21NNaO ([M+Na]+): 230.1515; found: 230.1513 
Trans-4-ethyl-3-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one and Cis-4-ethyl-3-
methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12af 
 
Conditions A : Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol, 30 
mol%), P(t-Bu)3●HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL). Chamber B, previously 
charged with Pentan-3-S78yl(2,4,6-trimethoxybenzyl)carbamoyl 4.11af (43.9mg, 0.133 mmol, 
1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), cataCXium AHI (12 mg, 
0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate   
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(130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL). The two chambers system was reacted 
for 18h at 120 °C. The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to 
provide Trans-4-ethyl-3-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12af as major 
diastereoisomer (20 mg, 0.068 mmol, 51 %, d.r. 85:15). 
Conditions B : CO atmosphere 
Following general procedure B, Pentan-3-yl(2,4,6-trimethoxybenzyl)carbamoyl 4.11af (43.9 
mg, 0.133 mmol, 1 equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), 
cataCXiumAHI (12 mg, 0.0266 mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) 
and cesium carbonate (130 mg, 0.4 mmol, 3.0 equiv) in mesitylene (2.62 mL), under CO 
atmosphere. The mixture was sztirred for 18h at 120°C. The crude mixture was purified by 
flash chromatography using first cyclohexane to elute mesitylene and then cyclohexane/EtOAc 
(75:25 to 0:1) as eluent, to provide Trans-4-ethyl-3-methyl-1-(2,4,6-
trimethoxybenzyl)azetidin-2-one 4.12af as major diastereoisomer (16 mg, 0.055 mmol, 41 %, 
d.r. 85:15). 
Trans-4-ethyl-3-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one (major diastereoisomer)  
1H NMR (250 MHz, CDCl3) δ = 6.11 (s, 2H), 4.55 (d, J = 13.9 Hz, 1H), 4.16 (dd, J = 13.9, 
1.1 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 6H), 2.78 –2.74 (m, 1H), 2.66 –2.61(m, 1H), 1.71 –1.63 (m, 
1H), 1.34 –1.26 (m, 1H), 1.17 (d, J = 7.3 Hz, 3H), 0.81 (t, J = 7.5 Hz, 3H). 13C NMR (63 MHz, 
CDCl3) δ = 170.5, 161.1, 159.7, 104.5, 90.3, 60.9, 55.8, 55.4, 48.9, 32.7, 25.2, 13.4, 9.4. IR 
(neat): ν =2952, 1749, 1610, 1140, 740 cm-1. HRMS (ESI): Calculated for C16H23NNaO4 
([M+Na]+): 316.1525; found: 316.1528 
Cis-4-ethyl-3-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one (minor diastereoisomer) : 
1H NMR (250 MHz, CDCl3) δ = 6.11 (s, 2H), 4.58 (d, J = 13.4 Hz, 1H), 4.11 (d, J = 14.0 Hz, 
1H), 3.81 (s, 3H), 3.80 (s, 6H), 3.18 –3.14 (m, 1H), 3.10 –3.04 (m, 1H), 1.72 –1.66 (m, 1H), 
1.43 –1.35 (m, 1H), 1.16 (d, J = 6.6 Hz, 3H), 0.81 (t, J = 7.5 Hz, 3H). 13C NMR (63 MHz, 
CDCl3) δ = 171.0, 56.3, 55.8, 46.3, 32.6, 21. 
  
262 
 
3.10. Synthesis of phosphonites 
Diethyl (4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate 4.15 
 
To a stirred solution of (+)-diethyl L-tartrate (2,49 mL, 14.5 mmol) in toluene (30 mL) was 
added 2,2-dimethoxypropane (5,33 mL, 43.4 mmol, 3 equiv) and TsOH (125 mg, 0.725 mmol) 
at romm temperature. The mixture was refluxed overnight. The mixture was allowed to room 
temperature and was quenched with a NaHCO3 solution. The biphasic mixture was extracted 
three times with EtOAc. The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude mixture was purified by silica gel 
chromatography to afford dimethyl 2,3-O-isopropylidene L-tartrate (3.35 g,13.62 mmol, 94%) 
as a colorless liquid. 
1H NMR (400 MHz, Chloroform-d) : δ = 4.65 (s, 2H), 4.17 (q, J = 7.2 Hz, 4H), 1.38 (s, 6H), 
1.21 (t, J = 7.2 Hz, 7H). Optical rotation : [α]D25 = ‒ 39.3 (c = 1.0, CHCl3) Lit.189 [a]D20 = -
40.2° (c = 1.03, CHCl3). 
 
TADDOL 4.16a190, 4.16b191, 4.16c190, 4.16d190, 4.16e192, 4.16f193, 4.16g191 were prepared 
according to the general procedure “TADDOL” and the reaction scheme shown below. All 
spectral data were in accordance with the literature. 
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(3aR,8aR)-2,2-Dimethyl-4,4,6,8,8-pentaphenyltetrahydro-
[1,3]dioxolo[4,5e][1,3,2]dioxaphosphepine 4.16a 
 
Following general procedure “Phosphonite”, 4.16a was obtained as a white solid (113 mg, 0.2 
mmol, 66 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 7.90 – 7.79 (m, 4H), 7.63 – 7.56 (m, 2H), 7.50 – 
7.43 (m, 7H), 7.39 – 7.15 (m, 12H), 5.63 (dd, J = 8.6, 4.7 Hz, 1H), 4.79 (d, J = 8.6 Hz, 1H), 
1.54 (s, 3H), 0.21 (s, 3H). 13C NMR (101 MHz, Chloroform-d) : δ = 146.9, 146.0 (d, JC,P = 
3.8 Hz), 142.0 (d, JC,P = 1.7 Hz), 141.5 (d, JC,P = 2.2 Hz), 141.3 (d, JC,P = 10.9 Hz), 130.9, 
130.2, 129.9, 129.5, 128.7, 128.7, 128.6, 128.5, 128.3, 128.1, 127.8, 127.8, 127.7, 127.6, 127.5, 
127.4, 127.3, 111.5, 84.1 (d, JC,P = 4.2 Hz), 83.4 (d, JC,P = 7.6 Hz), 82.7 (d, JC,P = 23.5 Hz), 
82.3 (d, JC,P = 4.3 Hz), 28.0, 24.9. 31P NMR (162 MHz, Chloroform-d) : δ = 156.5. Optical 
rotation : [a]D20 = +78.2° (c = 1.0, CHCl3) 
(3aR,8aR)-4,4,8,8-Tetrakis(3,5-di-tert-butylphenyl)-2,2-dimethyl-6-phenyltetrahydro-
[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine 4.16b 
 
Following general procedure “Phosphonite”, 4.16b was obtained as a white solid (211 mg, 
0.207 mmol, 69 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 7.92 – 7.85 (m, 2H), 7.58 – 7.53 (m, 2H), 7.46 – 
7.43 (m, 2H), 7.39 – 7.36 (m, 3H), 7.34 – 7.30 (m, 2H), 7.18 – 7.13 (m, 2H), 7.12 – 7.08 (m, 
2H), 7.05 – 7.03 (m, 2H), 5.49 (dd, J = 8.7, 3.6 Hz, 1H), 4.79 (d, J = 8.7 Hz, 1H), 1.46 (s, 3H), 
1.18 (s, 18H), 1.15 (s, 18H), 1.14 (s, 18H), 1.12 (s, 18H), 0.00 (s, 3H).   
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13C NMR (101 MHz, Chloroform-d) : δ = 149.8 (d, JC,P = 23.0 Hz), 149.0 (d, JC,P = 9.8 Hz), 
146.5, 145.7 (d, JC,P = 4.2 Hz), 142.7 (d, JC,P = 11.6 Hz), 141.7 (d, JC,P = 1.8 Hz), 140.7 (d, JC,P 
= 1.3 Hz), 130.7, 130.3, 130.1, 128.3, 128.3, 124.0, 122.4, 121.8, 120.9, 120.6, 120.6, 120.4, 
110.2, 84.5 (d, JC,P = 4.6 Hz), 84.4 (d, JC,P = 7.3 Hz), 84.2 (d, JC,P = 19.7 Hz), 83.3 (d, JC,P = 
5.3 Hz), 35.2, 35.1, 34.9, 31.7, 31.7, 31.6, 31.6, 31.5, 28.3, 23.8. 31P NMR (162 MHz, 
Chloroform-d) : δ = 155.0. Optical rotation : [a]D20 = -40.2° (c = 1.0, CHCl3) 
 
(3aR,8aR)-4,4,8,8-Tetrakis(4-fluorophenyl)-2,2-dimethyl-6-phenyltetrahydro-
[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine 4.16c 
 
 
Following general procedure “Phosphonite”, 4.16c was obtained as a white solid (174 mg, 0.27 
mmol, 90 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 7.91 – 7.76 (m, 4H), 7.63 – 7.52 (m, 4H), 7.51 – 
7.36 (m, 4H), 7.19 – 6.94 (m, 9H), 5.53 (dd, J = 8.7, 4.7 Hz, 1H), 4.70 (d, J = 8.7 Hz, 1H), 1.58 
(s, 3H), 0.35 (s, 3H). 13C NMR (101 MHz, Chloroform-d) : Many signals due to C-P and C-
F coupling 19F NMR (376 MHz, Chloroform-d) : δ = -113.9, -114.3, -115.1, -115.2. 31P NMR 
(162 MHz, Chloroform-d) : δ = 156.9. Optical rotation : [a]D20 = -72.5° (c = 1.0, CHCl3) 
HRMS (ESI): Calculated for C37H29F4NaO4P ([M+Na]+): 667.1632; found: 667.1643 
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(3aR,8aR)-2,2-Dimethyl-6-phenyl-4,4,8,8-tetra-p-tolyltetrahydro-[1,3]dioxolo[4,5-
e][1,3,2]dioxaphosphepine 4.16d 
 
 
Following general procedure “Phosphonite”, 4.16d was obtained as a white solid (170 mg, 0.27 
mmol, 90 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 7.88 – 7.81 (m, 2H), 7.78 – 7.72 (m, 2H), 7.51 – 
7.44 (m, 4H), 7.37 – 7.30 (m, 4H), 7.19 – 6.99 (m, 9H), 5.58 (dd, J = 8.7, 4.7 Hz, 1H), 4.77 (d, 
J = 8.6 Hz, 1H), 2.35 – 2.23 (m, 12H), 1.53 (s, 3H), 0.24 (s, 3H). 13C NMR (101 MHz, 
Chloroform-d) : δ = 144.3, 143.5 (d, JC,P = 3.7 Hz), 141.6 (d, JC,P = 10.9 Hz), 139.1 – 139.0 
(m), 138.9 (d, JC,P = 1.9 Hz), 137.2 (d, JC,P = 10.6 Hz), 136.8 (d, JC,P = 5.5 Hz), 130.7, 130.1, 
129.9, 129.4, 128.9, 128.8, 128.6, 128.6, 128.5, 128.4, 128.0, 127.4, 127.4, 111.3, 84.2 (d, JC,P 
= 3.4 Hz), 83.2 (d, JC,P = 7.6 Hz), 82.8 (d, JC,P = 23.5 Hz), 82.2 (d, JC,P = 4.5 Hz), 28.0, 25.0, 
21.3, 21.2, 21.2, 21.1. 31P NMR (162 MHz, Chloroform-d) : δ = 155.6. Optical rotation : 
[a]D20 = +58.4° (c = 1.06, CHCl3). HRMS (ESI): Calculated for C41H41O4P ([M+H]+): 
629.2815; found: 629.2807 
 
(3aR,8aR)-2,2-Dimethyl-4,4,8,8-tetrakis(perfluorophenyl)-6-phenyltetrahydro-
[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine 4.16e 
 
 
Following general procedure “Phosphonite”, 4.16e was obtained as a white solid (221 mg, 
0.237 mmol, 79 %).  
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1H NMR (400 MHz, Chloroform-d) : δ = 7.65 – 7.58 (m, 2H), 7.43 – 7.35 (m, 3H), 5.90 (d, J 
= 8.2 Hz, 1H), 5.68 (d, J = 8.2 Hz, 1H), 1.07 (s, 3H), 0.82 (s, 3H). 13C NMR (101 MHz, 
Chloroform-d) : Many signals due to C-P and C-F coupling. 19F NMR (376 MHz, 
Chloroform-d) : δ = -131.0 – -131.2 (m), -134.4 – -134.9 (m), -138.0 – -138.5 (m), -139.3 – -
139.9 (m), -150.5 – -150.9 (m), -151.3 – -151.7 (m), -151.9 – -152.1 (m), -152.5 – -152.7 (m), 
-160.0 – -160.2 (m), -160.7 – -160.9 (m), -161.0 – -161.3 (m), -161.4 – -161.8 (m). 31P NMR 
(162 MHz, Chloroform-d) : δ = 155.8. Optical rotation : [a]D20 = -94.5° (c = 1.0, CHCl3) 
HRMS (ESI): Calculated for C37H13F20O4P ([M+H]+): 933.0305; found: 933.0303 
(3aR,8aR)-4,4,8,8-Tetrakis(3,5-diisopropylphenyl)-2,2-dimethyl-6-phenyltetrahydro-
[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine 4.16f 
 
Following general procedure “Phosphonite”, L6 was obtained as a white solid (229 mg, 0.254 
mmol, 84 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 7.80 – 7.75 (m, 2H), 7.42 – 7.39 (m, 2H), 7.34 – 
7.30 (m, 3H), 7.23 – 7.20 (m, 2H), 7.11 – 7.06 (m, 2H), 6.89 – 6.74 (m, 6H), 5.47 (dd, J = 8.6, 
4.2 Hz, 1H), 4.80 (d, J = 8.6 Hz, 1H), 2.74 – 2.67 (m, 8H), 1.40 (s, 3H), 1.09 – 1.01 (m, 48H), 
0.00 (s, 3H). 13C NMR (101 MHz, Chloroform-d) : δ = 148.1 (d, JC,P = 14.1 Hz), 147.3 (d, 
JC,P = 17.7 Hz), 146.9, 146.5 (d, JC,P = 4.2 Hz), 142.3 (d, JC,P = 12.1 Hz), 141.8 (d, JC,P = 1.8 
Hz), 141.6 (d, JC,P = 1.9 Hz), 130.6, 130.2, 130.0, 128.4, 128.3, 125.2, 125.0, 124.9, 123.7, 
123.7, 123.6, 123.5, 123.3, 110.6, 84.5 (d, JC,P = 4.4 Hz), 84.0 (d, JC,P = 7.1 Hz), 83.5 (d, JC,P 
= 21.6 Hz), 83.0 (d, JC,P = 4.7 Hz), 34.6, 34.3, 34.3, 34.2, 28.2, 24.4, 24.3, 24.2, 24.2, 24.1, 
24.0.31P NMR (162 MHz, Chloroform-d) : δ = 155.46. Optical rotation : [a]D20 = +16.2° (c 
= 1.0, CHCl3) 
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(3aR,8aR)-4,4,8,8-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-2,2-dimethyl-6-
phenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine 4.16g 
 
Following general procedure “Phosphonite”, 4.16g was obtained as a yellow solid (271 mg, 
0.243 mmol, 81 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.35 – 8.31 (m, 2H), 8.05 – 8.00 (m, 2H), 7.94 – 
7.78 (m, 10H), 7.68 – 7.62 (m, 3H), 5.39 (dd, J = 8.8, 4.6 Hz, 1H), 4.48 (d, J = 8.7 Hz, 1H), 
1.65 (s, 3H), 0.34 (s, 3H). 13C NMR (101 MHz, Chloroform-d) : Many signals due to C-P and 
C-F coupling. 19F NMR (376 MHz, Chloroform-d) : δ = -63.1, -63.15, -63.21, -63.22. 31P 
NMR (162 MHz, Chloroform-d) : δ = 161.8. HRMS (ESI): Calculated for C45H26F24O4P 
([M+H]+): 1117.1185; found: 1117.1180 
Diethyl (2R,3R)-1,4-dioxaspiro[4.4]nonane-2,3-dicarboxylate 4.18 
 
To a solution of (+)-diethyl L-tartrate (8.33 mL, 48.5 mmol, 1 equiv) in toluene (50 mL) 
equipped with a Dean-Stark apparatus was added cyclopentanone (5.15 mL, 58.2 mmol, 1.2 
equiv) and p-toluenesulfonic acid monohydrate (0,923 g, 4.85 mmol, 0.1 equiv). The reaction 
mixture was heated at 140°C until no evolution of water was observed. The reaction mixture 
was extracted with ethyl acetate, dried over MgSO4 and concentrated under reduced pressure. 
The crude mixture was purified by silica gel chromatography to afford 4.18 (2.2 g, 8.1 mmol, 
17%) as a colorless oil.  
1H NMR (400 MHz, Chloroform-d) : δ = 4.73 (s, 2H), 4.27 (q, J = 7.1 Hz, 4H), 2.02 – 1.95 
(m, 2H), 1.90 – 1.83 (m, 2H), 1.81 – 1.78 (m, 1H), 1.73 – 1.68 (m, 3H), 1.32 (t, J = 7.1 Hz, 6H). 
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((2R,3R)-1,4-dioxaspiro[4.4]nonane-2,3-diyl)bis(bis(3,5-
bis(trifluoromethyl)phenyl)methanol) 4.16h 
 
Following general procedure “TADDOL”, the Grignard reagent generated from 3,5- 
bis(trifluoromethyl)bromobenzene (3.22 g, 11 mmol, 5.0 equiv) and magnesium (283 mg, 11.7 
mmol, 5.3 equiv) in THF was reacted with Diethyl (2R,3R)-1,4-dioxaspiro[4.4]nonane-2,3-
dicarboxylate 4.18 (600 mg, 2.2 mmol, 1.0 equiv). The crude mixture was purified by flash 
chromatography affording 4.16h (1,75 g, 1.68 mmol, 77%) as a yellow oil which solidified 
under vacuum. 
1H NMR (400 MHz, Chloroform-d) : δ = 8.05 (s, 4H), 7.94 (s, 2H), 7.84 (s, 6H), 4.94 (s, 2H), 
4.28 (s, 2H), 1.73 – 1.39 (m, 8H). 13C NMR (101 MHz, Chloroform-d) : δ =145.9, 143.6, 
132.32 (q, JC,F = 33.7 Hz), 131.87 (q, JC,F = 33.7 Hz), 128.23 (m), 127.55 (m), 123.3 (q, JC,F = 
273 Hz), 123.1 (q, JC,F = 273 Hz), 122.80 (m), 120.9, 81.2, 77.4, 77.1, 36.8, 22.6.19F NMR (376 
MHz, Chloroform-d) : -63.06, -63.19.  
(3a'R,8a'R)-4',4',8',8'-tetrakis(3,5-bis(trifluoromethyl)phenyl)-6'-
phenyltetrahydrospiro[cyclopentane-1,2'-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine] 
4.17h 
 
Following general procedure “Phosphonite”, 4.17h was obtained as a yellow solid (300 mg, 
0.271 mmol, 91 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.30 – 8.28 (m, 2H), 8.02 – 8.00 (m, 2H), 7.90 – 
7.88 (m, 3H), 7.88 – 7.86 (m, 2H), 7.85 – 7.84 (m, 3H), 7.83 – 7.76 (m, 2H), 7.71 – 7.61 (m, 
2H), 5.42 (dd, J = 8.7, 4.8 Hz, 1H), 4.38 (d, J = 8.7 Hz, 1H), 2.28 – 2.17 (m, 1H), 2.13 – 2.00 
(m, 1H), 1.76 – 1.62 (m, 2H), 1.50 – 1.37 (m, 1H), 1.33 – 1.27 (m, 1H), 0.57 – 0.45 (m, 1H), 
0.39 – 0.25 (m, 1H).   
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13C NMR (101 MHz, Chloroform-d) : Many signals due to C-P and C-F coupling. 19F NMR 
(376 MHz, Chloroform-d)  : δ =  -63.1, -63.1, -63.1, -63.2. 31P NMR (162 MHz, Chloroform-
d) : δ = 161.67.  
Diethyl (2R,3R)-2,3-bis(benzyloxy)succinate 4.19 
 
To a stirred suspension of NaH 60% (400 mg, 9.98 mmol, 2 equiv) in DMF (12 mL) at 0°C 
were added dropwise a solution of  (+)-diethyl L-tartrate (0.857 mL, 4.99 mmol, 1 equiv) in 
DMF (3 mL). The resulting mixture was stirred during two hours at 0°C, then benzyl bromide 
(1.8 mL, 15 mmol, 3 equiv) was added to the reaction mixture and the reaction was stirred for 
two hours at room temperature. The reaction was quenched with sat. NaHCO3 and extracted 
with diethyl ether. The combined organic layers were washed with water, dried over MgSO4, 
filtered and concentrated under reduce pressure. The crude mixture was purified by silica gel 
chromatography to afford 4.19 (750 mg, 1,941 mmol, 39%) as a colorless oil.  
1H NMR (400 MHz, Chloroform-d) : δ = 7.32 – 7.27 (m, 2H), 7.25 – 7.19 (m, 3H), 4.84 (d, J 
= 12.0 Hz, 2H), 4.42 (d, J = 12.0 Hz, 2H), 4.36 (s, 2H), 4.21 – 4.12 (m, 2H), 4.03 (m, 2H), 1.14 
(t, J = 7.2 Hz, 6H). 
(2R,3R)-2,3-bis(benzyloxy)-1,1,4,4-tetrakis(3,5-bis(trifluoromethyl)phenyl)butane-1,4-
diol 4.16i 
 
Following general procedure “TADDOL”, the Grignard reagent generated from 3,5- 
bis(trifluoromethyl)bromobenzene (2.27 g, 7.75 mmol, 5.0 equiv) and magnesium (200 mg, 
8.22 mmol, 5.3 equiv) in THF was reacted with diethyl (2R,3R)-2,3-bis(benzyloxy)succinate 
4.19 (600 mg, 1.55 mmol, 1.0 equiv). The crude mixture was purified by flash chromatography 
affording 4.16i (240 mg, 0,21 mmol, 14%) as a yellow oil which solidified under vacuum.   
270 
 
1H NMR (400 MHz, Chloroform-d) : δ = 8.17 (s, 4H), 8.03 – 7.92 (m, 4H), 7.92 – 7.86 (m, 
4H), 7.27 – 7.11 (m, 6H), 6.72 – 6.53 (m, 4H), 4.62 (s, 4H), 3.62 – 3.57 (m, 2H), 3.42 – 3.35 
(m, 2H). 13C NMR (101 MHz, Chloroform-d) : 147.0, 144.3, 135.7, 132.6 (q, JC,F = 33.9 Hz), 
131.9 (q, JC,F = 33.6 Hz), 128.62, 128.43, 128.22 (m), 127.29, 127.07 (m), 122.74 (m), 123.2 
(q, JC,F = 273 Hz), 123.1 (q, JC,F = 273 Hz),  122.47 (m), 81.0, 78.7, 77.4, 74.7. 19F NMR (376 
MHz, Chloroform-d) : δ = -63.13, -63.17. 
(5R,6R)-5,6-bis(benzyloxy)-4,4,7,7-tetrakis(3,5-bis(trifluoromethyl)phenyl)-2-phenyl-
1,3,2-dioxaphosphepane 4.17i 
 
Following general procedure “Phosphonite”, 4.17i was obtained as a yellow solid (180 mg, 
0.148 mmol, 92 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.43 – 8.36 (m, 2H), 8.19 – 8.14 (m, 2H), 8.10 – 
8.03 (m, 1H), 7.99 – 7.94 (m, 1H), 7.89 – 7.85 (m, 3H), 7.80 – 7.71 (m, 2H), 7.67 – 7.64 (m, 
2H), 7.62 – 7.53 (m, 4H), 7.37 – 7.30 (m, 3H), 7.15 – 6.97 (m, 5H), 6.46 – 6.19 (m, 2H), 5.28 
(d, J = 10.5 Hz, 1H), 5.10 (dd, J = 7.8, 5.1 Hz, 1H), 4.45 (d, J = 10.7 Hz, 1H), 4.37 (d, J = 7.8 
Hz, 1H), 4.01 (d, J = 11.1 Hz, 1H), 3.27 (d, J = 11.1 Hz, 1H). 13C NMR (101 MHz, 
Chloroform-d) : Many signals due to C-P and C-F coupling. 19F NMR (376 MHz, 
Chloroform-d) : δ = -62.9, -63.0, -63.0, -63.2. 
Diethyl (2R,3R)-2,3-dimethoxysuccinate 4.20 
 
 
To a stirred suspension of NaH 60% (2 g, 50 mmol, 2 equiv) in diethyl ether (250 mL) at 0°C 
were added (+)-diethyl L-tartrate (4.13 mL, 25 mmol, 1 equiv) and dimethyl sulfate (4.91 mL, 
51.2 mmol, 2.05 equiv). The resulting mixture was stirred overnight at room temperature. The 
reaction was quenched with sat. NaHCO3, the aqueous phase extracted with diethyl ether. The 
combined organic layers were washed with water, dried over MgSO4, filtered and concentrated 
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under reduce pressure. The crude mixture was purified by silica gel chromatography to afford 
4.20 (4.976 g, 21.242 mmol, 85%) as a colorless oil.  
1H NMR (400 MHz, Chloroform-d) : δ = 4.33-4.19 (m, 4H), 4.21 (s, 2H,), 3.45 (s, 6H), 1.30 
(t, J = 7.2 Hz, 6 H).  
(2R,3R)-1,1,4,4-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-2,3-dimethoxybutane-1,4-diol 
4.16j 
 
Following general procedure “TADDOL”, the Grignard reagent generated from 3,5- 
bis(trifluoromethyl)bromobenzene (12.5 g, 42.7 mmol, 5.0 equiv) and magnesium (1.1 g, 45.3 
mmol, 5.3 equiv) in THF was reacted with diethyl (2R,3R)-2,3-dimethoxysuccinate (2 g, 8.54 
mmol, 1.0 equiv). The crude mixture was purified by flash chromatography affording 6.3 g 
(6.31 mmol, 74%) of a yellow oil which solidified under vacuum. 
1H NMR (400 MHz, Chloroform-d) : δ = 8.11 – 8.06 (m, 4H), 7.95 – 7.91 (m, 4H), 7.92 – 
7.90 (m, 2H), 7.86 – 7.84 (m, 5H), 4.42 (s, 2H), 4.23 (s, 2H), 2.46 (s, 6H). 13C NMR (101 MHz, 
Chloroform-d) : δ = 146.72, 144.93, 132.71 (q, JC,F = 33.7 Hz), 132.07 (q, JC,F = 33.6 Hz), 
127.39 – 127.16 (m), 126.77 – 126.46 (m), 123.2 (q, JC,F = 273 Hz), 123.1 (q, JC,F = 273 Hz), 
122.47 (m), 122.42 – 122.21 (m), 84.21, 78.77, 60.66. 19F NMR (376 MHz, Chloroform-d) : 
δ = -63.12, -63.24. IR (neat): ν = 3290, 2884, 1625, 1460, 1365, 1005, 762 cm-1. HRMS (ESI): 
Calculated for C38H22F24O4 ([M-H]-): 997.1077; found: 997.1062. Optical rotation : [a]D20 = 
-1° (c = 1.0, CHCl3) 
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(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-5,6-dimethoxy-2-phenyl-1,3,2-
dioxaphosphepane 4.17j 
 
Following general procedure “Phosphonite”, 4.17j was obtained as a yellow solid (292 mg, 
0.264 mmol, 88 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.28 – 8.25 (m, 2H), 8.07 – 8.06 (m, 2H), 8.01 – 
7.98 (m, 1H), 7.89 (s, 1H), 7.88 (s, 1H), 7.85 (s, 2H), 7.79 (s, 1H), 7.77 – 7.71 (m, 2H), 7.69 (s, 
2H), 7.63 – 7.53 (m, 3H), 4.73 (dd, J = 7.9, 5.0 Hz, 1H), 3.86 (d, J = 7.9 Hz, 1H), 3.65 (s, 3H), 
2.55 (s, 3H). 13C NMR (101 MHz, Chloroform-d) : Many signals due to C-P and C-F 
coupling. 19F NMR (376 MHz, Chloroform-d)  : δ = -62.9, -63.0, -63.1, -63.2. 31P NMR (162 
MHz, Chloroform-d) : δ = 160.0. Optical rotation : [a]D20 = -36.0° (c = 1.01, CHCl3). HRMS 
(ESI): Calculated for C44H26F24O4P ([M+H]+): 1105.1180; found: 1105.1173 
Dichloro(3,5-bis(trifluoromethyl)phenyl)phosphine 4.20a 
 
Following general procedure “Dichloroarylphosphine”, the aryl lithium reagent generated from 
3,5- bis(trifluoromethyl)bromobenzene (6.16 g, 21.00 mmol, 1.0 equiv) and nbutyl lithium 
(2.13 M, 9.86 mL, 21.00 mmol, 1.0 equiv) in Et2O was reacted with (Et2N)2PCl (4.87 g, 4.87 
mL, 23.10 mmol, 1.1 equiv) and hydrogen chloride (2 M, 47.30 mL, 94.50 mmol, 4.5 equiv) in 
Et2O (47 mL). The crude mixture was purified by distillation under reduced pressure (6 x 10-2 
mbar, 35-45°C) affording 3.34 g (10.50 mmol, 50%) of a colorless oil. 
31P{1H} NMR (Chloroform-d, 162 MHz) : δ = 151.5 ppm. 19F{1H} NMR (Chloroform-d, 
376 MHz) : δ = -63.0 ppm. The physical and spectroscopic properties matched those described 
in the literature61. 
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Dichloro(o-tolyl)phosphine  4.20b 
 
Following general procedure “Dichloroarylphosphine”, the Grignard reagent formed from 2-
bromotoluene (3.83 mL, 31.8 mmol, 1.5 equiv) and magnesium (0.77 g, 31.8 mmol, 1.5 equiv) 
was reacted with (Et2N)2PCl (4.47 g, 21.2 mmol, 1.0 equiv) and HCl (2 M, 53 mL, 106.00 
mmol, 5 equiv) in Et2O (45 mL). The crude mixture was purified by distillation under reduced 
pressure (6x10-2 mbar, 55-60°C) affording 2.05 g (10.6 mmol, 50%) of a colorless oil. 
31P{1H} NMR (Chloroform-d, 162 MHz) : δ = 163.3 ppm. The physical and spectroscopic 
properties matched those described in the literature61.  
Dichloro(naphthalen-1-yl)phosphine 4.20c 
 
Following general procedure “Dichloroarylphosphine”, the Grignard reagent formed from 1-
bromo-naphtalene (4.35 g, 21.0 mmol, 1.1 equiv) and magnesium (0.51 g, 21 mmol, 1.1 equiv) 
was reacted with (Et2N)2PCl (4.0 g, 19.1 mmol, 1.0 equiv) and HCl (2 M, 47.8 mL, 95.5 mmol, 
5 equiv) in Et2O (40 mL). The crude mixture was purified by distillation under reduced pressure 
(10-1 mbar, 100-105°C) affording 2.85 g (12.4 mmol, 65%) of a colorless oil. 
31P{1H} NMR (Chloroform-d, 162 MHz) : δ = 162.8 ppm. The physical and spectroscopic 
properties matched those described in the literature194. 
Dichloro(3,5-di-tert-butylphenyl)phosphine 4.20d 
 
Following general procedure “Dichloroarylphosphine”, the Grignard reagent formed from 1-
bromo-3,5-di-tert-butylbenzene (5.65 g, 21.0 mmol, 1.1 equiv) and magnesium (0.51 g, 21 
mmol, 1.1 equiv) was reacted with (Et2N)2PCl (4.0 g, 19.1 mmol, 1.0 equiv) and HCl (2 M, 
47.8 mL, 95.5 mmol, 5 equiv) in Et2O (40 mL). The crude mixture was purified by distillation 
under reduced pressure (4x10-1 mbar, 105-110°C) affording 1.1 g (3.78 mmol, 20%) of a 
colorless oil.   
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31P{1H} NMR (Chloroform-d, 162 MHz) : δ = 164.0 ppm. The physical and spectroscopic 
properties matched those described in the literature195. 
Dichloro(3,5-dimethoxyphenyl)phosphine 4.20e 
 
Following general procedure “Dichloroarylphosphine”, the aryl lithium reagent generated from 
1-bromo-3,5-dimethoxybenzene (5.00 mg, 23.00 mmol, 1.0 equiv) and n-butyllithium (2 M, 
11.5 mL, 23.00 mmol, 1.0 equiv) in Et2O at -78 °C was reacted with (Et2N)2PCl (5.34 g, 25.30 
mmol, 1.1 equiv) and hydrogen chloride (2 M, 0.052 mL, 103.00 mmol, 4.5 equiv) in Et2O (52 
mL). The crude mixture was purified by distillation under reduced pressure (3 x 10-3 mbar, 104-
106 °C) affording 2.17 g (8.98 mmol, 39%) of a colorless oil. 
31P{1H} NMR (Chloroform-d, 162 MHz) : δ = 160.9 ppm. The physical and spectroscopic 
properties matched those described in the literature61.  
Dichloro(3,5-diisopropyl-4-methoxyphenyl)phosphine 4.20f 
 
Following general procedure Dichloroarylphosphine, the aryl lithium reagent generated from 
5-bromo-1,3-diisopropyl-2-methoxybenzene (5.0 g, 16.7 mmol, 1.0 equiv) and n-butyllithium 
(2 M, 11.5 mL, 16.7 mmol, 1.0 equiv) in Et2O at -78 °C was reacted with (Et2N)2PCl (3.5 g, 
16.7 mmol, 1.0 equiv) and hydrogen chloride (2 M, 47.7 mL, 83.5 mmol, 5 equiv) in Et2O (35 
mL). The crude mixture was purified by distillation under reduced pressure (4 x 10-1 mbar, 
110°C) affording 2.0 g (6.8 mmol, 41%) of a colorless oil. 
31P{1H} NMR (Chloroform-d, 162 MHz) : δ = 162.9 ppm. 
Dichloro(3,5-di-tert-butyl-4-methoxyphenyl)phosphine 4.20g 
 
Following general procedure “Dichloroarylphosphine”, the aryl lithium reagent generated from 
5-bromo-1,3-di-tert-butyl-2-methoxybenzene (4.5 g, 16.7 mmol, 1.0 equiv) and n-butyllithium   
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(2 M, 11.5 mL, 16.7 mmol, 1.0 equiv) in Et2O at -78 °C was reacted with (Et2N)2PCl (3.5 g, 
16.7 mmol, 1.0 equiv) and hydrogen chloride (2 M, 47.7 mL, 83.5 mmol, 5 equiv) in Et2O (35 
mL). The crude mixture was purified by distillation under reduced pressure (4 x 10-1 mbar, 
120°C) affording 2.7 g (8.4 mmol, 50%) of a colorless oil. 
31P{1H} NMR (Chloroform-d, 162 MHz) : δ = 164.2 ppm. The physical and spectroscopic 
properties matched those described in the literature196. 
(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-5,6-dimethoxy-2-(2,4,6-
triisopropylphenyl)-1,3,2-dioxaphosphepane 4.17k 
 
Following general procedure “Phosphonite”, 4.17k was obtained as a yellow solid (221 mg, 
0.18 mmol, 60%). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.39 – 8.36 (m, 2H), 8.09 – 8.02 (m, 2H), 7.95 – 
7.92 (m, 2H), 7.91 – 7.88 (m, 1H), 7.84 – 7.82 (m, 1H), 7.82 – 7.80 (m, 1H), 7.72 – 7.70 (m, 
2H), 7.62 – 7.60 (m, 2H), 7.09 (d, J = 3.2 Hz, 2H), 4.94 (dd, J = 7.9, 6.3 Hz, 1H), 4.10 (d, J = 
7.9 Hz, 1H), 3.86 (s, 2H), 3.70 (s, 3H), 2.89 (hept, J = 7.0 Hz, 1H), 2.44 (s, 3H), 1.31 – 1.21 
(m, 18H). 13C NMR (101 MHz, Chloroform-d) : Many signals due to C-P and C-F coupling 
19F NMR (235 MHz, Chloroform-d) : δ = -62.84, -62.88, -62.90, -63.13. 31P NMR (162 MHz, 
Chloroform-d) : δ = 172.9. Optical rotation : [a]D20 = -8.0° (c = 1.02, CHCl3) HRMS (ESI): 
Calculated for C53H44F24O4P ([M+H]+): 1231.2588; found: 1231.2592 
(5R,6R)-2,4,4,7,7-Pentakis(3,5-bis(trifluoromethyl)phenyl)-5,6-dimethoxy-1,3,2-
dioxaphosphepane 4.17l 
 
Following general procedure “Phosphonite”, 4.17l was obtained as a yellow solid (265 mg, 
0.214 mmol, 81 %). 
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1H NMR (400 MHz, Chloroform-d) : δ = 8.24 – 8.20 (m, 2H), 8.18 – 8.15 (m, 1H), 8.15 – 
8.14 (m, 1H), 8.09 – 8.08 (m, 1H), 8.03 – 8.01 (m, 1H), 8.01 – 7.97 (m, 2H), 7.94 – 7.92 (m, 
1H), 7.92 – 7.89 (m,1H), 7.84 – 7.79 (m, 2H), 7.68 – 7.64 (m, 2H), 4.79 – 4.72 (m, 1H), 3.98 
(d, J = 7.7 Hz, 1H), 3.63 (s, 3H), 2.60 (s, 3H). 13C NMR (101 MHz, Chloroform-d) : Many 
signals due to C-P and C-F coupling.  31P NMR (162 MHz, Chloroform-d) : δ = 153.7. 19F 
NMR (376 MHz, Chloroform-d) : δ = -63.09, -63.19, -63.38, -63.47, -63.52. Optical rotation 
: [a]D20 = -32.6° (c = 1.03, CHCl3). HRMS (ESI): Calculated for C46H24F30O4P ([M+H]+): 
1241.0928; found: 1241.0929 
(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-5,6-dimethoxy-2-(o-tolyl)-1,3,2-
dioxaphosphepane 4.17m 
 
Following general procedure “Phosphonite”, 4.17m was obtained as a yellow solid (302 mg, 
0.27 mmol, 90 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.26 – 8.21 (m, 2H), 8.07 – 8.02 (m, 2H), 7.94 – 
7.89 (m, 2H), 7.82 – 7.78 (m, 2H), 7.77 – 7.74 (m, 2H), 7.72 – 7.70 (m, 1H), 7.67 – 7.63 (m, 
2H), 7.44 – 7.32 (m, 2H), 7.20 – 7.13 (m, 1H), 4.71 (dd, J = 7.9, 5.3 Hz, 1H), 3.73 (d, J = 8.0 
Hz, 1H), 3.61 (s, 3H), 2.48 (s, 3H), 2.31 (s, 3H). 13C NMR (101 MHz, Chloroform-d) : Many 
signals due to C-P and C-F coupling. 31P NMR (162 MHz, Chloroform-d) : δ = 157.5. 19F 
NMR (376 MHz, Chloroform-d) : δ = -62.94, -63.05, -63.20, -63.24. Optical rotation : [a]D20 
= -27.1° (c = 1.0, CHCl3). HRMS (ESI): Calculated for C45H28F24O4P ([M+H]+): 1119.1336; 
found: 1119.1332 
(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-5,6-dimethoxy-2-(naphthalen-1-yl)-1,3,2-
dioxaphosphepane 4.17n 
 
Following general procedure “Phosphonite”, 4.17n was obtained as a yellow solid (280 mg, 
0.243 mmol, 81 %). 
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1H NMR (400 MHz, Chloroform-d) : δ = 8.56 – 8.49 (m, 1H), 8.30 – 8.24 (m, 2H), 8.13 – 
8.07 (m, 2H), 8.04 – 7.87 (m, 4H), 7.81 – 7.74 (m, 4H), 7.71 – 7.62 (m, 3H), 7.60 – 7.53 (m, 
3H), 4.79 (dd, J = 6.8 Hz, 1H), 3.83 (d, J = 8.0 Hz, 1H), 3.69 (s, 3H), 2.54 (s, 3H). 13C NMR 
(101 MHz, Chloroform-d) : Many signals due to C-P and C-F coupling. 19F NMR (376 MHz, 
Chloroform-d) : δ = -62.97, -63.08, -63.12, -63.15. 31P NMR (162 MHz, Chloroform-d) : δ 
= 165.7. Optical rotation : [a]D20 = -23.7° (c = 1.02, CHCl3). HRMS (ESI): Calculated for 
C48H28F24O4P ([M+H]+): 1155.1336; found: 1155.1320 
(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-2-(3,5-di-tert-butylphenyl)-5,6-
dimethoxy-1,3,2-dioxaphosphepane 4.17o 
 
Following general procedure “Phosphonite”, 4.17o was obtained as a yellow solid (299 mg, 
0.246 mmol, 82 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.29 – 8.24 (m, 2H), 8.10 – 8.05 (m, 2H), 7.94 – 
7.88 (m, 1H), 7.81 – 7.75 (m, 4H), 7.73 – 7.60 (m, 6H), 4.66 (dd, J = 8.0, 5.5 Hz, 1H), 3.67 (s, 
3H), 3.64 (d, J = 8.0 Hz, 1H), 2.47 (s, 3H), 1.32 (s, 18H). 13C NMR (101 MHz, Chloroform-
d) : Many signals due to C-P and C-F coupling. 19F NMR (376 MHz, Chloroform-d) : δ = -
62.98, -63.01, -63.05, -63.12. 31P NMR (162 MHz, Chloroform-d) : δ = 161.4. HRMS (ESI): 
Calculated for C52H42F24O4P ([M+H]+): 1217.2437; found: 1217.2432 
(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-2-(3,5-dimethoxyphenyl)-5,6-
dimethoxy-1,3,2-dioxaphosphepane 4.17p 
 
Following general procedure “Phosphonite”, 4.17p was obtained as a yellow solid (157 mg, 
0.135 mmol, 45 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.26 – 8.24 (m, 2H), 8.10 – 8.08 (m, 2H), 8.01 – 
7.97 (m, 1H), 7.90 – 7.88 (m, 1H), 7.88 – 7.87 (m, 1H), 7.85 – 7.84 (m, 2H), 7.80 – 7.77 (m, 
1H), 7.72 – 7.70 (m, 2H), 6.91 (d, J = 2.3 Hz, 1H), 6.88 (d, J = 2.3 Hz, 1H), 6.65 (t, J = 2.3 Hz, 
1H), 4.72 (dd, J = 7.9, 4.9 Hz, 1H), 3.86 (s, 6H), 3.85 (d, J = 8.0 Hz, 1H), 3.65 (s, 3H), 2.56 (s, 
3H). 13C NMR (101 MHz, Chloroform-d) : Many signals due to C-P and C-F coupling.   
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19F NMR (376 MHz, Chloroform-d) : δ = -62.97, -63.08, -63.12, -63.15. 31P NMR (162 MHz, 
Chloroform-d) : δ = 158.8. 19F NMR (376 MHz, Chloroform-d) : δ = -62.93, -62.97, -63.10, 
-63.11. Optical rotation : [a]D20 = -33.3° (c = 1.08, CHCl3) HRMS (ESI): Calculated for 
C46H30F24O6P ([M+H]+): 1165.1391; found: 1165.1393 
(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-2-(3,5-diisopropyl-4-
methoxyphenyl)-5,6-dimethoxy-1,3,2-dioxaphosphepane 4.17q 
 
Following general procedure “Phosphonite”, 4.17q was obtained as a yellow solid (287 mg, 
0.237 mmol, 79 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.29 – 8.24 (m, 2H), 8.10 – 8.06 (m, 2H), 7.93 – 
7.89 (m, 1H), 7.79 – 7.78 (m, 1H), 7.78 – 7.77 (m, 3H), 7.74 – 7.71 (m, 1H), 7.70 – 7.66 (m, 
2H), 7.56 (s, 1H), 7.53 (s, 1H), 4.64 (dd, J = 8.0, 5.6 Hz, 1H), 3.75 (s, 3H), 3.68 (s, 3H), 3.61 
(d, J = 8.0 Hz, 1H), 3.34 (hept, J = 6.9 Hz, 2H), 1.24 (d, J = 6.9 Hz, 6H), 1.21 (d, J = 6.9 Hz, 
6H). 13C NMR (101 MHz, Chloroform-d) : Many signals due to C-P and C-F coupling. 31P 
NMR (162 MHz, Chloroform-d) : δ = 160.4. 19F NMR (376 MHz, Chloroform-d) : δ = -
62.99, -63.01, -63.05, -63.12. Optical rotation : [a]D20 = -21.2° (c = 1.0, CHCl3). HRMS (ESI): 
Calculated for C1H40F24O5P ([M+H]+): 1219.2225; found: 1219.2234 
(5R,6R)-4,4,7,7-Tetrakis(3,5-bis(trifluoromethyl)phenyl)-2-(3,5-di-tert-butyl-4-
methoxyphenyl)-5,6-dimethoxy-1,3,2-dioxaphosphepane 4.17r 
 
Following general procedure “Phosphonite”, 4.17 r was obtained as a yellow solid (310 mg, 
0.249 mmol, 83 %). 
1H NMR (400 MHz, Chloroform-d) : δ = 8.29 – 8.25 (m, 2H), 8.10 – 8.05 (m, 2H), 7.94 – 
7.91 (m, 1H), 7.81 – 7.80 (m, 1H), 7.79 – 7.77 (m, 2H), 7.75 – 7.73 (m, 1H), 7.72 – 7.67 (m, 
3H), 7.19 (s, 2H), 4.64 (dd, J = 7.9, 5.6 Hz, 1H), 3.71 (s, 3H), 3.68 (s, 3H), 3.65 – 3.61 (m, 1H), 
2.47 (s, 3H), 1.42 (s,9H), 1.34 (s, 9H). 13C NMR (101 MHz, Chloroform-d) : Many signals 
due to C-P and C-F coupling. 31P NMR (162 MHz, Chloroform-d) : δ = 161.3.   
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19F NMR (376 MHz, Chloroform-d) : δ = -63.01, -63.05, -63.12. Optical rotation : [a]D20 = 
-20.3° (c = 1.06, CHCl3). HRMS (ESI): Calculated for C53H44F24O5P ([M+H]+): 1247.2538; 
found: 1247.2523 
3.11. Enantioselective version and application 
(R)-4-Methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one 4.12a 
 
Enantioselective reaction: CO atmosphere 
Following general procedure B, Isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (400 
mg, 1.33 mmol, 1 equiv) was reacted with PdCl2 (24 mg, 0.133 mmol, 10 mol%), L ligand (332 
mg , 0.266 mmol, 20 mol%), pivalic acid (41 mg, 0.4 mmol, 30 mol%) and cesium carbonate 
(650 mg, 2 mmol, 1.5 equiv) in mesitylene (26.2 mL), under CO atmosphere. The mixture was 
stirred for 18h at 120 °C. The crude mixture was purified by flash chromatography using first 
cyclohexane to elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent, to 
provide oil 2a (266 mg, 1 mmol, 75 %, e.r.: 92:8). 
Optical rotation : [a]D20 = +71.8° (c = 1.0, CHCl3) 
Enantioselective reaction: Two-chamber system: 
Following general procedure A, Chamber A was filled with Pd(OAc)2 (8.9 mg, 0.04 mmol,  30 
mol%), P(t-Bu)3.HBF4 (12 mg , 0.04 mmol, 30 mol%), COgen (97 mg, 0.4 mmol, 3.0 equiv), 
Cy2NMe (161 mg, 0.798 mmol, 6.0 equiv) and mesitylene (0.5 mL).  Chamber B, previously 
charged with isopropyl(2,4,6-trimethoxybenzyl)carbamoyl chloride (40 mg, 0.133 mmol, 1 
equiv) was reacted with PdCl2 (2.4 mg, 0.0133 mmol, 10 mol%), L ligand (33.2 mg , 0.0266 
mmol, 20 mol%), pivalic acid (4.1 mg, 0.04 mmol, 30 mol%) and cesium carbonate (65 mg, 
0.2 mmol, 1.5 equiv) in mesitylene (2.62 mL). The two chambers system was reacted for 18h 
at 120 °C. The crude mixture was purified by flash chromatography using first cyclohexane to 
elute mesitylene and then cyclohexane/EtOAc (75:25 to 0:1) as eluent., to provide oil 2a (30.5 
mg, 0.114 mmol, 86 %, e.r.: 86:14 ). 
1H NMR (400 MHz, Chloroform-d ) : δ = 6.11 (s, 2H), 4.57 (d, J = 13.9 Hz, 1H), 4.13 (d, J = 
13.8, 1H), 3.81 (s, 9H), 3.41 – 3.33 (m, 1H), 2.90 (dd, J = 14.2, 4.9 Hz, 1H), 2.38 (dd, J = 14.2, 
2.2, 1H), 1.17 (d, J = 6.0 Hz, 3H).   
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13C NMR (Chloroform-d, 101 MHz) : δ = 166.5, 161.2, 159.7, 104.6, 90.3, 55.8, 55.5, 47.0, 
43.8, 32.4, 18.7. IR (neat): ν = 2946, 1739, 1600, 1140cm-1. HRMS (ESI): Calculated for 
C14H19NNaO4 ([M+Na]+): 288.1206; found: 288.1208 
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(R)-4-Methylazetidin-2-one (+)-4.21 
 
4-methyl-1-(2,4,6-trimethoxybenzyl)azetidin-2-one (135 mg, 0.509 mmol, 1 equiv), K2S2O8 
(275 mg, 1.02 mmol, 2 equiv) and Na2HPO4.7H2O (273 mg, 1.02 mmol, 2 equiv) were stirred 
for 3h at 80 °C in MeCN/H2O [2:1] (18 mL). Then, the crude mixture was dried over MgSO4, 
filtered and evaporated. The residue was purified by chromatography on silica gel using 
AcOEt/EtOH [95:5] as eluent to provide (R)-4-methylazetidin-2-one 4a (33 mg, 0.388 mmol, 
76 %) as a yellowish oil. 
1H NMR (250 MHz, Chloroform-d) δ = 5.89 (br s, 1H), 3.83 – 3.73 (m, 1H), 3.11 (ddd, J = 
14.7, 5.0, 2.1 Hz, 1H), 2.55 (ddd, J = 14.8, 2.4, 1.5 Hz, 1H), 1.36 (d, J = 6.1 Hz, 3H). 13C NMR 
(63 MHz, Chloroform-d) δ = 168.2, 45.1, 44.0, 21.3. IR (neat): ν = 1739, 1381, 908, 728 cm-
1 [α]D20 = +2.8° (c = 1.14, CHCl3); lit. +3.6 (c = 2.3, CHCl3). 
The physical and spectroscopic properties matched those described in the literature197. 
(–)-2a,3,4,8b-Tetrahydronaphtho[1,2-b]azet-2(1H)-one (-)-4.23 
 
Compound (–)-2ac (95 mg, 0.269 mmol, 1 equiv), K2S2O8 (145 mg, 0.538 mmol, 2 equiv) and 
Na2HPO4.7H2O (144 mg, 0.538 mmol, 2 equiv) were stirred for 3h at 80 °C in MeCN/H2O 
[2:1] (9.4 mL). Then, the crude mixture was filtered through a pad of MgSO4, and rinsed with 
MeCN. The filtrate was then treated with NBS (52.7 mg, 0.296 mmol, 1.1 equiv) and TMSCl 
(3.5 mL, 0.0269 mmol, 0.1 equiv) and stirred for 30 min. The crude mixture was then 
evaporated and purified by chromatography on silica gel using DCM/MeOH 99:1 as eluent to 
provide oil compound 4ac (42 mg, 0.245 mmol, 91 %).  
1H NMR (250 MHz, Chloroform-d) δ = 7.27 – 7.06 (m, 4H), 6.21 (s, 1H), 4.59 (d, J = 5.0 Hz, 
1H), 3.65 – 3.59 (m, 1H), 2.83 – 2.57 (m, 2H), 2.28 – 2.17 (m, 1H), 1.69 – 1.42 (m, 1H). 13C 
NMR (63 MHz, Chloroform-d) δ = 170.8, 139.4, 134.1, 129.7, 129.1, 128.5, 126.6, 51.5, 50.6, 
26.9, 23.0. HRMS (ESI): Calculated for C11H11NNaO ([M+Na]+): 196.0733; found: 196.0731 
Optical rotation : [a]D20 = -89.3° (c = 1.0, CHCl3) The physical and spectroscopic properties 
matched those described in the literature178. 
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(1R,2R)-1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid hydrochloride (+).4.24 
 
 
Following a methodology from F. Fulöp et al., compound 4ac was refluxed for 3h in an aqueous 
HCl solution (2 mL, 6M). The solvent was removed under vacuum to provide oil compound 
5ac as a yellowish solid (32 mg, 0.139 mmol, 100 %).  
1H NMR (250 MHz, D2O) δ = 7.42 – 7.24 (m, 4H), 4.82 (d, J = 3.5 Hz, 1H), 3.19 (dt, J = 12.0, 
3.5 Hz, 1H), 3.10 – 2.91 (m, 2H), 2.37 – 2.23 (m, 1H), 2.15 – 1.95 (m, 1H). 13C NMR (101 
MHz, D2O) δ = 176.8, 136.6, 130.0, 129.7, 129.5, 128.8, 126.6, 49.5, 41.3, 27.0, 20.2. The 
physical and spectroscopic properties matched those described in the literature178.  
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